LIVE #WCLC26 — live KOL coverage of the World Conference on Lung Cancer View Full Coverage →
KOL Pulse · WCLC 2026 · Seoul · Sept 12–15

WCLC 2026 Slide Library

Every slide and data graphic shared by global KOLs, mirrored to our CDN and tagged by trial and theme. 2614 conference-week slides, 408 from the pre-meeting build-up. Filter by tag or search by trial, drug or author. ← Back to full WCLC 2026 coverage

Conference week

Slides from the Meeting

Presented at #WCLC26: Among patients with relapsed small-cell lung cancer after chemother
@NEJM · 2026-09-13 · OCR
Original Article: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Ther
@NEJM · 2026-09-14 · OCR
Original Article: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Ther
@NEJM · 2026-09-14 · OCR
🚨🚨 Randomized Trial #WCLC26 Small Cell Lung Cancer MRI +/-PCI 🚨 • MRI alone superior cogni
@PDBrownOnc · 2026-09-12 · OCR
Our @ImmunityBio team is having great reception at World Conference Lung Cancer (WCLC26) i
@DrPatrick · 2026-09-16 · OCR
Our @ImmunityBio team is having great reception at World Conference Lung Cancer (WCLC26) i
@DrPatrick · 2026-09-16 · OCR
what is the bar $SMMT final PFS analysis. Interesting Harmoni-2 results but Harmoni-3 di
@plainyogurt21 · 2026-09-15 · OCR
what is the bar $SMMT final PFS analysis. Interesting Harmoni-2 results but Harmoni-3 di
@plainyogurt21 · 2026-09-15 · OCR
what is the bar $SMMT final PFS analysis. Interesting Harmoni-2 results but Harmoni-3 di
@plainyogurt21 · 2026-09-15 · OCR
what is the bar $SMMT final PFS analysis. Interesting Harmoni-2 results but Harmoni-3 di
@plainyogurt21 · 2026-09-15 · OCR
Highlighted Studies at #WCLC26 1️⃣ HARMONi-2 In treatment-naïve, advanced NSCLC with PD-L
@dr_yakupergun · 2026-09-13 · OCR
🐾 @TheCORGILab is at #WCLC26! Four presentations at @IASLC #WCLC26: 📍 @JamesFanWu ×2 — AY
@TheCORGILab · 2026-09-12 · OCR
There's a lot to learn beyond the impressive B7-H3 ADC showing in 2L SCLC #WCLC26. Here's
@MaverickNY · 2026-09-13 · OCR
Awesome news & timing!! 🎉 New @theNCI R01 NoA supporting our liquid ecotypes in lung canc
@aadel_chaudhuri · 2026-09-10 · OCR
Standing ovation in support and recognition of Dr Ross Camidge at #WCLC2026 https://t.co/R
@LudaBazhenovaMD · 2026-09-12 · OCR
👉 Free for ESMO members: Essentials for Clinicians: Thoracic Tumours - a ‘must read’ for a
@myESMO · 2026-09-14 · OCR
#MEDIA – We’re pleased to share positive Phase III data from our collaborator MediLink’s s
@Roche · 2026-09-14 · OCR
Good morning Seoul!! starting our #WCLC2026 congress with the @IASLC Academy, our future i
@LuisRaezMD · 2026-09-10 · OCR
Good morning Seoul!! starting our #WCLC2026 congress with the @IASLC Academy, our future i
@LuisRaezMD · 2026-09-10 · OCR
From HER2 testing to HER2-directed ADCs in #NSCLC — how do you put it all together? Join D
@PeerView · 2026-09-10 · OCR
Small-cell lung cancer is an aggressive cancer that often comes back after initial treatme
@ilyassahinMD · 2026-09-13 · OCR
West China Sichuan Univeirstiy won one of the IASLC care team awards. First and only repor
@oncoOuLungCA · 2026-09-12 · OCR
West China Sichuan Univeirstiy won one of the IASLC care team awards. First and only repor
@oncoOuLungCA · 2026-09-12 · OCR
West China Sichuan Univeirstiy won one of the IASLC care team awards. First and only repor
@oncoOuLungCA · 2026-09-12 · OCR
West China Sichuan Univeirstiy won one of the IASLC care team awards. First and only repor
@oncoOuLungCA · 2026-09-12 · OCR
Big Pharma is filling its next pipeline from Chinese labs while Washington tries to decoup
@Unveiled_ChinaX · 2026-09-16
🚨🔥@OncoAlert Hot off the press. Just published @JTOonline in conjunction with presentation
@RManochakian · 2026-09-14 · OCR
MAVERICK: MRI surveillance +/- PCI for SCLC; SRS/WBRT if development of brain mets Primar
@5_utr · 2026-09-13 · OCR
What a way to close #WCLC26! A privilege to take the plenary stage today to discuss AI in
@fabiomoraesmd · 2026-09-15 · OCR
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from t
@BioNTech_Group · 2026-09-14 · OCR
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from t
@BioNTech_Group · 2026-09-14 · OCR
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @IAS
@RManochakian · 2026-09-13 · OCR
🚨🔥‼️@OncoAlert Hot off the press. #BigDeal & #PracticeChanging Just presented @IASLC #W
@RManochakian · 2026-09-12 · OCR
🚨🔥‼️@OncoAlert Hot off the press. #BigDeal & #PracticeChanging Just presented @IASLC #W
@RManochakian · 2026-09-12 · OCR
Winners, weak spots, and warning signs for PD(L)1×VEGF bispecifics at #WCLC26 Time to loo
@MaverickNY · 2026-09-15 · OCR
#WCLC26 The radiation oncology contingent gathers for a pic in Seoul https://t.co/fvOiLUC3
@SalmaJabbour1 · 2026-09-13 · OCR
#WCLC2026 Late-Breaking Oral (Sept 15): 🇨🇳DualityBio & $BNTX will unveil clinical data
@chuminhua432 · 2026-09-14 · OCR
#WCLC2026 Late-Breaking Oral (Sept 15): 🇨🇳DualityBio & $BNTX will unveil clinical data
@chuminhua432 · 2026-09-14 · OCR
Heading to @IASLC 2026 World Conference on Lung Cancer? - So are we! Reach out to Senior
@TheLancetOncol · 2026-09-10 · OCR
My forever mentor, friend, and colleague, @aadel_chaudhuri. Grateful for seven years of me
@BrunaPellini · 2026-09-12 · OCR
Great to see more amazing clinical results with another agent where the preclinical charac
@ElizSMcKenna · 2026-09-14 · OCR
❤️👏@Mal_Itchins 🇦🇺 The endpoint that matters most is the patient. As we develop better d
@JiaJennyLiu · 2026-09-14 · OCR
🇨🇳RemeGen & $ABBV 's PD-1/VEGF bispecific antibody RC148 (ABBV-1480) delivered an oral pr
@chuminhua432 · 2026-09-15 · OCR
@NarjustFlorezMD @StephenVLiu Science has no borders, and language should never be a barri
@susu_mail0513 · 2026-09-12 · OCR
💉Could less frequent tarlatamab dosing offer flexibility in #SCLC? In DeLLphi-309, 20 mg e
@ASCOPost · 2026-09-15 · OCR
$IBRX ImmunityBio is attending the World Conference on Lung Cancer in Seoul from Sept.12 t
@traderMichael_1 · 2026-09-14 · OCR
SWOG S1827 MAVERICK met primary endpoint with ⬆️ cognitive failure-free survival with MRI
@KatieKeaneMD · 2026-09-12 · OCR
A special evening at #WCLC26 celebrating 20 years of the Journal of Thoracic Oncology! 🥂
@JTOonline · 2026-09-14 · OCR
A special evening at #WCLC26 celebrating 20 years of the Journal of Thoracic Oncology! 🥂
@JTOonline · 2026-09-14 · OCR
A special evening at #WCLC26 celebrating 20 years of the Journal of Thoracic Oncology! 🥂
@JTOonline · 2026-09-14 · OCR
Dosing and schedules are not the most exciting of topics when it comes to cancer trials –
@MaverickNY · 2026-09-13 · OCR
Congratulation to all the speakers in the presidential session! #WCLC26 @JuliaRotow @alex
@LudaBazhenovaMD · 2026-09-13 · OCR
🫁 Phase 3️⃣ IMpower030: Perioperative atezolizumab + platinum chemo yielded a median event
@ASCOPost · 2026-09-15
MRI surveillance with no PCI is now SOC for limited- and extensive-stage SCLC. OS not yet
@HenryParkMD · 2026-09-12 · OCR
MRI surveillance with no PCI is now SOC for limited- and extensive-stage SCLC. OS not yet
@HenryParkMD · 2026-09-12 · OCR
MRI surveillance with no PCI is now SOC for limited- and extensive-stage SCLC. OS not yet
@HenryParkMD · 2026-09-12 · OCR
MRI surveillance with no PCI is now SOC for limited- and extensive-stage SCLC. OS not yet
@HenryParkMD · 2026-09-12 · OCR
Explaining at the "Initiation and plasticity" session of #WCLC2026 @IASLC that a significa
@ManelEsteller · 2026-09-13 · OCR
Recording in progress at #WCLC26 in Seoul 🇰🇷 @SarinaRicc Stay connected on the @IASLC Th
@M_Tagliamento · 2026-09-14 · OCR
Recording in progress at #WCLC26 in Seoul 🇰🇷 @SarinaRicc Stay connected on the @IASLC Th
@M_Tagliamento · 2026-09-14 · OCR
🇲🇽 A historic first photo of the Mexican Society of Thoracic Oncology — SMOTMX on the glob
@JorgeAlatorreA1 · 2026-09-14 · OCR
🇲🇽 A historic first photo of the Mexican Society of Thoracic Oncology — SMOTMX on the glob
@JorgeAlatorreA1 · 2026-09-14 · OCR
🇲🇽 A historic first photo of the Mexican Society of Thoracic Oncology — SMOTMX on the glob
@JorgeAlatorreA1 · 2026-09-14 · OCR
Roche/🇨🇳MediLink: B7-H3 ADC Tam-Peli (tambotatug pelitecan, YL201) hits positive Phase III
@chuminhua432 · 2026-09-13 · OCR
It was an honour to present at World Lung today in Seoul. An exciting session debating nov
@HazelOSulliva14 · 2026-09-13 · OCR
It was an honour to present at World Lung today in Seoul. An exciting session debating nov
@HazelOSulliva14 · 2026-09-13 · OCR
Radiotherapy plays a crucial role in curative, consolidative, and palliative therapy for l
@JoeChangMD · 2026-09-14 · OCR
Excited to share our latest from #WCLC26! We performed liquid bx of the TME (via Liquid E
@aadel_chaudhuri · 2026-09-14 · OCR
More often than we think, less can be more! #ChoosingWisely @csoncol @CancerGridIndia #WCL
@cspramesh · 2026-09-13 · OCR
Grateful once again to @IASLC for the opportunity to present our work on TCR clone dynamic
@CMartinezToledo · 2026-09-14 · OCR
Here we go! Presidential plenary @wclc26 @IASLC https://t.co/q6Yb96tZtQ
@LaurenMachos · 2026-09-13 · OCR
It’s an honor to be a member of the IASLC Board of Directors. Did you know you can volunte
@cbaldotto · 2026-09-11 · OCR
It’s an honor to be a member of the IASLC Board of Directors. Did you know you can volunte
@cbaldotto · 2026-09-11 · OCR
✈️ Heading to #Seoul, #Korea to deliver lecture at the World Conference on #Lung #Cancer #
@ManelEsteller · 2026-09-10 · OCR
@DrewMoghanaki delivering a fantastic comprehensive talk on SBRT/ SABR for patients with r
@KatieKeaneMD · 2026-09-12 · OCR
🔥Waking up with another milestone in #SCLC coming from #WCLC26 🔵 @NEJM TAISHAN-302: B7-H3
@YGaritaonaindia · 2026-09-13 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CD_AACR · 2026-09-11 · OCR
@MayoCancerCare @MayoClinic group at @IASLC. The best colleagues one could ever wish for @
@deeptibehl1 · 2026-09-13 · OCR
Meet the Editors at #WCLC26! 📚 JTO Editor-in-Chief Dr. Alex Adjei and JTO Clinical and Re
@JTOonline · 2026-09-13 · OCR
In business! @IASLC #WCLC2026 https://t.co/iRPZfiqsg4
@ManelEsteller · 2026-09-12 · OCR
Great congress on lung cancer. Arrived few days back. Enjoy this beautiful country and see
@EddieSantosMD · 2026-09-14 · OCR
Great congress on lung cancer. Arrived few days back. Enjoy this beautiful country and see
@EddieSantosMD · 2026-09-14
Great congress on lung cancer. Arrived few days back. Enjoy this beautiful country and see
@EddieSantosMD · 2026-09-14 · OCR
Great congress on lung cancer. Arrived few days back. Enjoy this beautiful country and see
@EddieSantosMD · 2026-09-14 · OCR
I’m presenting today at #WCLC2026 on behalf of @Jani_Chinmay 14,246 real-world NSCLC pati
@dan_morgen · 2026-09-13 · OCR
Out for our morning run in Seoul! Excited for another day at World Lung!! #wclc26 #well
@hari_keshava · 2026-09-11 · OCR
Ready for Day 1 of @IASLC #WCLC26! 🇰🇷🫁 Looking forward to connecting with other advocates
@sara_ricardez · 2026-09-11 · OCR
🔑 🫁#WCLC26 Study Highlights 👇 #OncTwitter #lcsm #LungCancer #hemonc #CancerResearch #Onco
@sawyer_bawek · 2026-09-13 · OCR
Pfizer is presenting five abstracts, including research in advanced ALK-positive NSCLC, at
@pfizer_news · 2026-09-10 · OCR
Featured during #WCLC26 🚨: ADAURA, a global phase III adjuvant trial in EGFR-mutated stage
@JTOonline · 2026-09-14 · OCR
Don't miss this #WCLC26 Presidential Symposium: @MSKCancerCenter lung cancer expert Dr. Al
@MSK_DeptOfMed · 2026-09-13 · OCR
Major FOMO not being at #WCLC26 @IASLC in South Korea in person 😭 BUT I can still attend V
@IvyLorena_Md · 2026-09-10 · OCR
I’m Presenting at #WCLC26 today! We tested 6 AI tools (ChatGPT, Gemini, Claude, Grok, ASC
@dan_morgen · 2026-09-12 · OCR
.@Annechiangmd presented at #WCLC in Seoul as a discussant for the exciting primary result
@YaleCancer · 2026-09-14 · OCR
.@Annechiangmd presented at #WCLC in Seoul as a discussant for the exciting primary result
@YaleCancer · 2026-09-14 · OCR
.@Annechiangmd presented at #WCLC in Seoul as a discussant for the exciting primary result
@YaleCancer · 2026-09-14 · OCR
.@Annechiangmd presented at #WCLC in Seoul as a discussant for the exciting primary result
@YaleCancer · 2026-09-14 · OCR
#WCLC2026 🇨🇳Biokin (SystImmun) updates global Phase 1 data for EGFR/HER3 bispecific ADC iz
@chuminhua432 · 2026-09-14 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CD_AACR · 2026-09-11 · OCR
Such an honor to represent @MCWRadOnc at @IASLC as a member of the Global Policy and Partn
@RohanPatelMD · 2026-09-15 · OCR
Such an honor to represent @MCWRadOnc at @IASLC as a member of the Global Policy and Partn
@RohanPatelMD · 2026-09-15 · OCR
Really helpful session for early trainees preparing for a career in oncology. Great discus
@GarradEvan · 2026-09-12 · OCR
Really helpful session for early trainees preparing for a career in oncology. Great discus
@GarradEvan · 2026-09-12 · OCR
Amazing #WCLC26 symposium on exercise and prehabilitation in lung cancer — from evidence t
@pompili_cecilia · 2026-09-12 · OCR
Amazing #WCLC26 symposium on exercise and prehabilitation in lung cancer — from evidence t
@pompili_cecilia · 2026-09-12 · OCR
Amazing #WCLC26 symposium on exercise and prehabilitation in lung cancer — from evidence t
@pompili_cecilia · 2026-09-12 · OCR
Amazing #WCLC26 symposium on exercise and prehabilitation in lung cancer — from evidence t
@pompili_cecilia · 2026-09-12 · OCR
Live in 1 hour! Don’t miss Drs. Planchard (@dplanchard), Horinouchi (@HHorinouchi) and Smi
@PeerView · 2026-09-15 · OCR
Join Caris at the @IASLC World Conference on Lung Cancer (WCLC). Connect with our team at
@carisls · 2026-09-14 · OCR
Join Caris at the @IASLC World Conference on Lung Cancer (WCLC). Connect with our team at
@carisls · 2026-09-14 · OCR
Join Caris at the @IASLC World Conference on Lung Cancer (WCLC). Connect with our team at
@carisls · 2026-09-14 · OCR
Great discussion covering broad range of NSCLC topics by @mollylisc at @IASLC #WCLC2026 h
@RielyMD · 2026-09-12 · OCR
Treating lung cancer is “K-Pop”! 🇰🇷🫰🏼@IASLC #WCLC26 @SamiraMascaren2 https://t.co/aiGRSxSx
@cbaldotto · 2026-09-12 · OCR
🤔 How will #WCLC26 shake up the lung cancer field?🫁 Expert opinions across medical oncolo
@CancerNetwrk · 2026-09-11 · OCR
Packed house at the @IASLC academy!! #wclc2026 @BalazsHalmosMD @TKato_Thoracic @DDorosho
@hari_keshava · 2026-09-10 · OCR
🚀 STARLORD presented at #WCLC2026 adds to growing phase II literature that SABR may be a s
@drviviantan · 2026-09-14 · OCR
wCLC2026 At Presidential Plenary @DrRoyHerbst gives 8 year update on ADAURA, adjuvant osi
@drgandara · 2026-09-13 · OCR
#WCLC26 #ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53,
@drsabita · 2026-09-13 · OCR
#WCLC26 #ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53,
@drsabita · 2026-09-13 · OCR
Truly excellent discussion on the rapidly changing landscape for treatment of small cell l
@RielyMD · 2026-09-13 · OCR
Honoured to participate in the #WCLC26, contributing to the discussion and exchange of ide
@CespedesMontse · 2026-09-12 · OCR
The International Association for the Study of Lung Cancer (IASLC) Board of Directors meet
@JoeChangMD · 2026-09-11 · OCR
The International Association for the Study of Lung Cancer (IASLC) Board of Directors meet
@JoeChangMD · 2026-09-11 · OCR
The International Association for the Study of Lung Cancer (IASLC) Board of Directors meet
@JoeChangMD · 2026-09-11
Good morning, Seoul! #WCLC2026 @IASLC https://t.co/t3gC2TW5hy
@ManelEsteller · 2026-09-14
Incredible time at my first #WCLC26, made even more special having my wife there as a pati
@GarradEvan · 2026-09-15 · OCR
Incredible time at my first #WCLC26, made even more special having my wife there as a pati
@GarradEvan · 2026-09-15 · OCR
Incredible time at my first #WCLC26, made even more special having my wife there as a pati
@GarradEvan · 2026-09-15 · OCR
#LungCancer research being presented as a mini oral presentation at #WCLC26 analyzed the p
@FoundationATCG · 2026-09-13 · OCR
#LungCancer research being presented as a mini oral presentation at #WCLC26 analyzed the p
@FoundationATCG · 2026-09-13 · OCR
At #WCLC26, @MSKCancerCenter lung cancer expert Adam Schoenfeld will share trial results o
@MSK_DeptOfMed · 2026-09-14
Wonderful Presentation by @StephenVLiu at #WCLC2026 on improving outcomes with systemic th
@Anil_Tibdewal · 2026-09-13 · OCR
🫁 In DeLLphi-308, subcutaneous tarlatamab showed a favorable safety profile and preliminar
@ASCOPost · 2026-09-16 · OCR
When work gives you a sister! How blessed we have been to get to work together on these am
@LaurenMachos · 2026-09-14 · OCR
Day 2 at #WCLC26 What a day. What a privilege. What a responsibility. Being an invited spe
@oceanblue11oct · 2026-09-13 · OCR
Day 2 at #WCLC26 What a day. What a privilege. What a responsibility. Being an invited spe
@oceanblue11oct · 2026-09-13 · OCR
Day 2 at #WCLC26 What a day. What a privilege. What a responsibility. Being an invited spe
@oceanblue11oct · 2026-09-13 · OCR
Day 2 at #WCLC26 What a day. What a privilege. What a responsibility. Being an invited spe
@oceanblue11oct · 2026-09-13 · OCR
Dr @Latinamd highlights the role and potential of @IASLC Thoracic Circle in building commu
@AnaVManana · 2026-09-12 · OCR
Dr @Latinamd highlights the role and potential of @IASLC Thoracic Circle in building commu
@AnaVManana · 2026-09-12 · OCR
Excellent examples from @NarjustFlorezMD as part of the #WCLC26 Communications Committee d
@AnaVManana · 2026-09-12 · OCR
Excellent examples from @NarjustFlorezMD as part of the #WCLC26 Communications Committee d
@AnaVManana · 2026-09-12 · OCR
If you are attending the #WCLC26 in Seoul, do not miss our Practical Skills #Workshop on #
@mahdi_iarc · 2026-09-12 · OCR
Happening right now! ES41 debate — should we convert the borderline resectable to resectab
@drkevin_chua_lm · 2026-09-14 · OCR
At #WCLC26, @DanaFarber’s @JuliaRotow presented primary results from DESTINY-Lung04, the f
@DanaFarberNews · 2026-09-14 · OCR
@DrewMoghanaki @FordePatrick @MARIANOPROVENCI @gerryhanna @finn_corinne @DoctorJSpicer @Li
@BrendonStilesMD · 2026-09-10 · OCR
@DrewMoghanaki @FordePatrick @MARIANOPROVENCI @gerryhanna @finn_corinne @DoctorJSpicer @Li
@BrendonStilesMD · 2026-09-10 · OCR
Proud to present our work at @IASLC #WCLC26 in Seoul! 🇰🇷 “Not All Residual Tumors Are Cr
@CruzAPhD · 2026-09-16 · OCR
#WCLC26 Views outside the auditorium @coexseoul https://t.co/V0u3ouIPbf
@drsabita · 2026-09-13 · OCR
#WCLC26 Views outside the auditorium @coexseoul https://t.co/V0u3ouIPbf
@drsabita · 2026-09-13 · OCR
Tomorrow could be a big day for EGFR+ #lungcancer at #WCLC26. Three important updates are
@EgfrUk · 2026-09-13 · OCR
Connect with Caris at the @IASLC World Conference on Lung Cancer (WCLC) and discover how w
@carisls · 2026-09-10 · OCR
Join Pfizer at #WCLC2026 as we share long-term safety data for an ALK tyrosine kinase inhi
@PfizerOncMed · 2026-09-14 · OCR
@IASLC #WCLC2026 🫁🇰🇷 Gender interface with lung cancer: 🧬Different disease biology 📉Dif
@LindaMThoracic · 2026-09-13 · OCR
@IASLC #WCLC2026 🫁🇰🇷 Gender interface with lung cancer: 🧬Different disease biology 📉Dif
@LindaMThoracic · 2026-09-13 · OCR
@IASLC #WCLC2026 🫁🇰🇷 Gender interface with lung cancer: 🧬Different disease biology 📉Dif
@LindaMThoracic · 2026-09-13 · OCR
@IASLC #WCLC2026 🫁🇰🇷 Gender interface with lung cancer: 🧬Different disease biology 📉Dif
@LindaMThoracic · 2026-09-13 · OCR
New at #WCLC26 34-year global trends in radon-attributable lung cancer mortality. Men's ra
@dan_morgen · 2026-09-14 · OCR
The science continues to drive the conversation. At #WCLC26, new Phase 3 insights from R
@GetAnktivanow · 2026-09-16 · OCR
The science continues to drive the conversation. At #WCLC26, new Phase 3 insights from R
@GetAnktivanow · 2026-09-16 · OCR
Having a great time at my first #WCLC26 @IASLC in Seoul! Learning a lot from talks on new
@JessieLiMD · 2026-09-13 · OCR
Having a great time at my first #WCLC26 @IASLC in Seoul! Learning a lot from talks on new
@JessieLiMD · 2026-09-13 · OCR
Having a great time at my first #WCLC26 @IASLC in Seoul! Learning a lot from talks on new
@JessieLiMD · 2026-09-13 · OCR
Extremely proud of our fellow @dan_morgen, who presented 3 posters at his first #WCLC26 in
@HemOncMiami · 2026-09-16 · OCR
Extremely proud of our fellow @dan_morgen, who presented 3 posters at his first #WCLC26 in
@HemOncMiami · 2026-09-16 · OCR
Extremely proud of our fellow @dan_morgen, who presented 3 posters at his first #WCLC26 in
@HemOncMiami · 2026-09-16 · OCR
Patients in India & LMICs are fighting to survive; they shouldn't have to fight to be coun
@R2SurviveCancer · 2026-09-15 · OCR
Patients in India & LMICs are fighting to survive; they shouldn't have to fight to be coun
@R2SurviveCancer · 2026-09-15 · OCR
In addition to great research, #WCLC2026 creates connections, friends, and fun. 🤍 https://
@LiveLung1 · 2026-09-13 · OCR
In addition to great research, #WCLC2026 creates connections, friends, and fun. 🤍 https://
@LiveLung1 · 2026-09-13 · OCR
In addition to great research, #WCLC2026 creates connections, friends, and fun. 🤍 https://
@LiveLung1 · 2026-09-13 · OCR
In addition to great research, #WCLC2026 creates connections, friends, and fun. 🤍 https://
@LiveLung1 · 2026-09-13 · OCR
$IBRX ImmunityBio’s robust fundamentals are structurally reinforced by a series of high-va
@traderMichael_1 · 2026-09-15 · OCR
Dr. Laura Petrillo @lpetrillz closing out the #WCLC26 plenary with a talk on advancing sur
@KatieKeaneMD · 2026-09-12 · OCR
We're presenting at #WCLC26 on the efficacy & safety of adjuvant RET kinase inhibitor in p
@LillyOncMed · 2026-09-12 · OCR
Attending #WCLC26 as part of @IASLC Academy. Excited for my first time at WCLC! See you i
@myrette_s · 2026-09-10 · OCR
Today in partnership with @TaihoOncology and Taiho Pharmaceutical, we announced first-line
@CullinanTx · 2026-09-13 · OCR
Great science and fun times at @IASLC #WCLC2026. https://t.co/FqyaOvoGr6
@deeptibehl1 · 2026-09-13 · OCR
Great science and fun times at @IASLC #WCLC2026. https://t.co/FqyaOvoGr6
@deeptibehl1 · 2026-09-13 · OCR
@IASLC #WCLC2026 We found the … creature? Mascot? With Rosalyn Juergens https://t.co/L3s
@LindaMThoracic · 2026-09-13 · OCR
WCLC（世界肺癌学会） 2026の大会長（Conference President / President of WCLC 2026）の共同大会長のアン・ミョンジュ先生と！！
@MSC_SAWADA · 2026-09-12 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CCR_AACR · 2026-09-13 · OCR
$SMMT - IVONESCIMAB'S SURVIVAL DATA IS OUT: A CLEAR WIN IN ONE GROUP OF PATIENTS, UNPROVEN
@Enkhmanal · 2026-09-14 · OCR
So excited for @YusooLee_ who gave an excellent talk on his work in my lab at #WCLC26 (in
@PeggyPHsu · 2026-09-13 · OCR
So excited for @YusooLee_ who gave an excellent talk on his work in my lab at #WCLC26 (in
@PeggyPHsu · 2026-09-13 · OCR
🆕 New Phase 3 results at #WCLC26 could open another first-line option for EGFR exon 20 ins
@EgfrUk · 2026-09-14 · OCR
At IASLC’s #WCLC26, we will present results from the planned interim analysis of the Phase
@CullinanTx · 2026-09-11 · OCR
🔬 Morning Brief — 14 Sep 2026 Today's science and health desks bring planetary puzzles, a
@weadvertizers · 2026-09-13 · OCR
We're at @IASLC's World Conference on Lung Cancer, a conference that brings together the g
@CatalystForRare · 2026-09-12 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CCR_AACR · 2026-09-14 · OCR
Huge congratulations to Ángeles Gil (@angelesgilg) on receiving the @IASLC Early Career Aw
@CruzAPhD · 2026-09-12 · OCR
At #WCLC26, we're excited to highlight 2 new posters: one on the clinical impact of NGS &
@FoundationATCG · 2026-09-12 · OCR
At #WCLC26, we're excited to highlight 2 new posters: one on the clinical impact of NGS &
@FoundationATCG · 2026-09-12 · OCR
👏 Congratulations to Prof. @LBadia5364 on receiving the 2026 Adi F. Gazdar IASLC Merit Aw
@CIMA_unav · 2026-09-14 · OCR
MET drives resistance across multiple tumor types. In lung cancer, mainly NSCLC, it emerge
@metcrusaders · 2026-09-14 · OCR
Congrats @sandraturner49 #WARD #WCLC26 LATAM with you ☢️💪 @Solar_Latam https://t.co/6G
@barrosonco · 2026-09-13 · OCR
🫁 Plenary session on EGFR Exon 20 ins #NSCLC data at #WCLC26 with abstract discussion by
@sophiawongyn · 2026-09-14 · OCR
🫁 Plenary session on EGFR Exon 20 ins #NSCLC data at #WCLC26 with abstract discussion by
@sophiawongyn · 2026-09-14 · OCR
🫁 Plenary session on EGFR Exon 20 ins #NSCLC data at #WCLC26 with abstract discussion by
@sophiawongyn · 2026-09-14 · OCR
🫁 Plenary session on EGFR Exon 20 ins #NSCLC data at #WCLC26 with abstract discussion by
@sophiawongyn · 2026-09-14 · OCR
Outstanding talk by Dr. Yeon Wook Kim @kimyw_snu_pulm on challenges and advances in #lungc
@aebchang · 2026-09-12 · OCR
Biopharma reaches new milestones as ivonescimab tops Keytruda in a landmark head-to-head l
@GeneOnlineNews · 2026-09-14 · OCR
Biopharma reaches new milestones as ivonescimab tops Keytruda in a landmark head-to-head l
@GeneOnlineNews · 2026-09-14 · OCR
🚨 HER2. New targets. New possibilities. 🔥 What’s next for HER2-overexpressing NSCLC? Jo
@SpeakJen · 2026-09-10 · OCR
#News for #Investors and #Media: At #WCLC26, we’re sharing new data across four abstracts
@BeOneMedicines · 2026-09-13 · OCR
Join us at #WCLC26 as @LuisPaz_Ares and @DrMarkAwad present the ROSETTA Lung-201 and ROSET
@ScienceAtBMS · 2026-09-13 · OCR
@BrainTumorDoc from @BaptistHealthSF #HebertWertheimCancerInstitute discusses his work in
@BrunaPellini · 2026-09-13 · OCR
I’ve got my Hear Her pin, do you? I may not treat patients, but I’m proud to support this
@CarolineM_Sey · 2026-09-13 · OCR
I’ve got my Hear Her pin, do you? I may not treat patients, but I’m proud to support this
@CarolineM_Sey · 2026-09-13 · OCR
🏆 Gearing up for the @IASLC #WCLC26 Opening Plenary and Distinguished Service Award Presen
@cancer_nurses · 2026-09-12 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CR_AACR · 2026-09-12 · OCR
Join us at #WCLC26 for Poster P2.256: Real-world outcomes with chemoradiation and durvalum
@LillyOncMed · 2026-09-11 · OCR
We’re in Seoul for #WCLC26, joining the global conversation on lung cancer. We’re sharing
@BeOneMedicines · 2026-09-11 · OCR
Dr. Matthew Meyerson opening #wclc2026 with a reminder of the poetry of science. @IASLC Se
@LAGurwitch · 2026-09-13 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CIR_AACR · 2026-09-12 · OCR
Thanks @IASLC for a wonderful #wclc26. Grateful to present our research on PRMT5 and MTAP
@md_hsu · 2026-09-16 · OCR
Thanks @IASLC for a wonderful #wclc26. Grateful to present our research on PRMT5 and MTAP
@md_hsu · 2026-09-16 · OCR
Thanks @IASLC for a wonderful #wclc26. Grateful to present our research on PRMT5 and MTAP
@md_hsu · 2026-09-16 · OCR
Thanks @IASLC for a wonderful #wclc26. Grateful to present our research on PRMT5 and MTAP
@md_hsu · 2026-09-16 · OCR
Presenting at #WCLC26 today during the MO05 session was an absolute honor and an unforgett
@angelesgilg · 2026-09-14 · OCR
We’re onsite at #WCLC26, speaking with leading experts about the studies and emerging data
@Onco_Nexus · 2026-09-12 · OCR
🟩⬜🟩 Destacada presencia andaluza en la World Conference on Lung Cancer (WCLC 2026), cita c
@saom_oncologia · 2026-09-15 · OCR
#wclc2026 great data and discussions in new era of SCLC treatment 1. Maverick trial puts a
@BZhangMD · 2026-09-13 · OCR
#wclc2026 great data and discussions in new era of SCLC treatment 1. Maverick trial puts a
@BZhangMD · 2026-09-13 · OCR
#wclc2026 great data and discussions in new era of SCLC treatment 1. Maverick trial puts a
@BZhangMD · 2026-09-13 · OCR
#wclc2026 great data and discussions in new era of SCLC treatment 1. Maverick trial puts a
@BZhangMD · 2026-09-13 · OCR
📍#WCLC2026: SWOG S1827/MAVERICK may reshape the role of PCI in SCLC. Among patients witho
@SakditadMD · 2026-09-14 · OCR
📍#WCLC2026: SWOG S1827/MAVERICK may reshape the role of PCI in SCLC. Among patients witho
@SakditadMD · 2026-09-14 · OCR
📍#WCLC2026: SWOG S1827/MAVERICK may reshape the role of PCI in SCLC. Among patients witho
@SakditadMD · 2026-09-14 · OCR
📍#WCLC2026: SWOG S1827/MAVERICK may reshape the role of PCI in SCLC. Among patients witho
@SakditadMD · 2026-09-14 · OCR
Welcome to the ES21 #WCLC26 starting from 16:45 today! RT innovation, immunotherapy, MRD-
@DrHongchengZhu · 2026-09-13 · OCR
Wrapping up an inspiring #WCLC26 in Seoul 🇰🇷 Two posters presented, a podcast recorded, t
@CMHidalgoFilho · 2026-09-15 · OCR
Wrapping up an inspiring #WCLC26 in Seoul 🇰🇷 Two posters presented, a podcast recorded, t
@CMHidalgoFilho · 2026-09-15 · OCR
Wrapping up an inspiring #WCLC26 in Seoul 🇰🇷 Two posters presented, a podcast recorded, t
@CMHidalgoFilho · 2026-09-15 · OCR
Wrapping up an inspiring #WCLC26 in Seoul 🇰🇷 Two posters presented, a podcast recorded, t
@CMHidalgoFilho · 2026-09-15 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CR_AACR · 2026-09-13 · OCR
The long awaited MAVERICK trial results are out❗️ 🧠 MRI surveillance +/- PCI in SCLC (n=3
@drviviantan · 2026-09-13 · OCR
The long awaited MAVERICK trial results are out❗️ 🧠 MRI surveillance +/- PCI in SCLC (n=3
@drviviantan · 2026-09-13 · OCR
ROCHE PONE EL FOCO EN LA SEGUNDA LÍNEA DEL SMALL CELL LUNG CANCER CON SU NUEVA APUESTA: T
@pharma_jonpi · 2026-09-15 · OCR
All set for the session! If you at at #WCLC26 , come hear the advocates speak ! @IASLC @Lu
@oceanblue11oct · 2026-09-13 · OCR
Excited to share our work on immune cell infiltrates in EGFR NSCLC led by @TaliAzen @Patel
@ThinkingCancer · 2026-09-14 · OCR
Excited to share our work on immune cell infiltrates in EGFR NSCLC led by @TaliAzen @Patel
@ThinkingCancer · 2026-09-14 · OCR
Live from #WCLC26! 📸 Our team is all set at Booth #706. Drop by to connect, share insights
@Cancers_MDPI · 2026-09-12 · OCR
@TonyFelefly @DrewMoghanaki @StephenVLiu We are still early on OS. Median OS is 30 mos.
@PDBrownOnc · 2026-09-13 · OCR
We're excited to be at the World Conference on Lung Cancer in Seoul! Visit Scanlan at Exhi
@ScanlanInc · 2026-09-10 · OCR
Four ribbons, four roles - but one purpose: to make lung cancer care more patient-centric,
@R2SurviveCancer · 2026-09-13 · OCR
$IBRX ImmunityBio is attending the World Conference on Lung Cancer in Seoul from Sept.12
@BertrandPirel · 2026-09-14 · OCR
Landmark, practice-changing data at @IASLC #WCLC26! 🚨 The Phase 3 MAVERIC trial compared P
@YasarHammor · 2026-09-13 · OCR
Landmark, practice-changing data at @IASLC #WCLC26! 🚨 The Phase 3 MAVERIC trial compared P
@YasarHammor · 2026-09-13 · OCR
Dusty is in Seoul, South Korea for the World Conference on Lung Cancer! We can’t wait to h
@LiveLung1 · 2026-09-11 · OCR
Join us tomorrow at #WCLC2026 for a mini-oral presentation featuring long-term PFS and OS
@ScienceAtBMS · 2026-09-12 · OCR
Today’s official #WCLC2026 press program featured results from our global Phase 1 randomiz
@ScienceAtBMS · 2026-09-12 · OCR
Advancing Innovation in Small Cell Lung Cancer at WCLC 2026 – Amgen @Amgen https://t.co
@OncoDailyBio · 2026-09-13 · OCR
An important result from WCLC 2026 that could change clinical practice! Presented at the
@dr_dirican · 2026-09-15 · OCR
MAVERICK challenges the role of PCI in SCLC. Primary endpoint: MRI surveillance alone imp
@Niccolo_Manjuba · 2026-09-12 · OCR
8-year OS update from ADAURA @WCLC2026 Still such an amazing story! https://t.co/JhOa2qZFg
@TejaVorugantiMD · 2026-09-13 · OCR
We presented 10 #LungCancer research studies at the IASLC 2026 World Conference on Lung Ca
@GO2forLungCancr · 2026-09-15 · OCR
Busy and exciting Exon 20 morning at #WCLC2026. Send your EGFR exon 20 insertion patients
@Exon20Group · 2026-09-14 · OCR
Representing 🇨🇦🇦🇺 at #WCLC2026 https://t.co/KX6q0AoH9k
@drviviantan · 2026-09-15 · OCR
Representing 🇨🇦🇦🇺 at #WCLC2026 https://t.co/KX6q0AoH9k
@drviviantan · 2026-09-15 · OCR
On September 14, Cullinan will host a virtual analyst and investor webcast to showcase zip
@CullinanTx · 2026-09-10 · OCR
Great to see familiar faces at #WCLC2026! 📸 Our team met with Associate Editor Dr. Snow a
@CurrentOncology · 2026-09-14 · OCR
Great to see familiar faces at #WCLC2026! 📸 Our team met with Associate Editor Dr. Snow a
@CurrentOncology · 2026-09-14 · OCR
India has 5.7% of the global lung cancer burden - but accounts for only 1.41% of global lu
@R2SurviveCancer · 2026-09-13 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CIR_AACR · 2026-09-12 · OCR
Couldn’t miss the experts discuss the future of liquid biopsy! #WCLC26 https://t.co/8Y1lZy
@TejaVorugantiMD · 2026-09-14 · OCR
📸 Great catching up with so many esteemed researchers and experts in the lung cancer commu
@Cancers_MDPI · 2026-09-14 · OCR
📸 Great catching up with so many esteemed researchers and experts in the lung cancer commu
@Cancers_MDPI · 2026-09-14 · OCR
Dr. Kazerooni @ellakaz with a tour de force on how to maximize the clinical impact of the
@aebchang · 2026-09-12 · OCR
At ES20, Sybil offered a compelling example of AI-enabled lung cancer screening. Using a s
@Dr_Ivanoncologo · 2026-09-13 · OCR
🤗We were delighted to meet with our editors in person at #WCLC2026! Thank you for the ins
@Cancers_MDPI · 2026-09-15 · OCR
🤗We were delighted to meet with our editors in person at #WCLC2026! Thank you for the ins
@Cancers_MDPI · 2026-09-15 · OCR
#WCLC2026 https://t.co/MzpSWvgByr
@MSC_SAWADA · 2026-09-14 · OCR
Eight-year ADAURA data are in. In resected stage IB–IIIA EGFR+ #lungcancer, estimated 8-y
@EgfrUk · 2026-09-15 · OCR
An outstanding Presidential Symposium 2 at #WCLC26. ARROS-1 is evaluating zidesamtinib, an
@Dr_Ivanoncologo · 2026-09-15 · OCR
Smile competition with the #WCLC26 Mascot… I think we both came prepared! 😄🐼 https://t.co
@R2SurviveCancer · 2026-09-13 · OCR
@NarjustFlorezMD @IASLC @AnaVManana @DrewMoghanaki @drshieldsmd @GlopesMd @fabiomoraesmd @
@hari_keshava · 2026-09-12 · OCR
Could not agree more with Dr. Heuvelmans—an impressive AUC is not sufficient to implement
@aebchang · 2026-09-12 · OCR
At ES09, one message stood out: precision oncology in metastatic NSCLC is not a one-time m
@Dr_Ivanoncologo · 2026-09-13 · OCR
Today at @IASLC's #WCLC2026, we presented updated data from our ongoing Phase 1/2 SOLARA t
@bhtherapeutics · 2026-09-15 · OCR
Today at @IASLC's #WCLC2026, we presented updated data from our ongoing Phase 1/2 SOLARA t
@bhtherapeutics · 2026-09-15 · OCR
🇰🇷 Day one at the #WCLC2026 in Seoul, proudly representing @ros1dersuk. Already learned
@ros1dersuk · 2026-09-12 · OCR
🇰🇷 Day one at the #WCLC2026 in Seoul, proudly representing @ros1dersuk. Already learned
@ros1dersuk · 2026-09-12 · OCR
🇰🇷 Day one at the #WCLC2026 in Seoul, proudly representing @ros1dersuk. Already learned
@ros1dersuk · 2026-09-12 · OCR
🇰🇷 Day one at the #WCLC2026 in Seoul, proudly representing @ros1dersuk. Already learned
@ros1dersuk · 2026-09-12 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@BCD_AACR · 2026-09-11 · OCR
A provocative point from #WCLC26: In borderline resectable NSCLC, only 62% ultimately und
@Niccolo_Manjuba · 2026-09-13 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@BCD_AACR · 2026-09-11 · OCR
📢Landmark 8-year update from the Phase III ADAURA trial Adjuvant osimertinib continues to
@OncologyCentral · 2026-09-14
What would I do…? My coverage is from the other side of the table: what would I do with th
@salgueiromp · 2026-09-13 · OCR
@DrRoyHerbst provided excellent updated analysis of ADAURA - Stage IB-IIIA (8yr OS Osi 79%
@OncWithGrant · 2026-09-13 · OCR
@DrRoyHerbst provided excellent updated analysis of ADAURA - Stage IB-IIIA (8yr OS Osi 79%
@OncWithGrant · 2026-09-13 · OCR
@DrRoyHerbst provided excellent updated analysis of ADAURA - Stage IB-IIIA (8yr OS Osi 79%
@OncWithGrant · 2026-09-13 · OCR
@DrRoyHerbst provided excellent updated analysis of ADAURA - Stage IB-IIIA (8yr OS Osi 79%
@OncWithGrant · 2026-09-13 · OCR
Thank you, @DrAlexLouie for visiting our booth at #WCLC2026 and for the engaging discussio
@CurrentOncology · 2026-09-15 · OCR
Thank you, @DrAlexLouie for visiting our booth at #WCLC2026 and for the engaging discussio
@CurrentOncology · 2026-09-15 · OCR
👉 Presented at #WCLC26. 👉Phase III MAVERICK 👉No improvement in OS with PCI for SCLC, acr
@EiocOncology · 2026-09-13 · OCR
Congratulstions on a well deserved Award! #WCLC2026 https://t.co/YZyVYwCZGA
@RRamiPorta · 2026-09-10 · OCR
@_ShankarSiva @DrewMoghanaki The cumulative incidence of BM was higher with MRI-only. My g
@TonyFelefly · 2026-09-13 · OCR
Updated @abbvie #NSCLC data on PD-1 and VEGF bispecific antibody plus Chemotherapy in Firs
@AbbVieUSOncMed · 2026-09-14 · OCR
$IBRX ImmunityBio’s robust fundamentals are structurally reinforced by a series of high-v
@BertrandPirel · 2026-09-15 · OCR
Honored to present our work on extracellular vesicle biomarkers for indeterminate pulmonar
@TKato_Thoracic · 2026-09-13 · OCR
Congratulations to my colleague Dr.Alison Wallace, leading a debate on whether to convert
@pmarignani · 2026-09-14 · OCR
Congratulations to Michael Rosario, PGY2, on his poster presentation at IASLC 2026 World C
@DHPathRes · 2026-09-16 · OCR
世界肺がん学会@ソウル #WCLC2026 https://t.co/jRCFpKENKB
@yonefunk · 2026-09-12 · OCR
Big Pharma is licensing tens of billions in cancer drugs from Chinese biotechs — and it's
@Blackintus · 2026-09-14
You can't match a MET drug to a patient until you find the MET alteration and know which o
@metcrusaders · 2026-09-13 · OCR
Collaborative registry of LCS in Argentina #wclc2026 #IASLC https://t.co/mkFHEUEgP6
@boyeras · 2026-09-13 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@MCR_AACR · 2026-09-13 · OCR
🌇 We're gearing up for another great day at @IASLC #WCLC26 in Seoul! 🌟 Stay tuned for our
@cancer_nurses · 2026-09-12 · OCR
🌇 We're gearing up for another great day at @IASLC #WCLC26 in Seoul! 🌟 Stay tuned for our
@cancer_nurses · 2026-09-12 · OCR
🌇 We're gearing up for another great day at @IASLC #WCLC26 in Seoul! 🌟 Stay tuned for our
@cancer_nurses · 2026-09-12 · OCR
🌇 We're gearing up for another great day at @IASLC #WCLC26 in Seoul! 🌟 Stay tuned for our
@cancer_nurses · 2026-09-12 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CRC_AACR · 2026-09-14 · OCR
Iscriviti al webinar gratuito SEOUL TALKS. Riflessioni sui principali risultati presentati
@ACCMEDorg · 2026-09-14 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@MCR_AACR · 2026-09-13 · OCR
Looking forward to sharing our work at #WCLC2026! I’ll be presenting two @FairLifeLCC pro
@KORINAPATELI · 2026-09-11 · OCR
Join the World Conference on Lung Cancer (WCLC) 2026 and connect with global experts drivi
@SSO_Singapore · 2026-09-12 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@MCT_AACR · 2026-09-13 · OCR
Ready ! #wclc2026 #seoul https://t.co/9DIUPn2EwQ
@boyeras · 2026-09-12 · OCR
🧬 BIOTECH WATCHLIST FOR TOMORROW If money rotates into higher-risk/high-reward sectors, b
@ChrisDaltonMacr · 2026-09-15 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@MCT_AACR · 2026-09-14 · OCR
🌏🔬 TRACKER PhD Candidate Dr Sarah Yeo is in Seoul for #WCLC2026, supported by the Rosemary
@TRACKERbiobank · 2026-09-14 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CRC_AACR · 2026-09-14 · OCR
PrE0510 is a randomized phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab w
@PrECOGonc · 2026-09-11 · OCR
Tomorrow at #WCLC2026: Join Zosia Piotrowska, Aaron C. Tan, and Jon Zugazagoitia for a cas
@PeerVoice · 2026-09-12 · OCR
At #WCLC26, the Phase III REZILIENT3 trial evaluated zipalertinib + chemotherapy as 1L tre
@dr_dirican · 2026-09-16 · OCR
At #WCLC26, the Phase III REZILIENT3 trial evaluated zipalertinib + chemotherapy as 1L tre
@dr_dirican · 2026-09-16 · OCR
Potential benefits and harms of LCS in Argentina. POSTER SESSION. This one was selected as
@boyeras · 2026-09-13 · OCR
Demonstrating my poor motor skills 😆 #wclc2026 https://t.co/xOMnTlmfck
@pam_patdu · 2026-09-12 · OCR
🏆 My first #WCLC, my first award! Truly honored to receive the WCLC 2026 Early Career Edu
@prorpan_12 · 2026-09-13 · OCR
🏆 My first #WCLC, my first award! Truly honored to receive the WCLC 2026 Early Career Edu
@prorpan_12 · 2026-09-13 · OCR
🏆 My first #WCLC, my first award! Truly honored to receive the WCLC 2026 Early Career Edu
@prorpan_12 · 2026-09-13 · OCR
🏆 My first #WCLC, my first award! Truly honored to receive the WCLC 2026 Early Career Edu
@prorpan_12 · 2026-09-13 · OCR
That's a wrap! The GLCC Members' Meeting has closed, having agreed our work for the next 1
@globalungcancer · 2026-09-11 · OCR
Dr. @WadeIams is attending #WCLC2026 this weekend in Seoul, where he’ll participate in sev
@theGHCR · 2026-09-10 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CAPR_AACR · 2026-09-12 · OCR
From #WCLC26 We presented our data on cytisine for tobacco cessation in adults >65 yo: one
@Max_Cani · 2026-09-14 · OCR
Worth following if you track where MET-altered research is headed #WCLC26 Monday Sessions
@metcrusaders · 2026-09-14 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CAPR_AACR · 2026-09-13 · OCR
NCARD research at #WCLC26, Seoul: neoantigen-specific T cells are found across tumour, lym
@NCARD_research · 2026-09-15 · OCR
@PDBrownOnc @TonyFelefly @DrewMoghanaki @StephenVLiu I know that the below is "estimated"
@ProtonStorey · 2026-09-13 · OCR
$IBRX ImmunityBio will present at two major investor and medical conferences: the World Co
@JesseGreenc1de · 2026-09-14 · OCR
Proud to see my work cited by #AstraZeneca in reporting the results of the Phase III #DeLL
@ShalataWalid · 2026-09-15 · OCR
Proud to see my work cited by #AstraZeneca in reporting the results of the Phase III #DeLL
@ShalataWalid · 2026-09-15 · OCR
#GILD / #GILEAD SCIENCES, INC. — EQUITY DEEP DIVE September 15, 2026 | USD throughout Quot
@Alfred3o3 · 2026-09-15 · OCR
Reunited in Seoul for #WCLC2026! 🇰🇷 Beyond excited to catch up with global friends and col
@ConnieLaiKY · 2026-09-13 · OCR
Reunited in Seoul for #WCLC2026! 🇰🇷 Beyond excited to catch up with global friends and col
@ConnieLaiKY · 2026-09-13 · OCR
This looks a lot better. Now let's see if ivonescimab OS outside Asia holds up https://t.c
@shaypaintal · 2026-09-15 · OCR
#WCLC2026 highlighted expanding biomarker-directed therapy, greater emphasis on intracrani
@iremkaramanMD · 2026-09-16 · OCR
Thank you to Zosia Piotrowska, Aaron C. Tan & Jon Zugazagoitia for an outstanding #WCLC202
@PeerVoice · 2026-09-14 · OCR
Recrutando no centro de pesquisa CIONC -Curitiba #WCLC26 https://t.co/W82SWMS5X8
@KarinaVian3031 · 2026-09-13 · OCR
James Hamrick Highlights Caris Life Sciences and Precision Oncology Alliance Research at W
@OncoDailyBio · 2026-09-13 · OCR
Mr @CalebEgwuenu , a commissioner on the #IASLC Lancet Commission, attended the planning m
@macafricaorg · 2026-09-11 · OCR
Look who all we met at WCLC 2026 @_ShankarSiva @DrewMoghanaki @lungoncdoc @sureshsenan @bj
@sujanapriya · 2026-09-16 · OCR
Look who all we met at WCLC 2026 @_ShankarSiva @DrewMoghanaki @lungoncdoc @sureshsenan @bj
@sujanapriya · 2026-09-16 · OCR
Look who all we met at WCLC 2026 @_ShankarSiva @DrewMoghanaki @lungoncdoc @sureshsenan @bj
@sujanapriya · 2026-09-16 · OCR
Look who all we met at WCLC 2026 @_ShankarSiva @DrewMoghanaki @lungoncdoc @sureshsenan @bj
@sujanapriya · 2026-09-16 · OCR
Visit @AACR Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest
@CEBP_AACR · 2026-09-11 · OCR
Presentes en el #WCLC 2026 (Congreso Mundial de Cáncer de Pulmón), Seúl, Corea del Sur 🇰🇷
@detectoincan · 2026-09-15 · OCR
We are proud that our Executive Director at Move Against Cancer Africa (MACA), Mr. @CalebE
@macafricaorg · 2026-09-14 · OCR
We are proud that our Executive Director at Move Against Cancer Africa (MACA), Mr. @CalebE
@macafricaorg · 2026-09-14 · OCR
We are proud that our Executive Director at Move Against Cancer Africa (MACA), Mr. @CalebE
@macafricaorg · 2026-09-14 · OCR
We are proud that our Executive Director at Move Against Cancer Africa (MACA), Mr. @CalebE
@macafricaorg · 2026-09-14 · OCR
📣 Poster P2.141 | #WCLC2026 Heading to the poster sessions in Seoul today? Be sure to lo
@TRACKERbiobank · 2026-09-14 · OCR
Read the Hot Topics article collections, featuring impactful, cutting-edge research publis
@CEBP_AACR · 2026-09-11 · OCR
SALTÓ LA SORPRESA EN EL WCLC26 EL LIDERAZGO GLOBAL DEL TARLATAMAB (AMGEN) COMO TREATMENT
@pharma_jonpi · 2026-09-13 · OCR
SALTÓ LA SORPRESA EN EL WCLC26 EL LIDERAZGO GLOBAL DEL TARLATAMAB (AMGEN) COMO TREATMENT
@pharma_jonpi · 2026-09-13 · OCR
Dr. @WadeIams, Director of Lung Cancer Research, represented GHCR at #WCLC26 in Seoul! 🌎
@theGHCR · 2026-09-14 · OCR
🆙 #WCLC26 #LCSM | MO06.04 raises an interesting question for EGFR-mutant NSCLC: In the TP5
@EmreCakirMD · 2026-09-16 · OCR
🆙 #WCLC26 #LCSM | MO06.04 raises an interesting question for EGFR-mutant NSCLC: In the TP5
@EmreCakirMD · 2026-09-16 · OCR
🆙 #WCLC26 #LCSM | MO06.04 raises an interesting question for EGFR-mutant NSCLC: In the TP5
@EmreCakirMD · 2026-09-16 · OCR
🆙 #WCLC26 #LCSM | MO06.04 raises an interesting question for EGFR-mutant NSCLC: In the TP5
@EmreCakirMD · 2026-09-16 · OCR
Looking forward to joining this #WCLC26 session on personalizing local therapy in oligomet
@Niccolo_Manjuba · 2026-09-12 · OCR
#PrecisionOncology will be at #WCLC2026 in Seoul, 12–15 September! Visit us at Booth 706
@precisonco_MDPI · 2026-09-13 · OCR
Phase 3 data Sep 13: Roche's new small-cell lung cancer drug cut the risk of death by 54%
@ETFGrowthHQ · 2026-09-16 · OCR
EGFR mutated lung cancer is teaching us an important lesson. At 8 years, ADAURA continues
@DrAlexEhsan · 2026-09-14 · OCR
We celebrate #NCCS clinicians and researchers presenting at the 2026 @IASLC World Conferen
@NCCS_SG · 2026-09-15 · OCR
B7 H3 may be changing the outlook for relapsed small cell lung cancer. In the Phase III A
@DrAlexEhsan · 2026-09-14 · OCR
🌏 That’s a wrap on #WCLC2026! Congratulations to Dr @stephenqwong on a fantastic poster, h
@TRACKERbiobank · 2026-09-15 · OCR
EGFR exon 20 insertion lung cancer has historically been difficult to treat. Phase III RE
@DrAlexEhsan · 2026-09-14 · OCR
ROS1 lung cancer shows why molecular testing can change everything. In ARROS 1, zidesamti
@DrAlexEhsan · 2026-09-14 · OCR
WCLC26 — Day 1 of the main event officially begins! Presidential Symposium I #WCLC26 htt
@hschao2 · 2026-09-12 · OCR
WCLC26 — Day 1 of the main event officially begins! Presidential Symposium I #WCLC26 htt
@hschao2 · 2026-09-12 · OCR
Al #WCLC2026 il dott. Giovanni Leuzzi presenterà uno studio che mostra come qualità di vit
@ALCASE_Italia · 2026-09-15 · OCR
@DrPatrick @ImmunityBio The science continues to drive the conversation. At #WCLC26, new
@__IBRX_ · 2026-09-16 · OCR
@DrPatrick @ImmunityBio The science continues to drive the conversation. At #WCLC26, new
@__IBRX_ · 2026-09-16 · OCR
#WCLC2026 | Can pleural effusion help when tissue is limited? With OncoCompass® Target, c
@BurningRock2014 · 2026-09-16 · OCR
Ivonescimab vs Pembrolizumab: New Data From HARMONi-2 in Advanced NSCLC – Summit Therapeut
@OncoDailyBio · 2026-09-16 · OCR
#WCLC2026 | Can multi-omics predict neoadjuvant response in LUSC? An OncoScreen®Plus & WT
@BurningRock2014 · 2026-09-16 · OCR
#WCLC2026 | Why can some ≤1 cm LUADs behave aggressively? OncoScreen® LungCore revealed e
@BurningRock2014 · 2026-09-16 · OCR
Taiho/Cullinan's zipalertinib + chemo cut progression/death risk 50% vs chemo alone in fir
@InsiLensCo · 2026-09-15
@IASLC  #WCLC26, #IASLCFoundation, #WellnessChallenge https://t.co/OspukGnGiy
@Smithduo3 · 2026-09-12 · OCR
🫁 Thank you, #WCLC26! It was a pleasure meeting researchers and healthcare professionals
@ClinPract_MDPI · 2026-09-16 · OCR
🫁 Thank you, #WCLC26! It was a pleasure meeting researchers and healthcare professionals
@ClinPract_MDPI · 2026-09-16 · OCR
🫁 Thank you, #WCLC26! It was a pleasure meeting researchers and healthcare professionals
@ClinPract_MDPI · 2026-09-16 · OCR
🫁 Thank you, #WCLC26! It was a pleasure meeting researchers and healthcare professionals
@ClinPract_MDPI · 2026-09-16 · OCR
Hyrnuo just moved to the FRONT of the line. Earlier access means targeted treatment reach
@KIRIAResearch · 2026-09-14 · OCR
Il nostro Presidente, Prof. Filippo Lococo, al Congresso Mondiale del Tumore del Polmone (
@ALCASE_Italia · 2026-09-16 · OCR
A Chinese Drug Beat the World's Best-Seller, Yet the Money Went Elsewhere. #AStock #ChinaS
@GangtiseAI · 2026-09-16 · OCR
A Chinese Drug Beat the World's Best-Seller, Yet the Money Went Elsewhere. #AStock #ChinaS
@GangtiseAI · 2026-09-16 · OCR
A Chinese Drug Beat the World's Best-Seller, Yet the Money Went Elsewhere. #AStock #ChinaS
@GangtiseAI · 2026-09-16 · OCR
Great to kick off #WCLC2026 with the joint @IASLC - @ESTRO_RT forum “Reimagining #radiothe
@_ShankarSiva · 2026-09-12 · OCR
Great to kick off #WCLC2026 with the joint @IASLC - @ESTRO_RT forum “Reimagining #radiothe
@_ShankarSiva · 2026-09-12 · OCR
Great to kick off #WCLC2026 with the joint @IASLC - @ESTRO_RT forum “Reimagining #radiothe
@_ShankarSiva · 2026-09-12 · OCR
Great to kick off #WCLC2026 with the joint @IASLC - @ESTRO_RT forum “Reimagining #radiothe
@_ShankarSiva · 2026-09-12 · OCR
Stage III #lungcancer receives the STARLORD treatment at #WCLC26. 〰️SABR to nodes up to 4
@_ShankarSiva · 2026-09-14 · OCR
Stage III #lungcancer receives the STARLORD treatment at #WCLC26. 〰️SABR to nodes up to 4
@_ShankarSiva · 2026-09-14 · OCR
#WCLC26 - as #radonc, we worry about excess adverse events when using induction chemo/IO i
@_ShankarSiva · 2026-09-14 · OCR
#WCLC26 - as #radonc, we worry about excess adverse events when using induction chemo/IO i
@_ShankarSiva · 2026-09-14 · OCR
#WCLC26 - as #radonc, we worry about excess adverse events when using induction chemo/IO i
@_ShankarSiva · 2026-09-14 · OCR
✈️Bye for now 🇰🇷 #WCLC26! A quick side quest to Shanghai 🇨🇳 give a talk to my colleague
@_ShankarSiva · 2026-09-12 · OCR
✈️Bye for now 🇰🇷 #WCLC26! A quick side quest to Shanghai 🇨🇳 give a talk to my colleague
@_ShankarSiva · 2026-09-12 · OCR
✈️Bye for now 🇰🇷 #WCLC26! A quick side quest to Shanghai 🇨🇳 give a talk to my colleague
@_ShankarSiva · 2026-09-12 · OCR
Wonderful memories of #WCLC26 -so good to connect with my international colleagues and 🌎fr
@_ShankarSiva · 2026-09-15 · OCR
Wonderful memories of #WCLC26 -so good to connect with my international colleagues and 🌎fr
@_ShankarSiva · 2026-09-15 · OCR
Wonderful memories of #WCLC26 -so good to connect with my international colleagues and 🌎fr
@_ShankarSiva · 2026-09-15 · OCR
Wonderful memories of #WCLC26 -so good to connect with my international colleagues and 🌎fr
@_ShankarSiva · 2026-09-15 · OCR
@DrewMoghanaki as discussant for session #WCLC26- highlighting perspectives of med, #radon
@_ShankarSiva · 2026-09-14 · OCR
@DrewMoghanaki as discussant for session #WCLC26- highlighting perspectives of med, #radon
@_ShankarSiva · 2026-09-14 · OCR
@DrewMoghanaki as discussant for session #WCLC26- highlighting perspectives of med, #radon
@_ShankarSiva · 2026-09-14 · OCR
@DrewMoghanaki as discussant for session #WCLC26- highlighting perspectives of med, #radon
@_ShankarSiva · 2026-09-14 · OCR
When life gives you flight delays… It’s yum cha time! #WCLC26 https://t.co/Mfhh7PEHd7
@anmwongNZ · 2026-09-10 · OCR
📸 Go get your hanbok photoshoot w 🫁besties @IASLC #WCLC26 @DKarikios Back of poster hall
@anmwongNZ · 2026-09-14 · OCR
📸 Go get your hanbok photoshoot w 🫁besties @IASLC #WCLC26 @DKarikios Back of poster hall
@anmwongNZ · 2026-09-14 · OCR
📸 Go get your hanbok photoshoot w 🫁besties @IASLC #WCLC26 @DKarikios Back of poster hall
@anmwongNZ · 2026-09-14 · OCR
Language matters Stigma matters @drCarterBawa breaks it down @IASLC #WCLC26 @DrewMogha
@anmwongNZ · 2026-09-13 · OCR
Language matters Stigma matters @drCarterBawa breaks it down @IASLC #WCLC26 @DrewMogha
@anmwongNZ · 2026-09-13 · OCR
Language matters Stigma matters @drCarterBawa breaks it down @IASLC #WCLC26 @DrewMogha
@anmwongNZ · 2026-09-13 · OCR
@IASLC plenary Phase III MAVERICK study: MRI improved cognitive failure free survival com
@anmwongNZ · 2026-09-12 · OCR
@IASLC plenary Phase III MAVERICK study: MRI improved cognitive failure free survival com
@anmwongNZ · 2026-09-12 · OCR
@IASLC plenary Phase III MAVERICK study: MRI improved cognitive failure free survival com
@anmwongNZ · 2026-09-12 · OCR
Absolutely loved loved loved #WCLC26 Wonder if we could use reusable conference lanyards?
@anmwongNZ · 2026-09-16 · OCR
Blown away by the 10 year effort of 🇨🇳 PNapp5A AI-tools studying >150k pts w pulmonary nod
@anmwongNZ · 2026-09-12 · OCR
Blown away by the 10 year effort of 🇨🇳 PNapp5A AI-tools studying >150k pts w pulmonary nod
@anmwongNZ · 2026-09-12 · OCR
Blown away by the 10 year effort of 🇨🇳 PNapp5A AI-tools studying >150k pts w pulmonary nod
@anmwongNZ · 2026-09-12 · OCR
Blown away by the 10 year effort of 🇨🇳 PNapp5A AI-tools studying >150k pts w pulmonary nod
@anmwongNZ · 2026-09-12 · OCR
Masterclass for CHANGE at our global policy session #WCLC26 📣 know your why 📣 reframe pr
@anmwongNZ · 2026-09-13 · OCR
Masterclass for CHANGE at our global policy session #WCLC26 📣 know your why 📣 reframe pr
@anmwongNZ · 2026-09-13 · OCR
Masterclass for CHANGE at our global policy session #WCLC26 📣 know your why 📣 reframe pr
@anmwongNZ · 2026-09-13 · OCR
Masterclass for CHANGE at our global policy session #WCLC26 📣 know your why 📣 reframe pr
@anmwongNZ · 2026-09-13 · OCR
One of my colleagues said “Equity is not really my thing” 👩🏻‍🔬Innovation is relevant only
@anmwongNZ · 2026-09-13 · OCR
One of my colleagues said “Equity is not really my thing” 👩🏻‍🔬Innovation is relevant only
@anmwongNZ · 2026-09-13 · OCR
One of my colleagues said “Equity is not really my thing” 👩🏻‍🔬Innovation is relevant only
@anmwongNZ · 2026-09-13 · OCR
One of my colleagues said “Equity is not really my thing” 👩🏻‍🔬Innovation is relevant only
@anmwongNZ · 2026-09-13 · OCR
🫰@boldcaleb’s talk on chronic & late-onset immunotherapy toxicity from patients’ perspecti
@anmwongNZ · 2026-09-14 · OCR
🫰@boldcaleb’s talk on chronic & late-onset immunotherapy toxicity from patients’ perspecti
@anmwongNZ · 2026-09-14 · OCR
🫰@boldcaleb’s talk on chronic & late-onset immunotherapy toxicity from patients’ perspecti
@anmwongNZ · 2026-09-14 · OCR
🫰@boldcaleb’s talk on chronic & late-onset immunotherapy toxicity from patients’ perspecti
@anmwongNZ · 2026-09-14 · OCR
And that’s a wrap on #WCLC26! 🇰🇷🫁 Had an unforgettable experience filled with insightful
@AwwadFa10 · 2026-09-15 · OCR
And that’s a wrap on #WCLC26! 🇰🇷🫁 Had an unforgettable experience filled with insightful
@AwwadFa10 · 2026-09-15 · OCR
And that’s a wrap on #WCLC26! 🇰🇷🫁 Had an unforgettable experience filled with insightful
@AwwadFa10 · 2026-09-15 · OCR
And that’s a wrap on #WCLC26! 🇰🇷🫁 Had an unforgettable experience filled with insightful
@AwwadFa10 · 2026-09-15 · OCR
Enjoying the e-poster sessions at #WCLC2026, with the presentation by @JamesFanWu on the e
@AwwadFa10 · 2026-09-13 · OCR
Enjoying the e-poster sessions at #WCLC2026, with the presentation by @JamesFanWu on the e
@AwwadFa10 · 2026-09-13 · OCR
Enjoying the e-poster sessions at #WCLC2026, with the presentation by @JamesFanWu on the e
@AwwadFa10 · 2026-09-13 · OCR
Wrapping up an incredible Day 1 at #WCLC2026 here in Seoul! 🇰🇷🫁 Grateful for the amazing
@AwwadFa10 · 2026-09-12 · OCR
Wrapping up an incredible Day 1 at #WCLC2026 here in Seoul! 🇰🇷🫁 Grateful for the amazing
@AwwadFa10 · 2026-09-12 · OCR
Wrapping up an incredible Day 1 at #WCLC2026 here in Seoul! 🇰🇷🫁 Grateful for the amazing
@AwwadFa10 · 2026-09-12 · OCR
Wrapping up an incredible Day 1 at #WCLC2026 here in Seoul! 🇰🇷🫁 Grateful for the amazing
@AwwadFa10 · 2026-09-12 · OCR
A highlight of #WCLC26 🇰🇷 was being honored with the Developing Countries Education Award.
@AwwadFa10 · 2026-09-16 · OCR
A highlight of #WCLC26 🇰🇷 was being honored with the Developing Countries Education Award.
@AwwadFa10 · 2026-09-16 · OCR
A highlight of #WCLC26 🇰🇷 was being honored with the Developing Countries Education Award.
@AwwadFa10 · 2026-09-16 · OCR
A highlight of #WCLC26 🇰🇷 was being honored with the Developing Countries Education Award.
@AwwadFa10 · 2026-09-16 · OCR
Seoul, the city that you are. 🇰🇷🤍 #WCLC26 https://t.co/wctj63LfGM
@AwwadFa10 · 2026-09-14 · OCR
Seoul, the city that you are. 🇰🇷🤍 #WCLC26 https://t.co/wctj63LfGM
@AwwadFa10 · 2026-09-14 · OCR
Seoul, the city that you are. 🇰🇷🤍 #WCLC26 https://t.co/wctj63LfGM
@AwwadFa10 · 2026-09-14 · OCR
WCLC 2026 kapsamında, IASLC Küresel Konsey’in ilk toplantısına Türkiye Delegesi olarak kat
@aytenkayicangir · 2026-09-13 · OCR
WCLC 2026 kapsamında, IASLC Küresel Konsey’in ilk toplantısına Türkiye Delegesi olarak kat
@aytenkayicangir · 2026-09-13 · OCR
WCLC 2026 kapsamında, IASLC Küresel Konsey’in ilk toplantısına Türkiye Delegesi olarak kat
@aytenkayicangir · 2026-09-13 · OCR
“Farkındalığı Artırmak” çalışma grubunda farklı ülkelerden temsilcilerle ortak hedefimiz i
@aytenkayicangir · 2026-09-13 · OCR
“Farkındalığı Artırmak” çalışma grubunda farklı ülkelerden temsilcilerle ortak hedefimiz i
@aytenkayicangir · 2026-09-13 · OCR
“Farkındalığı Artırmak” çalışma grubunda farklı ülkelerden temsilcilerle ortak hedefimiz i
@aytenkayicangir · 2026-09-13 · OCR
Slide of #WCLC26 so far from terrific discussant Anne Chiang. Which bubble tea flavor to
@BalazsHalmosMD · 2026-09-13 · OCR
Slide of #WCLC26 so far from terrific discussant Anne Chiang. Which bubble tea flavor to
@BalazsHalmosMD · 2026-09-13 · OCR
The ruling emperor of thoracic oncology #WCLC26 @iaslc @StephenVLiu https://t.co/VKz4x3i9K
@BalazsHalmosMD · 2026-09-14 · OCR
With such impressive data of clinically meaningful and widening OS benefit (especially for
@BalazsHalmosMD · 2026-09-13 · OCR
With such impressive data of clinically meaningful and widening OS benefit (especially for
@BalazsHalmosMD · 2026-09-13 · OCR
With such impressive data of clinically meaningful and widening OS benefit (especially for
@BalazsHalmosMD · 2026-09-13 · OCR
Starting #WCLC26 in Gangnam..in style! The Korean BBQ…. and after
@BalazsHalmosMD · 2026-09-10 · OCR
Most ADAURAble long-term OS results of adj OSimertinib showing dramatic benefits! While w
@BalazsHalmosMD · 2026-09-13 · OCR
Most ADAURAble long-term OS results of adj OSimertinib showing dramatic benefits! While w
@BalazsHalmosMD · 2026-09-13 · OCR
Most ADAURAble long-term OS results of adj OSimertinib showing dramatic benefits! While w
@BalazsHalmosMD · 2026-09-13 · OCR
Most ADAURAble long-term OS results of adj OSimertinib showing dramatic benefits! While w
@BalazsHalmosMD · 2026-09-13 · OCR
A true Maverick trial asking can we avoid PCI in management of (both LS/ES) SCLC pts? Whi
@BalazsHalmosMD · 2026-09-12 · OCR
A true Maverick trial asking can we avoid PCI in management of (both LS/ES) SCLC pts? Whi
@BalazsHalmosMD · 2026-09-12 · OCR
A true Maverick trial asking can we avoid PCI in management of (both LS/ES) SCLC pts? Whi
@BalazsHalmosMD · 2026-09-12 · OCR
Slide of the meeting #WCLC26 What truly matters in oncology/medicine! https://t.co/RDFylT2
@BalazsHalmosMD · 2026-09-14 · OCR
Drilon drillin’ us w amazing data on freshly approved resistance mutation-CNS active/TRK-s
@BalazsHalmosMD · 2026-09-14 · OCR
Drilon drillin’ us w amazing data on freshly approved resistance mutation-CNS active/TRK-s
@BalazsHalmosMD · 2026-09-14 · OCR
Had a great time at @yonsei_u in #Seoul!Thanks to @MetastasisRS board member Henry Park fo
@BravoCorderoLab · 2026-09-10 · OCR
Had a great time at @yonsei_u in #Seoul!Thanks to @MetastasisRS board member Henry Park fo
@BravoCorderoLab · 2026-09-10 · OCR
Great talk today by Jaime Schneider @DrJaimeLaurel from Harvard Medical School @harvardmed
@BravoCorderoLab · 2026-09-14 · OCR
Great talk today by Jaime Schneider @DrJaimeLaurel from Harvard Medical School @harvardmed
@BravoCorderoLab · 2026-09-14 · OCR
Looking forward to speaking this Sunday at #WCLC26 @IASLC! Excited to share our work on #T
@BravoCorderoLab · 2026-09-12 · OCR
Looking forward to speaking this Sunday at #WCLC26 @IASLC! Excited to share our work on #T
@BravoCorderoLab · 2026-09-12 · OCR
In the Phase 3 IMpower030 trial presented at #WCLC26, perioperative atezolizumab + chemo m
@CancerTherAdvsr · 2026-09-14 · OCR
In the Phase 3 IMpower030 trial presented at #WCLC26, perioperative atezolizumab + chemo m
@CancerTherAdvsr · 2026-09-14 · OCR
‼️ Adding amivantamab to chemo improves OS in #NSCLC who have EGRF ex20ins OS and PFS imp
@CancerTherAdvsr · 2026-09-15 · OCR
‼️ Adding amivantamab to chemo improves OS in #NSCLC who have EGRF ex20ins OS and PFS imp
@CancerTherAdvsr · 2026-09-15 · OCR
Phase 3 REZILIENT3 trial results presented at #WCLC2026: Adding the TKI zipalertinib to 1
@CancerTherAdvsr · 2026-09-15 · OCR
New data from #WCLC26 found adding intercalating gefitinib to adjuvant platinum-based chem
@CancerTherAdvsr · 2026-09-14 · OCR
New data from #WCLC26 found adding intercalating gefitinib to adjuvant platinum-based chem
@CancerTherAdvsr · 2026-09-14 · OCR
WCLC 2026 | What am I watching? 🫁 Three spaces. 15 readouts worth watching. 🔹 Early NSCL
@ChandrakanthMv · 2026-09-12 · OCR
WCLC 2026 | What am I watching? 🫁 Three spaces. 15 readouts worth watching. 🔹 Early NSCL
@ChandrakanthMv · 2026-09-12 · OCR
WCLC 2026 | What am I watching? 🫁 Three spaces. 15 readouts worth watching. 🔹 Early NSCL
@ChandrakanthMv · 2026-09-12 · OCR
EGFR exon 20 insertion: the 1L landscape is getting crowded. Three Phase III strategies,
@ChandrakanthMv · 2026-09-14 · OCR
HARMONi-2: PFS benefit — now an OS benefit Ivonescimab (PD-1 × VEGF) vs pembrolizumab in
@ChandrakanthMv · 2026-09-13 · OCR
HARMONi-2: PFS benefit — now an OS benefit Ivonescimab (PD-1 × VEGF) vs pembrolizumab in
@ChandrakanthMv · 2026-09-13 · OCR
👑 Has King Keytruda finally met its challenger? HARMONi-2 | PD-L1 TPS ≥1% | 1L advanced N
@ChandrakanthMv · 2026-09-13 · OCR
MDT-BRIDGE: Treat First. Decide Surgery Later? A simple but interesting concept in locall
@ChandrakanthMv · 2026-09-12 · OCR
MDT-BRIDGE: Treat First. Decide Surgery Later? A simple but interesting concept in locall
@ChandrakanthMv · 2026-09-12 · OCR
SCLC: Do we still need PCI? 🧠 SWOG S1827 MAVERICK challenges routine PCI in the MRI era.
@ChandrakanthMv · 2026-09-13 · OCR
SCLC: Do we still need PCI? 🧠 SWOG S1827 MAVERICK challenges routine PCI in the MRI era.
@ChandrakanthMv · 2026-09-13 · OCR
WCLC 2026 🫁 | 4 names worth remembering. For NSCLC, remember the two Zs: ZIP → EGFR exon
@ChandrakanthMv · 2026-09-14 · OCR
MAVERICK — Is routine PCI still needed in SCLC? 🧠 1️⃣ Why PCI? SCLC loves the brain. Olde
@ChandrakanthMv · 2026-09-16 · OCR
MAVERICK — Is routine PCI still needed in SCLC? 🧠 1️⃣ Why PCI? SCLC loves the brain. Olde
@ChandrakanthMv · 2026-09-16 · OCR
MAVERICK — Is routine PCI still needed in SCLC? 🧠 1️⃣ Why PCI? SCLC loves the brain. Olde
@ChandrakanthMv · 2026-09-16 · OCR
MAVERICK — Is routine PCI still needed in SCLC? 🧠 1️⃣ Why PCI? SCLC loves the brain. Olde
@ChandrakanthMv · 2026-09-16 · OCR
EGFR+ AFTER SURGERY: TKI ALONE — OR ADD CHEMO? In resected EGFR-mutant NSCLC, intercalati
@ChandrakanthMv · 2026-09-12 · OCR
EGFR+ AFTER SURGERY: TKI ALONE — OR ADD CHEMO? In resected EGFR-mutant NSCLC, intercalati
@ChandrakanthMv · 2026-09-12 · OCR
ADAURA at 8 years: does the survival benefit last? After just 3 years of adjuvant osimert
@ChandrakanthMv · 2026-09-14 · OCR
ADAURA at 8 years: does the survival benefit last? After just 3 years of adjuvant osimert
@ChandrakanthMv · 2026-09-14 · OCR
ADAURA at 8 years: does the survival benefit last? After just 3 years of adjuvant osimert
@ChandrakanthMv · 2026-09-14 · OCR
IASLC or WCLC — what’s the difference? 🫁🌍 IASLC is the global society. WCLC is its flagsh
@ChandrakanthMv · 2026-09-12 · OCR
DESTINY-Lung04 🫁 Can T-DXd move up front in HER2-mutant advanced NSCLC? T-DXd vs pembrol
@ChandrakanthMv · 2026-09-14 · OCR
PCI in SCLC: how did the story evolve? 🧠 From PREVENT → WATCH → FIND → TREAT • 1999: PCI
@ChandrakanthMv · 2026-09-16 · OCR
MAVERICK — CAN MRI SURVEILLANCE REPLACE ROUTINE PCI? 🧠 SWOG S1827 MAVERICK was a randomiz
@ChandrakanthMv · 2026-09-13 · OCR
LOW-GRADE ≠ LOW IMPACT We grade severity. Patients live the impact. Even “mild” diarrhea
@ChandrakanthMv · 2026-09-12 · OCR
ADAURA — 8 years later, what really matters? Only 3 years of adjuvant osimertinib — yet t
@ChandrakanthMv · 2026-09-14 · OCR
What made MAVERICK different? • It re-asked the PCI question in the modern MRI era. • No
@ChandrakanthMv · 2026-09-16 · OCR
REZILIENT 3 — a meaningful PFS win in EGFR exon 20 insertion NSCLC. Zipalertinib + chemot
@ChandrakanthMv · 2026-09-14 · OCR
WCLC 2026 SCLC trials — captured in one cartoon as a memory hook. 🥋 Treating SCLC increas
@ChandrakanthMv · 2026-09-16 · OCR
IMpower030: favorable signals — but did perioperative atezolizumab actually win? In resec
@ChandrakanthMv · 2026-09-13 · OCR
IMpower030: favorable signals — but did perioperative atezolizumab actually win? In resec
@ChandrakanthMv · 2026-09-13 · OCR
Two B7-H3 ADCs. Two positive phase 3 trials. One striking signal in relapsed SCLC. At WCL
@ChandrakanthMv · 2026-09-13 · OCR
EVOKE-03: More responses — but no survival gain? Phase III | 620 patients with untreated
@ChandrakanthMv · 2026-09-13 · OCR
EVOKE-03: More responses — but no survival gain? Phase III | 620 patients with untreated
@ChandrakanthMv · 2026-09-13 · OCR
KRAS G12C BEFORE SURGERY: TARGET FIRST, OPERATE NEXT? NAUTIKA1 explores a simple concept:
@ChandrakanthMv · 2026-09-12 · OCR
🧠 MAVERICK — beyond the headline • SWOG S1827 MAVERICK asked whether routine PCI can be o
@ChandrakanthMv · 2026-09-13 · OCR
TAISHAN-302: B7-H3 enters the phase III SCLC arena. In relapsed SCLC after platinum-based
@ChandrakanthMv · 2026-09-13 · OCR
TAISHAN-302: B7-H3 enters the phase III SCLC arena. In relapsed SCLC after platinum-based
@ChandrakanthMv · 2026-09-13 · OCR
TAISHAN-302: B7-H3 enters the phase III SCLC arena. In relapsed SCLC after platinum-based
@ChandrakanthMv · 2026-09-13 · OCR
TAISHAN-302: B7-H3 enters the phase III SCLC arena. In relapsed SCLC after platinum-based
@ChandrakanthMv · 2026-09-13 · OCR
EVOKE-03: More response ≠ longer survival SG + pembrolizumab vs pembrolizumab in PD-L1 ≥5
@ChandrakanthMv · 2026-09-13 · OCR
🚨 ARROS-1: Zidesamtinib up front in ROS1+ NSCLC? In TKI-naïve advanced ROS1+ NSCLC, zides
@ChandrakanthMv · 2026-09-14 · OCR
🧠 MAVERICK asks a simple question: Do all patients with SCLC still need PCI — or can we w
@ChandrakanthMv · 2026-09-13 · OCR
ARTEMIS-008: B7-H3 delivers in relapsed SCLC. 🎯 Risvutatug rezetecan (Ris-Rez), a B7-H3–d
@ChandrakanthMv · 2026-09-13 · OCR
ARTEMIS-008: B7-H3 delivers in relapsed SCLC. 🎯 Risvutatug rezetecan (Ris-Rez), a B7-H3–d
@ChandrakanthMv · 2026-09-13 · OCR
ARTEMIS-008: B7-H3 delivers in relapsed SCLC. 🎯 Risvutatug rezetecan (Ris-Rez), a B7-H3–d
@ChandrakanthMv · 2026-09-13 · OCR
ARTEMIS-008: B7-H3 delivers in relapsed SCLC. 🎯 Risvutatug rezetecan (Ris-Rez), a B7-H3–d
@ChandrakanthMv · 2026-09-13 · OCR
Excellent presentation by @RobertoBoreaMD at #WCLC26 on our work on whole transcriptomics
@ChristianRolfo · 2026-09-15 · OCR
Excellent presentation by @RobertoBoreaMD at #WCLC26 on our work on whole transcriptomics
@ChristianRolfo · 2026-09-15 · OCR
Excellent presentation by @RobertoBoreaMD at #WCLC26 on our work on whole transcriptomics
@ChristianRolfo · 2026-09-15 · OCR
Excellent presentation by @drgandara on KRASG12C analysis im non-squamous NSCLC INNTHE EMP
@ChristianRolfo · 2026-09-14 · OCR
@GlopesMd presenting data on enhanced detection of actionable fusions in NSCLC combining
@ChristianRolfo · 2026-09-15 · OCR
@CharuAggarwalMD presenting at #WCLC26 interesting data on tumor informed MRD ctDNA in ear
@ChristianRolfo · 2026-09-15 · OCR
@CharuAggarwalMD presenting at #WCLC26 interesting data on tumor informed MRD ctDNA in ear
@ChristianRolfo · 2026-09-15 · OCR
@CharuAggarwalMD presenting at #WCLC26 interesting data on tumor informed MRD ctDNA in ear
@ChristianRolfo · 2026-09-15 · OCR
Feeling fortunate that #WCLC26 is in Korea this year! First meal with my parents and in-la
@chulkimMD · 2026-09-10 · OCR
Record attendance for WCLC! More than 8000 attendees!! #WCLC26 https://t.co/lJs9dbjmOG
@chulkimMD · 2026-09-12 · OCR
That’s a wrap! The @IASLC Leadership Development Program provided valuable lessons in lead
@chulkimMD · 2026-09-11 · OCR
With my @IASLC academy mentee, Dr. Leonard Gil-Santana @leogilsan! #WCLC26 https://t.co/
@chulkimMD · 2026-09-12 · OCR
Opening ceremony starting with welcoming remarks from the chairs! #WCLC26 https://t.co/mu
@chulkimMD · 2026-09-12 · OCR
Opening ceremony starting with welcoming remarks from the chairs! #WCLC26 https://t.co/mu
@chulkimMD · 2026-09-12 · OCR
👀 WCLC 2026: studies not to miss @IASLC My selection of the must-see studies at #WCLC26
@diegoadiazg · 2026-09-10 · OCR
👀 WCLC 2026: studies not to miss @IASLC My selection of the must-see studies at #WCLC26
@diegoadiazg · 2026-09-10 · OCR
👀 WCLC 2026: studies not to miss @IASLC My selection of the must-see studies at #WCLC26
@diegoadiazg · 2026-09-10 · OCR
🫁 IMpower030: perioperative atezolizumab did not meet its primary endpoint in resectable N
@diegoadiazg · 2026-09-13 · OCR
🫁 IMpower030: perioperative atezolizumab did not meet its primary endpoint in resectable N
@diegoadiazg · 2026-09-13 · OCR
🫁 IMpower030: perioperative atezolizumab did not meet its primary endpoint in resectable N
@diegoadiazg · 2026-09-13 · OCR
🫁 IMpower030: perioperative atezolizumab did not meet its primary endpoint in resectable N
@diegoadiazg · 2026-09-13 · OCR
#WCLC26 | Debate: Should we convert borderline resectable NSCLC to resectable? An importa
@diegoadiazg · 2026-09-14 · OCR
#WCLC26 | Debate: Should we convert borderline resectable NSCLC to resectable? An importa
@diegoadiazg · 2026-09-14 · OCR
#WCLC26 | Debate: Should we convert borderline resectable NSCLC to resectable? An importa
@diegoadiazg · 2026-09-14 · OCR
🫁 PAPILLON: OS in EGFR Ex20ins NSCLC. @chulkimMD At 48.6 months of follow-up, 1L amivant
@diegoadiazg · 2026-09-14 · OCR
🫁 PAPILLON: OS in EGFR Ex20ins NSCLC. @chulkimMD At 48.6 months of follow-up, 1L amivant
@diegoadiazg · 2026-09-14 · OCR
🫁 PAPILLON: OS in EGFR Ex20ins NSCLC. @chulkimMD At 48.6 months of follow-up, 1L amivant
@diegoadiazg · 2026-09-14 · OCR
🫁 PAPILLON: OS in EGFR Ex20ins NSCLC. @chulkimMD At 48.6 months of follow-up, 1L amivant
@diegoadiazg · 2026-09-14 · OCR
🫁 Molecular risk stratification may identify early-stage NSCLC patients who benefit from a
@diegoadiazg · 2026-09-13 · OCR
🫁 Molecular risk stratification may identify early-stage NSCLC patients who benefit from a
@diegoadiazg · 2026-09-13 · OCR
🫁 Molecular risk stratification may identify early-stage NSCLC patients who benefit from a
@diegoadiazg · 2026-09-13 · OCR
🫁 Molecular risk stratification may identify early-stage NSCLC patients who benefit from a
@diegoadiazg · 2026-09-13 · OCR
🫁 DESTINY-Lung04: T-DXd in HER2-mutant NSCLC. @JuliaRotow First-line T-DXd significantly
@diegoadiazg · 2026-09-14 · OCR
🫁 DESTINY-Lung04: T-DXd in HER2-mutant NSCLC. @JuliaRotow First-line T-DXd significantly
@diegoadiazg · 2026-09-14 · OCR
🫁 DESTINY-Lung04: T-DXd in HER2-mutant NSCLC. @JuliaRotow First-line T-DXd significantly
@diegoadiazg · 2026-09-14 · OCR
🫁 DESTINY-Lung04: T-DXd in HER2-mutant NSCLC. @JuliaRotow First-line T-DXd significantly
@diegoadiazg · 2026-09-14 · OCR
🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck
@diegoadiazg · 2026-09-13 · OCR
🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck
@diegoadiazg · 2026-09-13 · OCR
🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck
@diegoadiazg · 2026-09-13 · OCR
🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck
@diegoadiazg · 2026-09-13 · OCR
🫁 ARROS-1: Zidesamtinib in TKI-naive ROS1+ NSCLC. @alexdrilon Zidesamtinib demonstrated
@diegoadiazg · 2026-09-14 · OCR
🫁 ARROS-1: Zidesamtinib in TKI-naive ROS1+ NSCLC. @alexdrilon Zidesamtinib demonstrated
@diegoadiazg · 2026-09-14 · OCR
🫁 ARROS-1: Zidesamtinib in TKI-naive ROS1+ NSCLC. @alexdrilon Zidesamtinib demonstrated
@diegoadiazg · 2026-09-14 · OCR
🫁 ARROS-1: Zidesamtinib in TKI-naive ROS1+ NSCLC. @alexdrilon Zidesamtinib demonstrated
@diegoadiazg · 2026-09-14 · OCR
🫁 NAUTIKA1: neoadjuvant divarasib shows activity in KRAS G12C+ NSCLC. @ChaftJamie In thi
@diegoadiazg · 2026-09-13 · OCR
🫁 NAUTIKA1: neoadjuvant divarasib shows activity in KRAS G12C+ NSCLC. @ChaftJamie In thi
@diegoadiazg · 2026-09-13 · OCR
🫁 NAUTIKA1: neoadjuvant divarasib shows activity in KRAS G12C+ NSCLC. @ChaftJamie In thi
@diegoadiazg · 2026-09-13 · OCR
🫁 NAUTIKA1: neoadjuvant divarasib shows activity in KRAS G12C+ NSCLC. @ChaftJamie In thi
@diegoadiazg · 2026-09-13 · OCR
🫁 ADAURA: 8y OS with adjuvant osimertinib. @DrRoyHerbst @IASLC In II-IIIA disease, the p
@diegoadiazg · 2026-09-13 · OCR
🫁 ADAURA: 8y OS with adjuvant osimertinib. @DrRoyHerbst @IASLC In II-IIIA disease, the p
@diegoadiazg · 2026-09-13 · OCR
🫁 ADAURA: 8y OS with adjuvant osimertinib. @DrRoyHerbst @IASLC In II-IIIA disease, the p
@diegoadiazg · 2026-09-13 · OCR
🫁 EVOKE-03: adding a Trop-2 ADC to pembrolizumab did not improve outcomes in PD-L1-high NS
@diegoadiazg · 2026-09-13 · OCR
🫁 EVOKE-03: adding a Trop-2 ADC to pembrolizumab did not improve outcomes in PD-L1-high NS
@diegoadiazg · 2026-09-13 · OCR
🫁 EVOKE-03: adding a Trop-2 ADC to pembrolizumab did not improve outcomes in PD-L1-high NS
@diegoadiazg · 2026-09-13 · OCR
🫁 EVOKE-03: adding a Trop-2 ADC to pembrolizumab did not improve outcomes in PD-L1-high NS
@diegoadiazg · 2026-09-13 · OCR
🫁 REZILIENT 3: EGFR Ex20ins NSCLC. First-line zipalertinib + platinum-pemetrexed signifi
@diegoadiazg · 2026-09-14 · OCR
🫁 REZILIENT 3: EGFR Ex20ins NSCLC. First-line zipalertinib + platinum-pemetrexed signifi
@diegoadiazg · 2026-09-14 · OCR
🫁 REZILIENT 3: EGFR Ex20ins NSCLC. First-line zipalertinib + platinum-pemetrexed signifi
@diegoadiazg · 2026-09-14 · OCR
🫁 REZILIENT 3: EGFR Ex20ins NSCLC. First-line zipalertinib + platinum-pemetrexed signifi
@diegoadiazg · 2026-09-14 · OCR
🫁 B7-H3 ADCs continue to reshape second-line SCLC. #wclc26 ARTEMIS-008 showed a significa
@diegoadiazg · 2026-09-13 · OCR
🫁 B7-H3 ADCs continue to reshape second-line SCLC. #wclc26 ARTEMIS-008 showed a significa
@diegoadiazg · 2026-09-13 · OCR
🫁 B7-H3 ADCs continue to reshape second-line SCLC. #wclc26 ARTEMIS-008 showed a significa
@diegoadiazg · 2026-09-13 · OCR
🫁 B7-H3 ADCs continue to reshape second-line SCLC. #wclc26 ARTEMIS-008 showed a significa
@diegoadiazg · 2026-09-13 · OCR
🫁 A new second-line option for relapsed SCLC. #wclc26 TAISHAN-302 showed a major survival
@diegoadiazg · 2026-09-13 · OCR
🫁 A new second-line option for relapsed SCLC. #wclc26 TAISHAN-302 showed a major survival
@diegoadiazg · 2026-09-13 · OCR
🫁 A new second-line option for relapsed SCLC. #wclc26 TAISHAN-302 showed a major survival
@diegoadiazg · 2026-09-13 · OCR
🫁 A new second-line option for relapsed SCLC. #wclc26 TAISHAN-302 showed a major survival
@diegoadiazg · 2026-09-13 · OCR
🧠 MAVERICK trial. MRI surveillance may replace PCI in SCLC. #WCLC26 MRI surveillance alon
@diegoadiazg · 2026-09-12 · OCR
🧠 MAVERICK trial. MRI surveillance may replace PCI in SCLC. #WCLC26 MRI surveillance alon
@diegoadiazg · 2026-09-12 · OCR
🧠 MAVERICK trial. MRI surveillance may replace PCI in SCLC. #WCLC26 MRI surveillance alon
@diegoadiazg · 2026-09-12 · OCR
🧠 MAVERICK trial. MRI surveillance may replace PCI in SCLC. #WCLC26 MRI surveillance alon
@diegoadiazg · 2026-09-12 · OCR
Time to start understanding mechanisms of resistance to zongertinib, which is rapidly beco
@dplanchard · 2026-09-15 · OCR
Time to start understanding mechanisms of resistance to zongertinib, which is rapidly beco
@dplanchard · 2026-09-15 · OCR
Time to start understanding mechanisms of resistance to zongertinib, which is rapidly beco
@dplanchard · 2026-09-15 · OCR
Stunning data from the ADAURA trial, settling the debate once and for all: osimertinib is
@dplanchard · 2026-09-13 · OCR
Stunning data from the ADAURA trial, settling the debate once and for all: osimertinib is
@dplanchard · 2026-09-13 · OCR
Stunning data from the ADAURA trial, settling the debate once and for all: osimertinib is
@dplanchard · 2026-09-13 · OCR
Testing for BRAF V600E in all NSCLC pts is crucial, regardless of smoking status ! Great e
@dplanchard · 2026-09-15 · OCR
HARMONi-2: demonstrated the PFS and OS benefit!!! Ivonescimab vs pembrolizumab in 1L PD-L
@Dr_ElvinaA · 2026-09-13 · OCR
HARMONi-2: demonstrated the PFS and OS benefit!!! Ivonescimab vs pembrolizumab in 1L PD-L
@Dr_ElvinaA · 2026-09-13 · OCR
#WCLC26 HER2-mutant NSCLC: ADC vs TKI 👀 1L T-DXd: ORR 70%, mPFS 14.3 mo, but no OS signal
@Dr_ElvinaA · 2026-09-14 · OCR
#WCLC26 HER2-mutant NSCLC: ADC vs TKI 👀 1L T-DXd: ORR 70%, mPFS 14.3 mo, but no OS signal
@Dr_ElvinaA · 2026-09-14 · OCR
#WCLC26 HER2-mutant NSCLC: ADC vs TKI 👀 1L T-DXd: ORR 70%, mPFS 14.3 mo, but no OS signal
@Dr_ElvinaA · 2026-09-14 · OCR
Interesting signal from #WCLC26: visceral obesity—not BMI alone—may matter in lung cancer
@Dr_ElvinaA · 2026-09-12 · OCR
Interesting signal from #WCLC26: visceral obesity—not BMI alone—may matter in lung cancer
@Dr_ElvinaA · 2026-09-12 · OCR
Interesting signal from #WCLC26: visceral obesity—not BMI alone—may matter in lung cancer
@Dr_ElvinaA · 2026-09-12 · OCR
#WCLC26: Sac-TMT showed promising activity in previously treated NSCLC with actionable alt
@Dr_ElvinaA · 2026-09-14 · OCR
#WCLC26: Sac-TMT showed promising activity in previously treated NSCLC with actionable alt
@Dr_ElvinaA · 2026-09-14 · OCR
Cross-trial (not head-to-head) look at 1L EGFR ex20ins data: PAPILLON has the OS maturity
@Dr_ElvinaA · 2026-09-14 · OCR
Cross-trial (not head-to-head) look at 1L EGFR ex20ins data: PAPILLON has the OS maturity
@Dr_ElvinaA · 2026-09-14 · OCR
A key limitation of HARMONi-2 is the control arm: pembrolizumab monotherapy was used even
@Dr_ElvinaA · 2026-09-16 · OCR
ADAURA Trial 8-Year Overall Survival Update Overall Population (IB–IIIA): 79% vs 64% (HR
@Dr_ElvinaA · 2026-09-14 · OCR
Especially after ARTEMIS-008 and TAISHO-302, MRI surveillance looks like an increasingly a
@Dr_ElvinaA · 2026-09-13 · OCR
Especially after ARTEMIS-008 and TAISHO-302, MRI surveillance looks like an increasingly a
@Dr_ElvinaA · 2026-09-13 · OCR
#WCLC26 – A turning point for relapsed #SCLC? Two B7-H3 ADC trials vs topotecan: -TAISH
@Dr_ElvinaA · 2026-09-13 · OCR
I thoroughly enjoyed reading this recently published article led by @TroyKleberMD. It pull
@DrewMoghanaki · 2026-09-11 · OCR
I thoroughly enjoyed reading this recently published article led by @TroyKleberMD. It pull
@DrewMoghanaki · 2026-09-11 · OCR
As #WCLC26 attendees get excited for updates about novel drug combinations for stage III N
@DrewMoghanaki · 2026-09-10 · OCR
Does anyone know what happened to the 11 patients who were candidates for a PACIFIC treatm
@DrewMoghanaki · 2026-09-15 · OCR
Lots of chatter about the phase III PRIME-Lung study at #WCLC26 which tests the hypothesis
@DrewMoghanaki · 2026-09-12 · OCR
Lots of chatter about the phase III PRIME-Lung study at #WCLC26 which tests the hypothesis
@DrewMoghanaki · 2026-09-12 · OCR
Lots of chatter about the phase III PRIME-Lung study at #WCLC26 which tests the hypothesis
@DrewMoghanaki · 2026-09-12 · OCR
Lots of chatter about the phase III PRIME-Lung study at #WCLC26 which tests the hypothesis
@DrewMoghanaki · 2026-09-12 · OCR
Curious how stigma affects lung cancer outcomes? Follow the slides below by @drCarterBawa.
@DrewMoghanaki · 2026-09-13 · OCR
Curious how stigma affects lung cancer outcomes? Follow the slides below by @drCarterBawa.
@DrewMoghanaki · 2026-09-13 · OCR
Curious how stigma affects lung cancer outcomes? Follow the slides below by @drCarterBawa.
@DrewMoghanaki · 2026-09-13 · OCR
For those who weren't at #WCLC26, a critical question remains regarding the approach of st
@DrewMoghanaki · 2026-09-14 · OCR
Powerful slide by Dr. Karen Kelley, CEO of @IASLC, highlighting the ongoing national lung
@DrewMoghanaki · 2026-09-13 · OCR
Another life goal achieved today after inviting @sandraturner49 to #WCLC26 in Seoul to sha
@DrewMoghanaki · 2026-09-13 · OCR
#WCLC26 https://t.co/AMI9yCWtC6
@DrewMoghanaki · 2026-09-13 · OCR
Unfortunate fact: people who develop lung cancer often develop more lung cancers, regardle
@DrewMoghanaki · 2026-09-15 · OCR
Why are David Harpole and I smiling? Well, it’s because that’s what people generally do wh
@DrewMoghanaki · 2026-09-13 · OCR
The “Healthy Lungs California” initiative is discussed at an after hours session at #WCLC
@DrewMoghanaki · 2026-09-13 · OCR
https://t.co/P1sASmmddC
@DrewMoghanaki · 2026-09-12 · OCR
Dr. Karen Kelley also highlighted how the @WHO is building more awareness about lung healt
@DrewMoghanaki · 2026-09-13 · OCR
Curious how to address the “wicked” problem of stigma? See the recommendations below, whic
@DrewMoghanaki · 2026-09-13 · OCR
Curious how to address the “wicked” problem of stigma? See the recommendations below, whic
@DrewMoghanaki · 2026-09-13 · OCR
Great discussion followed clarifying that despite an adjusted sample size, the study is ap
@DrewMoghanaki · 2026-09-13 · OCR
Key slide (primary outcome) https://t.co/sxzo9UCTLo
@DrewMoghanaki · 2026-09-12 · OCR
Reassuring slide (secondary outcome) https://t.co/AZgnR515cj
@DrewMoghanaki · 2026-09-12 · OCR
🚨 TAISHAN-302 | A major new option in relapsed SCLC Phase 3 data in NEJM: Tambotatug peli
@DrRishabhOnco · 2026-09-13 · OCR
DESTINY-Lung04: impressive PFS with first-line T-DXd, but the OS curve tells a very differ
@DrRishabhOnco · 2026-09-14 · OCR
DESTINY-Lung04: impressive PFS with first-line T-DXd, but the OS curve tells a very differ
@DrRishabhOnco · 2026-09-14 · OCR
DESTINY-Lung04: impressive PFS with first-line T-DXd, but the OS curve tells a very differ
@DrRishabhOnco · 2026-09-14 · OCR
TAISHAN-302 🔥 Tam-Peli vs topotecan in relapsed SCLC: OS: 13.3 vs 9.4 mo HR 0.46 | P<0.0
@DrRishabhOnco · 2026-09-13 · OCR
ADAURA keeps delivering. Now with 8-year survival data. 🔥 In resected EGFR-mutated NSCLC,
@DrRishabhOnco · 2026-09-14 · OCR
ADAURA keeps delivering. Now with 8-year survival data. 🔥 In resected EGFR-mutated NSCLC,
@DrRishabhOnco · 2026-09-14 · OCR
ADAURA keeps delivering. Now with 8-year survival data. 🔥 In resected EGFR-mutated NSCLC,
@DrRishabhOnco · 2026-09-14 · OCR
The next phase in ROS1 beautifully summarised in a few slides by @Mal_Itchins #WCLC26 http
@DrRiyazShah · 2026-09-14 · OCR
The next phase in ROS1 beautifully summarised in a few slides by @Mal_Itchins #WCLC26 http
@DrRiyazShah · 2026-09-14 · OCR
The next phase in ROS1 beautifully summarised in a few slides by @Mal_Itchins #WCLC26 http
@DrRiyazShah · 2026-09-14 · OCR
The next phase in ROS1 beautifully summarised in a few slides by @Mal_Itchins #WCLC26 http
@DrRiyazShah · 2026-09-14 · OCR
DESTINY-Lung04; front line, no protocol mandated x over; n454; 23% have brain mets; mPFS 8
@DrRiyazShah · 2026-09-14 · OCR
DESTINY-Lung04; front line, no protocol mandated x over; n454; 23% have brain mets; mPFS 8
@DrRiyazShah · 2026-09-14 · OCR
DESTINY-Lung04; front line, no protocol mandated x over; n454; 23% have brain mets; mPFS 8
@DrRiyazShah · 2026-09-14 · OCR
DESTINY-Lung04; front line, no protocol mandated x over; n454; 23% have brain mets; mPFS 8
@DrRiyazShah · 2026-09-14 · OCR
Here’s one I wasn’t expecting. @StephenVLiu debating why X isn’t the best SM framework for
@DrRiyazShah · 2026-09-12 · OCR
IMpower030: final analysis; hierarchical stats testing (grrrrr); #WCLC26 https://t.co/y2Af
@DrRiyazShah · 2026-09-13 · OCR
IMpower030: final analysis; hierarchical stats testing (grrrrr); #WCLC26 https://t.co/y2Af
@DrRiyazShah · 2026-09-13 · OCR
IMpower030: final analysis; hierarchical stats testing (grrrrr); #WCLC26 https://t.co/y2Af
@DrRiyazShah · 2026-09-13 · OCR
IMpower030: final analysis; hierarchical stats testing (grrrrr); #WCLC26 https://t.co/y2Af
@DrRiyazShah · 2026-09-13 · OCR
MAVERICK discussant Dr Harada rightly discusses MR in context of machine availability; hug
@DrRiyazShah · 2026-09-12 · OCR
ARROS-1 update in TKI NAÏVE: Zidesamtinib P1/2; n629 enrolled, 183 TKI naïve; ORR 94%; CR
@DrRiyazShah · 2026-09-14 · OCR
ARROS-1 update in TKI NAÏVE: Zidesamtinib P1/2; n629 enrolled, 183 TKI naïve; ORR 94%; CR
@DrRiyazShah · 2026-09-14 · OCR
ARROS-1 update in TKI NAÏVE: Zidesamtinib P1/2; n629 enrolled, 183 TKI naïve; ORR 94%; CR
@DrRiyazShah · 2026-09-14 · OCR
ARROS-1 update in TKI NAÏVE: Zidesamtinib P1/2; n629 enrolled, 183 TKI naïve; ORR 94%; CR
@DrRiyazShah · 2026-09-14 · OCR
Everything you need to know about front line treatment options in EGFR ex20ins space in a
@DrRiyazShah · 2026-09-14 · OCR
Everything you need to know about front line treatment options in EGFR ex20ins space in a
@DrRiyazShah · 2026-09-14 · OCR
Everything you need to know about front line treatment options in EGFR ex20ins space in a
@DrRiyazShah · 2026-09-14 · OCR
Everything you need to know about front line treatment options in EGFR ex20ins space in a
@DrRiyazShah · 2026-09-14 · OCR
Congratulations @pompili_cecilia #WCLC26 https://t.co/Q615y9HfQ4
@DrRiyazShah · 2026-09-13 · OCR
REZILIENT 3; EGFR ex20ins; zipalertinib + chemo vs chemo alone (x over to zip at PD-64%did
@DrRiyazShah · 2026-09-14 · OCR
REZILIENT 3; EGFR ex20ins; zipalertinib + chemo vs chemo alone (x over to zip at PD-64%did
@DrRiyazShah · 2026-09-14 · OCR
REZILIENT 3; EGFR ex20ins; zipalertinib + chemo vs chemo alone (x over to zip at PD-64%did
@DrRiyazShah · 2026-09-14 · OCR
REZILIENT 3; EGFR ex20ins; zipalertinib + chemo vs chemo alone (x over to zip at PD-64%did
@DrRiyazShah · 2026-09-14 · OCR
DeLLphi-309; RP2; testing q3 and q4; n252; PK similar; efficacy similar; more low grade IC
@DrRiyazShah · 2026-09-13 · OCR
DeLLphi-309; RP2; testing q3 and q4; n252; PK similar; efficacy similar; more low grade IC
@DrRiyazShah · 2026-09-13 · OCR
DeLLphi-309; RP2; testing q3 and q4; n252; PK similar; efficacy similar; more low grade IC
@DrRiyazShah · 2026-09-13 · OCR
DeLLphi-309; RP2; testing q3 and q4; n252; PK similar; efficacy similar; more low grade IC
@DrRiyazShah · 2026-09-13 · OCR
ARTEMIS-008; Ris-Rez B7-H3 ADC; P3 RCT in relapsed SCLC v topo; n461; 87% ES-SCLC; WOW OS
@DrRiyazShah · 2026-09-13 · OCR
ARTEMIS-008; Ris-Rez B7-H3 ADC; P3 RCT in relapsed SCLC v topo; n461; 87% ES-SCLC; WOW OS
@DrRiyazShah · 2026-09-13 · OCR
ARTEMIS-008; Ris-Rez B7-H3 ADC; P3 RCT in relapsed SCLC v topo; n461; 87% ES-SCLC; WOW OS
@DrRiyazShah · 2026-09-13 · OCR
ARTEMIS-008; Ris-Rez B7-H3 ADC; P3 RCT in relapsed SCLC v topo; n461; 87% ES-SCLC; WOW OS
@DrRiyazShah · 2026-09-13 · OCR
Caicun Zhou President of @IASLC rightly highlights the global problem of drug access. #WCL
@DrRiyazShah · 2026-09-12 · OCR
PAPILLON update final OS; remember X over to ami in control arm permitted (76% did); disco
@DrRiyazShah · 2026-09-13 · OCR
PAPILLON update final OS; remember X over to ami in control arm permitted (76% did); disco
@DrRiyazShah · 2026-09-13 · OCR
PAPILLON update final OS; remember X over to ami in control arm permitted (76% did); disco
@DrRiyazShah · 2026-09-13 · OCR
PAPILLON update final OS; remember X over to ami in control arm permitted (76% did); disco
@DrRiyazShah · 2026-09-13 · OCR
Total respect; ADAURA #WCLC26 May his memory be a blessing https://t.co/GdjOzSV76t
@DrRiyazShah · 2026-09-13 · OCR
EVOKE-03/KEYNOTE D46; Sac-govitecan trop2ADC; P3RCT; high PDL1 (>50%) randomised to Pembro
@DrRiyazShah · 2026-09-13 · OCR
EVOKE-03/KEYNOTE D46; Sac-govitecan trop2ADC; P3RCT; high PDL1 (>50%) randomised to Pembro
@DrRiyazShah · 2026-09-13 · OCR
EVOKE-03/KEYNOTE D46; Sac-govitecan trop2ADC; P3RCT; high PDL1 (>50%) randomised to Pembro
@DrRiyazShah · 2026-09-13 · OCR
EVOKE-03/KEYNOTE D46; Sac-govitecan trop2ADC; P3RCT; high PDL1 (>50%) randomised to Pembro
@DrRiyazShah · 2026-09-13 · OCR
MDT-BRIDGE update; P2; 76% of borderline resectable became resectable; seems like a delive
@DrRiyazShah · 2026-09-13 · OCR
MDT-BRIDGE update; P2; 76% of borderline resectable became resectable; seems like a delive
@DrRiyazShah · 2026-09-13 · OCR
MDT-BRIDGE update; P2; 76% of borderline resectable became resectable; seems like a delive
@DrRiyazShah · 2026-09-13 · OCR
MDT-BRIDGE update; P2; 76% of borderline resectable became resectable; seems like a delive
@DrRiyazShah · 2026-09-13 · OCR
Congratulations @CharuAggarwalMD #WCLC26 https://t.co/LOcZCIdcjr
@DrRiyazShah · 2026-09-12 · OCR
Congratulations @CharuAggarwalMD #WCLC26 https://t.co/LOcZCIdcjr
@DrRiyazShah · 2026-09-12 · OCR
NAUTIKA1; KRAS G12C Divarasib neoadjuvant for 8w: n=20; pCR 16% MPR 42%; ORR 55%. Nodal do
@DrRiyazShah · 2026-09-13 · OCR
NAUTIKA1; KRAS G12C Divarasib neoadjuvant for 8w: n=20; pCR 16% MPR 42%; ORR 55%. Nodal do
@DrRiyazShah · 2026-09-13 · OCR
NAUTIKA1; KRAS G12C Divarasib neoadjuvant for 8w: n=20; pCR 16% MPR 42%; ORR 55%. Nodal do
@DrRiyazShah · 2026-09-13 · OCR
NAUTIKA1; KRAS G12C Divarasib neoadjuvant for 8w: n=20; pCR 16% MPR 42%; ORR 55%. Nodal do
@DrRiyazShah · 2026-09-13 · OCR
Tam-Peli B7-H3 ADC; TAISHEN-302 P3RCTin relapse v topo ; open label; n451; median FU 9m; l
@DrRiyazShah · 2026-09-13 · OCR
Tam-Peli B7-H3 ADC; TAISHEN-302 P3RCTin relapse v topo ; open label; n451; median FU 9m; l
@DrRiyazShah · 2026-09-13 · OCR
Tam-Peli B7-H3 ADC; TAISHEN-302 P3RCTin relapse v topo ; open label; n451; median FU 9m; l
@DrRiyazShah · 2026-09-13 · OCR
Tam-Peli B7-H3 ADC; TAISHEN-302 P3RCTin relapse v topo ; open label; n451; median FU 9m; l
@DrRiyazShah · 2026-09-13 · OCR
ADAURA update; exploratory long term OS; at 8y OS HR 0.53; 16% absolute benefit in OS at 8
@DrRiyazShah · 2026-09-13 · OCR
ADAURA update; exploratory long term OS; at 8y OS HR 0.53; 16% absolute benefit in OS at 8
@DrRiyazShah · 2026-09-13 · OCR
ADAURA update; exploratory long term OS; at 8y OS HR 0.53; 16% absolute benefit in OS at 8
@DrRiyazShah · 2026-09-13 · OCR
ADAURA update; exploratory long term OS; at 8y OS HR 0.53; 16% absolute benefit in OS at 8
@DrRiyazShah · 2026-09-13 · OCR
MAVERICK; SWOG 1827: SCLC; primary endpoint changed from OS to CFFS; n304; superior CFFS w
@DrRiyazShah · 2026-09-12 · OCR
MAVERICK; SWOG 1827: SCLC; primary endpoint changed from OS to CFFS; n304; superior CFFS w
@DrRiyazShah · 2026-09-12 · OCR
MAVERICK; SWOG 1827: SCLC; primary endpoint changed from OS to CFFS; n304; superior CFFS w
@DrRiyazShah · 2026-09-12 · OCR
MAVERICK; SWOG 1827: SCLC; primary endpoint changed from OS to CFFS; n304; superior CFFS w
@DrRiyazShah · 2026-09-12 · OCR
@MatthewEvison1 on integrating smoking cessation into the lung cancer pathway. #WCLC26 htt
@DrRiyazShah · 2026-09-13 · OCR
RAPHAEL trial: IIT RP2 adjuvant gefitinib + chemo vs chemo in resected II-IIIB EGFR(common
@DrRiyazShah · 2026-09-13 · OCR
RAPHAEL trial: IIT RP2 adjuvant gefitinib + chemo vs chemo in resected II-IIIB EGFR(common
@DrRiyazShah · 2026-09-13 · OCR
RAPHAEL trial: IIT RP2 adjuvant gefitinib + chemo vs chemo in resected II-IIIB EGFR(common
@DrRiyazShah · 2026-09-13 · OCR
RAPHAEL trial: IIT RP2 adjuvant gefitinib + chemo vs chemo in resected II-IIIB EGFR(common
@DrRiyazShah · 2026-09-13 · OCR
@BalazsHalmosMD @KolPulseAI @BalazsHalmosMD waiting for ADAURA data like… https://t.co/z46
@drshieldsmd · 2026-09-13 · OCR
Dr. Roy Herbst @DrRoyHerbst @dartmouth presents the updated 8Y OS follow up analysis of AD
@drshieldsmd · 2026-09-13 · OCR
Dr. Roy Herbst @DrRoyHerbst @dartmouth presents the updated 8Y OS follow up analysis of AD
@drshieldsmd · 2026-09-13 · OCR
Fierce patient advocate and lung cancer survivor @jillfeldman4 asking key questions on the
@drshieldsmd · 2026-09-13 · OCR
MAVERICK @SWOG S1827 phase 3 trial Dr. Chad Rustoven presented at @IASLC #WCLC26 comparing
@drshieldsmd · 2026-09-12 · OCR
MAVERICK @SWOG S1827 phase 3 trial Dr. Chad Rustoven presented at @IASLC #WCLC26 comparing
@drshieldsmd · 2026-09-12 · OCR
MAVERICK @SWOG S1827 phase 3 trial Dr. Chad Rustoven presented at @IASLC #WCLC26 comparing
@drshieldsmd · 2026-09-12 · OCR
MAVERICK @SWOG S1827 phase 3 trial Dr. Chad Rustoven presented at @IASLC #WCLC26 comparing
@drshieldsmd · 2026-09-12 · OCR
Dr. Chul Kim @chulkimMD expertly presenting the final OS results of PAPILLON investigating
@drshieldsmd · 2026-09-13 · OCR
Dr. Chul Kim @chulkimMD expertly presenting the final OS results of PAPILLON investigating
@drshieldsmd · 2026-09-13 · OCR
Dr. Chul Kim @chulkimMD expertly presenting the final OS results of PAPILLON investigating
@drshieldsmd · 2026-09-13 · OCR
Loving all the amazing skincare products here at @oliveyoung in #korea #glassskingoals #WC
@drshieldsmd · 2026-09-12 · OCR
Loving all the amazing skincare products here at @oliveyoung in #korea #glassskingoals #WC
@drshieldsmd · 2026-09-12 · OCR
Cutting edge presentation by my fabulous mentor Dr. Christine Lovly @christine_lovly @city
@drshieldsmd · 2026-09-13 · OCR
Cutting edge presentation by my fabulous mentor Dr. Christine Lovly @christine_lovly @city
@drshieldsmd · 2026-09-13 · OCR
Cutting edge presentation by my fabulous mentor Dr. Christine Lovly @christine_lovly @city
@drshieldsmd · 2026-09-13 · OCR
Cutting edge presentation by my fabulous mentor Dr. Christine Lovly @christine_lovly @city
@drshieldsmd · 2026-09-13 · OCR
Classic. For the doctor who needs no introduction at microphone 3. @IASLC #WCLC26 @Corey
@drshieldsmd · 2026-09-14 · OCR
Classic. For the doctor who needs no introduction at microphone 3. @IASLC #WCLC26 @Corey
@drshieldsmd · 2026-09-14 · OCR
Incredibly grateful for our wonderfully kind and collaborative thoracic oncology community
@drshieldsmd · 2026-09-15 · OCR
Incredibly grateful for our wonderfully kind and collaborative thoracic oncology community
@drshieldsmd · 2026-09-15 · OCR
Incredibly grateful for our wonderfully kind and collaborative thoracic oncology community
@drshieldsmd · 2026-09-15 · OCR
Incredibly grateful for our wonderfully kind and collaborative thoracic oncology community
@drshieldsmd · 2026-09-15 · OCR
Love all the special moments with friends at @IASLC #WCLC26! @lungoncdoc @maraantonoff @
@drshieldsmd · 2026-09-14 · OCR
Love all the special moments with friends at @IASLC #WCLC26! @lungoncdoc @maraantonoff @
@drshieldsmd · 2026-09-14 · OCR
Love all the special moments with friends at @IASLC #WCLC26! @lungoncdoc @maraantonoff @
@drshieldsmd · 2026-09-14 · OCR
Love all the special moments with friends at @IASLC #WCLC26! @lungoncdoc @maraantonoff @
@drshieldsmd · 2026-09-14 · OCR
Having a wonderful time at the @IASLC plenary and enjoyed checking out the @starfieldlibra
@drshieldsmd · 2026-09-12 · OCR
Having a wonderful time at the @IASLC plenary and enjoyed checking out the @starfieldlibra
@drshieldsmd · 2026-09-12 · OCR
Lovely to chat with @IASLC President Dr. Paul Van Schil while we await our flights home fr
@drshieldsmd · 2026-09-15 · OCR
Dr. Li Zhang presents the TAISHAN-302 Phase 3 study of Tam-Peli B7-H3 ADC (YL201) followin
@drshieldsmd · 2026-09-13 · OCR
Dr. Li Zhang presents the TAISHAN-302 Phase 3 study of Tam-Peli B7-H3 ADC (YL201) followin
@drshieldsmd · 2026-09-13 · OCR
Dr. Li Zhang presents the TAISHAN-302 Phase 3 study of Tam-Peli B7-H3 ADC (YL201) followin
@drshieldsmd · 2026-09-13 · OCR
Dr. Li Zhang presents the TAISHAN-302 Phase 3 study of Tam-Peli B7-H3 ADC (YL201) followin
@drshieldsmd · 2026-09-13 · OCR
Dr. Giannis Mountzios @g_mountzios presented at @IASLC #WCLC26 the EVOKE-03 Phase 3 study
@drshieldsmd · 2026-09-13 · OCR
Dr. Giannis Mountzios @g_mountzios presented at @IASLC #WCLC26 the EVOKE-03 Phase 3 study
@drshieldsmd · 2026-09-13 · OCR
Dr. Giannis Mountzios @g_mountzios presented at @IASLC #WCLC26 the EVOKE-03 Phase 3 study
@drshieldsmd · 2026-09-13 · OCR
Dr. Giannis Mountzios @g_mountzios presented at @IASLC #WCLC26 the EVOKE-03 Phase 3 study
@drshieldsmd · 2026-09-13 · OCR
Dr. Jie Wang presents the ARTEMIS-008 Phase 3 results of Ris-Rez compared to topotecan in
@drshieldsmd · 2026-09-13 · OCR
Dr. Jie Wang presents the ARTEMIS-008 Phase 3 results of Ris-Rez compared to topotecan in
@drshieldsmd · 2026-09-13 · OCR
Dr. Jie Wang presents the ARTEMIS-008 Phase 3 results of Ris-Rez compared to topotecan in
@drshieldsmd · 2026-09-13 · OCR
Thank you Dr. Anne Chiang @Annechiangmd @YaleCancer here at @IASLC #WCLC26 for highlightin
@drshieldsmd · 2026-09-13 · OCR
Thank you Dr. Anne Chiang @Annechiangmd @YaleCancer here at @IASLC #WCLC26 for highlightin
@drshieldsmd · 2026-09-13 · OCR
Thank you Dr. Anne Chiang @Annechiangmd @YaleCancer here at @IASLC #WCLC26 for highlightin
@drshieldsmd · 2026-09-13 · OCR
Dr. Julia Rotow @JuliaRotow presents the DESTINY-Lung-04 data of trastuzumab deruxtecan vs
@drshieldsmd · 2026-09-14 · OCR
Dr. Julia Rotow @JuliaRotow presents the DESTINY-Lung-04 data of trastuzumab deruxtecan vs
@drshieldsmd · 2026-09-14 · OCR
Dr. Julia Rotow @JuliaRotow presents the DESTINY-Lung-04 data of trastuzumab deruxtecan vs
@drshieldsmd · 2026-09-14 · OCR
So proud of my dear friend Dr. Anne Chiang @Annechiangmd @YaleCancer who provided a though
@drshieldsmd · 2026-09-13 · OCR
So proud of my dear friend Dr. Anne Chiang @Annechiangmd @YaleCancer who provided a though
@drshieldsmd · 2026-09-13 · OCR
So proud of my dear friend Dr. Anne Chiang @Annechiangmd @YaleCancer who provided a though
@drshieldsmd · 2026-09-13 · OCR
So proud of my dear friend Dr. Anne Chiang @Annechiangmd @YaleCancer who provided a though
@drshieldsmd · 2026-09-13 · OCR
Excited for today’s presidential session for meaningful updates in #SCLC at #WCLC26! https
@drshieldsmd · 2026-09-12 · OCR
Congratulations Dr. Benjamin Lok @BenLok @pmcancercentre for receiving the Heine Hansen Le
@drshieldsmd · 2026-09-13 · OCR
Congratulations Dr. Jianjun Jay Zhang @UTMDAnderson for receiving the @IASLC @fred_hirsch
@drshieldsmd · 2026-09-12 · OCR
Honored to serve as the @IASLC SCLC committee co-chair with the esteemed Dr. Shigeki Umemu
@drshieldsmd · 2026-09-15 · OCR
Dr. Alexander Drilon @alexdrilon presents the ARROS-1 study with zidesamtinib (NVL-520) in
@drshieldsmd · 2026-09-14 · OCR
Dr. Alexander Drilon @alexdrilon presents the ARROS-1 study with zidesamtinib (NVL-520) in
@drshieldsmd · 2026-09-14 · OCR
Dr. Alexander Drilon @alexdrilon presents the ARROS-1 study with zidesamtinib (NVL-520) in
@drshieldsmd · 2026-09-14 · OCR
Dr. Daniel Tan presents the results of REZILENT 3 at @iaslc #WCLC26 meeting its primary en
@drshieldsmd · 2026-09-14 · OCR
Dr. Daniel Tan presents the results of REZILENT 3 at @iaslc #WCLC26 meeting its primary en
@drshieldsmd · 2026-09-14 · OCR
Dr. Daniel Tan presents the results of REZILENT 3 at @iaslc #WCLC26 meeting its primary en
@drshieldsmd · 2026-09-14 · OCR
@IASLC President Dr. Caicun Zhou outlines his initiatives during the Presidential Session:
@drshieldsmd · 2026-09-12 · OCR
@IASLC President Dr. Caicun Zhou outlines his initiatives during the Presidential Session:
@drshieldsmd · 2026-09-12 · OCR
سعيد بالمشاركة بتمثيل مركز الكويت لمكافحة السرطان في المؤتمر السنوي لأورام الرئة المقام حا
@DrZ_84 · 2026-09-12 · OCR
سعيد بالمشاركة بتمثيل مركز الكويت لمكافحة السرطان في المؤتمر السنوي لأورام الرئة المقام حا
@DrZ_84 · 2026-09-12 · OCR
سعيد بالمشاركة بتمثيل مركز الكويت لمكافحة السرطان في المؤتمر السنوي لأورام الرئة المقام حا
@DrZ_84 · 2026-09-12 · OCR
سعيد بالمشاركة بتمثيل مركز الكويت لمكافحة السرطان في المؤتمر السنوي لأورام الرئة المقام حا
@DrZ_84 · 2026-09-12 · OCR
Exciting time for emerging treatments in ES-SCLC: As Tarlatamab potentially moves into the
@DrZ_84 · 2026-09-13 · OCR
Exciting time for emerging treatments in ES-SCLC: As Tarlatamab potentially moves into the
@DrZ_84 · 2026-09-13 · OCR
Exciting time for emerging treatments in ES-SCLC: As Tarlatamab potentially moves into the
@DrZ_84 · 2026-09-13 · OCR
Exciting time for emerging treatments in ES-SCLC: As Tarlatamab potentially moves into the
@DrZ_84 · 2026-09-13 · OCR
Adjuvant Osimertinib Following complete resection R0 (+/- adjuvant chemo) in Early Stage E
@DrZ_84 · 2026-09-13 · OCR
Adjuvant Osimertinib Following complete resection R0 (+/- adjuvant chemo) in Early Stage E
@DrZ_84 · 2026-09-13 · OCR
Adjuvant Osimertinib Following complete resection R0 (+/- adjuvant chemo) in Early Stage E
@DrZ_84 · 2026-09-13 · OCR
Adjuvant Osimertinib Following complete resection R0 (+/- adjuvant chemo) in Early Stage E
@DrZ_84 · 2026-09-13 · OCR
Baseline risk assessment, MRD, tumor biology, and optimal treatment duration are important
@DrZ_84 · 2026-09-13 · OCR
Baseline risk assessment, MRD, tumor biology, and optimal treatment duration are important
@DrZ_84 · 2026-09-13 · OCR
Join us today at #WCLC26 for the 1st joint IASLC–EMRO Forum, focusing on lung cancer resea
@DrZ_84 · 2026-09-12 · OCR
Join us today at #WCLC26 for the 1st joint IASLC–EMRO Forum, focusing on lung cancer resea
@DrZ_84 · 2026-09-12 · OCR
Join us today at #WCLC26 for the 1st joint IASLC–EMRO Forum, focusing on lung cancer resea
@DrZ_84 · 2026-09-12 · OCR
Join us today at #WCLC26 for the 1st joint IASLC–EMRO Forum, focusing on lung cancer resea
@DrZ_84 · 2026-09-12 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 1, d
@eChinaHealth · 2026-09-14 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 1, d
@eChinaHealth · 2026-09-14 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 1, d
@eChinaHealth · 2026-09-14 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 1, d
@eChinaHealth · 2026-09-14 · OCR
One great feature of the #WCLC26 app: the live stream offers real-time multilingual subtit
@eChinaHealth · 2026-09-12 · OCR
One great feature of the #WCLC26 app: the live stream offers real-time multilingual subtit
@eChinaHealth · 2026-09-12 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 2, d
@eChinaHealth · 2026-09-14 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 2, d
@eChinaHealth · 2026-09-14 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 2, d
@eChinaHealth · 2026-09-14 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 2, d
@eChinaHealth · 2026-09-14 · OCR
eChinaHealth team at #WCLC26 in Seoul! 🇰🇷 Looking forward to a great few days of learning
@eChinaHealth · 2026-09-12 · OCR
At #WCLC26: medical communication is global, but channels are local. What works in the US
@eChinaHealth · 2026-09-12 · OCR
At #WCLC26: medical communication is global, but channels are local. What works in the US
@eChinaHealth · 2026-09-12 · OCR
At #WCLC26: medical communication is global, but channels are local. What works in the US
@eChinaHealth · 2026-09-12 · OCR
At #WCLC26: medical communication is global, but channels are local. What works in the US
@eChinaHealth · 2026-09-12 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 3, d
@eChinaHealth · 2026-09-15 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 3, d
@eChinaHealth · 2026-09-15 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 3, d
@eChinaHealth · 2026-09-15 · OCR
"eChinaHealth News" provides comprehensive Chinese-language coverage of WCLC 2026 Day 3, d
@eChinaHealth · 2026-09-15 · OCR
Happening now! Presidential session at #WCLC2026 A negative study, but yet informative, s
@ElinardouHelena · 2026-09-13 · OCR
Happening now! Presidential session at #WCLC2026 A negative study, but yet informative, s
@ElinardouHelena · 2026-09-13 · OCR
Happening now! Presidential session at #WCLC2026 A negative study, but yet informative, s
@ElinardouHelena · 2026-09-13 · OCR
Happening now! Presidential session at #WCLC2026 A negative study, but yet informative, s
@ElinardouHelena · 2026-09-13 · OCR
What a great way to open the #wclc2026 @IASLC #Academy Workshop with brilliant presentatio
@ElinardouHelena · 2026-09-11 · OCR
What a great way to open the #wclc2026 @IASLC #Academy Workshop with brilliant presentatio
@ElinardouHelena · 2026-09-11 · OCR
What a great way to open the #wclc2026 @IASLC #Academy Workshop with brilliant presentatio
@ElinardouHelena · 2026-09-11
What a great way to open the #wclc2026 @IASLC #Academy Workshop with brilliant presentatio
@ElinardouHelena · 2026-09-11 · OCR
After a long 16 hrs… Seoul! for #wclc2026 @IASLC #Academy mentor- super proud! and invite
@ElinardouHelena · 2026-09-11 · OCR
After a long 16 hrs… Seoul! for #wclc2026 @IASLC #Academy mentor- super proud! and invite
@ElinardouHelena · 2026-09-11 · OCR
After a long 16 hrs… Seoul! for #wclc2026 @IASLC #Academy mentor- super proud! and invite
@ElinardouHelena · 2026-09-11 · OCR
After a long 16 hrs… Seoul! for #wclc2026 @IASLC #Academy mentor- super proud! and invite
@ElinardouHelena · 2026-09-11 · OCR
🌟 Join us today at #WCLC2026 for the Highlights of the Day! We’ll review and distill the k
@ElinardouHelena · 2026-09-14 · OCR
🌟 Join us today at #WCLC2026 for the Highlights of the Day! We’ll review and distill the k
@ElinardouHelena · 2026-09-14 · OCR
OS ⬆️ with bi-specific ivonescimab Harmoni-2 #WCLC26 @IASLC https://t.co/IvvjnofNc9
@FernandoOnco · 2026-09-13 · OCR
DESTINY-Lung04 🚨 T-DXd in 1L HER2m NSCLC: ORR 70%. PFS, ✅ OS not ARROS-1 🔥 Zidesamtinib
@FernandoOnco · 2026-09-14 · OCR
DESTINY-Lung04 🚨 T-DXd in 1L HER2m NSCLC: ORR 70%. PFS, ✅ OS not ARROS-1 🔥 Zidesamtinib
@FernandoOnco · 2026-09-14 · OCR
DESTINY-Lung04 🚨 T-DXd in 1L HER2m NSCLC: ORR 70%. PFS, ✅ OS not ARROS-1 🔥 Zidesamtinib
@FernandoOnco · 2026-09-14 · OCR
DESTINY-Lung04 🚨 T-DXd in 1L HER2m NSCLC: ORR 70%. PFS, ✅ OS not ARROS-1 🔥 Zidesamtinib
@FernandoOnco · 2026-09-14 · OCR
Supertecan B7-H3 a topotecan dressed to kill #sclc #WCLC26 @IASLC @BalazsHalmosMD https://
@FernandoOnco · 2026-09-13 · OCR
Supertecan B7-H3 a topotecan dressed to kill #sclc #WCLC26 @IASLC @BalazsHalmosMD https://
@FernandoOnco · 2026-09-13 · OCR
Supertecan B7-H3 a topotecan dressed to kill #sclc #WCLC26 @IASLC @BalazsHalmosMD https://
@FernandoOnco · 2026-09-13 · OCR
Supertecan B7-H3 a topotecan dressed to kill #sclc #WCLC26 @IASLC @BalazsHalmosMD https://
@FernandoOnco · 2026-09-13 · OCR
ADAURA shows OSimertinib strong after 8y in OS #WCLC26 @IASLC @OncoAlert @OncBrothers @on
@FernandoOnco · 2026-09-13 · OCR
REZILIENT-3 | EGFR exon20ins NSCLC Zipalertinib + chemotherapy delivered a striking PFS b
@FernandoOnco · 2026-09-14 · OCR
REZILIENT-3 | EGFR exon20ins NSCLC Zipalertinib + chemotherapy delivered a striking PFS b
@FernandoOnco · 2026-09-14 · OCR
REZILIENT-3 | EGFR exon20ins NSCLC Zipalertinib + chemotherapy delivered a striking PFS b
@FernandoOnco · 2026-09-14 · OCR
REZILIENT-3 | EGFR exon20ins NSCLC Zipalertinib + chemotherapy delivered a striking PFS b
@FernandoOnco · 2026-09-14 · OCR
#WCLC26 DeLLphi-309 Can we extend #tarlatamab dosing intervals in relapsed #SCLC? ORR: 10
@FernandoOnco · 2026-09-13 · OCR
#WCLC26 DeLLphi-309 Can we extend #tarlatamab dosing intervals in relapsed #SCLC? ORR: 10
@FernandoOnco · 2026-09-13 · OCR
#WCLC26 DeLLphi-309 Can we extend #tarlatamab dosing intervals in relapsed #SCLC? ORR: 10
@FernandoOnco · 2026-09-13 · OCR
Not all EGFR mutations are equal. PAPILLON: OS was not significant in ITT (HR 0.87), but
@FernandoOnco · 2026-09-13 · OCR
Not all EGFR mutations are equal. PAPILLON: OS was not significant in ITT (HR 0.87), but
@FernandoOnco · 2026-09-13 · OCR
Not all EGFR mutations are equal. PAPILLON: OS was not significant in ITT (HR 0.87), but
@FernandoOnco · 2026-09-13 · OCR
Not all EGFR mutations are equal. PAPILLON: OS was not significant in ITT (HR 0.87), but
@FernandoOnco · 2026-09-13 · OCR
#WCLC26 Good morning 🇰🇷 @BalazsHalmosMD @NarjustFlorezMD @lungoncdoc @StephenVLiu @IASLC
@FernandoOnco · 2026-09-14 · OCR
MRI surveillance is safe to SCLC and confirm less cognitive impairment @IASLC #WCLC26 http
@FernandoOnco · 2026-09-12 · OCR
MRI surveillance is safe to SCLC and confirm less cognitive impairment @IASLC #WCLC26 http
@FernandoOnco · 2026-09-12 · OCR
MRI surveillance is safe to SCLC and confirm less cognitive impairment @IASLC #WCLC26 http
@FernandoOnco · 2026-09-12 · OCR
MRI surveillance is safe to SCLC and confirm less cognitive impairment @IASLC #WCLC26 http
@FernandoOnco · 2026-09-12 · OCR
Impressive PFS with Ris-Rez in relapsed SCLC: 7.2 vs 3.0 mo, HR 0.33. But cross-trial comp
@FernandoOnco · 2026-09-13 · OCR
Come to our poster 3.414. In 2021 @jillfeldman4 and other members of @IASLC’s patient advo
@FionnualaCrowle · 2026-09-15 · OCR
Great to catch up with @JamesFanWu !! Thrilled with my Corgi sticker. #WCLC26 https://t.c
@FionnualaCrowle · 2026-09-13 · OCR
Great to catch up with @JamesFanWu !! Thrilled with my Corgi sticker. #WCLC26 https://t.c
@FionnualaCrowle · 2026-09-13 · OCR
Can we intercept lung cancer? Come hear about our immunoprevention trial, Nadunolimab for
@FionnualaCrowle · 2026-09-14 · OCR
Can we intercept lung cancer? Come hear about our immunoprevention trial, Nadunolimab for
@FionnualaCrowle · 2026-09-14 · OCR
Come see @dan_morgen ‘s poster on an AI decision tool across genomic subtypes! @Jani_Chinm
@FionnualaCrowle · 2026-09-13 · OCR
Arrived in Seoul!! #WCLC26 https://t.co/uR29pzBJMq
@FionnualaCrowle · 2026-09-12 · OCR
Congrats to @nh_osei and mentor extraordinaire @DDoroshow on their oral presentation today
@FionnualaCrowle · 2026-09-13 · OCR
Congrats to @nh_osei and mentor extraordinaire @DDoroshow on their oral presentation today
@FionnualaCrowle · 2026-09-13 · OCR
Congrats to @nh_osei and mentor extraordinaire @DDoroshow on their oral presentation today
@FionnualaCrowle · 2026-09-13 · OCR
Congrats to @nh_osei and mentor extraordinaire @DDoroshow on their oral presentation today
@FionnualaCrowle · 2026-09-13 · OCR
Great place to reflect on all the #WCLC26 data. Until next time Seoul! 📍 Inwangsan Mou
@FionnualaCrowle · 2026-09-15 · OCR
Great place to reflect on all the #WCLC26 data. Until next time Seoul! 📍 Inwangsan Mou
@FionnualaCrowle · 2026-09-15
Great place to reflect on all the #WCLC26 data. Until next time Seoul! 📍 Inwangsan Mou
@FionnualaCrowle · 2026-09-15
Important study presented by @AnaVManana- outside the exam room our patients have many soc
@FionnualaCrowle · 2026-09-13 · OCR
Important study presented by @AnaVManana- outside the exam room our patients have many soc
@FionnualaCrowle · 2026-09-13 · OCR
Important study presented by @AnaVManana- outside the exam room our patients have many soc
@FionnualaCrowle · 2026-09-13 · OCR
Important study presented by @AnaVManana- outside the exam room our patients have many soc
@FionnualaCrowle · 2026-09-13 · OCR
Seokchon Lake and Olympic Park in the same 4 mile run loop? Phenomenal views!!! #WCLC26 ht
@FionnualaCrowle · 2026-09-13 · OCR
#WCLC26 🌟First report of a combination of a #bispecific targeting PDL1 x VEGF (pumitamig)
@g_mountzios · 2026-09-15 · OCR
#WCLC26 🌟First report of a combination of a #bispecific targeting PDL1 x VEGF (pumitamig)
@g_mountzios · 2026-09-15 · OCR
#WCLC26 🌟First report of a combination of a #bispecific targeting PDL1 x VEGF (pumitamig)
@g_mountzios · 2026-09-15 · OCR
#WCLC26 🌟First report of a combination of a #bispecific targeting PDL1 x VEGF (pumitamig)
@g_mountzios · 2026-09-15 · OCR
@MarianaBrandao0 did the impossible 🙅 in #WCLC26: She managed to discuss 5 high-impact ab
@g_mountzios · 2026-09-15 · OCR
@MarianaBrandao0 did the impossible 🙅 in #WCLC26: She managed to discuss 5 high-impact ab
@g_mountzios · 2026-09-15 · OCR
@MarianaBrandao0 did the impossible 🙅 in #WCLC26: She managed to discuss 5 high-impact ab
@g_mountzios · 2026-09-15 · OCR
@MarianaBrandao0 did the impossible 🙅 in #WCLC26: She managed to discuss 5 high-impact ab
@g_mountzios · 2026-09-15 · OCR
Best way to start #WCLC26 with the @IASLC Academy workshop where I had the honor to partic
@g_mountzios · 2026-09-11 · OCR
Best way to start #WCLC26 with the @IASLC Academy workshop where I had the honor to partic
@g_mountzios · 2026-09-11 · OCR
Time to leave 🛫an unforgettable #WCLC26 and majestic Seoul 👘… What stays on is breakthrou
@g_mountzios · 2026-09-15 · OCR
Time to leave 🛫an unforgettable #WCLC26 and majestic Seoul 👘… What stays on is breakthrou
@g_mountzios · 2026-09-15 · OCR
Time to leave 🛫an unforgettable #WCLC26 and majestic Seoul 👘… What stays on is breakthrou
@g_mountzios · 2026-09-15 · OCR
Time to leave 🛫an unforgettable #WCLC26 and majestic Seoul 👘… What stays on is breakthrou
@g_mountzios · 2026-09-15 · OCR
🔬 Marta Martínez-Cutillas del @HospiPtaHierro presenta en #WCLC2026 el póster: ➡️ Excess
@gecp_org · 2026-09-13 · OCR
@ManuelDomine, Head of the Thoracic Tumors and Clinical Trials Unit at @Hospital_FJD in M
@gecp_org · 2026-09-14 · OCR
🗣️ @MARIANOPROVENCI, President of the #GECP, presents the results of the DUMAS trial as a
@gecp_org · 2026-09-14 · OCR
🔬 Marta Martínez-Cutillas del @HospiPtaHierro presenta en #WCLC2026 el póster: ➡️ Cause
@gecp_org · 2026-09-13 · OCR
🗣️ La Dra. @VirginiaCalvo6, oncóloga del @HospiPtaHierro presenta en el Poster Tour de #WC
@gecp_org · 2026-09-13 · OCR
🗣️ La Dra. @VirginiaCalvo6, oncóloga del @HospiPtaHierro presenta en el Poster Tour de #WC
@gecp_org · 2026-09-13 · OCR
🗣️ Dr. @MARIANOPROVENCI, President of the #GECP, is taking part in #WCLC2026 in theinterac
@gecp_org · 2026-09-13 · OCR
Bartomeu Massutí, secretario del #GECP, presenta en #WCLC2026 el póster: ➡️ Persistent N2
@gecp_org · 2026-09-13 · OCR
⭕@AVanessaOspinaS @HospiPtaHierro presents new results from NADIM II and REAL-NADIM at #W
@gecp_org · 2026-09-14 · OCR
⭕@AVanessaOspinaS @HospiPtaHierro presents new results from NADIM II and REAL-NADIM at #W
@gecp_org · 2026-09-14 · OCR
🔬 Bartomeu Massutí, Secretary of the #GECP, present the following poster at #WCLC2026: ➡
@gecp_org · 2026-09-14 · OCR
🗣️ Ana San Martín Doblado @HospiPtaHierro presents new GECP results on the gut microbiome
@gecp_org · 2026-09-13 · OCR
🔬 @VirginiaCalvo6 @HospiPtaHierro presents a new #GECP poster at #WCLC2026: ➡️ PALACE, C
@gecp_org · 2026-09-14 · OCR
🔬 Marta Martínez-Cutillas @HospiPtaHierro present the following poster at #WCLC2026: ➡️ C
@gecp_org · 2026-09-13 · OCR
⭕🗣️ @angelesgilg @HospiPtaHierro presenta en #WCLC2026 nuevos resultados del GECP sobre e
@gecp_org · 2026-09-14 · OCR
🔬 @sierra_belen @HospiPtaHierro presents a new #GECP poster at #WCLC2026: ➡️ Tumor BCR R
@gecp_org · 2026-09-14 · OCR
🔬 @ManuelDomine , jefe de la Unidad de Tumores Torácicos y Ensayos Clínicos de la @Hospita
@gecp_org · 2026-09-14 · OCR
Bartomeu Massutí, Secretary of the #GECP, present the following poster at #WCLC2026: ➡️
@gecp_org · 2026-09-13 · OCR
@AVanessaOspinaS miembro del GECP @HospiPtaHierro presenta en #WCLC2026 nuevos resultados
@gecp_org · 2026-09-14 · OCR
@AVanessaOspinaS miembro del GECP @HospiPtaHierro presenta en #WCLC2026 nuevos resultados
@gecp_org · 2026-09-14 · OCR
🔬 @VirginiaCalvo6 @HospiPtaHierro presenta en #WCLC2026 un nuevo póster del #GECP: ➡️ P
@gecp_org · 2026-09-14 · OCR
🔬 @sierra_belen @HospiPtaHierro presenta en #WCLC2026 un nuevo póster del #GECP: ➡️ Tumo
@gecp_org · 2026-09-14 · OCR
⭕ 🗣️ @angelesgilg @HospiPtaHierro presents new GECP results on tertiary lymphoid structur
@gecp_org · 2026-09-14 · OCR
🔬 @Serna_Blasco, researcher at @HospiPtaHierro in Madrid, presents a new #GECP poster at
@gecp_org · 2026-09-15 · OCR
⭕The #GECP concludes its participation at #WCLC2026 with three poster presentations focuse
@gecp_org · 2026-09-15 · OCR
🗣️ @MARIANOPROVENCI presidente del GECP, presenta en #WCLC2026 los resultados del estudio
@gecp_org · 2026-09-14 · OCR
🔬 Bartomeu Massutí, secretario del #GECP, presenta en #WCLC2026 el póster: ➡️ ATHENEA, a
@gecp_org · 2026-09-14 · OCR
🔬 @Serna_Blasco, investigador del @HospiPtaHierro de Madrid, presenta en #WCLC2026 un nu
@gecp_org · 2026-09-15 · OCR
🔬 Cristina Martínez-Toledo @HospiPtaHierro presents a new #GECP poster at #WCLC2026: ➡️
@gecp_org · 2026-09-14 · OCR
🔬 Alejandro Rodríguez-Festa, researcher at the Instituto de Investigación Sanitaria Puerta
@gecp_org · 2026-09-15 · OCR
⭕ @VirginiaCalvo6 @HospiPtaHierro presents the GECP ARIAN study during the Poster Tour at
@gecp_org · 2026-09-13 · OCR
🔬 El #GECP cierra su participación en #WCLC2026 con cinco trabajos en formato póster sobre
@gecp_org · 2026-09-15 · OCR
🔬 Cristina Martínez-Toledo @HospiPtaHierro presenta en #WCLC2026 el póster: ➡️ Top 1% Ba
@gecp_org · 2026-09-14 · OCR
🗣️ Ana Sanmartin Doblado del @HospiPtaHierro presenta en #WCLC2026 nuevos resultados del G
@gecp_org · 2026-09-13 · OCR
🔬 Marta Martínez-Cutillas @HospiPtaHierro present the following poster at #WCLC2026: ➡️
@gecp_org · 2026-09-13 · OCR
🔬 Alejandro Rodríguez-Festa, investigador del Instituto de Investigación Sanitaria Puerta
@gecp_org · 2026-09-15 · OCR
🗣️ El Dr. @MARIANOPROVENCI , presidente del #GECP, participa en #WCLC2026 en la sesión int
@gecp_org · 2026-09-13 · OCR
🇪🇸 Rumbo a Seúl. Los profesionales de oncología españoles se preparan para conocer las últ
@GIDOncologia · 2026-09-11 · OCR
🇪🇸 Rumbo a Seúl. Los profesionales de oncología españoles se preparan para conocer las últ
@GIDOncologia · 2026-09-11 · OCR
#WCLC26 Conocer estas novedades de primera mano es fundamental para seguir avanzando en el
@GIDOncologia · 2026-09-14 · OCR
#WCLC26 Conocer estas novedades de primera mano es fundamental para seguir avanzando en el
@GIDOncologia · 2026-09-14 · OCR
#WCLC26 Conocer estas novedades de primera mano es fundamental para seguir avanzando en el
@GIDOncologia · 2026-09-14 · OCR
Del 12 al 15 de septiembre, especialistas de todo el mundo se reunirán en el WCLC 2026 par
@GIDOncologia · 2026-09-11 · OCR
Del 12 al 15 de septiembre, especialistas de todo el mundo se reunirán en el WCLC 2026 par
@GIDOncologia · 2026-09-11 · OCR
The footwear to beat @iaslc #wclc26 @lungoncdoc @iaslc #WCLC26 @oncoalert @oncodaily @l
@GlopesMd · 2026-09-12 · OCR
Two B7-H3 ADCs presented at #WCLC26 produced very encouraging results in relapsed SCLC: AR
@GlopesMd · 2026-09-13 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight When AI meets oncolo
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight When AI meets oncolo
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight When AI meets oncolo
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight When AI meets oncolo
@GlopesMd · 2026-09-12 · OCR
Three positive first-line phase III trials now shape EGFR exon 20 insertion NSCLC: • PAPIL
@GlopesMd · 2026-09-14 · OCR
#WCLC26 Starting for me and many friends with a policy workshop - How do we transform evid
@GlopesMd · 2026-09-11 · OCR
#WCLC26 Starting for me and many friends with a policy workshop - How do we transform evid
@GlopesMd · 2026-09-11 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Age and biomarkers i
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Age and biomarkers i
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Age and biomarkers i
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Age and biomarkers i
@GlopesMd · 2026-09-12 · OCR
Major positive #WCLC26 result in relapsed SCLC: TAISHAN-302. Tambotatug pelitecan (Tam-Pe
@GlopesMd · 2026-09-13 · OCR
Alright. First flight: ✈️ FLL to DFW Where is everyone? In Seoul already? @iaslc #WCLC2
@GlopesMd · 2026-09-10 · OCR
Potentially practice-changing #WCLC26 Presidential Symposium result: SWOG S1827/MAVERICK
@GlopesMd · 2026-09-13 · OCR
Alright! After a taxi ride that felt longer than my 15-hour flight from DFW, I’m in Seoul!
@GlopesMd · 2026-09-11 · OCR
Random walk in Seoul @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvesterc
@GlopesMd · 2026-09-12 · OCR
Random walk in Seoul @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvesterc
@GlopesMd · 2026-09-12 · OCR
Random walk in Seoul @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvesterc
@GlopesMd · 2026-09-12 · OCR
Random walk in Seoul @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvesterc
@GlopesMd · 2026-09-12 · OCR
One new thing I learned in Korea this trip: aegyo. I knew Japan’s kawaii culture—Hello Ki
@GlopesMd · 2026-09-12 · OCR
Quick take from #WCLC26: Tam-Peli showed a clear overall survival advantage vs topotecan
@GlopesMd · 2026-09-13 · OCR
Important #WCLC26 result in relapsed SCLC: ARTEMIS-008. Risvutatug rezetecan (Ris-Rez) vs
@GlopesMd · 2026-09-13 · OCR
Preliminary #WCLC26 preview: HARMONi-2 Based on the company press release, ivonescimab vs
@GlopesMd · 2026-09-13 · OCR
Good bye Seoul! Thank you for an incredible #WCLC26 See you soon! Next stop: Singapore
@GlopesMd · 2026-09-15 · OCR
Good bye Seoul! Thank you for an incredible #WCLC26 See you soon! Next stop: Singapore
@GlopesMd · 2026-09-15 · OCR
Good bye Seoul! Thank you for an incredible #WCLC26 See you soon! Next stop: Singapore
@GlopesMd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium: DESTINY-Lung04 1L T-DXd vs pembrolizumab + platinum/pemet
@GlopesMd · 2026-09-14 · OCR
Beautiful last day in Seoul for #wclc26 @iaslc @oncoalert @oncodaily @larvol @tribeMDUS @
@GlopesMd · 2026-09-14 · OCR
#WCLC26: REZILIENT 3 in 1L EGFR exon20+ NSCLC. Zipalertinib + chemo vs chemo: • PFS 14.5
@GlopesMd · 2026-09-14 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight AI decision support
@GlopesMd · 2026-09-12 · OCR
Good morning, Seoul! See you at COEX? @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribe
@GlopesMd · 2026-09-11 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Cross-trial comparis
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Cross-trial comparis
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Cross-trial comparis
@GlopesMd · 2026-09-12 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Presentation Spotlight Cross-trial comparis
@GlopesMd · 2026-09-12 · OCR
Presidential Symposium at #WCLC26: final OS from PAPILLON in 1L EGFR exon 20 insertion NSC
@GlopesMd · 2026-09-14 · OCR
FDA expands sevabertinib in HER2-mutant NSCLC. Accelerated approval now includes 1L advan
@GlopesMd · 2026-09-10 · OCR
With #WHA78 we are moving from commitment to implementation - @iaslc #WCLC26 @oncoalert
@GlopesMd · 2026-09-11 · OCR
@uicc own’s @YannickRomero starting the discussion - tobacco, national cancer plans, cervi
@GlopesMd · 2026-09-11 · OCR
@uicc own’s @YannickRomero starting the discussion - tobacco, national cancer plans, cervi
@GlopesMd · 2026-09-11 · OCR
@InstitutoTorax my good friend Ricardo Sales dos Santos showed the amazing work he’s been
@GlopesMd · 2026-09-11 · OCR
@InstitutoTorax my good friend Ricardo Sales dos Santos showed the amazing work he’s been
@GlopesMd · 2026-09-11 · OCR
@InstitutoTorax my good friend Ricardo Sales dos Santos showed the amazing work he’s been
@GlopesMd · 2026-09-11 · OCR
@InstitutoTorax my good friend Ricardo Sales dos Santos showed the amazing work he’s been
@GlopesMd · 2026-09-11 · OCR
@hilaryarobbins continued the session with the role of the researcher. Policy makers hav
@GlopesMd · 2026-09-11 · OCR
Sylvester Thoracic Working Group at #WCLC26 — Co-authored Presentation ARROS-1: zidesamti
@GlopesMd · 2026-09-14 · OCR
Sylvester Thoracic Working Group at #WCLC26 — co-authored presentation. ARROS-1: zidesamt
@GlopesMd · 2026-09-14 · OCR
One place I return to whenever I am in Seoul: Bongeunsa Temple, across from COEX. During
@GlopesMd · 2026-09-11 · OCR
Starting to @IASLC #WCLC26 Day -1 in Seoul 🇰🇷 with the #IASLCAcademy. Lots of very interes
@herbloong · 2026-09-11 · OCR
Starting to @IASLC #WCLC26 Day -1 in Seoul 🇰🇷 with the #IASLCAcademy. Lots of very interes
@herbloong · 2026-09-11 · OCR
Starting to @IASLC #WCLC26 Day -1 in Seoul 🇰🇷 with the #IASLCAcademy. Lots of very interes
@herbloong · 2026-09-11 · OCR
Starting to @IASLC #WCLC26 Day -1 in Seoul 🇰🇷 with the #IASLCAcademy. Lots of very interes
@herbloong · 2026-09-11 · OCR
#WCLC19 🇪🇸 vs. #WCLC26 🇰🇷 @IASLC #LCSM https://t.co/T1kbEg9i5c
@herbloong · 2026-09-14 · OCR
Thanks @IASLC #WCLC26! Was a blast! See you all in #Denver for #WCLC27 😀 https://t.co/q2L5
@herbloong · 2026-09-15 · OCR
Thanks @IASLC #WCLC26! Was a blast! See you all in #Denver for #WCLC27 😀 https://t.co/q2L5
@herbloong · 2026-09-15 · OCR
Managed to snap a quick 🤳 with @lungoncdoc at @IASLC #WCLC26! Thanks for sharing constan
@herbloong · 2026-09-13 · OCR
A couple of #happy #Wefies 📸 at @IASLC #WCLC26 🇰🇷. Looking forward to the formal start of
@herbloong · 2026-09-11 · OCR
A couple of #happy #Wefies 📸 at @IASLC #WCLC26 🇰🇷. Looking forward to the formal start of
@herbloong · 2026-09-11 · OCR
A couple of #happy #Wefies 📸 at @IASLC #WCLC26 🇰🇷. Looking forward to the formal start of
@herbloong · 2026-09-11 · OCR
A couple of #happy #Wefies 📸 at @IASLC #WCLC26 🇰🇷. Looking forward to the formal start of
@herbloong · 2026-09-11 · OCR
A strong contingent from #hongkong 🇭🇰 at @IASLC #WCLC26! https://t.co/G2MuRx2ulU
@herbloong · 2026-09-14 · OCR
A strong contingent from #hongkong 🇭🇰 at @IASLC #WCLC26! https://t.co/G2MuRx2ulU
@herbloong · 2026-09-14 · OCR
A quick recap on talk titled #Powers & #Perils of #ADC combinations delivered at @IASLC #W
@herbloong · 2026-09-15 · OCR
A quick recap on talk titled #Powers & #Perils of #ADC combinations delivered at @IASLC #W
@herbloong · 2026-09-15 · OCR
A quick recap on talk titled #Powers & #Perils of #ADC combinations delivered at @IASLC #W
@herbloong · 2026-09-15 · OCR
A quick recap on talk titled #Powers & #Perils of #ADC combinations delivered at @IASLC #W
@herbloong · 2026-09-15 · OCR
Kicked off the official programme of @IASLC #WCLC26 with the our 8:00am session 🌅 WS04 dis
@herbloong · 2026-09-12 · OCR
Kicked off the official programme of @IASLC #WCLC26 with the our 8:00am session 🌅 WS04 dis
@herbloong · 2026-09-12 · OCR
Kicked off the official programme of @IASLC #WCLC26 with the our 8:00am session 🌅 WS04 dis
@herbloong · 2026-09-12 · OCR
Kicked off the official programme of @IASLC #WCLC26 with the our 8:00am session 🌅 WS04 dis
@herbloong · 2026-09-12 · OCR
Easiest to get around #Seoul 🇰🇷 with it’s #killertraffic 🚦🚗🚕🚙🚗🚙🚗🚙🚗 is on the #subway! Reme
@herbloong · 2026-09-11 · OCR
A pleasure meeting @CracovianL69109 in person at International Association for the Study
@herbloong · 2026-09-15 · OCR
🆙#WCLC26 #LCSM OA04.03 🔥Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atez
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM OA04.03 🔥Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atez
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM OA04.03 🔥Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atez
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM OA04.03 🔥Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atez
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🤝 @herbloong #LCSM @IASLC @OncoAlert https://t.co/draHeNMpQc
@HHorinouchi · 2026-09-12 · OCR
🔥 @PeerView From Data to Decisions in HER2-Overexpressing NSCLC 🎯Detecting Alterations, Im
@HHorinouchi · 2026-09-11 · OCR
🌟 #WCLC26 🆕 Features 🗣️Enjoy in YOUR Language 🇰🇷🇨🇳🇺🇸🇯🇵🇪🇸🇫🇷🇮🇹🇩🇪... 🔥 #AI Powered Real-Time
@HHorinouchi · 2026-09-11 · OCR
🌟First @NEJM from #WCLC26🆙 🔥TAISHAN-302: Tambotatug pelitecan (B7-H3 ADC) vs topotecan in
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🤝Powerful💪 @IASLC Board Members ☑️Caicun Zhou (President) ☑️Paul Van Schil
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant NSC
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant NSC
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant NSC
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant NSC
@HHorinouchi · 2026-09-15 · OCR
🌟 #WCLC26 Meet🆙 🤩Seeing @herbloong everywhere👀 #LCSM @IASLC @OncoAlert https://t.co/jBWKVz
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🔥Connected @IASLC staff with Riaing Stars From Japan @JLCS_OFFICIAL 🇯🇵 #LC
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🔥Secured 🏆Award Winner @kimyw_snu_pulm 🎊Congratulations!!! Young Investiga
@HHorinouchi · 2026-09-13 · OCR
🔥Great Summary and DIscussion on #ROS1 🎙️ Malinda Itchins #WCLC26 @IASLC @OncoAlert @ros1c
@HHorinouchi · 2026-09-14 · OCR
🔥Great Summary and DIscussion on #ROS1 🎙️ Malinda Itchins #WCLC26 @IASLC @OncoAlert @ros1c
@HHorinouchi · 2026-09-14 · OCR
🔥Great Summary and DIscussion on #ROS1 🎙️ Malinda Itchins #WCLC26 @IASLC @OncoAlert @ros1c
@HHorinouchi · 2026-09-14 · OCR
🔥 #WCLC26 "Record Breaking Number"🌟 🔢Total delegates: 8203🔥 🔢In Person: 7233🎉 🎊Congratula
@HHorinouchi · 2026-09-14 · OCR
🆙 #WCLC26 #LCSM Oral Session 🔥 Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pe
@HHorinouchi · 2026-09-15 · OCR
🆙 #WCLC26 #LCSM Oral Session 🔥 Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pe
@HHorinouchi · 2026-09-15 · OCR
🆙 #WCLC26 #LCSM Oral Session 🔥 Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pe
@HHorinouchi · 2026-09-15 · OCR
🆙 #WCLC26 #LCSM Oral Session 🔥 Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pe
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥A Phase III Randomized Multicenter Trial of Adjuvant Gefitini
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥A Phase III Randomized Multicenter Trial of Adjuvant Gefitini
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥A Phase III Randomized Multicenter Trial of Adjuvant Gefitini
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥A Phase III Randomized Multicenter Trial of Adjuvant Gefitini
@HHorinouchi · 2026-09-13 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Safety, Pharmacokinetics, and Preliminary Antitumor Ac
@HHorinouchi · 2026-09-15 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Safety, Pharmacokinetics, and Preliminary Antitumor Ac
@HHorinouchi · 2026-09-15 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Safety, Pharmacokinetics, and Preliminary Antitumor Ac
@HHorinouchi · 2026-09-15 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Safety, Pharmacokinetics, and Preliminary Antitumor Ac
@HHorinouchi · 2026-09-15 · OCR
🔥Great Discussion on Great Abstract 🌟Beyond Efficacy: Calibrating Adjuvant Therapy in EGFR
@HHorinouchi · 2026-09-13 · OCR
🔥Great Discussion on Great Abstract 🌟Beyond Efficacy: Calibrating Adjuvant Therapy in EGFR
@HHorinouchi · 2026-09-13 · OCR
🔥Great Discussion on Great Abstract 🌟Beyond Efficacy: Calibrating Adjuvant Therapy in EGFR
@HHorinouchi · 2026-09-13 · OCR
🔥Great Discussion on Great Abstract 🌟Beyond Efficacy: Calibrating Adjuvant Therapy in EGFR
@HHorinouchi · 2026-09-13 · OCR
🔥Greatt Summary and Discussion on EGFR Ex20ins ⁉️PAPILON vs. WU KONG 28 vs. REZILIENT 3 🎙️
@HHorinouchi · 2026-09-14 · OCR
🔥Greatt Summary and Discussion on EGFR Ex20ins ⁉️PAPILON vs. WU KONG 28 vs. REZILIENT 3 🎙️
@HHorinouchi · 2026-09-14 · OCR
🔥Greatt Summary and Discussion on EGFR Ex20ins ⁉️PAPILON vs. WU KONG 28 vs. REZILIENT 3 🎙️
@HHorinouchi · 2026-09-14 · OCR
🔥Greatt Summary and Discussion on EGFR Ex20ins ⁉️PAPILON vs. WU KONG 28 vs. REZILIENT 3 🎙️
@HHorinouchi · 2026-09-14 · OCR
🤖Experienced Big Wave of #AI in #WCLC26 ? 🔥Join Us! @IASLC #AI Artificial Intelligence Tas
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥ARTEMIDE-01: Updated Efficacy Results of Rilvegostomig f
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥ARTEMIDE-01: Updated Efficacy Results of Rilvegostomig f
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥ARTEMIDE-01: Updated Efficacy Results of Rilvegostomig f
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥ARTEMIDE-01: Updated Efficacy Results of Rilvegostomig f
@HHorinouchi · 2026-09-15 · OCR
🤣It's really @IASLC #WCLC26 in Seoul, Korea🇰🇷 🎙 @karenkellymd Karen Kelly CEO #LCSM @OncoA
@HHorinouchi · 2026-09-12 · OCR
🤣It's really @IASLC #WCLC26 in Seoul, Korea🇰🇷 🎙 @karenkellymd Karen Kelly CEO #LCSM @OncoA
@HHorinouchi · 2026-09-12 · OCR
🌟 #WCLC26 Meet🆙 🔥Secured 2️⃣ 🔝 #LCSM influencers🤣 🤝 @GlopesMd @lungoncdoc @IASLC @OncoAler
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🔥 Prof. James CH. Yang, @NReguart @StephenVLiu @bensolomon1 @IASLC @OncoAl
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🤝 @g_mountzios @JuliaRotow @sands_jacob #LCSM @IASLC @OncoAlert https://t.
@HHorinouchi · 2026-09-15 · OCR
🔜The Faculty Feud: #ADC Experts Live Showdown! 🔥Interactive Discussion about Updated and B
@HHorinouchi · 2026-09-13 · OCR
🆙 @IASLC in Action💪 🌍Global Council Inaugural Meeting 🌏 ✅Reducing Risk (Smoking, Working
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🤝 @sands_jacob @NReguart #LCSM @IASLC @OncoAlert https://t.co/xDlrByzljc
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitax
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitax
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitax
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitax
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast
@HHorinouchi · 2026-09-15 · OCR
🎊Congratulations💐 🔥 @pompili_cecilia 🌟 @IASLC Robert J. Ginsberg Lectureship Award for Sur
@HHorinouchi · 2026-09-13 · OCR
🌟 #WCLC26 Meet🆙 🤝 @ZerAlona #LCSM @IASLC @OncoAlert https://t.co/b3LmMbOINP
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4
@HHorinouchi · 2026-09-15 · OCR
👋See you at #WCLC27 🗓️September 11-14, 2027 🏔️ #Denver Hometown of @IASLC 🎊Congratulatio
@HHorinouchi · 2026-09-15 · OCR
🌟 #WCLC26 Meet🆙 🤝Prof. Beung-Chul Ahn 🔥Just Got 🇰🇷"Pop" Star 🌟➕🔝Influencer❤️ #LCSM @IASLC
@HHorinouchi · 2026-09-13 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥160Mgfurmonertinib for EGFR-Mutated NSCLC With Leptomeni
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥160Mgfurmonertinib for EGFR-Mutated NSCLC With Leptomeni
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥160Mgfurmonertinib for EGFR-Mutated NSCLC With Leptomeni
@HHorinouchi · 2026-09-15 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥160Mgfurmonertinib for EGFR-Mutated NSCLC With Leptomeni
@HHorinouchi · 2026-09-15 · OCR
👏🏽👏🏽 how about a record number year for #WCLC26 . Thanks to all the delegates attending in
@IASLC · 2026-09-14 · OCR
Wrapping up Day 1 of #WCLC26 at tonight’s Welcome Reception! 🍽️ A great evening of reconn
@IASLC · 2026-09-12 · OCR
Wrapping up Day 1 of #WCLC26 at tonight’s Welcome Reception! 🍽️ A great evening of reconn
@IASLC · 2026-09-12 · OCR
A big congratulations to our #WCLC26 award recipients! 🏆👏 Today’s Awards Luncheon celebra
@IASLC · 2026-09-12 · OCR
A big congratulations to our #WCLC26 award recipients! 🏆👏 Today’s Awards Luncheon celebra
@IASLC · 2026-09-12 · OCR
A big congratulations to our #WCLC26 award recipients! 🏆👏 Today’s Awards Luncheon celebra
@IASLC · 2026-09-12 · OCR
A big congratulations to our #WCLC26 award recipients! 🏆👏 Today’s Awards Luncheon celebra
@IASLC · 2026-09-12 · OCR
That’s a wrap on #WCLC26! 🌏🫁 Thank you to everyone who joined us in Seoul for four days o
@IASLC · 2026-09-15 · OCR
That’s a wrap on #WCLC26! 🌏🫁 Thank you to everyone who joined us in Seoul for four days o
@IASLC · 2026-09-15 · OCR
That’s a wrap on #WCLC26! 🌏🫁 Thank you to everyone who joined us in Seoul for four days o
@IASLC · 2026-09-15 · OCR
#WCLC26 Awards luncheon begins with a recognition of @JTOonline 20th anniversary! Congrats
@IASLC · 2026-09-12 · OCR
#WCLC26 Awards luncheon begins with a recognition of @JTOonline 20th anniversary! Congrats
@IASLC · 2026-09-12 · OCR
#WCLC26 Awards luncheon begins with a recognition of @JTOonline 20th anniversary! Congrats
@IASLC · 2026-09-12 · OCR
Global dialogue in action at #WCLC26! 🌏🤝 It’s great to see a full room for the Joint IASL
@IASLC · 2026-09-12 · OCR
Global dialogue in action at #WCLC26! 🌏🤝 It’s great to see a full room for the Joint IASL
@IASLC · 2026-09-12 · OCR
Looking to the future of #lungcancer education at #WCLC26. Great discussion on how clinici
@IASLC · 2026-09-12 · OCR
Looking to the future of #lungcancer education at #WCLC26. Great discussion on how clinici
@IASLC · 2026-09-12 · OCR
Did you know about Lung Cancer 360? It’s IASLC’s on-demand education center, giving you ye
@IASLC · 2026-09-14 · OCR
Day 3 of #WCLC26 is underway! We’re starting the day with Presidential Symposium 2, highl
@IASLC · 2026-09-13 · OCR
Happening now: The #WCLC26 Opening Plenary! https://t.co/7Vk6Uqiwx8
@IASLC · 2026-09-12 · OCR
Happening now: The #WCLC26 Opening Plenary! https://t.co/7Vk6Uqiwx8
@IASLC · 2026-09-12 · OCR
Happening now: The #WCLC26 Opening Plenary! https://t.co/7Vk6Uqiwx8
@IASLC · 2026-09-12 · OCR
🎙️ Live from #WCLC26: Sunday Highlights! Dr. @NarjustFlorezMD talks with Dr. Chad Rusthove
@IASLC · 2026-09-14 · OCR
🏆 The rematch is ON! Join us for the Interactive Closing Lunch: The Ultimate WCLC Rematch
@IASLC · 2026-09-15 · OCR
🎙️Monday Highlights from #WCLC26! Drs. @StephenVLiu & @NarjustFlorezMD are joined by @ale
@IASLC · 2026-09-15 · OCR
An interactive debate is underway at #WCLC26! Clinical Dilemmas in SCLC: Debating the Use
@IASLC · 2026-09-13 · OCR
An interactive debate is underway at #WCLC26! Clinical Dilemmas in SCLC: Debating the Use
@IASLC · 2026-09-13 · OCR
🎧 New #LungCancerConsidered episode in #Mandarin Chinese! Dr. @susu_mail0513 is joined by
@IASLC · 2026-09-16 · OCR
🎙️ Day 3 of #WCLC26 brought new data on moving targeted therapies earlier in #LungCancer t
@IASLC · 2026-09-16 · OCR
In Harmoni-2 Keytruda outperformed KN-042, and still $SMMT ivonescimab beat it on OS. Yes
@JacobPlieth · 2026-09-13 · OCR
Meanwhile, $AZN $DSNKY are filing on these data. Sure, why not? #WCLC26 https://t.co/0Xg2U
@JacobPlieth · 2026-09-14 · OCR
Meanwhile, $AZN $DSNKY are filing on these data. Sure, why not? #WCLC26 https://t.co/0Xg2U
@JacobPlieth · 2026-09-14 · OCR
Nice Arros-1 vs Trust I/II vs Trident-1 cross-trial comparisons by #WCLC26 discussant Mali
@JacobPlieth · 2026-09-14 · OCR
Nice Arros-1 vs Trust I/II vs Trident-1 cross-trial comparisons by #WCLC26 discussant Mali
@JacobPlieth · 2026-09-14 · OCR
For $CGEM followers, I really don't know where this leaves zipalertinib. Rezilient-3 disco
@JacobPlieth · 2026-09-14 · OCR
Here's an important detail from #WCLC26 about Harmoni-2: the positive OS data are from a 2
@JacobPlieth · 2026-09-14 · OCR
Harmoni-2 OS curves, via Caicun Zhou #WCLC26 $SMMT https://t.co/ATdWa0ptOE
@JacobPlieth · 2026-09-13 · OCR
Harmoni-2 OS curves, via Caicun Zhou #WCLC26 $SMMT https://t.co/ATdWa0ptOE
@JacobPlieth · 2026-09-13 · OCR
@old_pes40130 @BiotechObserver I think 11% for Papillon - with this caveat #WCLC26 https:/
@JacobPlieth · 2026-09-14 · OCR
Excited for @fabiomoraesmd’s plenary on the perspective of AI in clinical decision making
@JamesFanWu · 2026-09-15 · OCR
Come by #WCLC26 — PT1.01.04: adolescent and young adult lung cancer in East Asia, 1990–202
@JamesFanWu · 2026-09-12 · OCR
Come by and say hello — I'd love to talk through this one. 📍 Row 3 · 🕤 9:30–11am · P3.018
@JamesFanWu · 2026-09-14 · OCR
Wife and son sending me off for Day 1 of @IASLC #WCLC26 🫁 Let’s see everyone’s day 1 fit c
@JamesFanWu · 2026-09-11 · OCR
Wife and son sending me off for Day 1 of @IASLC #WCLC26 🫁 Let’s see everyone’s day 1 fit c
@JamesFanWu · 2026-09-11 · OCR
Seoul 🇰🇷 — Full Day 1 ⏰ 3:00 AM — wide awake ☕️ 5:20 AM — out in search of coffee Explorin
@JamesFanWu · 2026-09-10 · OCR
Finally got some quality time with my good friend, mentor, and collaborator @fabiomoraesmd
@JamesFanWu · 2026-09-12 · OCR
Excited for my first session of @IASLC #WCLC26 🫁 Looking forward to hear from leaders in
@JamesFanWu · 2026-09-11 · OCR
Excited for my first session of @IASLC #WCLC26 🫁 Looking forward to hear from leaders in
@JamesFanWu · 2026-09-11 · OCR
Excited for my first session of @IASLC #WCLC26 🫁 Looking forward to hear from leaders in
@JamesFanWu · 2026-09-11 · OCR
Excited for my first session of @IASLC #WCLC26 🫁 Looking forward to hear from leaders in
@JamesFanWu · 2026-09-11 · OCR
Very proud of @GoAudiE for leading our study in young and middle-aged individuals with lun
@JamesFanWu · 2026-09-13 · OCR
Very proud of @GoAudiE for leading our study in young and middle-aged individuals with lun
@JamesFanWu · 2026-09-13 · OCR
Very proud of @GoAudiE for leading our study in young and middle-aged individuals with lun
@JamesFanWu · 2026-09-13 · OCR
Come hear @n_libonati this morning — worth the walk for her award winning project! Today
@JamesFanWu · 2026-09-15 · OCR
Thank you to @cspramesh and @DDRHuang for stopping by our poster! Your insights for this p
@JamesFanWu · 2026-09-13 · OCR
My first #selfie of @IASLC #WCLC26 🫁 at 7:20am first thing in the morning right before the
@JamesFanWu · 2026-09-12 · OCR
It was great to meet Dr. @riess_md in person today at my poster! Really enjoyed our chat a
@JamesFanWu · 2026-09-15 · OCR
Presenting at #WCLC26 @GoAudiE — PT1.01.05: lung cancer in young and middle-aged adults ac
@JamesFanWu · 2026-09-12 · OCR
Great to see you @FionnualaCrowle and catch up on a special occasion nonetheless! You won’
@JamesFanWu · 2026-09-13 · OCR
Ready for day 2 of @IASLC #WCLC26 with coffee and poster in hand!! ☕️📊 https://t.co/SKeBnD
@JamesFanWu · 2026-09-12 · OCR
Early morning Seoul independent coffee shops Cert Coffee and Fritz Coffee Company before d
@JamesFanWu · 2026-09-14 · OCR
Early morning Seoul independent coffee shops Cert Coffee and Fritz Coffee Company before d
@JamesFanWu · 2026-09-14 · OCR
Early morning Seoul independent coffee shops Cert Coffee and Fritz Coffee Company before d
@JamesFanWu · 2026-09-14 · OCR
My son requested his own badge and a picture with the @IASLC #WCLC26 mascot! Wishes grante
@JamesFanWu · 2026-09-11 · OCR
My son requested his own badge and a picture with the @IASLC #WCLC26 mascot! Wishes grante
@JamesFanWu · 2026-09-11 · OCR
Ready for my first World Lung, and I'm presenting two posters at #WCLC26 in Seoul! 🫁 @IASL
@JamesFanWu · 2026-09-11 · OCR
Getting to meet your international collaborators in person is the beauty of conferences li
@JamesFanWu · 2026-09-13 · OCR
Thanks for stopping by and catching up at our poster @herbloong! Always enjoy discussing f
@JamesFanWu · 2026-09-13 · OCR
Rare date night with my beautiful wife at @IASLC #WCLC26 celebration night 💕 Grateful for
@JamesFanWu · 2026-09-16 · OCR
Rare date night with my beautiful wife at @IASLC #WCLC26 celebration night 💕 Grateful for
@JamesFanWu · 2026-09-16 · OCR
Rare date night with my beautiful wife at @IASLC #WCLC26 celebration night 💕 Grateful for
@JamesFanWu · 2026-09-16
Ready for day 3 of @IASLC #WCLC26 New dress shirt, new bow tie. Same @Florez_Lab #HearH
@JamesFanWu · 2026-09-14 · OCR
Always great to see @NarjustFlorezMD ❤️ Glad we got to bump into each other at the @IASLC
@JamesFanWu · 2026-09-16 · OCR
Final OS for 🦋 1L amivantamab +chemo for #EGFR exon20ins NSCLC showed OS benefit of 0.57,
@jennifermarksmd · 2026-09-13 · OCR
Final OS for 🦋 1L amivantamab +chemo for #EGFR exon20ins NSCLC showed OS benefit of 0.57,
@jennifermarksmd · 2026-09-13 · OCR
Final OS for 🦋 1L amivantamab +chemo for #EGFR exon20ins NSCLC showed OS benefit of 0.57,
@jennifermarksmd · 2026-09-13 · OCR
Biggest take away from SWOG S1827/MAVERICK trial - MRI surveillance alone resulted in imp
@jennifermarksmd · 2026-09-12 · OCR
Biggest take away from SWOG S1827/MAVERICK trial - MRI surveillance alone resulted in imp
@jennifermarksmd · 2026-09-12 · OCR
Biggest take away from SWOG S1827/MAVERICK trial - MRI surveillance alone resulted in imp
@jennifermarksmd · 2026-09-12 · OCR
Feeling fancy in our hanboks at @IASLC #WCLC26 . #lcsm https://t.co/GP8tBQ9NJ3
@jennifermarksmd · 2026-09-14 · OCR
Feeling fancy in our hanboks at @IASLC #WCLC26 . #lcsm https://t.co/GP8tBQ9NJ3
@jennifermarksmd · 2026-09-14 · OCR
Debates in #meso , #TET, and #SCLC is on 🔥🔥🔥 🧐Does surgery still play a role in meso? 📌Co
@jennifermarksmd · 2026-09-12 · OCR
Always love to see a drug beating topotecan. For #sclc. Tam-Peli (B7-H3 ADC) vs topotecan
@jennifermarksmd · 2026-09-13 · OCR
Always love to see a drug beating topotecan. For #sclc. Tam-Peli (B7-H3 ADC) vs topotecan
@jennifermarksmd · 2026-09-13 · OCR
Always love to see a drug beating topotecan. For #sclc. Tam-Peli (B7-H3 ADC) vs topotecan
@jennifermarksmd · 2026-09-13 · OCR
Always love to see a drug beating topotecan. For #sclc. Tam-Peli (B7-H3 ADC) vs topotecan
@jennifermarksmd · 2026-09-13 · OCR
Excellent discussion by Dr. @Annechiangmd summarizing the B7H3 ADCs and the evolving land
@jennifermarksmd · 2026-09-13 · OCR
Excellent discussion by Dr. @Annechiangmd summarizing the B7H3 ADCs and the evolving land
@jennifermarksmd · 2026-09-13 · OCR
Excellent discussion by Dr. @Annechiangmd summarizing the B7H3 ADCs and the evolving land
@jennifermarksmd · 2026-09-13 · OCR
Excellent discussion by Dr. @Annechiangmd summarizing the B7H3 ADCs and the evolving land
@jennifermarksmd · 2026-09-13 · OCR
Meeting Korean cuties at #WCLC26 🐻‍❄️ @IASLC #lcsm https://t.co/xnKT81UM8x
@jennifermarksmd · 2026-09-12 · OCR
Meeting Korean cuties at #WCLC26 🐻‍❄️ @IASLC #lcsm https://t.co/xnKT81UM8x
@jennifermarksmd · 2026-09-12 · OCR
Dr. Malinda Itchins reviews the ARROS-1 trial and where zida fits into @ros1cancer space.
@jennifermarksmd · 2026-09-14 · OCR
Dr. Malinda Itchins reviews the ARROS-1 trial and where zida fits into @ros1cancer space.
@jennifermarksmd · 2026-09-14 · OCR
ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53, with most
@jennifermarksmd · 2026-09-13 · OCR
ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53, with most
@jennifermarksmd · 2026-09-13 · OCR
ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53, with most
@jennifermarksmd · 2026-09-13 · OCR
ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53, with most
@jennifermarksmd · 2026-09-13 · OCR
Impressive results presented by @alexdrilon . Zidesamtinib in ROS1+ TKI naive pts showed O
@jennifermarksmd · 2026-09-14 · OCR
Impressive results presented by @alexdrilon . Zidesamtinib in ROS1+ TKI naive pts showed O
@jennifermarksmd · 2026-09-14 · OCR
Impressive results presented by @alexdrilon . Zidesamtinib in ROS1+ TKI naive pts showed O
@jennifermarksmd · 2026-09-14 · OCR
Impressive results presented by @alexdrilon . Zidesamtinib in ROS1+ TKI naive pts showed O
@jennifermarksmd · 2026-09-14 · OCR
1L Zipalertinib +chemo for #EGFRex20ins showed ✅PFS benefit 🚫No OS benefit 🙈With very hi
@jennifermarksmd · 2026-09-14 · OCR
1L Zipalertinib +chemo for #EGFRex20ins showed ✅PFS benefit 🚫No OS benefit 🙈With very hi
@jennifermarksmd · 2026-09-14 · OCR
1L Zipalertinib +chemo for #EGFRex20ins showed ✅PFS benefit 🚫No OS benefit 🙈With very hi
@jennifermarksmd · 2026-09-14 · OCR
1L Zipalertinib +chemo for #EGFRex20ins showed ✅PFS benefit 🚫No OS benefit 🙈With very hi
@jennifermarksmd · 2026-09-14 · OCR
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary e
@jennifermarksmd · 2026-09-14 · OCR
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary e
@jennifermarksmd · 2026-09-14 · OCR
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary e
@jennifermarksmd · 2026-09-14 · OCR
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary e
@jennifermarksmd · 2026-09-14 · OCR
Beautiful discussion by @LudaBazhenovaMD of the 1L landscape for #EGFRex20ins NSCLC. Limi
@jennifermarksmd · 2026-09-14 · OCR
Beautiful discussion by @LudaBazhenovaMD of the 1L landscape for #EGFRex20ins NSCLC. Limi
@jennifermarksmd · 2026-09-14 · OCR
Beautiful discussion by @LudaBazhenovaMD of the 1L landscape for #EGFRex20ins NSCLC. Limi
@jennifermarksmd · 2026-09-14 · OCR
Beautiful discussion by @LudaBazhenovaMD of the 1L landscape for #EGFRex20ins NSCLC. Limi
@jennifermarksmd · 2026-09-14 · OCR
Another B7H3, Ris-Rez, with impressive OS (18.5m v 10.3m HR 0.46) in #SCLC compared to top
@jennifermarksmd · 2026-09-13 · OCR
Another B7H3, Ris-Rez, with impressive OS (18.5m v 10.3m HR 0.46) in #SCLC compared to top
@jennifermarksmd · 2026-09-13 · OCR
Another B7H3, Ris-Rez, with impressive OS (18.5m v 10.3m HR 0.46) in #SCLC compared to top
@jennifermarksmd · 2026-09-13 · OCR
Another B7H3, Ris-Rez, with impressive OS (18.5m v 10.3m HR 0.46) in #SCLC compared to top
@jennifermarksmd · 2026-09-13 · OCR
Persistent OS gain-widens over time to 15% at 8 yr. More evidence that the we are eradicat
@jennifermarksmd · 2026-09-13 · OCR
Persistent OS gain-widens over time to 15% at 8 yr. More evidence that the we are eradicat
@jennifermarksmd · 2026-09-13 · OCR
Persistent OS gain-widens over time to 15% at 8 yr. More evidence that the we are eradicat
@jennifermarksmd · 2026-09-13 · OCR
Important findings from the MAVERICK study. Cognitive toxicity is not an abstract endpoint
@jillfeldman4 · 2026-09-13 · OCR
Important findings from the MAVERICK study. Cognitive toxicity is not an abstract endpoint
@jillfeldman4 · 2026-09-13 · OCR
Congratulations Dr @pompili_cecilia for receiving the Robert J Ginsberg Lectureship Award.
@jillfeldman4 · 2026-09-13 · OCR
Congratulations Dr @pompili_cecilia for receiving the Robert J Ginsberg Lectureship Award.
@jillfeldman4 · 2026-09-13 · OCR
Stop by this really important poster P3.414! showing improvement in respectful language af
@jillfeldman4 · 2026-09-15 · OCR
Thank you @IASLC for your continued commitment to advancing #lungcancer research, care, a
@jillfeldman4 · 2026-09-12 · OCR
Thank you @IASLC for your continued commitment to advancing #lungcancer research, care, a
@jillfeldman4 · 2026-09-12 · OCR
Dr. @JuliaRotow presents Ph3 DESTINY-Lung04 T-DXd vs Pembro-chemo #WCLC26. ✅️ PFS 14.3 vs
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @JuliaRotow presents Ph3 DESTINY-Lung04 T-DXd vs Pembro-chemo #WCLC26. ✅️ PFS 14.3 vs
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @JuliaRotow presents Ph3 DESTINY-Lung04 T-DXd vs Pembro-chemo #WCLC26. ✅️ PFS 14.3 vs
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @JuliaRotow presents Ph3 DESTINY-Lung04 T-DXd vs Pembro-chemo #WCLC26. ✅️ PFS 14.3 vs
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @DrRoyHerbst presents exploratory 8-year analysis of ADAURA Trial at #WCLC26. At 8 yea
@Joshua_Reuss · 2026-09-13 · OCR
Dr. @DrRoyHerbst presents exploratory 8-year analysis of ADAURA Trial at #WCLC26. At 8 yea
@Joshua_Reuss · 2026-09-13 · OCR
Dr. @DrRoyHerbst presents exploratory 8-year analysis of ADAURA Trial at #WCLC26. At 8 yea
@Joshua_Reuss · 2026-09-13 · OCR
Dr. @alexdrilon presents TKI-naive cohort from ph 1/2 ARROS-1 Trial. #WCLC26 ✅️ impressiv
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @alexdrilon presents TKI-naive cohort from ph 1/2 ARROS-1 Trial. #WCLC26 ✅️ impressiv
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @alexdrilon presents TKI-naive cohort from ph 1/2 ARROS-1 Trial. #WCLC26 ✅️ impressiv
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @alexdrilon presents TKI-naive cohort from ph 1/2 ARROS-1 Trial. #WCLC26 ✅️ impressiv
@Joshua_Reuss · 2026-09-14 · OCR
Thrilled to see my 🌟 @LombardiCancer colleague Dr @chulkimMD present final OS data for pha
@Joshua_Reuss · 2026-09-13 · OCR
Dr. @LudaBazhenovaMD with an excellent breakdown of emerging/approved frontline treatment
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @LudaBazhenovaMD with an excellent breakdown of emerging/approved frontline treatment
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @LudaBazhenovaMD with an excellent breakdown of emerging/approved frontline treatment
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @LudaBazhenovaMD with an excellent breakdown of emerging/approved frontline treatment
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @danieltanmd presents ph3 REZILIENT3 zipalertinib+chemo vs chemo #WCLC26. ✅️ PFS 14.5m
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @danieltanmd presents ph3 REZILIENT3 zipalertinib+chemo vs chemo #WCLC26. ✅️ PFS 14.5m
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @danieltanmd presents ph3 REZILIENT3 zipalertinib+chemo vs chemo #WCLC26. ✅️ PFS 14.5m
@Joshua_Reuss · 2026-09-14 · OCR
Dr. @danieltanmd presents ph3 REZILIENT3 zipalertinib+chemo vs chemo #WCLC26. ✅️ PFS 14.5m
@Joshua_Reuss · 2026-09-14 · OCR
Another risk factor for lung cancer risk: presence of Family History #wclc26 https://t.co/
@KSamalaMD · 2026-09-12 · OCR
Prospective Studies on the role of SBRT for resectable NSLC #wclc26 https://t.co/uRVpdWdHs
@KSamalaMD · 2026-09-12 · OCR
#HARMONI2 #WCLC26 Efficacy Results ✅️median OS: 30.8 vs 22.6 mos ✅️ subgroup analysis fa
@KSamalaMD · 2026-09-15 · OCR
#HARMONI2 #WCLC26 Efficacy Results ✅️median OS: 30.8 vs 22.6 mos ✅️ subgroup analysis fa
@KSamalaMD · 2026-09-15 · OCR
#HARMONI2 #WCLC26 Efficacy Results ✅️median OS: 30.8 vs 22.6 mos ✅️ subgroup analysis fa
@KSamalaMD · 2026-09-15 · OCR
#HARMONI2 OS analysis : #Ivonescimab vs #pemmbrolizumab in PDL1 high NSCLC #WCLC26 https:/
@KSamalaMD · 2026-09-15 · OCR
#HARMONI2 OS analysis : #Ivonescimab vs #pemmbrolizumab in PDL1 high NSCLC #WCLC26 https:/
@KSamalaMD · 2026-09-15 · OCR
Bispecific Antibody + chemo as 1L mNSCLC #RC148 #WCLC26 https://t.co/NyZAN1OPt4
@KSamalaMD · 2026-09-15 · OCR
Bispecific Antibody + chemo as 1L mNSCLC #RC148 #WCLC26 https://t.co/NyZAN1OPt4
@KSamalaMD · 2026-09-15 · OCR
Bispecific Antibody + chemo as 1L mNSCLC #RC148 #WCLC26 https://t.co/NyZAN1OPt4
@KSamalaMD · 2026-09-15 · OCR
Rethinking role of RT in ES SCLC by @gwalls89 #WCLC26 Era of ICI in ES SCLC https://t.co
@KSamalaMD · 2026-09-12 · OCR
#PAPILLON Final OS Data #WCLC26 ✅️Median OS: 34.3 mos vs 27.9 mos HR. 87 (not statistical
@KSamalaMD · 2026-09-13 · OCR
#PAPILLON Final OS Data #WCLC26 ✅️Median OS: 34.3 mos vs 27.9 mos HR. 87 (not statistical
@KSamalaMD · 2026-09-13 · OCR
#PAPILLON Final OS Data #WCLC26 ✅️Median OS: 34.3 mos vs 27.9 mos HR. 87 (not statistical
@KSamalaMD · 2026-09-13 · OCR
#PAPILLON Final OS Data #WCLC26 ✅️Median OS: 34.3 mos vs 27.9 mos HR. 87 (not statistical
@KSamalaMD · 2026-09-13 · OCR
Conclusion: #PAPILLON demonstrated the longest median OS to date for exon20 EGFRm NSCLC #W
@KSamalaMD · 2026-09-13 · OCR
@APassaroMD Efficacy ✅️ significant updated Median OS: HR 0.76 ✅️ median OS benefit regar
@KSamalaMD · 2026-09-15 · OCR
@APassaroMD Efficacy ✅️ significant updated Median OS: HR 0.76 ✅️ median OS benefit regar
@KSamalaMD · 2026-09-15 · OCR
#LONESTAR study #WCLC26 https://t.co/xCKKUnVZEG
@KSamalaMD · 2026-09-15 · OCR
#LONESTAR study #WCLC26 https://t.co/xCKKUnVZEG
@KSamalaMD · 2026-09-15 · OCR
#ElfeD with #Pumitamig #BNT32401 for mNSCLC #WCLC26 (SCLC focus) https://t.co/kbQO9LBzGR
@KSamalaMD · 2026-09-15 · OCR
#ADAURA 8 year OS data by @DrRoyHerbst ✅️ significant OS data: HR 0.52 ✅️seen across all
@KSamalaMD · 2026-09-13 · OCR
#ADAURA 8 year OS data by @DrRoyHerbst ✅️ significant OS data: HR 0.52 ✅️seen across all
@KSamalaMD · 2026-09-13 · OCR
#ADAURA 8 year OS data by @DrRoyHerbst ✅️ significant OS data: HR 0.52 ✅️seen across all
@KSamalaMD · 2026-09-13 · OCR
#ADAURA 8 year OS data by @DrRoyHerbst ✅️ significant OS data: HR 0.52 ✅️seen across all
@KSamalaMD · 2026-09-13 · OCR
#TrastuzumabDeruxtecan #DestinyLung04 #WCLC26 ✅️ PFS: 14.3 mos vs 8.3 mos HR 0.63 ✅️ PFS
@KSamalaMD · 2026-09-14 · OCR
#TrastuzumabDeruxtecan #DestinyLung04 #WCLC26 ✅️ PFS: 14.3 mos vs 8.3 mos HR 0.63 ✅️ PFS
@KSamalaMD · 2026-09-14 · OCR
#TrastuzumabDeruxtecan #DestinyLung04 #WCLC26 ✅️ PFS: 14.3 mos vs 8.3 mos HR 0.63 ✅️ PFS
@KSamalaMD · 2026-09-14 · OCR
#TrastuzumabDeruxtecan #DestinyLung04 #WCLC26 ✅️ PFS: 14.3 mos vs 8.3 mos HR 0.63 ✅️ PFS
@KSamalaMD · 2026-09-14 · OCR
Oligomets and Oligoprogession in metastatic NSCLC by Florence Keane #WCLC26 Trial landscap
@KSamalaMD · 2026-09-12 · OCR
#REZILIENT Trial by Dr @danieltanmd #WCLC26 #Zipalertinib for #exon20 NSCLC Endpoint: ✅️
@KSamalaMD · 2026-09-14 · OCR
#REZILIENT Trial by Dr @danieltanmd #WCLC26 #Zipalertinib for #exon20 NSCLC Endpoint: ✅️
@KSamalaMD · 2026-09-14 · OCR
#REZILIENT Trial by Dr @danieltanmd #WCLC26 #Zipalertinib for #exon20 NSCLC Endpoint: ✅️
@KSamalaMD · 2026-09-14 · OCR
#REZILIENT Trial by Dr @danieltanmd #WCLC26 #Zipalertinib for #exon20 NSCLC Endpoint: ✅️
@KSamalaMD · 2026-09-14 · OCR
Efficacy Results #RC148 ✅️ confirmed ORR 76.7% (overall) Older pts had better ORR: 85% In
@KSamalaMD · 2026-09-15 · OCR
Efficacy Results #RC148 ✅️ confirmed ORR 76.7% (overall) Older pts had better ORR: 85% In
@KSamalaMD · 2026-09-15 · OCR
Last session for me this #WCLC26 Four days of learnings, networking and gaining new persp
@KSamalaMD · 2026-09-15 · OCR
Last session for me this #WCLC26 Four days of learnings, networking and gaining new persp
@KSamalaMD · 2026-09-15 · OCR
@APassaroMD Conclusion: ✅️ Updated OS analysis with extended follow up in Western patients
@KSamalaMD · 2026-09-15 · OCR
Opening ceromonies @IASLC #WCLC26 https://t.co/JunbaXRGwP
@KSamalaMD · 2026-09-12 · OCR
#TALENT study in Taiwan: • 2.1% detection rate • family history as a significant lung canc
@KSamalaMD · 2026-09-12 · OCR
Final analysis of #IMPower030 by @bensolomon1 #WCLC26 https://t.co/B3ohECUzs2
@KSamalaMD · 2026-09-13 · OCR
Conclusion : #Harmoni2 #WCLC26 https://t.co/Frtpg4gmT2
@KSamalaMD · 2026-09-15 · OCR
Initial results (SCLC cohort) #WCLC26 ✅️ ORR: 70.4% (overall) ✅️ DCR: 93.3% ✅️ ORR with DL
@KSamalaMD · 2026-09-15 · OCR
Initial results (SCLC cohort) #WCLC26 ✅️ ORR: 70.4% (overall) ✅️ DCR: 93.3% ✅️ ORR with DL
@KSamalaMD · 2026-09-15 · OCR
Initial results (SCLC cohort) #WCLC26 ✅️ ORR: 70.4% (overall) ✅️ DCR: 93.3% ✅️ ORR with DL
@KSamalaMD · 2026-09-15 · OCR
A promising combination therapy with ADC for SCLC #WCLC26 https://t.co/e6M1VoM0PY
@KSamalaMD · 2026-09-15 · OCR
Can we use ctDNA to de escalate therapy after LCT? #WCLC26 https://t.co/pqnQ50oQyR
@KSamalaMD · 2026-09-12 · OCR
Adjuvant Management for Actionable Genetic Alterations by Eun Young Kim #WCLC26 Current
@KSamalaMD · 2026-09-12 · OCR
✅️Proof of concept: Real world implementation of risk models for lung cancer screening #W
@KSamalaMD · 2026-09-12 · OCR
Study design •small study but indeed very powerful as we now use KRAs directed therapy in
@KSamalaMD · 2026-09-13 · OCR
Study design •small study but indeed very powerful as we now use KRAs directed therapy in
@KSamalaMD · 2026-09-13 · OCR
@gwalls89 Additional things to consider during the ICI era #wclc26 https://t.co/AYTlL7Ra9e
@KSamalaMD · 2026-09-12 · OCR
#WCLC26 #destinlyLung04 Safety data ILD remains an important AE and should be monitored c
@KSamalaMD · 2026-09-14 · OCR
#WCLC26 #destinlyLung04 Safety data ILD remains an important AE and should be monitored c
@KSamalaMD · 2026-09-14 · OCR
Conclusion: ✅️ findings do not support the use of LCT after ipi / nivo induction in mNSCLC
@KSamalaMD · 2026-09-15 · OCR
Conclusion #WCLC26 https://t.co/cNFYpvk1wV
@KSamalaMD · 2026-09-15 · OCR
Neoadjuvant #Divarasib in #KRASG12C NSCLC #NAUTIKA1 #WCLC26 https://t.co/7qbokFTI7v
@KSamalaMD · 2026-09-13 · OCR
@bensolomon1 #WCLC26 Results: ✅️ IRF- assessed EFS: 62.8 vs 34.9 mos but ❌️ statisticall
@KSamalaMD · 2026-09-13 · OCR
#MDTBridge #wclc26 https://t.co/FDunJOhBUM
@KSamalaMD · 2026-09-13 · OCR
#MDTBridge #wclc26 https://t.co/FDunJOhBUM
@KSamalaMD · 2026-09-13 · OCR
@DrRoyHerbst Dr @APassaroMD discussion on #ADAURA • postponement of recurrence, no longer
@KSamalaMD · 2026-09-13 · OCR
@DrRoyHerbst Dr @APassaroMD discussion on #ADAURA • postponement of recurrence, no longer
@KSamalaMD · 2026-09-13 · OCR
@gwalls89 Meta on the role of RT in ES SCLC • Thoracic RT improved OS and PFS #wclc26 http
@KSamalaMD · 2026-09-12 · OCR
Summary #destinlyLung04 #WCLC26 ✅️ met its primary endpoint: 6 month improvement in PFS ✅
@KSamalaMD · 2026-09-14 · OCR
안녕하세요 from Seoul! ✌️🇰🇷 @IASLC #WCLC26 https://t.co/WzsR92sq1n
@KSamalaMD · 2026-09-14 · OCR
#RAPHAEL trial -role of Gefitinib + chemo in resected NSCLC #WCLC26 https://t.co/qmoKuMOq
@KSamalaMD · 2026-09-13 · OCR
Persons who never smoked and women are often missed. Def need to focus on this population.
@KSamalaMD · 2026-09-12 · OCR
@IASLC consensus statment on primary RT for Stage IV NSCLC #WCLC26 https://t.co/E88DsA5E
@KSamalaMD · 2026-09-12 · OCR
Neoadjuvant divarasib demonstrated promising antitumot activity #Wclc26 https://t.co/TUm43
@KSamalaMD · 2026-09-13 · OCR
Neoadjuvant divarasib demonstrated promising antitumot activity #Wclc26 https://t.co/TUm43
@KSamalaMD · 2026-09-13 · OCR
Key takeaways for non smoking lung cancer: #wCLC26 https://t.co/QROOXRqEkk
@KSamalaMD · 2026-09-12 · OCR
Nice summary of the rationale for SBRT for oligoprogressive NSCLC #WCLC26 https://t.co/L3
@KSamalaMD · 2026-09-12 · OCR
Promising antitumor activity : ORR: 55%m MPR: 42% Manageable safety profile Ongoing #KRA
@KSamalaMD · 2026-09-13 · OCR
✅️Surgical outcomes: ALL patients who underwent surgery achieved R0 resection #WCLC26 http
@KSamalaMD · 2026-09-13 · OCR
Risk factors for Lung Cancer: presence of endogenous and exogenous exposomes #wclc26 https
@KSamalaMD · 2026-09-12 · OCR
Can we target the primary lesion thru consolidation RT prior to oligoprogression? #WCLC26
@KSamalaMD · 2026-09-12 · OCR
@alexdrilon #ARROS1 ✅️ focus of this trial is on TKI naive ROS1 NSCLC #WCLC26 https://t.c
@KSamalaMD · 2026-09-14 · OCR
@alexdrilon #ARROS1 ✅️ focus of this trial is on TKI naive ROS1 NSCLC #WCLC26 https://t.c
@KSamalaMD · 2026-09-14 · OCR
Study design: intercalating gefitinib dose (given on Day 15-18) #Wclc26 https://t.co/5nyPI
@KSamalaMD · 2026-09-13 · OCR
@IASLC Primary RT for mestastic NSCLC: Hope or Hype? #WCLC26 https://t.co/yMOY8K8BBM
@KSamalaMD · 2026-09-12 · OCR
✅️EFS: 100% on pts who achieved PCR #WCLC26 https://t.co/zgletAXSse
@KSamalaMD · 2026-09-13 · OCR
✅️EFS: 100% on pts who achieved PCR #WCLC26 https://t.co/zgletAXSse
@KSamalaMD · 2026-09-13 · OCR
@alexdrilon Impressive efficacy results ✅️ ORR at 94% ✅️ DOR >=6 mos: 96% ✅️ Intracranial
@KSamalaMD · 2026-09-14 · OCR
@alexdrilon Impressive efficacy results ✅️ ORR at 94% ✅️ DOR >=6 mos: 96% ✅️ Intracranial
@KSamalaMD · 2026-09-14 · OCR
@alexdrilon Impressive efficacy results ✅️ ORR at 94% ✅️ DOR >=6 mos: 96% ✅️ Intracranial
@KSamalaMD · 2026-09-14 · OCR
@danieltanmd Conclusion: ✅️ median PFS significant with 6 mo benefit ✅️ Gr 3 AEs in combo
@KSamalaMD · 2026-09-14 · OCR
@danieltanmd Conclusion: ✅️ median PFS significant with 6 mo benefit ✅️ Gr 3 AEs in combo
@KSamalaMD · 2026-09-14 · OCR
#RAPHAEL trial baseline characteristics #WCLC26 https://t.co/Jmqg0P1Pvs
@KSamalaMD · 2026-09-13 · OCR
Hello from Seoul #WCLC26 https://t.co/c68WRWRuAD
@KSamalaMD · 2026-09-12 · OCR
No difference in outcomes if we pause tageted therapy during RT #WCLC26 https://t.co/3h54v
@KSamalaMD · 2026-09-12 · OCR
Conlusion: • MDT def helps pts achieve better outcomes #WCLC26 https://t.co/HzOwd9glBg
@KSamalaMD · 2026-09-13 · OCR
@gwalls89 Current data on role of PCI #wclc26 https://t.co/z3Lx6t0cFo
@KSamalaMD · 2026-09-12 · OCR
@bensolomon1 Key secondary endpoints: #WCLC26 https://t.co/NKAEj9ckCZ
@KSamalaMD · 2026-09-13 · OCR
@bensolomon1 Key secondary endpoints: #WCLC26 https://t.co/NKAEj9ckCZ
@KSamalaMD · 2026-09-13 · OCR
@bensolomon1 #IMPower030 did not meet primary endpoints of improved IRF-EFS https://t.co/5
@KSamalaMD · 2026-09-13 · OCR
#WCLC26 https://t.co/dMNR75NxEm
@KSamalaMD · 2026-09-12 · OCR
Safety: Expected AEs noted (nausea, diarrhea, rashes) #WCLC26 https://t.co/pvxWhPOaoi
@KSamalaMD · 2026-09-13 · OCR
Results of AMIGO-1 (LACOG 0821), a phase II trial of amivantamab + lazertinib + pemetrexed
@LACOG_group · 2026-09-14 · OCR
Results of AMIGO-1 (LACOG 0821), a phase II trial of amivantamab + lazertinib + pemetrexed
@LACOG_group · 2026-09-14 · OCR
Results of AMIGO-1 (LACOG 0821), a phase II trial of amivantamab + lazertinib + pemetrexed
@LACOG_group · 2026-09-14 · OCR
Results of AMIGO-1 (LACOG 0821), a phase II trial of amivantamab + lazertinib + pemetrexed
@LACOG_group · 2026-09-14 · OCR
We are pleased to announce that AMIGO-1 (LACOG 0821), from LACOG Lung, will be presented a
@LACOG_group · 2026-09-11 · OCR
We are pleased to announce that AMIGO-1 (LACOG 0821), from LACOG Lung, will be presented a
@LACOG_group · 2026-09-11 · OCR
#WCLC26 🇰🇷 Great meeting this morning with the @IASLC Communications Subcommittee. A true
@Latinamd · 2026-09-12 · OCR
#WCLC26 Communications Debate #1: Is X still the best social media platform for scientific
@Latinamd · 2026-09-12 · OCR
#WCLC26 Communications Debate #1: Is X still the best social media platform for scientific
@Latinamd · 2026-09-12 · OCR
Say not more. Being able to give a #tarlatamab for #SCLC without requiring an overnight ad
@Latinamd · 2026-09-15 · OCR
Great lung cancer research coming up at #WCLC26! 🫁🇰🇷 Here are my top oral abstracts to wat
@Latinamd · 2026-09-12 · OCR
#WCLC26 🇰🇷 I couldn’t look away from the graphic images of tobacco-related diseases on ci
@Latinamd · 2026-09-11 · OCR
📣 #WCLC26 Dont miss the session today by the @IASLC Communications committee on How to Ge
@Latinamd · 2026-09-11 · OCR
#WCLC26 Plenary Sessions and oral abstracts I’m following during the meeting 👇 #WCLC26 #L
@Latinamd · 2026-09-12 · OCR
#WCLC26 Grateful for the 🌎 community of Women in Thoracic Oncology I’ve gotten to know thr
@Latinamd · 2026-09-13 · OCR
#WCLC26 🇰🇷 Pre-conference visit to the DMZ between North and South Korea. I was so captiva
@Latinamd · 2026-09-11 · OCR
#WCLC26 🇰🇷 Pre-conference visit to the DMZ between North and South Korea. I was so captiva
@Latinamd · 2026-09-11 · OCR
#WCLC26 🇰🇷 Pre-conference visit to the DMZ between North and South Korea. I was so captiva
@Latinamd · 2026-09-11 · OCR
👏👏Standing ovation and recognition of @DRCamidge receiving the @IASLC Paul Dunn Award in
@Latinamd · 2026-09-12 · OCR
#WCLC26 Multidisciplinary Thoracic Tumor Board in the Joseon Dinasty🇰🇷 Can you pick up
@Latinamd · 2026-09-15 · OCR
#WCLC26 Ready to start the @IASLC Communications session with my fellow #boricua🇵🇷 oncolog
@Latinamd · 2026-09-12 · OCR
#WCLC26 Presidential Symposium Day 2 #ADAURA: Adjuvant osimertinib — exploratory 8-year O
@Latinamd · 2026-09-14 · OCR
#WCLC26 Presidential Symposium Day 2 #ADAURA: Adjuvant osimertinib — exploratory 8-year O
@Latinamd · 2026-09-14 · OCR
#WCLC26 Presidential Symposium Day 2 #ADAURA: Adjuvant osimertinib — exploratory 8-year O
@Latinamd · 2026-09-14 · OCR
#WCLC26 Presidential Symposium Day 2 #ADAURA: Adjuvant osimertinib — exploratory 8-year O
@Latinamd · 2026-09-14 · OCR
#WCLC26 @IASLC communications panel addresses how AI will change communications via social
@Latinamd · 2026-09-12 · OCR
#WCLC26 🇰🇷was busy, but we still found time to record a podcast for @OncNewsCentral with t
@Latinamd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#PAPILLON: First-Line Amivantamab-Chemotherapy vs C
@Latinamd · 2026-09-14 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#PAPILLON: First-Line Amivantamab-Chemotherapy vs C
@Latinamd · 2026-09-14 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#PAPILLON: First-Line Amivantamab-Chemotherapy vs C
@Latinamd · 2026-09-14 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#PAPILLON: First-Line Amivantamab-Chemotherapy vs C
@Latinamd · 2026-09-14 · OCR
🔥 #WCLC26 #TAISHAN-302 🎯Tam-Peli (YL201), a B7-H3 ADC, vs topotecan in relapsed SCLC: ▶️
@Latinamd · 2026-09-13 · OCR
🔥 #WCLC26 #TAISHAN-302 🎯Tam-Peli (YL201), a B7-H3 ADC, vs topotecan in relapsed SCLC: ▶️
@Latinamd · 2026-09-13 · OCR
🔥 #WCLC26 #TAISHAN-302 🎯Tam-Peli (YL201), a B7-H3 ADC, vs topotecan in relapsed SCLC: ▶️
@Latinamd · 2026-09-13 · OCR
#WCLC26 Our traditional @iaslc #WCLC picture holding the 🇵🇷 flag with the amazing @AnaVMan
@Latinamd · 2026-09-15 · OCR
#WCLC26 Our traditional @iaslc #WCLC picture holding the 🇵🇷 flag with the amazing @AnaVMan
@Latinamd · 2026-09-15 · OCR
#WCLC26 Our traditional @iaslc #WCLC picture holding the 🇵🇷 flag with the amazing @AnaVMan
@Latinamd · 2026-09-15 · OCR
🔥 #WCLC26 #ARTEMIS008 🎯 Riz Rez (risvutatug rezetecan ) B7-H3 ADC, vs topotecan in relaps
@Latinamd · 2026-09-13 · OCR
🔥 #WCLC26 #ARTEMIS008 🎯 Riz Rez (risvutatug rezetecan ) B7-H3 ADC, vs topotecan in relaps
@Latinamd · 2026-09-13 · OCR
🔥 #WCLC26 #ARTEMIS008 🎯 Riz Rez (risvutatug rezetecan ) B7-H3 ADC, vs topotecan in relaps
@Latinamd · 2026-09-13 · OCR
#WCLC26 Presidential Symposium Day 2 🎯REZILIENT 3: First line #Zipalertinib + platinum/p
@Latinamd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium Day 2 🎯REZILIENT 3: First line #Zipalertinib + platinum/p
@Latinamd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium Day 2 🎯REZILIENT 3: First line #Zipalertinib + platinum/p
@Latinamd · 2026-09-15 · OCR
#WCLC26 Day2 What’s on the schedule today? Presidential Symposium starting at 8am KST Wh
@Latinamd · 2026-09-12 · OCR
#WCLC26 Day2 What’s on the schedule today? Presidential Symposium starting at 8am KST Wh
@Latinamd · 2026-09-12 · OCR
@IASLC #WCLC26 Plenary Session happening now. Dr. Caicun Zhou, @IASLC President, opened wi
@Latinamd · 2026-09-12 · OCR
@IASLC #WCLC26 Plenary Session happening now. Dr. Caicun Zhou, @IASLC President, opened wi
@Latinamd · 2026-09-12 · OCR
@IASLC #WCLC26 Plenary Session happening now. Dr. Caicun Zhou, @IASLC President, opened wi
@Latinamd · 2026-09-12 · OCR
Today is Day 1 of @IASLC #WCLC26 in Seoul, Korea🇰🇷! Excited to hear about the science , c
@Latinamd · 2026-09-11 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#DESTINY-Lung04: First-line trastuzumab deruxtecan
@Latinamd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#DESTINY-Lung04: First-line trastuzumab deruxtecan
@Latinamd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#DESTINY-Lung04: First-line trastuzumab deruxtecan
@Latinamd · 2026-09-15 · OCR
#WCLC26 Presidential Symposium Day 2 🔥#DESTINY-Lung04: First-line trastuzumab deruxtecan
@Latinamd · 2026-09-15 · OCR
@LuisRaezMD Made it to #WCLC26 in Korea🇰🇷 after a long ✈️ and look who I found at the airp
@Latinamd · 2026-09-10 · OCR
#WCLC26 Communication Session Debate #2 Sifting Through the Noise: using social media for
@Latinamd · 2026-09-12 · OCR
#WCLC26 Communication Session Debate #2 Sifting Through the Noise: using social media for
@Latinamd · 2026-09-12 · OCR
#WCLC26 Dr Caicun Zhou starts the @IASLC Communications session describing the evolving la
@Latinamd · 2026-09-12 · OCR
#WCLC26 Day 2 Presidential Symposium looking forward to all the data on targeted therapies
@Latinamd · 2026-09-13 · OCR
#WCLC26 Communication session now 🆙 @lungoncdoc provides a Patient Advocates’ Guide to Fin
@Latinamd · 2026-09-12 · OCR
#WCLC26 Communication session now 🆙 @lungoncdoc provides a Patient Advocates’ Guide to Fin
@Latinamd · 2026-09-12 · OCR
#WCLC26 Communication session now 🆙 @lungoncdoc provides a Patient Advocates’ Guide to Fin
@Latinamd · 2026-09-12 · OCR
🧠 #WCLC26 #MAVERICK (SWOG S1827) finally answers a long-standing question: PCI vs brain MR
@Latinamd · 2026-09-12 · OCR
🧠 #WCLC26 #MAVERICK (SWOG S1827) finally answers a long-standing question: PCI vs brain MR
@Latinamd · 2026-09-12 · OCR
🧠 #WCLC26 #MAVERICK (SWOG S1827) finally answers a long-standing question: PCI vs brain MR
@Latinamd · 2026-09-12 · OCR
#WCLC26 Loving the @IASLC mascot. Who needs a therapy dog when you can have a therapy tedd
@Latinamd · 2026-09-12 · OCR
#WCLC26 Day 2 Presidential Symposium 🔥#ARROS1: #Zidesamtinib in TKI-naive Patients With
@Latinamd · 2026-09-15 · OCR
#WCLC26 Day 2 Presidential Symposium 🔥#ARROS1: #Zidesamtinib in TKI-naive Patients With
@Latinamd · 2026-09-15 · OCR
#WCLC26 Getting ready for a running 🏃‍♂️ excursion in Seoul with my new RasOnc friend from
@Latinamd · 2026-09-12 · OCR
#WCLC26 some serious competitors for the @IASLC Wellness Challenge running 🏃‍♂️ this am b
@Latinamd · 2026-09-12 · OCR
#WCLC26 was a truly global 🌎 meeting . Where else could you meet lung cancer experts from
@Latinamd · 2026-09-16 · OCR
#WCLC26 was a truly global 🌎 meeting . Where else could you meet lung cancer experts from
@Latinamd · 2026-09-16 · OCR
#WCLC26 was a truly global 🌎 meeting . Where else could you meet lung cancer experts from
@Latinamd · 2026-09-16 · OCR
#WCLC26 was a truly global 🌎 meeting . Where else could you meet lung cancer experts from
@Latinamd · 2026-09-16
#WCLC26 @IASLC Oral abstracts on Tuesday 9/15 that I’m watching👇 https://t.co/vjhFaQT3yf
@Latinamd · 2026-09-12 · OCR
#WCLC26 @iaslc Plenary session continues on Monday w targeted therapy top abstracts #lcsm
@Latinamd · 2026-09-12 · OCR
@GlopesMd I loved the aegyo too #WCLC26 @IASLC https://t.co/JMMkEnXgHV
@Latinamd · 2026-09-12 · OCR
#WCLC26 Grateful to travel to Korea to learn about latest in #lungcancer research and shar
@Latinamd · 2026-09-16 · OCR
#WCLC26 Grateful to travel to Korea to learn about latest in #lungcancer research and shar
@Latinamd · 2026-09-16 · OCR
#WCLC26 The questions after the discussions are the best part: ❓How will we select between
@Latinamd · 2026-09-13 · OCR
Groundbreaking data at #WCLC26 , MAVERICK! So honored to play a small role in this practic
@LauraAlderMD · 2026-09-12 · OCR
Groundbreaking data at #WCLC26 , MAVERICK! So honored to play a small role in this practic
@LauraAlderMD · 2026-09-12 · OCR
Groundbreaking data at #WCLC26 , MAVERICK! So honored to play a small role in this practic
@LauraAlderMD · 2026-09-12 · OCR
Groundbreaking data at #WCLC26 , MAVERICK! So honored to play a small role in this practic
@LauraAlderMD · 2026-09-12 · OCR
Phenomenal presentation by @chulkimMD on PAPILLON OS @ #WCLC26! ⭐️OS impressive improveme
@LauraAlderMD · 2026-09-13 · OCR
Dr @JuliaRotow with terrific presentation of DESTINY-Lung04 #WCLC26. ORR 70% vs 44.5%, imp
@LauraAlderMD · 2026-09-14 · OCR
Dr @JuliaRotow with terrific presentation of DESTINY-Lung04 #WCLC26. ORR 70% vs 44.5%, imp
@LauraAlderMD · 2026-09-14 · OCR
A truly wonderful #WCLC26! Grateful for exciting updates advancing patient outcomes, the c
@LauraAlderMD · 2026-09-15 · OCR
A truly wonderful #WCLC26! Grateful for exciting updates advancing patient outcomes, the c
@LauraAlderMD · 2026-09-15 · OCR
A truly wonderful #WCLC26! Grateful for exciting updates advancing patient outcomes, the c
@LauraAlderMD · 2026-09-15 · OCR
A truly wonderful #WCLC26! Grateful for exciting updates advancing patient outcomes, the c
@LauraAlderMD · 2026-09-15 · OCR
Excited to present two posters at the SCLC poster session this morning at #WCLC26! 🕤 9:30–
@LauraAlderMD · 2026-09-14 · OCR
Another ADC joins the SCLC armamentarium! Tam-Peli with huge OS, PFS and intracranial ben
@LauraAlderMD · 2026-09-13 · OCR
Another ADC joins the SCLC armamentarium! Tam-Peli with huge OS, PFS and intracranial ben
@LauraAlderMD · 2026-09-13 · OCR
Another ADC joins the SCLC armamentarium! Tam-Peli with huge OS, PFS and intracranial ben
@LauraAlderMD · 2026-09-13 · OCR
Dr Goldman #WCLC26 presenting DeLLphi-309 interval dosing of Tarlatamab: q2 vs q3 vs q4 we
@LauraAlderMD · 2026-09-13 · OCR
Dr Goldman #WCLC26 presenting DeLLphi-309 interval dosing of Tarlatamab: q2 vs q3 vs q4 we
@LauraAlderMD · 2026-09-13 · OCR
Dr Goldman #WCLC26 presenting DeLLphi-309 interval dosing of Tarlatamab: q2 vs q3 vs q4 we
@LauraAlderMD · 2026-09-13 · OCR
Dr Chiappori presenting LB2102, an armored DLL3-CAR-T Cell Therapy #WCLC26. CRS and ICANS
@LauraAlderMD · 2026-09-13 · OCR
Dr Chiappori presenting LB2102, an armored DLL3-CAR-T Cell Therapy #WCLC26. CRS and ICANS
@LauraAlderMD · 2026-09-13 · OCR
Dr Chiappori presenting LB2102, an armored DLL3-CAR-T Cell Therapy #WCLC26. CRS and ICANS
@LauraAlderMD · 2026-09-13 · OCR
Dr @LudaBazhenovaMD giving a phenomenal overview of the EGFR exon 20ins landscape #WCLC26
@LauraAlderMD · 2026-09-14 · OCR
Dr @LudaBazhenovaMD giving a phenomenal overview of the EGFR exon 20ins landscape #WCLC26
@LauraAlderMD · 2026-09-14 · OCR
Dr @LudaBazhenovaMD giving a phenomenal overview of the EGFR exon 20ins landscape #WCLC26
@LauraAlderMD · 2026-09-14 · OCR
Dr @LudaBazhenovaMD giving a phenomenal overview of the EGFR exon 20ins landscape #WCLC26
@LauraAlderMD · 2026-09-14 · OCR
Dr @alexdrilon presenting ARROS-1, Zidesamtinib for ROS1 NSCLC in 1L. - ORR 94%, PFS NR!
@LauraAlderMD · 2026-09-14 · OCR
Dr @alexdrilon presenting ARROS-1, Zidesamtinib for ROS1 NSCLC in 1L. - ORR 94%, PFS NR!
@LauraAlderMD · 2026-09-14 · OCR
Dr @alexdrilon presenting ARROS-1, Zidesamtinib for ROS1 NSCLC in 1L. - ORR 94%, PFS NR!
@LauraAlderMD · 2026-09-14 · OCR
Dr Daniel Tan presents REZILIENT 3 at #WCLC26, Zipalertinib offers oral TKI option (+chemo
@LauraAlderMD · 2026-09-14 · OCR
Dr Daniel Tan presents REZILIENT 3 at #WCLC26, Zipalertinib offers oral TKI option (+chemo
@LauraAlderMD · 2026-09-14 · OCR
Dr Daniel Tan presents REZILIENT 3 at #WCLC26, Zipalertinib offers oral TKI option (+chemo
@LauraAlderMD · 2026-09-14 · OCR
Dr Daniel Tan presents REZILIENT 3 at #WCLC26, Zipalertinib offers oral TKI option (+chemo
@LauraAlderMD · 2026-09-14 · OCR
Terrific presentation by Dr Anne Chiang @YaleCancer discussing both B7H3 ADC presentations
@LauraAlderMD · 2026-09-13 · OCR
Terrific presentation by Dr Anne Chiang @YaleCancer discussing both B7H3 ADC presentations
@LauraAlderMD · 2026-09-13 · OCR
Terrific presentation by Dr Anne Chiang @YaleCancer discussing both B7H3 ADC presentations
@LauraAlderMD · 2026-09-13 · OCR
Terrific presentation by Dr Anne Chiang @YaleCancer discussing both B7H3 ADC presentations
@LauraAlderMD · 2026-09-13 · OCR
Dr @DrRoyHerbst presenting 8 year (!) data on ADAURA. #WCLC26 Highlights are ongoing survi
@LauraAlderMD · 2026-09-13 · OCR
Dr @DrRoyHerbst presenting 8 year (!) data on ADAURA. #WCLC26 Highlights are ongoing survi
@LauraAlderMD · 2026-09-13 · OCR
Dr @DrRoyHerbst presenting 8 year (!) data on ADAURA. #WCLC26 Highlights are ongoing survi
@LauraAlderMD · 2026-09-13 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-13 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-13 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-13 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-13 · OCR
Presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF grante
@lcrf_org · 2026-09-12 · OCR
Presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF grante
@lcrf_org · 2026-09-12 · OCR
Presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF grante
@lcrf_org · 2026-09-12 · OCR
Presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF grante
@lcrf_org · 2026-09-12 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-14 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-14 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-14 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-14 · OCR
#WCLC26 Day 3, Sept. 14: A second Presidential Symposium includes 5 more abstracts on impo
@lcrf_org · 2026-09-13 · OCR
#WCLC26 Day 2, Sept. 13: The first Presidential Symposium includes four abstracts on Phase
@lcrf_org · 2026-09-12 · OCR
Among those presenting today at the World Conference on Lung Cancer: LCRF grantees Dr. Jai
@lcrf_org · 2026-09-14 · OCR
Among those presenting today at the World Conference on Lung Cancer: LCRF grantees Dr. Jai
@lcrf_org · 2026-09-14 · OCR
Among those presenting today at the World Conference on Lung Cancer: LCRF grantees Dr. Jai
@lcrf_org · 2026-09-14 · OCR
Among those presenting today at the World Conference on Lung Cancer: LCRF grantees Dr. Jai
@lcrf_org · 2026-09-14 · OCR
Presenting today at the World Conference on Lung Cancer: LCRF grantee Dr. William Feng. #
@lcrf_org · 2026-09-13 · OCR
Presenting today at the World Conference on Lung Cancer: LCRF grantee Dr. William Feng. #
@lcrf_org · 2026-09-13 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-15 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-15 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-15 · OCR
Among those presenting today at the World Conference on Lung Cancer in Seoul, South Korea:
@lcrf_org · 2026-09-15 · OCR
Presenting today at the World Conference on Lung Cancer: LCRF grantee Dr. Xiuning Le from
@lcrf_org · 2026-09-15 · OCR
Presenting today at the World Conference on Lung Cancer: LCRF grantee Dr. Xiuning Le from
@lcrf_org · 2026-09-15 · OCR
#WCLC26 Day 4, Sept. 15: The closing plenary session will focus on artificial intelligence
@lcrf_org · 2026-09-15 · OCR
The World Conference on Lung Cancer is the world’s largest multidisciplinary meeting dedic
@lcrf_org · 2026-09-16 · OCR
Proud to have completed the IASLC Academy Program at #WCLC26. Grateful to @ClaudioVladmir
@leogilsan · 2026-09-12 · OCR
Proud to have completed the IASLC Academy Program at #WCLC26. Grateful to @ClaudioVladmir
@leogilsan · 2026-09-12 · OCR
Proud to have completed the IASLC Academy Program at #WCLC26. Grateful to @ClaudioVladmir
@leogilsan · 2026-09-12 · OCR
Proud to have completed the IASLC Academy Program at #WCLC26. Grateful to @ClaudioVladmir
@leogilsan · 2026-09-12 · OCR
Amazing session with the IASLC Early Career Section at #WCLC26. Great insights into IASLC
@leogilsan · 2026-09-12 · OCR
Amazing session with the IASLC Early Career Section at #WCLC26. Great insights into IASLC
@leogilsan · 2026-09-12 · OCR
Beyond #WCLC26. 🫰🏽Seoul 🇰🇷 https://t.co/5PTuvicGII
@leogilsan · 2026-09-15 · OCR
Beyond #WCLC26. 🫰🏽Seoul 🇰🇷 https://t.co/5PTuvicGII
@leogilsan · 2026-09-15 · OCR
Beyond #WCLC26. 🫰🏽Seoul 🇰🇷 https://t.co/5PTuvicGII
@leogilsan · 2026-09-15
🇧🇷 mentees at the @IASLC Academy Program and @ClaudioVladmir. #WCLC26. @GBOT_Alerta @CMHid
@leogilsan · 2026-09-12 · OCR
Navigating progressive NSCLC without a clear molecular map now at #WCLC26, under the excel
@leogilsan · 2026-09-14 · OCR
Navigating progressive NSCLC without a clear molecular map now at #WCLC26, under the excel
@leogilsan · 2026-09-14 · OCR
🌟 Thanks to @chulkimMD for joining us at #WCLC26 for an amazing interview this morning!
@Lung_Cancers · 2026-09-12 · OCR
🌟 Thanks to @StephenVLiu for joining us for a fantastic interview at #WCLC26! ➡️ Stay tu
@Lung_Cancers · 2026-09-15
🫁 Gearing up for @IASLC #WCLC26 Presidential Symposium featuring: 🌟 ADAURA: @DrRoyHerbst
@Lung_Cancers · 2026-09-13 · OCR
🫁 Gearing up for @IASLC #WCLC26 Presidential Symposium featuring: 🌟 ADAURA: @DrRoyHerbst
@Lung_Cancers · 2026-09-13 · OCR
🫁 Gearing up for @IASLC #WCLC26 Presidential Symposium featuring: 🌟 ADAURA: @DrRoyHerbst
@Lung_Cancers · 2026-09-13 · OCR
🫁 We're so excited for @IASLC #WCLC26 to officially kick off in Seoul tomorrow! 🌟 Don't
@Lung_Cancers · 2026-09-11 · OCR
🫁 What data are you most excited to see presented at the #WCLC26 Presidential Symposia? 🌟
@Lung_Cancers · 2026-09-12 · OCR
🌟 Thanks to @NarjustFlorezMD for joining us at #WCLC26 for a fantastic interview on today'
@Lung_Cancers · 2026-09-12 · OCR
🫁 Coming up at #WCLC26: The second Presidential Symposium begins with lectureship award pr
@Lung_Cancers · 2026-09-13 · OCR
👏 We're wrapping up a truly amazing #WCLC26, filled with inspiring sessions, great convers
@Lung_Cancers · 2026-09-15 · OCR
👏 We're wrapping up a truly amazing #WCLC26, filled with inspiring sessions, great convers
@Lung_Cancers · 2026-09-15 · OCR
👏 We're wrapping up a truly amazing #WCLC26, filled with inspiring sessions, great convers
@Lung_Cancers · 2026-09-15 · OCR
👏 We're wrapping up a truly amazing #WCLC26, filled with inspiring sessions, great convers
@Lung_Cancers · 2026-09-15 · OCR
🫁 It's been an amazing first day at @IASLC #WCLC26, full of fantastic interviews, conversa
@Lung_Cancers · 2026-09-12 · OCR
🫁 It's been an amazing first day at @IASLC #WCLC26, full of fantastic interviews, conversa
@Lung_Cancers · 2026-09-12 · OCR
🫁 It's been an amazing first day at @IASLC #WCLC26, full of fantastic interviews, conversa
@Lung_Cancers · 2026-09-12 · OCR
🫁 It's been an amazing first day at @IASLC #WCLC26, full of fantastic interviews, conversa
@Lung_Cancers · 2026-09-12 · OCR
🫁 Coming up at #WCLC26: The Pro Con Debates on Hot Topics in Mesothelioma, Thymoma, and SC
@Lung_Cancers · 2026-09-11 · OCR
🫁 It's hard to believe it's the final day of @IASLC #WCLC26 in Seoul, but time flies durin
@Lung_Cancers · 2026-09-14 · OCR
🌟 Thanks to @DrRoyHerbst of @DartmouthCancer for joining us at @IASLC #WCLC26 for a fantas
@Lung_Cancers · 2026-09-13 · OCR
🌞 Today's the day - the IASLC World Conference on Lung Cancer kicks off in Seoul this morn
@Lung_Cancers · 2026-09-11 · OCR
🌞 Today's the day - the IASLC World Conference on Lung Cancer kicks off in Seoul this morn
@Lung_Cancers · 2026-09-11 · OCR
🫁 Coming up at @IASLC #WCLC26: The opening plenary with distinguished service award presen
@Lung_Cancers · 2026-09-12 · OCR
🫁 Coming up at @IASLC #WCLC26: The opening plenary with distinguished service award presen
@Lung_Cancers · 2026-09-12 · OCR
🫁 Coming up at @IASLC #WCLC26: The opening plenary with distinguished service award presen
@Lung_Cancers · 2026-09-12 · OCR
🫁 Coming up at @IASLC #WCLC26: The opening plenary with distinguished service award presen
@Lung_Cancers · 2026-09-12 · OCR
🫁 Coming up at #WCLC26: The global communication workshop titled "Getting the Message Acro
@Lung_Cancers · 2026-09-12 · OCR
@sara_pilotto @QuistMorten The @IASLC #WCLC26 workshop on exercise in lung cancer & launch
@Lung_Cancers · 2026-09-11 · OCR
🫁 We're counting down until @IASLC #WCLC26 begins in Seoul this weekend! ⭐ Don't miss thi
@Lung_Cancers · 2026-09-11 · OCR
🌟 An amazing start to the @IASLC #WCLC26 Presidential Symposium presentations, which kicke
@Lung_Cancers · 2026-09-12 · OCR
🫁 It's been another amazing day at #WCLC26, filled with ground-breaking presentations, tho
@Lung_Cancers · 2026-09-13 · OCR
🫁 It's been another amazing day at #WCLC26, filled with ground-breaking presentations, tho
@Lung_Cancers · 2026-09-13 · OCR
🫁 It's been another amazing day at #WCLC26, filled with ground-breaking presentations, tho
@Lung_Cancers · 2026-09-13 · OCR
🫁 It's been another amazing day at #WCLC26, filled with ground-breaking presentations, tho
@Lung_Cancers · 2026-09-13 · OCR
🌟 We're looking forward to another great day at #WCLC26! 🫁 Today kicks off at 8 AM KST
@Lung_Cancers · 2026-09-12 · OCR
🌞 We're looking forward to another great day at #WCLC26 in Seoul! 🌟 Today begins with th
@Lung_Cancers · 2026-09-13 · OCR
🫁 Catching up on all #WCLC26 news as you head home from Seoul? ➡️ Find top news, video c
@Lung_Cancers · 2026-09-16 · OCR
🫁 Catching up on all #WCLC26 news as you head home from Seoul? ➡️ Find top news, video c
@Lung_Cancers · 2026-09-16 · OCR
🫁 Catching up on all #WCLC26 news as you head home from Seoul? ➡️ Find top news, video c
@Lung_Cancers · 2026-09-16 · OCR
🫁 Catching up on all #WCLC26 news as you head home from Seoul? ➡️ Find top news, video c
@Lung_Cancers · 2026-09-16 · OCR
🌟 Thanks to @triparnasen for joining us for a fantastic interview about her research, this
@Lung_Cancers · 2026-09-14 · OCR
The #WCLC26 press conference is underway, and features: 🌟 @triparnasen, @OSUCCC_James 🌟 @
@Lung_Cancers · 2026-09-14 · OCR
🌟 Thanks to @Latinamd for joining us at #WCLC26 for a great interview on the communication
@Lung_Cancers · 2026-09-15 · OCR
🫁 Happening now: The #WCLC26 opening plenary with distinguished service award presentation
@Lung_Cancers · 2026-09-12 · OCR
🫁 Happening now: The #WCLC26 opening plenary with distinguished service award presentation
@Lung_Cancers · 2026-09-12 · OCR
🫁 Happening now: The #WCLC26 opening plenary with distinguished service award presentation
@Lung_Cancers · 2026-09-12 · OCR
🫁 Happening now: The #WCLC26 opening plenary with distinguished service award presentation
@Lung_Cancers · 2026-09-12 · OCR
🫁 Thanks to @JVelottaMD for joining us for an excellent interview on the California Lung C
@Lung_Cancers · 2026-09-13 · OCR
🌟 Thanks to @Joshua_Reuss for joining us at #WCLC26 for a fantastic interview! ➡️ Stay t
@Lung_Cancers · 2026-09-14 · OCR
New #lungcancer treatment data from #WCLC26. Gotistobart improved overall survival compar
@LungCancerEu · 2026-09-14 · OCR
🆕 New Phase 3 results in early-stage #lungcancer. In resectable stage II–IIIB NSCLC, peri
@LungCancerEu · 2026-09-12 · OCR
🆕 More treatment does not always mean better outcomes. New Phase 3 LONESTAR trial results
@LungCancerEu · 2026-09-12 · OCR
Our President, Debra Montague, is joining an international panel at #WCLC2026 this morning
@LungCancerEu · 2026-09-11 · OCR
🧠 Presented at #WCLC26 today: Phase 3 MAVERICK could change follow-up for small cell #lung
@LungCancerEu · 2026-09-13 · OCR
Better #lungcancer diagnosis will take collaboration across the whole pathway. At #WCLC26
@LungCancerEu · 2026-09-13 · OCR
Evidence alone will not deliver #lungcancer screening. At #WCLC26 in Seoul, Lung Cancer E
@LungCancerEu · 2026-09-12 · OCR
The science has moved. Now Europe must. At #WCLC26, we saw advances that could change #lu
@LungCancerEu · 2026-09-15 · OCR
Lung Connect India Foundation is incredibly proud to have three of our members representin
@LungConnectIN · 2026-09-13 · OCR
Lung Connect India Foundation is incredibly proud to have three of our members representin
@LungConnectIN · 2026-09-13 · OCR
Lung Connect India Foundation is incredibly proud to have three of our members representin
@LungConnectIN · 2026-09-13 · OCR
We are pleased to share that our Lead Counselor, Ms. Vandana Mahajan, took patient advocac
@LungConnectIN · 2026-09-14 · OCR
We are pleased to share that our Lead Counselor, Ms. Vandana Mahajan, took patient advocac
@LungConnectIN · 2026-09-14 · OCR
Patient voices belong at the table, not just in the room. 💙 At WCLC 2026 in Seoul, our te
@LungConnectIN · 2026-09-15 · OCR
Patient voices belong at the table, not just in the room. 💙 At WCLC 2026 in Seoul, our te
@LungConnectIN · 2026-09-15 · OCR
In case you are at #WCLC26, please come and check out research from the LUNGevity team @Be
@LUNGevity · 2026-09-13 · OCR
In case you are at #WCLC26, please come and check out research from the LUNGevity team @Be
@LUNGevity · 2026-09-13 · OCR
In case you are at #WCLC26, please come and check out research from the LUNGevity team @Be
@LUNGevity · 2026-09-13 · OCR
In case you are at #WCLC26, please come and check out research from the LUNGevity team @Be
@LUNGevity · 2026-09-13 · OCR
Presentations by LUNGevity staff and collaborators are shaping the global conversation abo
@LUNGevity · 2026-09-10 · OCR
Presentations by LUNGevity staff and collaborators are shaping the global conversation abo
@LUNGevity · 2026-09-10 · OCR
ADCs are not just chemo on a stick. They can modulate tumor microenvironment, have CNS pen
@LUNGevity · 2026-09-13 · OCR
ADCs are not just chemo on a stick. They can modulate tumor microenvironment, have CNS pen
@LUNGevity · 2026-09-13 · OCR
ADCs are not just chemo on a stick. They can modulate tumor microenvironment, have CNS pen
@LUNGevity · 2026-09-13 · OCR
ADCs are not just chemo on a stick. They can modulate tumor microenvironment, have CNS pen
@LUNGevity · 2026-09-13 · OCR
#WCLC26 here we come! Excited to learn the latest in lung cancer news and to share our res
@LUNGevity · 2026-09-10 · OCR
The 2026 World Conference on Lung Cancer, held Sept. 12-15 in Korea, features 6 presentati
@LUNGevity · 2026-09-10 · OCR
The 2026 World Conference on Lung Cancer, held Sept. 12-15 in Korea, features 6 presentati
@LUNGevity · 2026-09-10 · OCR
The 2026 World Conference on Lung Cancer, held Sept. 12-15 in Korea, features 6 presentati
@LUNGevity · 2026-09-10 · OCR
The 2026 World Conference on Lung Cancer, held Sept. 12-15 in Korea, features 6 presentati
@LUNGevity · 2026-09-10 · OCR
Low grade doesn’t mean low impact! Fantastic presentation by @BellKingKal discussing “poop
@LUNGevity · 2026-09-13 · OCR
Low grade doesn’t mean low impact! Fantastic presentation by @BellKingKal discussing “poop
@LUNGevity · 2026-09-13 · OCR
Low grade doesn’t mean low impact! Fantastic presentation by @BellKingKal discussing “poop
@LUNGevity · 2026-09-13 · OCR
Low grade doesn’t mean low impact! Fantastic presentation by @BellKingKal discussing “poop
@LUNGevity · 2026-09-13 · OCR
National cancer plans drive lifesaving progress, but only 4 of 142 countries studied had f
@LUNGevity · 2026-09-16 · OCR
My biggest concern: ILD/pneumonitis. With T-DXd: ‼️Any grade: 20.8% • Grade ≥3: 4.4% • Gr
@lungoncdoc · 2026-09-14 · OCR
8 YEARS later, and the ADAURA curves are still speaking. In resected EGFR+ NSCLC, adjuvan
@lungoncdoc · 2026-09-13 · OCR
8 YEARS later, and the ADAURA curves are still speaking. In resected EGFR+ NSCLC, adjuvan
@lungoncdoc · 2026-09-13 · OCR
The slides we have been waiting for: PCI is officially dead in small cell lung cancer. 🫳🏽
@lungoncdoc · 2026-09-12 · OCR
The slides we have been waiting for: PCI is officially dead in small cell lung cancer. 🫳🏽
@lungoncdoc · 2026-09-12 · OCR
What parallel universe am I living in?! Dr. @StephenVLiu argues that X is NO longer the b
@lungoncdoc · 2026-09-12 · OCR
What parallel universe am I living in?! Dr. @StephenVLiu argues that X is NO longer the b
@lungoncdoc · 2026-09-12 · OCR
Very excited about the #MAVERICK study for our patients with SCLC. Is PCI still needed i
@lungoncdoc · 2026-09-12 · OCR
‼️ SAVE THIS TWEET if you see patients with EGFR exon 20 NSCLC ‼️ Beautiful discussion by
@lungoncdoc · 2026-09-14 · OCR
‼️ SAVE THIS TWEET if you see patients with EGFR exon 20 NSCLC ‼️ Beautiful discussion by
@lungoncdoc · 2026-09-14 · OCR
‼️ SAVE THIS TWEET if you see patients with EGFR exon 20 NSCLC ‼️ Beautiful discussion by
@lungoncdoc · 2026-09-14 · OCR
7 years of lorlatinib: 3 things I’m taking back to clinic #WCLC26 @IASLC https://t.co/M0
@lungoncdoc · 2026-09-15 · OCR
As we await the 8-year ADAURA update at #WCLC26, our study adds another piece of the story
@lungoncdoc · 2026-09-13 · OCR
This slide says a lot… and put this in the context of no OS and CFFS #WCLC26 @IASLC https
@lungoncdoc · 2026-09-12 · OCR
Grateful to co-chair a #WCLC26 session on navigation as a catalyst for change in lung canc
@lungoncdoc · 2026-09-14 · OCR
Join us TODAY for the @IASLC communications workshop at 14:00 @maraantonoff #WCLC26 http
@lungoncdoc · 2026-09-11 · OCR
For a single-arm study w/ still-maturing follow-up… 94% ORR + 90% 1-y PFS + strong CNS con
@lungoncdoc · 2026-09-14 · OCR
For a single-arm study w/ still-maturing follow-up… 94% ORR + 90% 1-y PFS + strong CNS con
@lungoncdoc · 2026-09-14 · OCR
Look who I found on day 1 of #WCLC26 @IASLC @maraantonoff @BalazsHalmosMD https://t.co/c
@lungoncdoc · 2026-09-12 · OCR
@Latinamd talks about the @IASLC Thoracic Circle! Join now! #wclc26 https://t.co/wPBYC1DHR
@lungoncdoc · 2026-09-12 · OCR
When in Korea, you try the vegan bibimbap (비빔밥) #WCLC26 @IASLC https://t.co/QAxucqoKo3
@lungoncdoc · 2026-09-15
When in Korea, you try the vegan bibimbap (비빔밥) #WCLC26 @IASLC https://t.co/QAxucqoKo3
@lungoncdoc · 2026-09-15
Obsessed with the @IASLC #WCLC26 mascot! 🥹 https://t.co/iWstVQlC2K
@lungoncdoc · 2026-09-12 · OCR
Sorry I missed the official committee photo! But I made it to the unofficial one 😀 #WCLC2
@lungoncdoc · 2026-09-12 · OCR
‼️ Pay attention, y’all. There is a NEW emerging standard of care for our patients with SC
@lungoncdoc · 2026-09-13 · OCR
Made it to Seoul! #WCLC26 https://t.co/7mHasUwn60
@lungoncdoc · 2026-09-11 · OCR
Making all sorts of new friends here at #WCLC26. Come join us for the poster session hap
@lungoncdoc · 2026-09-13 · OCR
Great to spend some time at #WCLC26 with a phenomenal colleague and friend @LeXiuning http
@lungoncdoc · 2026-09-14 · OCR
Congratulations to @pompili_cecilia on the Ginsberg Lectureship Award for Surgery! A true
@lungoncdoc · 2026-09-13 · OCR
Leading today’s #WCLC26 Poster Tour on Pulmonology & Staging 1. EBUS transtunnel forceps
@lungoncdoc · 2026-09-12 · OCR
REZILIENT 3: zipalertinib + chemo in 1L EGFR exon20ins NSCLC. ▫️PFS: 14.5 vs 8.5 mo (HR
@lungoncdoc · 2026-09-14 · OCR
Riz Rez (say that five times fast) is up next here at #WCLC26 @IASLC https://t.co/cOpwrH9m
@lungoncdoc · 2026-09-13 · OCR
The efficacy is there. T-DXd vs pembro + chemo: ▫️mPFS: 14.3 vs 8.3 mo (HR 0.63) ▫️ORR: 7
@lungoncdoc · 2026-09-14 · OCR
The efficacy is there. T-DXd vs pembro + chemo: ▫️mPFS: 14.3 vs 8.3 mo (HR 0.63) ▫️ORR: 7
@lungoncdoc · 2026-09-14 · OCR
Congratulations to our very own @UTMDAnderson Dr. Jay Zhang on the @fred_hirsch translatio
@lungoncdoc · 2026-09-12 · OCR
B7H3 ADCs are entering the chat here at #WCLC26 @IASLC https://t.co/ZBr62tjvub
@lungoncdoc · 2026-09-12 · OCR
3. Ask about what patients may not volunteer. Cognition, mood, weight, edema and lipids a
@lungoncdoc · 2026-09-15 · OCR
3. Ask about what patients may not volunteer. Cognition, mood, weight, edema and lipids a
@lungoncdoc · 2026-09-15 · OCR
1. Toxicity doesn’t necessarily keep accumulating with time. Most selected TRAEs emerged
@lungoncdoc · 2026-09-15 · OCR
@IASLC communications workshop committee starts now! #WCLC26 https://t.co/SlLM9GCdHl
@lungoncdoc · 2026-09-12 · OCR
But OS is where things get nuanced… No OS benefit with T-DXd: HR 1.15 (95% CI 0.88-1.52).
@lungoncdoc · 2026-09-14 · OCR
But OS is where things get nuanced… No OS benefit with T-DXd: HR 1.15 (95% CI 0.88-1.52).
@lungoncdoc · 2026-09-14 · OCR
2. Manage toxicity rather than reflexively abandoning therapy. Only 6% discontinued for T
@lungoncdoc · 2026-09-15 · OCR
2/ We know ADAURA recommends a 3 year duration of osimertinib, but are patients really ab
@lungoncdoc · 2026-09-13 · OCR
But ADAURA is just the beginning. ▫️Can MRD guide escalation, or de-escalation? ▫️Is 3 y
@lungoncdoc · 2026-09-13 · OCR
Impressive OS benefit seen here #WCLC26 @IASLC https://t.co/fmd3kigJg5
@lungoncdoc · 2026-09-13 · OCR
The efficacy with zipalertinib + chemo is impressive, but toxicity worth noting. Grade ≥3
@lungoncdoc · 2026-09-14 · OCR
The efficacy with zipalertinib + chemo is impressive, but toxicity worth noting. Grade ≥3
@lungoncdoc · 2026-09-14 · OCR
Oh and one bonus signal for thought: hypercholesterolemia was associated with improved PFS
@lungoncdoc · 2026-09-15 · OCR
@IASLC ILD rate of 11.7%: is this the toxicity signal we should be most honed in on among
@lungoncdoc · 2026-09-13 · OCR
Patient characteristics for #MAVERICK #WCLC26 @IASLC https://t.co/2kpTGP62Bm
@lungoncdoc · 2026-09-12 · OCR
With multiple B7H3 ADCs in our pipeline, how will we choose the right agent for our patien
@lungoncdoc · 2026-09-13 · OCR
WCLC 2026 opened in Seoul on Saturday 12 September. Six studies came out of the press brie
@LungSummit · 2026-09-12 · OCR
First-line T-DXd nearly doubled mPFS against pembrolizumab plus chemotherapy in HER2-mutan
@LungSummit · 2026-09-15 · OCR
Ivonescimab extended OS against pembrolizumab in 1L PD-L1-positive NSCLC, with no chemothe
@LungSummit · 2026-09-15 · OCR
EVOKE-03/KEYNOTE-D46 tested the combination first line in metastatic NSCLC with a PD-L1 TP
@LungSummit · 2026-09-14 · OCR
All ten TKI-naive ARROS-1 patients evaluable for brain response responded intracranially,
@LungSummit · 2026-09-15 · OCR
Median overall survival 13.3 months against 9.4 with topotecan, stratified hazard ratio 0.
@LungSummit · 2026-09-14 · OCR
Eight years after randomisation in ADAURA, three of them on treatment, the adjuvant osimer
@LungSummit · 2026-09-15 · OCR
Zipalertinib plus chemotherapy adds six months of mPFS in 1L EGFR exon 20 insertion NSCLC.
@LungSummit · 2026-09-15 · OCR
During #WCLC2026 by @IASLC, two B7-H3 antibody-drug conjugates reported phase 3 survival d
@LungSummit · 2026-09-14 · OCR
🧠 Cognitive failure-free survival favoured brain MRI surveillance alone over surveillance
@LungSummit · 2026-09-14 · OCR
ARTEMIS-008 randomised 461 patients in China with small cell lung cancer relapsed after pl
@LungSummit · 2026-09-14 · OCR
Five readouts in one Seoul afternoon, and the two EGFR exon 20 trials pulled opposite ways
@LungSummit · 2026-09-15 · OCR
#WCLC26 | ADAURA 8-year OS update 📚 JTO full text: https://t.co/NPr2K3lxYi 🧬 Exploratory
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ADAURA 8-year OS update 📚 JTO full text: https://t.co/NPr2K3lxYi 🧬 Exploratory
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ADAURA 8-year OS update 📚 JTO full text: https://t.co/NPr2K3lxYi 🧬 Exploratory
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ADAURA 8-year OS update 📚 JTO full text: https://t.co/NPr2K3lxYi 🧬 Exploratory
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | HARMONi-2 🧬 Ph3: 1L ivonescimab vs pembro in PD-L1+ advanced NSCLC (TPS ≥1%; n=
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | HARMONi-2 🧬 Ph3: 1L ivonescimab vs pembro in PD-L1+ advanced NSCLC (TPS ≥1%; n=
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | HARMONi-2 🧬 Ph3: 1L ivonescimab vs pembro in PD-L1+ advanced NSCLC (TPS ≥1%; n=
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | SWOG S1827/MAVERICK 🧠 Ph3: MRI surveillance vs PCI + MRI after 1L therapy in LS
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | SWOG S1827/MAVERICK 🧠 Ph3: MRI surveillance vs PCI + MRI after 1L therapy in LS
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | SWOG S1827/MAVERICK 🧠 Ph3: MRI surveillance vs PCI + MRI after 1L therapy in LS
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | SWOG S1827/MAVERICK 🧠 Ph3: MRI surveillance vs PCI + MRI after 1L therapy in LS
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 (pre-planned interim) 🧬 Ph3: Risvutatug Rezetecan (Ris-Rez), a B7-H
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 (pre-planned interim) 🧬 Ph3: Risvutatug Rezetecan (Ris-Rez), a B7-H
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 (pre-planned interim) 🧬 Ph3: Risvutatug Rezetecan (Ris-Rez), a B7-H
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 (pre-planned interim) 🧬 Ph3: Risvutatug Rezetecan (Ris-Rez), a B7-H
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 (1st interim) 📚 Simultaneously published in NEJM https://t.co/iyQXEI
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 (1st interim) 📚 Simultaneously published in NEJM https://t.co/iyQXEI
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 (1st interim) 📚 Simultaneously published in NEJM https://t.co/iyQXEI
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 (1st interim) 📚 Simultaneously published in NEJM https://t.co/iyQXEI
@M_Torasawa · 2026-09-13 · OCR
#WCLC26 | PAPILLON final OS update 🧬 Ph3: 1L amivantamab + chemo vs chemo in advanced EGF
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | PAPILLON final OS update 🧬 Ph3: 1L amivantamab + chemo vs chemo in advanced EGF
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | PAPILLON final OS update 🧬 Ph3: 1L amivantamab + chemo vs chemo in advanced EGF
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | PAPILLON final OS update 🧬 Ph3: 1L amivantamab + chemo vs chemo in advanced EGF
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | HARMONi updated OS 🧬 Global Ph3: ivonescimab + chemo vs placebo + chemo after p
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | HARMONi updated OS 🧬 Global Ph3: ivonescimab + chemo vs placebo + chemo after p
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | DeLLphi-308 💉 Ph1b: subcutaneous tarlatamab in previously treated ES-SCLC (N=60
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | DeLLphi-308 💉 Ph1b: subcutaneous tarlatamab in previously treated ES-SCLC (N=60
@M_Torasawa · 2026-09-15 · OCR
#WCLC26 | DESTINY-Lung04 🧬 Ph3: 1L T-DXd vs pembrolizumab + chemo in advanced HER2m NSCLC
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | DESTINY-Lung04 🧬 Ph3: 1L T-DXd vs pembrolizumab + chemo in advanced HER2m NSCLC
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | DESTINY-Lung04 🧬 Ph3: 1L T-DXd vs pembrolizumab + chemo in advanced HER2m NSCLC
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | DESTINY-Lung04 🧬 Ph3: 1L T-DXd vs pembrolizumab + chemo in advanced HER2m NSCLC
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | REZILIENT-3 🧬 Ph3: 1L zipalertinib + platinum/pemetrexed vs chemo in metastatic
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | REZILIENT-3 🧬 Ph3: 1L zipalertinib + platinum/pemetrexed vs chemo in metastatic
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | REZILIENT-3 🧬 Ph3: 1L zipalertinib + platinum/pemetrexed vs chemo in metastatic
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | REZILIENT-3 🧬 Ph3: 1L zipalertinib + platinum/pemetrexed vs chemo in metastatic
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ARROS-1 🧬 Zidesamtinib 100 mg QD in advanced ROS1+ NSCLC, focusing on ROS1 TKI-
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ARROS-1 🧬 Zidesamtinib 100 mg QD in advanced ROS1+ NSCLC, focusing on ROS1 TKI-
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ARROS-1 🧬 Zidesamtinib 100 mg QD in advanced ROS1+ NSCLC, focusing on ROS1 TKI-
@M_Torasawa · 2026-09-14 · OCR
#WCLC26 | ARROS-1 🧬 Zidesamtinib 100 mg QD in advanced ROS1+ NSCLC, focusing on ROS1 TKI-
@M_Torasawa · 2026-09-14 · OCR
Causes and Patterns of Mortality After Surgery in Patients With Non-Small Cell Lung Cancer
@ManuelDomine · 2026-09-13 · OCR
ARIAN, a Phase III, Randomized Study of Adjuvant Treatment With Sacituzumab and Zimberelim
@ManuelDomine · 2026-09-13 · OCR
ARIAN, a Phase III, Randomized Study of Adjuvant Treatment With Sacituzumab and Zimberelim
@ManuelDomine · 2026-09-13 · OCR
ARIAN, a Phase III, Randomized Study of Adjuvant Treatment With Sacituzumab and Zimberelim
@ManuelDomine · 2026-09-13 · OCR
Excess Mortality After Curative Surgery for Non-Small Cell Lung Cancer: A Population-Based
@ManuelDomine · 2026-09-13 · OCR
Persistent N2 disease following Ch+IO is uncommon but associated with significantly poorer
@ManuelDomine · 2026-09-13 · OCR
MERLIN, Tarlatamab treatment for limited small cell lung cancer in patients in maintenance
@ManuelDomine · 2026-09-14 · OCR
ATHENEA, a Phase II Study of Atezolizumab as Neoadjuvant, Adjuvant and Maintenance Treatme
@ManuelDomine · 2026-09-15 · OCR
Tumor BCR Repertoire Metrics Outperform PD-L1 and TMB as Survival Biomarkers in NSCLC Afte
@ManuelDomine · 2026-09-15 · OCR
REZILIENT 3 Phase III Zipalertinib +. Chemotherapy vs Chemotherapy EGFR Ex20 ins Very pro
@ManuelDomine · 2026-09-14 · OCR
REZILIENT 3 Phase III Zipalertinib +. Chemotherapy vs Chemotherapy EGFR Ex20 ins Very pro
@ManuelDomine · 2026-09-14 · OCR
REZILIENT 3 Phase III Zipalertinib +. Chemotherapy vs Chemotherapy EGFR Ex20 ins Very pro
@ManuelDomine · 2026-09-14 · OCR
REZILIENT 3 Phase III Zipalertinib +. Chemotherapy vs Chemotherapy EGFR Ex20 ins Very pro
@ManuelDomine · 2026-09-14 · OCR
NSCLC Exhibits Distinct Spatial Immune and Metabolic Signatures Linked to Relapse After Pe
@ManuelDomine · 2026-09-15 · OCR
PL03: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Explorator
@ManuelDomine · 2026-09-13 · OCR
PL03: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Explorator
@ManuelDomine · 2026-09-13 · OCR
PL03: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Explorator
@ManuelDomine · 2026-09-13 · OCR
PL03: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Explorator
@ManuelDomine · 2026-09-13 · OCR
Not All Residual Tumors Are Created Equal: Perioperative Chemoimmunotherapy Differentially
@ManuelDomine · 2026-09-16 · OCR
Grateful to connect with other women thoracic surgeons from around the world at #wclc26. T
@maraantonoff · 2026-09-13 · OCR
Grateful to connect with other women thoracic surgeons from around the world at #wclc26. T
@maraantonoff · 2026-09-13 · OCR
Grateful to connect with other women thoracic surgeons from around the world at #wclc26. T
@maraantonoff · 2026-09-13 · OCR
Grateful to connect with other women thoracic surgeons from around the world at #wclc26. T
@maraantonoff · 2026-09-13 · OCR
I'm SO honored to have been a part of the @IASLC Academy as a mentor again this year, watc
@maraantonoff · 2026-09-11 · OCR
I'm SO honored to have been a part of the @IASLC Academy as a mentor again this year, watc
@maraantonoff · 2026-09-11 · OCR
So proud to celebrate my dear friend @pompili_cecilia, recipient of the Robert J. Ginsberg
@maraantonoff · 2026-09-13 · OCR
So proud to celebrate my dear friend @pompili_cecilia, recipient of the Robert J. Ginsberg
@maraantonoff · 2026-09-13 · OCR
So proud to celebrate my dear friend @pompili_cecilia, recipient of the Robert J. Ginsberg
@maraantonoff · 2026-09-13 · OCR
So proud to celebrate my dear friend @pompili_cecilia, recipient of the Robert J. Ginsberg
@maraantonoff · 2026-09-13 · OCR
This is fun. @IASLC #wclc2026 https://t.co/zvh5Z6RCHG
@maraantonoff · 2026-09-12 · OCR
More than a decade ago, Dr Dan Gomez and I connected through a shared interest in using lo
@maraantonoff · 2026-09-13 · OCR
I’m grateful to @Lung_Cancers for disseminating important, timely, and accurate info on al
@maraantonoff · 2026-09-14 · OCR
After four long days of travel disruptions, flight cancellations and transfers, delighted
@MartinBarr10 · 2026-09-12 · OCR
A full-house as the Plenary Session of the @IASLC #WCLC26 has kicked off! 🌎 🫁 🇰🇷 https://t
@MartinBarr10 · 2026-09-12 · OCR
A full-house as the Plenary Session of the @IASLC #WCLC26 has kicked off! 🌎 🫁 🇰🇷 https://t
@MartinBarr10 · 2026-09-12 · OCR
A full-house as the Plenary Session of the @IASLC #WCLC26 has kicked off! 🌎 🫁 🇰🇷 https://t
@MartinBarr10 · 2026-09-12 · OCR
Day 4, #WCLC26 in #Seoul: Grateful to the @IASLC for the opportunity to present our resear
@MartinBarr10 · 2026-09-15 · OCR
Meeting & greeting some of the 🇮🇪 contingent at the @IASLC #WCLC26 at @coexseoul https://t
@MartinBarr10 · 2026-09-14 · OCR
Kudos to Team #VIKTOR for an excellent and informative demo of the VIKTOR platform- integr
@MartinBarr10 · 2026-09-14 · OCR
Kudos to Team #VIKTOR for an excellent and informative demo of the VIKTOR platform- integr
@MartinBarr10 · 2026-09-14 · OCR
And that's a wrap for #WCLC26 What a fantastic four days of science, collaboration & conne
@MartinBarr10 · 2026-09-16 · OCR
And that's a wrap for #WCLC26 What a fantastic four days of science, collaboration & conne
@MartinBarr10 · 2026-09-16 · OCR
And that's a wrap for #WCLC26 What a fantastic four days of science, collaboration & conne
@MartinBarr10 · 2026-09-16 · OCR
At WCLC 2026, Prof. Yilong Wu of Guangdong Provincial People's Hospital reported phase 2 J
@MedJ0401 · 2026-09-14 · OCR
At WCLC 2026, Prof. Yilong Wu of Guangdong Provincial People's Hospital reported phase 2 J
@MedJ0401 · 2026-09-14 · OCR
At WCLC 2026, Prof. Yilong Wu of Guangdong Provincial People's Hospital reported phase 2 J
@MedJ0401 · 2026-09-14 · OCR
At WCLC 2026, Prof. Yilong Wu of Guangdong Provincial People's Hospital reported phase 2 J
@MedJ0401 · 2026-09-14 · OCR
Just in from WCLC 2026 @IASLC 🔥 HARMONi-2 has delivered its OS readout—and it’s a strikin
@MedJ0401 · 2026-09-15 · OCR
Just in from WCLC 2026 @IASLC 🔥 HARMONi-2 has delivered its OS readout—and it’s a strikin
@MedJ0401 · 2026-09-15 · OCR
Just in from WCLC 2026 @IASLC 🔥 HARMONi-2 has delivered its OS readout—and it’s a strikin
@MedJ0401 · 2026-09-15 · OCR
Ris-Rez vs topotecan: median overall survival 18.5 vs 10.3 months in relapsed SCLC. Prof.
@MedJ0401 · 2026-09-14 · OCR
Ris-Rez vs topotecan: median overall survival 18.5 vs 10.3 months in relapsed SCLC. Prof.
@MedJ0401 · 2026-09-14 · OCR
Ris-Rez vs topotecan: median overall survival 18.5 vs 10.3 months in relapsed SCLC. Prof.
@MedJ0401 · 2026-09-14 · OCR
Ris-Rez vs topotecan: median overall survival 18.5 vs 10.3 months in relapsed SCLC. Prof.
@MedJ0401 · 2026-09-14 · OCR
Tam-peli improved median overall survival to 13.3 vs 9.4 months with topotecan in relapsed
@MedJ0401 · 2026-09-14 · OCR
Tam-peli improved median overall survival to 13.3 vs 9.4 months with topotecan in relapsed
@MedJ0401 · 2026-09-14 · OCR
Tam-peli improved median overall survival to 13.3 vs 9.4 months with topotecan in relapsed
@MedJ0401 · 2026-09-14 · OCR
At WCLC 2026, Li Zhang's team at Sun Yat-sen University Cancer Center reported a 76.7% con
@MedJ0401 · 2026-09-16 · OCR
At WCLC 2026, Li Zhang's team at Sun Yat-sen University Cancer Center reported a 76.7% con
@MedJ0401 · 2026-09-16 · OCR
At WCLC 2026, Li Zhang's team at Sun Yat-sen University Cancer Center reported a 76.7% con
@MedJ0401 · 2026-09-16 · OCR
At WCLC 2026, Li Zhang's team at Sun Yat-sen University Cancer Center reported a 76.7% con
@MedJ0401 · 2026-09-16 · OCR
Two Chinese phase 3 trials take B7-H3 ADCs to the WCLC 2026 Presidential Symposium: TAISHA
@MedJ0401 · 2026-09-11 · OCR
Two Chinese phase 3 trials take B7-H3 ADCs to the WCLC 2026 Presidential Symposium: TAISHA
@MedJ0401 · 2026-09-11 · OCR
At WCLC 2026, EVOKE-03 gave clinicians something new to weigh. ⚖️ SG + pembrolizumab repor
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026, EVOKE-03 gave clinicians something new to weigh. ⚖️ SG + pembrolizumab repor
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026, EVOKE-03 gave clinicians something new to weigh. ⚖️ SG + pembrolizumab repor
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026, EVOKE-03 gave clinicians something new to weigh. ⚖️ SG + pembrolizumab repor
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an exploratory 8-year ADAURA update reported sustained overall-survi
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an exploratory 8-year ADAURA update reported sustained overall-survi
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an exploratory 8-year ADAURA update reported sustained overall-survi
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an exploratory 8-year ADAURA update reported sustained overall-survi
@MedJ0401 · 2026-09-15 · OCR
WCLC 2026 preview: Prof. Caicun Zhou's team at Shanghai East Hospital has five studies on
@MedJ0401 · 2026-09-10 · OCR
On a Seoul stage this morning, three careers met around one purpose: better lung cancer ca
@MedJ0401 · 2026-09-15 · OCR
On a Seoul stage this morning, three careers met around one purpose: better lung cancer ca
@MedJ0401 · 2026-09-15 · OCR
On a Seoul stage this morning, three careers met around one purpose: better lung cancer ca
@MedJ0401 · 2026-09-15 · OCR
WCLC 2026 @IASLC honored Luis M. Montuenga, D. Ross Camidge @DRCamidge , Wendy Cooper an
@MedJ0401 · 2026-09-15 · OCR
WCLC 2026 @IASLC honored Luis M. Montuenga, D. Ross Camidge @DRCamidge , Wendy Cooper an
@MedJ0401 · 2026-09-15
WCLC 2026 @IASLC honored Luis M. Montuenga, D. Ross Camidge @DRCamidge , Wendy Cooper an
@MedJ0401 · 2026-09-15 · OCR
WCLC 2026 @IASLC honored Luis M. Montuenga, D. Ross Camidge @DRCamidge , Wendy Cooper an
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , first-line trastuzumab deruxtecan improved PFS in advanced HER2-muta
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , first-line trastuzumab deruxtecan improved PFS in advanced HER2-muta
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , first-line trastuzumab deruxtecan improved PFS in advanced HER2-muta
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , first-line trastuzumab deruxtecan improved PFS in advanced HER2-muta
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an IASLC-CAALC-CSCO forum featuring China-based experts Yilong Wu an
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an IASLC-CAALC-CSCO forum featuring China-based experts Yilong Wu an
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an IASLC-CAALC-CSCO forum featuring China-based experts Yilong Wu an
@MedJ0401 · 2026-09-15 · OCR
At WCLC 2026 @IASLC , an IASLC-CAALC-CSCO forum featuring China-based experts Yilong Wu an
@MedJ0401 · 2026-09-15 · OCR
94% overall. 100% in the brain. 🧠 At IASLC @IASLC WCLC 2026, Alexander Drilon of Memorial
@MedJ0401 · 2026-09-15 · OCR
94% overall. 100% in the brain. 🧠 At IASLC @IASLC WCLC 2026, Alexander Drilon of Memorial
@MedJ0401 · 2026-09-15 · OCR
94% overall. 100% in the brain. 🧠 At IASLC @IASLC WCLC 2026, Alexander Drilon of Memorial
@MedJ0401 · 2026-09-15 · OCR
94% overall. 100% in the brain. 🧠 At IASLC @IASLC WCLC 2026, Alexander Drilon of Memorial
@MedJ0401 · 2026-09-15 · OCR
Workshop with colleagues @JamesFanWu @guicorreiamd @LukasDelasos @nh_osei @dan_morgen Cec
@mgonzalezvelMD · 2026-09-12 · OCR
ARROS-1 update zidesamtinib in ROS1 TKI-naive NSCLC by @alexdrilon at #WCLC26 Take: ORR 9
@mgonzalezvelMD · 2026-09-14 · OCR
ARROS-1 update zidesamtinib in ROS1 TKI-naive NSCLC by @alexdrilon at #WCLC26 Take: ORR 9
@mgonzalezvelMD · 2026-09-14 · OCR
ARROS-1 update zidesamtinib in ROS1 TKI-naive NSCLC by @alexdrilon at #WCLC26 Take: ORR 9
@mgonzalezvelMD · 2026-09-14 · OCR
DeLLphi-309 (Ph2) extended-interval tarlatamab dosing in SCLC, presented by Jonathan Goldm
@mgonzalezvelMD · 2026-09-13 · OCR
DeLLphi-309 (Ph2) extended-interval tarlatamab dosing in SCLC, presented by Jonathan Goldm
@mgonzalezvelMD · 2026-09-13 · OCR
ADAURA 8-year OS @DrRoyHerbst at #WCLC26 in EGFR-mutated early-stage NSCLC. Take: 8-yr O
@mgonzalezvelMD · 2026-09-13 · OCR
ADAURA 8-year OS @DrRoyHerbst at #WCLC26 in EGFR-mutated early-stage NSCLC. Take: 8-yr O
@mgonzalezvelMD · 2026-09-13 · OCR
ADAURA 8-year OS @DrRoyHerbst at #WCLC26 in EGFR-mutated early-stage NSCLC. Take: 8-yr O
@mgonzalezvelMD · 2026-09-13 · OCR
Waiting for @BalazsHalmosMD for the graveyard, zombie or fallen warriors meme Pembrolizu
@mgonzalezvelMD · 2026-09-13 · OCR
I check ctDNA in the clinic all the time and always watch in anxiety without an easy plan
@mgonzalezvelMD · 2026-09-13 · OCR
I check ctDNA in the clinic all the time and always watch in anxiety without an easy plan
@mgonzalezvelMD · 2026-09-13 · OCR
I check ctDNA in the clinic all the time and always watch in anxiety without an easy plan
@mgonzalezvelMD · 2026-09-13 · OCR
Three Phase III 1L trials now compete in the hunger games of EGFR exon 20 insertion NSCLC.
@mgonzalezvelMD · 2026-09-14 · OCR
Three Phase III 1L trials now compete in the hunger games of EGFR exon 20 insertion NSCLC.
@mgonzalezvelMD · 2026-09-14 · OCR
Three Phase III 1L trials now compete in the hunger games of EGFR exon 20 insertion NSCLC.
@mgonzalezvelMD · 2026-09-14 · OCR
TAISHAN-302 (Zhang L, et al) and ARTEMIS-008 (Wang J, et al) #WCLC26 @IASLC discussion by
@mgonzalezvelMD · 2026-09-13 · OCR
Clinical trial activation by Natasha Leighl #WCLC26 #LCSM https://t.co/nmPzbu19It
@mgonzalezvelMD · 2026-09-12 · OCR
Clinical trial activation by Natasha Leighl #WCLC26 #LCSM https://t.co/nmPzbu19It
@mgonzalezvelMD · 2026-09-12 · OCR
EVOKE-03/KND46 negative readout for a Sac-GT. Take: Dual primary endpoint, neither met. P
@mgonzalezvelMD · 2026-09-13 · OCR
EVOKE-03/KND46 negative readout for a Sac-GT. Take: Dual primary endpoint, neither met. P
@mgonzalezvelMD · 2026-09-13 · OCR
Congratulations to my wonderful friend @CharuAggarwalMD for receiving the lectureship awar
@NaglaAKarimMD · 2026-09-12 · OCR
Congratulations to my wonderful friend @CharuAggarwalMD for receiving the lectureship awar
@NaglaAKarimMD · 2026-09-12 · OCR
Congratulations to my wonderful friend @CharuAggarwalMD for receiving the lectureship awar
@NaglaAKarimMD · 2026-09-12 · OCR
Arriving to Beautiful Seoul & could not resist walking right away to #Starfield_Library &
@NaglaAKarimMD · 2026-09-11 · OCR
Arriving to Beautiful Seoul & could not resist walking right away to #Starfield_Library &
@NaglaAKarimMD · 2026-09-11 · OCR
Arriving to Beautiful Seoul & could not resist walking right away to #Starfield_Library &
@NaglaAKarimMD · 2026-09-11 · OCR
Arriving to Beautiful Seoul & could not resist walking right away to #Starfield_Library &
@NaglaAKarimMD · 2026-09-11 · OCR
In between running to catch up on our sessions & meetings! Thankful for our oncology famil
@NaglaAKarimMD · 2026-09-14 · OCR
In between running to catch up on our sessions & meetings! Thankful for our oncology famil
@NaglaAKarimMD · 2026-09-14 · OCR
In between running to catch up on our sessions & meetings! Thankful for our oncology famil
@NaglaAKarimMD · 2026-09-14 · OCR
In between running to catch up on our sessions & meetings! Thankful for our oncology famil
@NaglaAKarimMD · 2026-09-14 · OCR
We are so excited and looking forward to the presidential session especially the MAVERICK
@NaglaAKarimMD · 2026-09-12 · OCR
We are so excited and looking forward to the presidential session especially the MAVERICK
@NaglaAKarimMD · 2026-09-12 · OCR
We are so excited and looking forward to the presidential session especially the MAVERICK
@NaglaAKarimMD · 2026-09-12 · OCR
Using E-Cigarettes after smoking cessation carries higher risk of lung cancer! #WCLC26 @IA
@NaglaAKarimMD · 2026-09-12 · OCR
Too many great pre-conference sessions @IASLC #WCLC26 Moving from the policy making engage
@NaglaAKarimMD · 2026-09-11 · OCR
Too many great pre-conference sessions @IASLC #WCLC26 Moving from the policy making engage
@NaglaAKarimMD · 2026-09-11 · OCR
Too many great pre-conference sessions @IASLC #WCLC26 Moving from the policy making engage
@NaglaAKarimMD · 2026-09-11 · OCR
Too many great pre-conference sessions @IASLC #WCLC26 Moving from the policy making engage
@NaglaAKarimMD · 2026-09-11 · OCR
@Latinamd so grateful for being here #WCLC26 @IASLC https://t.co/RsHxP1XgZb
@NaglaAKarimMD · 2026-09-14 · OCR
@Latinamd so grateful for being here #WCLC26 @IASLC https://t.co/RsHxP1XgZb
@NaglaAKarimMD · 2026-09-14 · OCR
@Latinamd so grateful for being here #WCLC26 @IASLC https://t.co/RsHxP1XgZb
@NaglaAKarimMD · 2026-09-14 · OCR
@Latinamd so grateful for being here #WCLC26 @IASLC https://t.co/RsHxP1XgZb
@NaglaAKarimMD · 2026-09-14 · OCR
Great start of #WCLC26 learning about lung cancer policy network @lungcancerhita @IASLC @O
@NaglaAKarimMD · 2026-09-11 · OCR
Great Work! MRI Surveillance carried less risks of cognitive impairment without difference
@NaglaAKarimMD · 2026-09-12 · OCR
Great Work! MRI Surveillance carried less risks of cognitive impairment without difference
@NaglaAKarimMD · 2026-09-12 · OCR
Great Work! MRI Surveillance carried less risks of cognitive impairment without difference
@NaglaAKarimMD · 2026-09-12 · OCR
Thank you to @IASLC and #WCLC26 for supporting the first IASLC-EMRO forum where we discuss
@NaglaAKarimMD · 2026-09-13 · OCR
Thank you to @IASLC and #WCLC26 for supporting the first IASLC-EMRO forum where we discuss
@NaglaAKarimMD · 2026-09-13 · OCR
It was such a great pleasure presenting to our oligometastatic subcommittee the updates ab
@NaglaAKarimMD · 2026-09-12 · OCR
It was such a great pleasure presenting to our oligometastatic subcommittee the updates ab
@NaglaAKarimMD · 2026-09-12 · OCR
It was such a great pleasure presenting to our oligometastatic subcommittee the updates ab
@NaglaAKarimMD · 2026-09-12 · OCR
First things first: a Korean skincare haul! 🛍️✨ Day 1 in Seoul with Stephen, and we clearl
@NarjustFlorezMD · 2026-09-10 · OCR
First things first: a Korean skincare haul! 🛍️✨ Day 1 in Seoul with Stephen, and we clearl
@NarjustFlorezMD · 2026-09-10 · OCR
Quick sightseeing stop with Stephen at one of Seoul’s most iconic libraries 📚🇰🇷 #WCLC26 h
@NarjustFlorezMD · 2026-09-10 · OCR
Quick sightseeing stop with Stephen at one of Seoul’s most iconic libraries 📚🇰🇷 #WCLC26 h
@NarjustFlorezMD · 2026-09-10 · OCR
Quick sightseeing stop with Stephen at one of Seoul’s most iconic libraries 📚🇰🇷 #WCLC26 h
@NarjustFlorezMD · 2026-09-10 · OCR
Quick sightseeing stop with Stephen at one of Seoul’s most iconic libraries 📚🇰🇷 #WCLC26 h
@NarjustFlorezMD · 2026-09-10 · OCR
Great people, meaningful conversations, and another memorable WCLC. 💙 Grateful for the fr
@NarjustFlorezMD · 2026-09-14 · OCR
Great people, meaningful conversations, and another memorable WCLC. 💙 Grateful for the fr
@NarjustFlorezMD · 2026-09-14 · OCR
Great people, meaningful conversations, and another memorable WCLC. 💙 Grateful for the fr
@NarjustFlorezMD · 2026-09-14 · OCR
Great people, meaningful conversations, and another memorable WCLC. 💙 Grateful for the fr
@NarjustFlorezMD · 2026-09-14 · OCR
An unforgettable evening with the IASLC Board of Directors, celebrating global collaborati
@NarjustFlorezMD · 2026-09-12 · OCR
An unforgettable evening with the IASLC Board of Directors, celebrating global collaborati
@NarjustFlorezMD · 2026-09-12 · OCR
Studio mode: ON 🎙️ Bringing you highlights and conversations from #WCLC26 https://t.co/56Y
@NarjustFlorezMD · 2026-09-14 · OCR
Studio mode: ON 🎙️ Bringing you highlights and conversations from #WCLC26 https://t.co/56Y
@NarjustFlorezMD · 2026-09-14 · OCR
Studio mode: ON 🎙️ Bringing you highlights and conversations from #WCLC26 https://t.co/56Y
@NarjustFlorezMD · 2026-09-14 · OCR
First picture with the official #WCLC26 mascots secured! Clearly, I have already met some
@NarjustFlorezMD · 2026-09-11 · OCR
First picture with the official #WCLC26 mascots secured! Clearly, I have already met some
@NarjustFlorezMD · 2026-09-11 · OCR
Never underestimate the power of a hallway conversation. Today’s quick exchange can beco
@NarjustFlorezMD · 2026-09-12 · OCR
Never underestimate the power of a hallway conversation. Today’s quick exchange can beco
@NarjustFlorezMD · 2026-09-12 · OCR
Good Morning Seoul! 🇰🇷 I wake up grateful for this day #WCLC26 https://t.co/yDK9RmON91
@NarjustFlorezMD · 2026-09-10 · OCR
Good Morning Seoul! 🇰🇷 I wake up grateful for this day #WCLC26 https://t.co/yDK9RmON91
@NarjustFlorezMD · 2026-09-10 · OCR
Back in the studio to bring you the latest of #WCLC26 https://t.co/HYRqSRrrUU
@NarjustFlorezMD · 2026-09-13 · OCR
Back in the studio to bring you the latest of #WCLC26 https://t.co/HYRqSRrrUU
@NarjustFlorezMD · 2026-09-13 · OCR
A seat at the table. A voice for our patients. A responsibility to move the field forward.
@NarjustFlorezMD · 2026-09-11 · OCR
Tomorrow at #WCLC26! Join us as we move exercise in lung cancer from evidence to global im
@NarjustFlorezMD · 2026-09-11 · OCR
Tomorrow at #WCLC26! Join us as we move exercise in lung cancer from evidence to global im
@NarjustFlorezMD · 2026-09-11 · OCR
Beautiful sunrise in Seoul 🇰🇷 as we get ready to start #WCLC26 https://t.co/DEuU2eUAZC
@NarjustFlorezMD · 2026-09-11 · OCR
Science has no borders, and language should never be a barrier. Live translation through
@NarjustFlorezMD · 2026-09-12 · OCR
For the 4th year in a row, we recorded live from the WCLC No better time to discuss scien
@NarjustFlorezMD · 2026-09-16 · OCR
For the 4th year in a row, we recorded live from the WCLC No better time to discuss scien
@NarjustFlorezMD · 2026-09-16 · OCR
For the 4th year in a row, we recorded live from the WCLC No better time to discuss scien
@NarjustFlorezMD · 2026-09-16 · OCR
This year, we brought new voices to Lung Cancer Cancer Considered, including our patient a
@NarjustFlorezMD · 2026-09-16 · OCR
This year, we brought new voices to Lung Cancer Cancer Considered, including our patient a
@NarjustFlorezMD · 2026-09-16 · OCR
This year, we brought new voices to Lung Cancer Cancer Considered, including our patient a
@NarjustFlorezMD · 2026-09-16 · OCR
What a day for #SCLC! Two positive phase III ADC trials today at #WCLC26 ARTEMIS-008 and T
@NReguart · 2026-09-13 · OCR
So wonderful to see Luis Montuenga receiving this well-deserved recognition at #WCLC26! 👏👏
@NReguart · 2026-09-12 · OCR
So wonderful to see Luis Montuenga receiving this well-deserved recognition at #WCLC26! 👏👏
@NReguart · 2026-09-12 · OCR
Nice discussion by Dr Lyudmila Bazhenova: EGFR exon20ins: how to choose first-line? PAPILL
@NReguart · 2026-09-14 · OCR
Nice discussion by Dr Lyudmila Bazhenova: EGFR exon20ins: how to choose first-line? PAPILL
@NReguart · 2026-09-14 · OCR
Nice discussion by Dr Lyudmila Bazhenova: EGFR exon20ins: how to choose first-line? PAPILL
@NReguart · 2026-09-14 · OCR
REZILIENT3 in EGFR exon20ins NSCLC! 🔥 impressive PFS benefit with Zipalertinib plus chemo:
@NReguart · 2026-09-14 · OCR
REZILIENT3 in EGFR exon20ins NSCLC! 🔥 impressive PFS benefit with Zipalertinib plus chemo:
@NReguart · 2026-09-14 · OCR
REZILIENT3 in EGFR exon20ins NSCLC! 🔥 impressive PFS benefit with Zipalertinib plus chemo:
@NReguart · 2026-09-14 · OCR
Congrats Michele Rota @mrota2906 @hospitalclinic #WCLC2026 for the Adi F Gazdar Fellowship
@NReguart · 2026-09-12 · OCR
DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetre
@NReguart · 2026-09-14 · OCR
DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetre
@NReguart · 2026-09-14 · OCR
DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetre
@NReguart · 2026-09-14 · OCR
DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetre
@NReguart · 2026-09-14 · OCR
IASLC AWARDS LUNCHEON Congratulations to all awardees !! #WCLC26 https://t.co/CYY1KX1APT
@NReguart · 2026-09-12 · OCR
Final OS from PAPILLON in Ex20ins #WCLC26 Amivantamab + chemo vs chemo 34.3 vs 27.9 mo, HR
@NReguart · 2026-09-13 · OCR
Final OS from PAPILLON in Ex20ins #WCLC26 Amivantamab + chemo vs chemo 34.3 vs 27.9 mo, HR
@NReguart · 2026-09-13 · OCR
Highlights from #WCLC26 #CommunityOncology: NSCLC 1. #ADAURA Update Adj mEGFR 2. #PAPIL
@OncBrothers · 2026-09-15 · OCR
5. #HARMONi: 2L (after 3rd gen EGFRi), Ivonescimab (PD1/VEGF BsAb) + Chemo vs Chemo in EGF
@OncBrothers · 2026-09-15 · OCR
5. #HARMONi: 2L (after 3rd gen EGFRi), Ivonescimab (PD1/VEGF BsAb) + Chemo vs Chemo in EGF
@OncBrothers · 2026-09-15 · OCR
1. #ADAURA: Ph3, resectable NSCLC w/ mEGFR, adj 3yrs of #osimertinib Vs placebo. 8yr updat
@OncBrothers · 2026-09-15 · OCR
1. #ADAURA: Ph3, resectable NSCLC w/ mEGFR, adj 3yrs of #osimertinib Vs placebo. 8yr updat
@OncBrothers · 2026-09-15 · OCR
1. #ADAURA: Ph3, resectable NSCLC w/ mEGFR, adj 3yrs of #osimertinib Vs placebo. 8yr updat
@OncBrothers · 2026-09-15 · OCR
1. #ADAURA: Ph3, resectable NSCLC w/ mEGFR, adj 3yrs of #osimertinib Vs placebo. 8yr updat
@OncBrothers · 2026-09-15 · OCR
6. #MAVERICK: Ph3, MRI vs. MRI + PCI in limited or extensive stage small cell lung cancer:
@OncBrothers · 2026-09-15 · OCR
6. #MAVERICK: Ph3, MRI vs. MRI + PCI in limited or extensive stage small cell lung cancer:
@OncBrothers · 2026-09-15 · OCR
6. #MAVERICK: Ph3, MRI vs. MRI + PCI in limited or extensive stage small cell lung cancer:
@OncBrothers · 2026-09-15 · OCR
6. #MAVERICK: Ph3, MRI vs. MRI + PCI in limited or extensive stage small cell lung cancer:
@OncBrothers · 2026-09-15 · OCR
4. #ARROS1: PhI/II, 1L in TKI naive ROS1+ mNSCLC, Zidesamtinib: - Approved in 2026 in 2L
@OncBrothers · 2026-09-15 · OCR
4. #ARROS1: PhI/II, 1L in TKI naive ROS1+ mNSCLC, Zidesamtinib: - Approved in 2026 in 2L
@OncBrothers · 2026-09-15 · OCR
4. #ARROS1: PhI/II, 1L in TKI naive ROS1+ mNSCLC, Zidesamtinib: - Approved in 2026 in 2L
@OncBrothers · 2026-09-15 · OCR
4. #ARROS1: PhI/II, 1L in TKI naive ROS1+ mNSCLC, Zidesamtinib: - Approved in 2026 in 2L
@OncBrothers · 2026-09-15 · OCR
‼️ Keep an eye out for @FionnualaCrowle as she takes over the @OncLive account for #WCLC26
@OncLive · 2026-09-13 · OCR
Moving to mROS1 🎯! @alexdrilon @MSKCancerCenter presents the 1L results of ARROS-1. Zidesa
@OncLive · 2026-09-14 · OCR
Moving to mROS1 🎯! @alexdrilon @MSKCancerCenter presents the 1L results of ARROS-1. Zidesa
@OncLive · 2026-09-14 · OCR
Moving to mROS1 🎯! @alexdrilon @MSKCancerCenter presents the 1L results of ARROS-1. Zidesa
@OncLive · 2026-09-14 · OCR
Moving to mROS1 🎯! @alexdrilon @MSKCancerCenter presents the 1L results of ARROS-1. Zidesa
@OncLive · 2026-09-14 · OCR
Day 1 of #WCLC2026 is here and we’re ready to kick things into high gear! Starting the day
@OncLive · 2026-09-12 · OCR
Day 1 of #WCLC2026 is here and we’re ready to kick things into high gear! Starting the day
@OncLive · 2026-09-12 · OCR
Day 1 of #WCLC2026 is here and we’re ready to kick things into high gear! Starting the day
@OncLive · 2026-09-12 · OCR
Day 1 of #WCLC2026 is here and we’re ready to kick things into high gear! Starting the day
@OncLive · 2026-09-12 · OCR
First presidential session this morning- long term update of ADAURA presented by @DrRoyHer
@OncLive · 2026-09-13 · OCR
First presidential session this morning- long term update of ADAURA presented by @DrRoyHer
@OncLive · 2026-09-13 · OCR
First presidential session this morning- long term update of ADAURA presented by @DrRoyHer
@OncLive · 2026-09-13 · OCR
Second #WCLC26 presidential presentation this morning presented by @chulkimMD @LombardiCan
@OncLive · 2026-09-14 · OCR
Second #WCLC26 presidential presentation this morning presented by @chulkimMD @LombardiCan
@OncLive · 2026-09-14 · OCR
Second #WCLC26 presidential presentation this morning presented by @chulkimMD @LombardiCan
@OncLive · 2026-09-14 · OCR
This mornings poster session was all about biomarkers 🎯 !!! @fred_hirsch @AMoriarty24 @nh_
@OncLive · 2026-09-14 · OCR
This mornings poster session was all about biomarkers 🎯 !!! @fred_hirsch @AMoriarty24 @nh_
@OncLive · 2026-09-14 · OCR
This mornings poster session was all about biomarkers 🎯 !!! @fred_hirsch @AMoriarty24 @nh_
@OncLive · 2026-09-14 · OCR
This mornings poster session was all about biomarkers 🎯 !!! @fred_hirsch @AMoriarty24 @nh_
@OncLive · 2026-09-14 · OCR
That’s a wrap from me at #WCLC26! Thank you to @OncLive for having me. @FionnualaCrowle ht
@OncLive · 2026-09-14 · OCR
📢 A new contender in first line setting for mEGFR exon 20 insertions- Zipalertinib plus ch
@OncLive · 2026-09-14 · OCR
📢 A new contender in first line setting for mEGFR exon 20 insertions- Zipalertinib plus ch
@OncLive · 2026-09-14 · OCR
📢 A new contender in first line setting for mEGFR exon 20 insertions- Zipalertinib plus ch
@OncLive · 2026-09-14 · OCR
📢 A new contender in first line setting for mEGFR exon 20 insertions- Zipalertinib plus ch
@OncLive · 2026-09-14 · OCR
I am @FionnualaCrowle, thoracic oncologist from @TischCancer and I will be bringing you th
@OncLive · 2026-09-13 · OCR
Final presentation in this presidential session-Results of Destiny-Lung04 presented by @Ju
@OncLive · 2026-09-14 · OCR
Final presentation in this presidential session-Results of Destiny-Lung04 presented by @Ju
@OncLive · 2026-09-14 · OCR
Final presentation in this presidential session-Results of Destiny-Lung04 presented by @Ju
@OncLive · 2026-09-14 · OCR
Final presentation in this presidential session-Results of Destiny-Lung04 presented by @Ju
@OncLive · 2026-09-14 · OCR
The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 👉Advanced #SCLC & #Mesothelioma 🇰🇷 We’re kicking
@OncoAlert · 2026-09-11 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.05 Expression an
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.05 Expression an
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.05 Expression an
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.04 First-Line Y
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.04 First-Line Y
@OncoAlert · 2026-09-10 · OCR
We are Tracking #WCLC26 🇰🇷🫁 in Real time The People, the conversations and the Trials Fi
@OncoAlert · 2026-09-12 · OCR
We are Tracking #WCLC26 🇰🇷🫁 in Real time The People, the conversations and the Trials Fi
@OncoAlert · 2026-09-12 · OCR
We are Tracking #WCLC26 🇰🇷🫁 in Real time The People, the conversations and the Trials Fi
@OncoAlert · 2026-09-12 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstracts to be presented Next week OA05.02 P
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstracts to be presented Next week OA05.02 P
@OncoAlert · 2026-09-10 · OCR
We are Tracking #WCLC26 🇰🇷🫁 in Real time Here are the impact and the sentiment of the S
@OncoAlert · 2026-09-14 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.02 A Phase 2 Tr
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.02 A Phase 2 Tr
@OncoAlert · 2026-09-10 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.02 A Phase 2 Tr
@OncoAlert · 2026-09-10 · OCR
Global Communication Workshop Brings Perspectives and Debate to #WCLC26 - Stephen Liu @St
@oncodaily · 2026-09-12 · OCR
Discussions Around the DeLLphi-305 Trial @mohitmanrao @drshieldsmd @Latinamd @Amgen @g_mo
@oncodaily · 2026-09-10 · OCR
Jill Feldman and Misty Shields Asking Key Questions on the Implementation of ADAURA @jill
@oncodaily · 2026-09-14 · OCR
WCLC 2026 Highlights a New Era in Lung Cancer - Nagla Abdel Karim @NaglaAKarimMD https:
@oncodaily · 2026-09-14 · OCR
Jill Feldman Asking Key Questions on the Implementation of ADAURA at IASLC - Misty Shields
@oncodaily · 2026-09-14
🫁 Phase III DESTINY-Lung04 data: trastuzumab deruxtecan reduced the risk of progression or
@oncodaily · 2026-09-14 · OCR
Phase III TAISHAN-302 data show tambotatug pelitecan improved outcomes vs topotecan in rel
@oncodaily · 2026-09-14 · OCR
New 8-year ADAURA data: 79% of patients with completely resected Stage IB–IIIA EGFR-mutate
@oncodaily · 2026-09-14 · OCR
Pramesh CS on Refreshing Early Morning Run and #WCLC2026 Attendance @cspramesh https://
@oncodaily · 2026-09-12 · OCR
@NaglaAKarimMD @IASLC @lungoncdoc @LauraAlderMD @drshieldsmd @CharuAggarwalMD @OncoAlert @
@oncodaily · 2026-09-15 · OCR
LUNGevity Foundation is Going to Seoul to The 2026 World Conference on Lung Cancer @LUNGe
@oncodaily · 2026-09-11 · OCR
Major Positive #WCLC26 Results in Relapsed SCLC - GILBERTO de lima LOPES Junior @GlopesMd
@oncodaily · 2026-09-14
Promising ARROS-1 Data in First-Line ROS1 NSCLC - Stephen Liu @StephenVLiu @alexdrilon h
@oncodaily · 2026-09-16 · OCR
Bringing Greece’s Lung Cancer Support and Nursing Programs to WCLC 2026 - Korina Pateli -
@oncodaily · 2026-09-15
Bringing the Patient Perspective From India to the World Conference on Lung Cancer 2026 -
@oncodaily · 2026-09-15 · OCR
@g_mountzios @IASLC @ZPiotrowskaMD @JairBar4 @ZerAlona @marinagarassino @herbloong Best Wa
@oncodaily · 2026-09-12 · OCR
@GlopesMd Finding Peace and Reflection at Beautiful Bongeunsa Temple During WCLC26 - GILBE
@oncodaily · 2026-09-12 · OCR
@DrRishabhOnco My top 10 trials to watch at WCLC26 - Rishabh Jain @DrRishabhOnco https:
@oncodaily · 2026-09-11 · OCR
Julia Rotow (@JuliaRotow) Presents DESTINY-Lung-04 Data at WCLC 2026 - Misty Shields (@drs
@oncodaily · 2026-09-16 · OCR
@cspramesh @TheLancet @IASLC @uicc @CancerGridIndia @RRamiPorta @WisdomVania @TheLancetOnc
@oncodaily · 2026-09-12 · OCR
@g_mountzios Early Efficacy of Pumitamig and Elfie-D ADC Combo at WCLC26 - Giannis Mountzi
@oncodaily · 2026-09-15 · OCR
@jillfeldman4 @drshieldsmd Jill Feldman and Misty Shields Asking Key Questions on the Impl
@oncodaily · 2026-09-14 · OCR
@herbloong @lungoncdoc @IASLC Great Connecting With Eric K. Singhi at WCLC26 - Herbert Loo
@oncodaily · 2026-09-14 · OCR
@JoeChangMD A Busy Day Ahead of the World Conference on Lung Cancer - Joe Chang @JoeChang
@oncodaily · 2026-09-13 · OCR
🫁 Could first-line maintenance become the next major treatment frontier in extensive-stage
@OncodailyLung · 2026-09-13 · OCR
DeLLphi-305 Opens a New Chapter in ES-SCLC Maintenance Therapy - Amol Akhade and Ben Creel
@OncodailyLung · 2026-09-11 · OCR
On My Way to WCLC26 - Professor Nagla Karim @NaglaAKarimMD https://t.co/2NeoQzpakX
@OncodailyLung · 2026-09-11 · OCR
Discussing New Directions in Lung Cancer Research at WCLC26 - Upal Basu Roy, PhD, MPH @LU
@OncodailyLung · 2026-09-14 · OCR
Starting #WCLC26 Day-1 in Seou - Herbert Loong @herbloong https://t.co/GMWxw5h5OY
@OncodailyLung · 2026-09-11 · OCR
Global Policy Press Briefing at WCLC26 - Prof. Andreas Charalambous @AndreasC466 https://
@OncodailyLung · 2026-09-13 · OCR
Celebrating the @IASLC Awards at WCLC26 - Yvonne Diaz @Yvonne_Diaz_ @boldcaleb https://t
@OncodailyLung · 2026-09-13 · OCR
TAISHAN-302 Marks Another Milestone in Small-Cell Lung Cancer - Yago Garitaonaindía @YGar
@OncodailyLung · 2026-09-14 · OCR
Last day at WCLC 2026, King Keytruda survived? - Amol Akhade @SuyogCancer https://t.co/Ei
@OncodailyLung · 2026-09-15 · OCR
DESTINY-Lung04 and the 1L HER2 NSCLC Landscape at #WCLC26 - Thomas Newsom-Davis @tnewsomd
@OncodailyLung · 2026-09-16 · OCR
TAISHAN-302 Marks Another Milestone in Small-Cell Lung Cancer - Yago Garitaonaindia @YGar
@OncodailyLung · 2026-09-14 · OCR
Time to Leave an Unforgettable #WCLC26 and Majestic Seoul - Giannis Mountzios @g_mountzio
@OncodailyLung · 2026-09-16 · OCR
Reflections from Unforgettable WCLC26 on Innovation Science and AI - Dr. Fabio Ynoe de Mor
@OncodailyLung · 2026-09-16 · OCR
Great data on ADAURA today at @IASLC #WCLC26 presented by @DrRoyHerbst & discussant @APass
@OncogeneCancer · 2026-09-13 · OCR
Great data on ADAURA today at @IASLC #WCLC26 presented by @DrRoyHerbst & discussant @APass
@OncogeneCancer · 2026-09-13 · OCR
Great data on ADAURA today at @IASLC #WCLC26 presented by @DrRoyHerbst & discussant @APass
@OncogeneCancer · 2026-09-13 · OCR
Great data on ADAURA today at @IASLC #WCLC26 presented by @DrRoyHerbst & discussant @APass
@OncogeneCancer · 2026-09-13 · OCR
Drs @juliarotow & James Yang present on HER2 - inc DESTINY, BEAMION, more at #WCLC26. Dr Y
@OncogeneCancer · 2026-09-14 · OCR
Drs @juliarotow & James Yang present on HER2 - inc DESTINY, BEAMION, more at #WCLC26. Dr Y
@OncogeneCancer · 2026-09-14 · OCR
Drs @juliarotow & James Yang present on HER2 - inc DESTINY, BEAMION, more at #WCLC26. Dr Y
@OncogeneCancer · 2026-09-14 · OCR
Drs @juliarotow & James Yang present on HER2 - inc DESTINY, BEAMION, more at #WCLC26. Dr Y
@OncogeneCancer · 2026-09-14 · OCR
WCLC 2026 | SCLC Pumitamig + B7-H3 ADC elfe-D shows a striking early signal: • ORR 70.4%
@OncologyMarwarD · 2026-09-15 · OCR
WCLC 2026 | SCLC Pumitamig + B7-H3 ADC elfe-D shows a striking early signal: • ORR 70.4%
@OncologyMarwarD · 2026-09-15 · OCR
WCLC 2026 | SCLC Pumitamig + B7-H3 ADC elfe-D shows a striking early signal: • ORR 70.4%
@OncologyMarwarD · 2026-09-15 · OCR
WCLC 2026 | SCLC Pumitamig + B7-H3 ADC elfe-D shows a striking early signal: • ORR 70.4%
@OncologyMarwarD · 2026-09-15 · OCR
#WCLC26 | PAPILLON Amivantamab + chemotherapy: mOS 34.3 vs 27.9 mo in EGFR exon20ins NSCL
@OncologyMarwarD · 2026-09-14 · OCR
#WCLC26 | PAPILLON Amivantamab + chemotherapy: mOS 34.3 vs 27.9 mo in EGFR exon20ins NSCL
@OncologyMarwarD · 2026-09-14 · OCR
#WCLC26 | TAISHAN-302 vs ARTEMIS-008 Two B7-H3 ADCs, identical OS HR 0.46 vs topotecan. R
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 vs ARTEMIS-008 Two B7-H3 ADCs, identical OS HR 0.46 vs topotecan. R
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 vs ARTEMIS-008 Two B7-H3 ADCs, identical OS HR 0.46 vs topotecan. R
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 vs ARTEMIS-008 Two B7-H3 ADCs, identical OS HR 0.46 vs topotecan. R
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 : MDT-BRIDGE suggests that resectability in stage III NSCLC should be viewed as a
@OncologyMarwarD · 2026-09-13 · OCR
WCLC 2026 | EGFR exon20ins NSCLC PAPILLON is more mature; REZILIENT-3 shows strong PFS, w
@OncologyMarwarD · 2026-09-14 · OCR
WCLC 2026 | EGFR exon20ins NSCLC PAPILLON is more mature; REZILIENT-3 shows strong PFS, w
@OncologyMarwarD · 2026-09-14 · OCR
WCLC 2026 | EGFR exon20ins NSCLC PAPILLON is more mature; REZILIENT-3 shows strong PFS, w
@OncologyMarwarD · 2026-09-14 · OCR
REZILIENT-3 | WCLC 2026 Zipalertinib + chemotherapy significantly improved PFS in 1L EGFR
@OncologyMarwarD · 2026-09-14 · OCR
REZILIENT-3 | WCLC 2026 Zipalertinib + chemotherapy significantly improved PFS in 1L EGFR
@OncologyMarwarD · 2026-09-14 · OCR
REZILIENT-3 | WCLC 2026 Zipalertinib + chemotherapy significantly improved PFS in 1L EGFR
@OncologyMarwarD · 2026-09-14 · OCR
#WCLC26 | ROS1+ NSCLC Zidesamtinib shows a striking early 1L signal: ORR 94%, CR 15%, 12-
@OncologyMarwarD · 2026-09-14 · OCR
#WCLC26 | ROS1+ NSCLC Zidesamtinib shows a striking early 1L signal: ORR 94%, CR 15%, 12-
@OncologyMarwarD · 2026-09-14 · OCR
WCLC 2026 | DESTINY-Lung04 1L T-DXd improved PFS (14.3 vs 8.3 mo; HR 0.63) and ORR (70% v
@OncologyMarwarD · 2026-09-14 · OCR
WCLC 2026 | DESTINY-Lung04 1L T-DXd improved PFS (14.3 vs 8.3 mo; HR 0.63) and ORR (70% v
@OncologyMarwarD · 2026-09-14 · OCR
WCLC 2026 | DESTINY-Lung04 1L T-DXd improved PFS (14.3 vs 8.3 mo; HR 0.63) and ORR (70% v
@OncologyMarwarD · 2026-09-14 · OCR
WCLC 2026 | DESTINY-Lung04 1L T-DXd improved PFS (14.3 vs 8.3 mo; HR 0.63) and ORR (70% v
@OncologyMarwarD · 2026-09-14 · OCR
#WCLC26 | ADAURA 8-year update Adjuvant osimertinib continues to deliver durable OS benef
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | ADAURA 8-year update Adjuvant osimertinib continues to deliver durable OS benef
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | ADAURA 8-year update Adjuvant osimertinib continues to deliver durable OS benef
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 Ris-Rez improved OS (18.5 vs 10.3 mo; HR 0.46) and PFS (7.2 vs 3.0
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 Ris-Rez improved OS (18.5 vs 10.3 mo; HR 0.46) and PFS (7.2 vs 3.0
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | ARTEMIS-008 Ris-Rez improved OS (18.5 vs 10.3 mo; HR 0.46) and PFS (7.2 vs 3.0
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 In relapsed SCLC, Tam-Peli (YL201) significantly improved outcomes
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 In relapsed SCLC, Tam-Peli (YL201) significantly improved outcomes
@OncologyMarwarD · 2026-09-13 · OCR
#WCLC26 | TAISHAN-302 In relapsed SCLC, Tam-Peli (YL201) significantly improved outcomes
@OncologyMarwarD · 2026-09-13 · OCR
🚨 #WCLC26 | SWOG S1827/MAVERICK MRI surveillance improved CFFS vs PCI+MRI (HR 0.60), with
@OncologyMarwarD · 2026-09-12 · OCR
🚨 #WCLC26 | SWOG S1827/MAVERICK MRI surveillance improved CFFS vs PCI+MRI (HR 0.60), with
@OncologyMarwarD · 2026-09-12 · OCR
🚨 #WCLC26 | SWOG S1827/MAVERICK MRI surveillance improved CFFS vs PCI+MRI (HR 0.60), with
@OncologyMarwarD · 2026-09-12 · OCR
🚨 #WCLC26 | SWOG S1827/MAVERICK MRI surveillance improved CFFS vs PCI+MRI (HR 0.60), with
@OncologyMarwarD · 2026-09-12 · OCR
⭐️#WCLC26 #OncUpdate MRI surveillance alone vs MRI+PCI in #SCLC ✅MRI alone→⬆️ cognitive
@OncUpdates · 2026-09-13 · OCR
⭐️#WCLC26 #OncUpdate MRI surveillance alone vs MRI+PCI in #SCLC ✅MRI alone→⬆️ cognitive
@OncUpdates · 2026-09-13 · OCR
⭐️#WCLC26 #OncUpdate MRI surveillance alone vs MRI+PCI in #SCLC ✅MRI alone→⬆️ cognitive
@OncUpdates · 2026-09-13 · OCR
🫁 #WCLC26 Plenary @DrRoyHerbst 🔥 ADAURA: Adjuvant osimertinib in resected EGFRm stage IB
@OncUpdates · 2026-09-14 · OCR
🫁 #WCLC26 Plenary @DrRoyHerbst 🔥 ADAURA: Adjuvant osimertinib in resected EGFRm stage IB
@OncUpdates · 2026-09-14 · OCR
🫁 #WCLC26 Plenary @DrRoyHerbst 🔥 ADAURA: Adjuvant osimertinib in resected EGFRm stage IB
@OncUpdates · 2026-09-14 · OCR
#WCLC26 — The Studies to Watch Seoul, 12–15 September A clinical map of the key questions
@ozdogan_md · 2026-09-11 · OCR
Two negative Phase 3 atezolizumab trials—but two very different messages. IMpower030 miss
@ozdogan_md · 2026-09-12 · OCR
#WCLC26 closes with a landmark result: #ivonescimab became the first PD-1 × VEGF bispecifi
@ozdogan_md · 2026-09-15 · OCR
#WCLC26 Presidential 1 redrew the map Two B7-H3 ADCs reduced the risk of death by 54% ver
@ozdogan_md · 2026-09-13 · OCR
A striking early signal from #WCLC26 Pumitamig plus elfetabart drozuntecan achieved a 70.
@ozdogan_md · 2026-09-12 · OCR
Five trials and one practice map from #WCLC26 Presidential 2 ADAURA’s OS benefit endures
@ozdogan_md · 2026-09-14 · OCR
B7-H3 is no longer just a promising tumor marker. At #WCLC26, two independent Phase 3 ADC
@ozdogan_md · 2026-09-13 · OCR
@Bayer 's sevabertinib is a new first-line oral option for advanced HER2-mutant non-squamo
@ozdogan_md · 2026-09-10 · OCR
The best part of crossing ✈️ the planet 🌏 for work ☢️ is meeting some fantastic friends 🇰🇷
@przybyszmd · 2026-09-12 · OCR
#RadOncs’ dinner 🥘 at the #WCLC26 🇰🇷 https://t.co/zAcPlveAeP
@przybyszmd · 2026-09-14 · OCR
#RadOncs’ dinner 🥘 at the #WCLC26 🇰🇷 https://t.co/zAcPlveAeP
@przybyszmd · 2026-09-14 · OCR
#RadOncs’ dinner 🥘 at the #WCLC26 🇰🇷 https://t.co/zAcPlveAeP
@przybyszmd · 2026-09-14 · OCR
Crazy 🤪 agenda today at the International Association for the Study of Lung Cancer #WCLC2
@przybyszmd · 2026-09-14 · OCR
Crazy 🤪 agenda today at the International Association for the Study of Lung Cancer #WCLC2
@przybyszmd · 2026-09-14 · OCR
Crazy 🤪 agenda today at the International Association for the Study of Lung Cancer #WCLC2
@przybyszmd · 2026-09-14 · OCR
Crazy 🤪 agenda today at the International Association for the Study of Lung Cancer #WCLC2
@przybyszmd · 2026-09-14 · OCR
A wonderful #WCLC26 🇰🇷 🍜 break today! Time to catch up ⛳️ 🍷 🫁. Thanks for (teaching us ho
@przybyszmd · 2026-09-12 · OCR
A wonderful #WCLC26 🇰🇷 🍜 break today! Time to catch up ⛳️ 🍷 🫁. Thanks for (teaching us ho
@przybyszmd · 2026-09-12 · OCR
19.000 km away, 🇧🇷 ➡️ 🇰🇷, our team at #RadioSerra delivered another year of great academic
@przybyszmd · 2026-09-15 · OCR
19.000 km away, 🇧🇷 ➡️ 🇰🇷, our team at #RadioSerra delivered another year of great academic
@przybyszmd · 2026-09-15 · OCR
19.000 km away, 🇧🇷 ➡️ 🇰🇷, our team at #RadioSerra delivered another year of great academic
@przybyszmd · 2026-09-15 · OCR
19.000 km away, 🇧🇷 ➡️ 🇰🇷, our team at #RadioSerra delivered another year of great academic
@przybyszmd · 2026-09-15 · OCR
Locked 🔐 in all steps for today @ COEX 🇰🇷!!! #WCLC26 🫁 #RadOnc #한국폐암환우협회 https://t.co/cKgf
@przybyszmd · 2026-09-16 · OCR
Locked 🔐 in all steps for today @ COEX 🇰🇷!!! #WCLC26 🫁 #RadOnc #한국폐암환우협회 https://t.co/cKgf
@przybyszmd · 2026-09-16 · OCR
#WCLC26 🫁 First day and the 👨🏽‍⚕️ 👩🏽‍⚕️ MSC Committee is on fire 🔥! Let’s go!!! #Seoul 🇰🇷
@przybyszmd · 2026-09-12 · OCR
Today; we put efforts 🏋🏽 together for @IASLC 🫁 Payor Summit Initiative in #Seoul 🇰🇷 at the
@przybyszmd · 2026-09-14 · OCR
Today; we put efforts 🏋🏽 together for @IASLC 🫁 Payor Summit Initiative in #Seoul 🇰🇷 at the
@przybyszmd · 2026-09-14 · OCR
Today; we put efforts 🏋🏽 together for @IASLC 🫁 Payor Summit Initiative in #Seoul 🇰🇷 at the
@przybyszmd · 2026-09-14 · OCR
Today; we put efforts 🏋🏽 together for @IASLC 🫁 Payor Summit Initiative in #Seoul 🇰🇷 at the
@przybyszmd · 2026-09-14 · OCR
Hello #SouthKorea 🇰🇷! We are finally here - 우리는 드디어 여기에 왔습니다. Let’s kick off #WCLC26 🫁! #I
@przybyszmd · 2026-09-12 · OCR
Hello #SouthKorea 🇰🇷! We are finally here - 우리는 드디어 여기에 왔습니다. Let’s kick off #WCLC26 🫁! #I
@przybyszmd · 2026-09-12 · OCR
Hello #SouthKorea 🇰🇷! We are finally here - 우리는 드디어 여기에 왔습니다. Let’s kick off #WCLC26 🫁! #I
@przybyszmd · 2026-09-12 · OCR
👀 POV: exchanging cases, conducts, decisions and data is the best thing about practicing o
@przybyszmd · 2026-09-15 · OCR
👀 POV: exchanging cases, conducts, decisions and data is the best thing about practicing o
@przybyszmd · 2026-09-15 · OCR
👀 POV: exchanging cases, conducts, decisions and data is the best thing about practicing o
@przybyszmd · 2026-09-15 · OCR
That’s a wrap for #WCLC26 🇰🇷! What an amazing time. 🫁 Our patients always deserve the #bes
@przybyszmd · 2026-09-16 · OCR
That’s a wrap for #WCLC26 🇰🇷! What an amazing time. 🫁 Our patients always deserve the #bes
@przybyszmd · 2026-09-16 · OCR
안녕히 계세요 Good bye PCI 👋🏾 👋🏾 #SCLC #WCLC26 🫁 🇰🇷 https://t.co/fYaOGKiSCg
@przybyszmd · 2026-09-13 · OCR
안녕히 계세요 Good bye PCI 👋🏾 👋🏾 #SCLC #WCLC26 🫁 🇰🇷 https://t.co/fYaOGKiSCg
@przybyszmd · 2026-09-13 · OCR
안녕히 계세요 Good bye PCI 👋🏾 👋🏾 #SCLC #WCLC26 🫁 🇰🇷 https://t.co/fYaOGKiSCg
@przybyszmd · 2026-09-13 · OCR
WCLC Plenary 1- Maverick trial showing MRI surveillance in small cell lung cancer shows su
@pueyl · 2026-09-12 · OCR
WCLC Plenary 1- Maverick trial showing MRI surveillance in small cell lung cancer shows su
@pueyl · 2026-09-12 · OCR
WCLC Plenary 1- Maverick trial showing MRI surveillance in small cell lung cancer shows su
@pueyl · 2026-09-12 · OCR
What a lovely waterfall plot! Impressive ORR 94% for ROS1 inhibitor-ARROS1 #wclc26 https:
@pueyl · 2026-09-14 · OCR
What a lovely waterfall plot! Impressive ORR 94% for ROS1 inhibitor-ARROS1 #wclc26 https:
@pueyl · 2026-09-14 · OCR
PDL1+ macrophages showed tumour infiltration for transformed NSCLC to SCLC. Increased TP53
@pueyl · 2026-09-13 · OCR
PDL1+ macrophages showed tumour infiltration for transformed NSCLC to SCLC. Increased TP53
@pueyl · 2026-09-13 · OCR
Great to see my mentor, @ChristianRolfo present CONCORDANCE-2 at @IASLC #WCLC26 Liquid bi
@RobertoBoreaMD · 2026-09-14 · OCR
Grateful to share our poster at #WCLC26 on the obesity paradox in pts with #NSCLC treated
@RobertoBoreaMD · 2026-09-15 · OCR
Grateful to share our poster at #WCLC26 on the obesity paradox in pts with #NSCLC treated
@RobertoBoreaMD · 2026-09-15 · OCR
Great talk by @BrunaPellini at #WCLC26: ctDNA monitoring is now clinically available for
@RobertoBoreaMD · 2026-09-14 · OCR
Great talk by @BrunaPellini at #WCLC26: ctDNA monitoring is now clinically available for
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo at #WCLC26: across 11,862 patients with advanced #NSCLC, actionable driver
@RobertoBoreaMD · 2026-09-15 · OCR
@DavidGandara at #WCLC26: in PD-L1-high nonsquamous #NSCLC, #KRAS G12C stood out for benef
@RobertoBoreaMD · 2026-09-14 · OCR
@DavidGandara at #WCLC26: in PD-L1-high nonsquamous #NSCLC, #KRAS G12C stood out for benef
@RobertoBoreaMD · 2026-09-14 · OCR
@DavidGandara at #WCLC26: in PD-L1-high nonsquamous #NSCLC, #KRAS G12C stood out for benef
@RobertoBoreaMD · 2026-09-14 · OCR
@DavidGandara at #WCLC26: in PD-L1-high nonsquamous #NSCLC, #KRAS G12C stood out for benef
@RobertoBoreaMD · 2026-09-14 · OCR
@DavidGandara presenting PROphetNSCLC at #WCLC26 The test holds its predictive power unde
@RobertoBoreaMD · 2026-09-14 · OCR
Terrific discussion by #AnneChang at #WCLC2026 on ADCs in SCLC @IASLC TAISHAN-302 and ART
@RobertoBoreaMD · 2026-09-13 · OCR
Terrific discussion by #AnneChang at #WCLC2026 on ADCs in SCLC @IASLC TAISHAN-302 and ART
@RobertoBoreaMD · 2026-09-13 · OCR
Terrific discussion by #AnneChang at #WCLC2026 on ADCs in SCLC @IASLC TAISHAN-302 and ART
@RobertoBoreaMD · 2026-09-13 · OCR
New from @DiegoEnricoMD from @rolfolab at #WCLC26: a tissue RNA-Seq view of the fusion lan
@RobertoBoreaMD · 2026-09-14 · OCR
New from @DiegoEnricoMD from @rolfolab at #WCLC26: a tissue RNA-Seq view of the fusion lan
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo from @OSUCCC_James @OhioStateMedOnc at #WCLC26 on clonal hematopoiesis vs
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo from @OSUCCC_James @OhioStateMedOnc at #WCLC26 on clonal hematopoiesis vs
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo from @OSUCCC_James @OhioStateMedOnc at #WCLC26 on clonal hematopoiesis vs
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo from @OSUCCC_James @OhioStateMedOnc at #WCLC26 on clonal hematopoiesis vs
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo at #WCLC26 on MTAP loss in NSCLC across tissue and plasma. In a large re
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo at #WCLC26 on MTAP loss in NSCLC across tissue and plasma. In a large re
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo at #WCLC26 on MTAP loss in NSCLC across tissue and plasma. In a large re
@RobertoBoreaMD · 2026-09-14 · OCR
@ChristianRolfo at #WCLC26 on MTAP loss in NSCLC across tissue and plasma. In a large re
@RobertoBoreaMD · 2026-09-14 · OCR
@GlopesMd at #WCLC26 on pairing #ctRNA with #ctDNA in NSCLC. The RNA layer added 38.7% mo
@RobertoBoreaMD · 2026-09-15 · OCR
@GlopesMd at #WCLC26 on pairing #ctRNA with #ctDNA in NSCLC. The RNA layer added 38.7% mo
@RobertoBoreaMD · 2026-09-15 · OCR
@CharuAggarwalMD at #WCLC26 Post-surgical #ctDNA #MRD is becoming a real risk stratifier
@RobertoBoreaMD · 2026-09-15 · OCR
@CharuAggarwalMD at #WCLC26 Post-surgical #ctDNA #MRD is becoming a real risk stratifier
@RobertoBoreaMD · 2026-09-15 · OCR
@CharuAggarwalMD at #WCLC26 Post-surgical #ctDNA #MRD is becoming a real risk stratifier
@RobertoBoreaMD · 2026-09-15 · OCR
MAVERICK trial presented at #WCLC26 @IASLC by Phase III MRI brain surveillance ± PCI in L
@RobertoBoreaMD · 2026-09-12 · OCR
MAVERICK trial presented at #WCLC26 @IASLC by Phase III MRI brain surveillance ± PCI in L
@RobertoBoreaMD · 2026-09-12 · OCR
MAVERICK trial presented at #WCLC26 @IASLC by Phase III MRI brain surveillance ± PCI in L
@RobertoBoreaMD · 2026-09-12 · OCR
TAISHAN-302: Phase 3 trial of Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC (N=451) a
@RobertoBoreaMD · 2026-09-13 · OCR
TAISHAN-302: Phase 3 trial of Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC (N=451) a
@RobertoBoreaMD · 2026-09-13 · OCR
TAISHAN-302: Phase 3 trial of Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC (N=451) a
@RobertoBoreaMD · 2026-09-13 · OCR
TAISHAN-302: Phase 3 trial of Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC (N=451) a
@RobertoBoreaMD · 2026-09-13 · OCR
ARTEMIS-008 Risvutatug Rezetecan vs Topotecan in relapsed SCLC OS • Median OS: 18.5 vs 1
@RobertoBoreaMD · 2026-09-13 · OCR
ARTEMIS-008 Risvutatug Rezetecan vs Topotecan in relapsed SCLC OS • Median OS: 18.5 vs 1
@RobertoBoreaMD · 2026-09-13 · OCR
Reprogramming TME and novel therapeutic avenues for immunotherapy version 2.0 @Gmazzaschi9
@RobertoFerrara_ · 2026-09-15 · OCR
ADC anti B7H3: promising results in pretreated SCLC. It would be nice to see the impact of
@RobertoFerrara_ · 2026-09-13 · OCR
ADC anti B7H3: promising results in pretreated SCLC. It would be nice to see the impact of
@RobertoFerrara_ · 2026-09-13 · OCR
ADC anti B7H3: promising results in pretreated SCLC. It would be nice to see the impact of
@RobertoFerrara_ · 2026-09-13 · OCR
Evoke 03 Sacituzumab Gov+ Pembro no benefit in OS. In 2026 it's time to integrate other bi
@RobertoFerrara_ · 2026-09-13 · OCR
Evoke 03 Sacituzumab Gov+ Pembro no benefit in OS. In 2026 it's time to integrate other bi
@RobertoFerrara_ · 2026-09-13 · OCR
Evoke 03 Sacituzumab Gov+ Pembro no benefit in OS. In 2026 it's time to integrate other bi
@RobertoFerrara_ · 2026-09-13 · OCR
@MarianaBrandao0 giving a very comprehensive discussion of 5 oral abstracts at #WCLC2026.
@RobertoFerrara_ · 2026-09-15 · OCR
@MarianaBrandao0 giving a very comprehensive discussion of 5 oral abstracts at #WCLC2026.
@RobertoFerrara_ · 2026-09-15 · OCR
@MarianaBrandao0 giving a very comprehensive discussion of 5 oral abstracts at #WCLC2026.
@RobertoFerrara_ · 2026-09-15 · OCR
One of the best sessions at @IASLC #WCLC26 so far, featuring @ManelEsteller @BravoCorderoL
@SandraOrtizCua1 · 2026-09-13 · OCR
One of the best sessions at @IASLC #WCLC26 so far, featuring @ManelEsteller @BravoCorderoL
@SandraOrtizCua1 · 2026-09-13 · OCR
One of the best sessions at @IASLC #WCLC26 so far, featuring @ManelEsteller @BravoCorderoL
@SandraOrtizCua1 · 2026-09-13 · OCR
One of the best sessions at @IASLC #WCLC26 so far, featuring @ManelEsteller @BravoCorderoL
@SandraOrtizCua1 · 2026-09-13 · OCR
This #WCLC26 is special because it is the first lung cancer conference of my little sister
@SandraOrtizCua1 · 2026-09-14 · OCR
This #WCLC26 is special because it is the first lung cancer conference of my little sister
@SandraOrtizCua1 · 2026-09-14 · OCR
This #WCLC26 is special because it is the first lung cancer conference of my little sister
@SandraOrtizCua1 · 2026-09-14 · OCR
Join us for the interactive session on the use of preclinical models to understand the tum
@SandraOrtizCua1 · 2026-09-13 · OCR
Inspiring talk by Matthew Meyerson @IASLC #WCLC26. https://t.co/S7BaiCQY8Z
@SandraOrtizCua1 · 2026-09-12 · OCR
Inspiring talk by Matthew Meyerson @IASLC #WCLC26. https://t.co/S7BaiCQY8Z
@SandraOrtizCua1 · 2026-09-12 · OCR
Inspiring talk by Matthew Meyerson @IASLC #WCLC26. https://t.co/S7BaiCQY8Z
@SandraOrtizCua1 · 2026-09-12 · OCR
First days in Seoul, what an amazing city ! 🌟 Ready for @IASLC #WCLC26 ! https://t.co/nW
@SandraOrtizCua1 · 2026-09-11 · OCR
First days in Seoul, what an amazing city ! 🌟 Ready for @IASLC #WCLC26 ! https://t.co/nW
@SandraOrtizCua1 · 2026-09-11 · OCR
First days in Seoul, what an amazing city ! 🌟 Ready for @IASLC #WCLC26 ! https://t.co/nW
@SandraOrtizCua1 · 2026-09-11 · OCR
First days in Seoul, what an amazing city ! 🌟 Ready for @IASLC #WCLC26 ! https://t.co/nW
@SandraOrtizCua1 · 2026-09-11 · OCR
EVOKE-03 did not meet the primary endpoint. PFS 11.8 vs 7.7m, HR 0.81 but did not meet th
@StephenVLiu · 2026-09-13 · OCR
EVOKE-03 did not meet the primary endpoint. PFS 11.8 vs 7.7m, HR 0.81 but did not meet th
@StephenVLiu · 2026-09-13 · OCR
EVOKE-03 did not meet the primary endpoint. PFS 11.8 vs 7.7m, HR 0.81 but did not meet th
@StephenVLiu · 2026-09-13 · OCR
Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improv
@StephenVLiu · 2026-09-12 · OCR
We now have TWO studies showing B7-H3 ADCs vastly superior to standard topotecan for relap
@StephenVLiu · 2026-09-13 · OCR
Dr. Chad Rusthoven at #WCLC26 presents results from SWOG S1827, the phase III MAVERICK stu
@StephenVLiu · 2026-09-12 · OCR
Dr. Chad Rusthoven at #WCLC26 presents results from SWOG S1827, the phase III MAVERICK stu
@StephenVLiu · 2026-09-12 · OCR
Dr. Chad Rusthoven at #WCLC26 presents results from SWOG S1827, the phase III MAVERICK stu
@StephenVLiu · 2026-09-12 · OCR
Dr. Chad Rusthoven at #WCLC26 presents results from SWOG S1827, the phase III MAVERICK stu
@StephenVLiu · 2026-09-12 · OCR
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with
@StephenVLiu · 2026-09-14 · OCR
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with
@StephenVLiu · 2026-09-14 · OCR
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with
@StephenVLiu · 2026-09-14 · OCR
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resecta
@StephenVLiu · 2026-09-13 · OCR
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resecta
@StephenVLiu · 2026-09-13 · OCR
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resecta
@StephenVLiu · 2026-09-13 · OCR
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resecta
@StephenVLiu · 2026-09-13 · OCR
MRI alone, without PCI, showed a significant improvement in cognitive failure free surviva
@StephenVLiu · 2026-09-12 · OCR
Another wow curve. Ris-rez improves OS over topotecan, mOS 18.5m (!) vs 10.3m, OS HR 0.46
@StephenVLiu · 2026-09-13 · OCR
Dr. @g_mountzios at #WCLC26 presents results of EVOKE-03 / KEYNOTE D46: phase III study of
@StephenVLiu · 2026-09-13 · OCR
Dr. @g_mountzios at #WCLC26 presents results of EVOKE-03 / KEYNOTE D46: phase III study of
@StephenVLiu · 2026-09-13 · OCR
Dr. @g_mountzios at #WCLC26 presents results of EVOKE-03 / KEYNOTE D46: phase III study of
@StephenVLiu · 2026-09-13 · OCR
Phase II study of first-line QLC5508 (MHB088C, a B7-H3 ADC) with either QL1706 (PD1/CTLA4
@StephenVLiu · 2026-09-15 · OCR
Phase II study of first-line QLC5508 (MHB088C, a B7-H3 ADC) with either QL1706 (PD1/CTLA4
@StephenVLiu · 2026-09-15 · OCR
Phase II study of first-line QLC5508 (MHB088C, a B7-H3 ADC) with either QL1706 (PD1/CTLA4
@StephenVLiu · 2026-09-15 · OCR
Phase II study of first-line QLC5508 (MHB088C, a B7-H3 ADC) with either QL1706 (PD1/CTLA4
@StephenVLiu · 2026-09-15 · OCR
Dr. @JuliaRotow at #WCLC26 with primary results from DESTINY-Lung04: first-line trastuzuma
@StephenVLiu · 2026-09-14 · OCR
Dr. @JuliaRotow at #WCLC26 with primary results from DESTINY-Lung04: first-line trastuzuma
@StephenVLiu · 2026-09-14 · OCR
Dr. @JuliaRotow at #WCLC26 with primary results from DESTINY-Lung04: first-line trastuzuma
@StephenVLiu · 2026-09-14 · OCR
Dr. @JuliaRotow at #WCLC26 with primary results from DESTINY-Lung04: first-line trastuzuma
@StephenVLiu · 2026-09-14 · OCR
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (t
@StephenVLiu · 2026-09-13 · OCR
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (t
@StephenVLiu · 2026-09-13 · OCR
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (t
@StephenVLiu · 2026-09-13 · OCR
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (t
@StephenVLiu · 2026-09-13 · OCR
Dr. @bensolomon1 presents IMpower 030: perioperative atezolizumab + chemo in resectable NS
@StephenVLiu · 2026-09-13 · OCR
Dr. @bensolomon1 presents IMpower 030: perioperative atezolizumab + chemo in resectable NS
@StephenVLiu · 2026-09-13 · OCR
Dr. @bensolomon1 presents IMpower 030: perioperative atezolizumab + chemo in resectable NS
@StephenVLiu · 2026-09-13 · OCR
Dr. @bensolomon1 presents IMpower 030: perioperative atezolizumab + chemo in resectable NS
@StephenVLiu · 2026-09-13 · OCR
8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in
@StephenVLiu · 2026-09-13 · OCR
8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in
@StephenVLiu · 2026-09-13 · OCR
8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in
@StephenVLiu · 2026-09-13 · OCR
8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in
@StephenVLiu · 2026-09-13 · OCR
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of b
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of b
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of b
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of b
@StephenVLiu · 2026-09-14 · OCR
Dr. Jie Wang presents results from phase III ARTEMIS-008 trial of risvutatug rezetecan (ri
@StephenVLiu · 2026-09-13 · OCR
Dr. Jie Wang presents results from phase III ARTEMIS-008 trial of risvutatug rezetecan (ri
@StephenVLiu · 2026-09-13 · OCR
Dr. Jie Wang presents results from phase III ARTEMIS-008 trial of risvutatug rezetecan (ri
@StephenVLiu · 2026-09-13 · OCR
Dr. @chulkimMD from @LombardiCancer presents final OS analysis on phase III PAPILLON trial
@StephenVLiu · 2026-09-14 · OCR
Dr. @chulkimMD from @LombardiCancer presents final OS analysis on phase III PAPILLON trial
@StephenVLiu · 2026-09-14 · OCR
Dr. @chulkimMD from @LombardiCancer presents final OS analysis on phase III PAPILLON trial
@StephenVLiu · 2026-09-14 · OCR
All ready for the #WCLC26 Presidential Plenary! https://t.co/MzIkfFvSUq
@StephenVLiu · 2026-09-13 · OCR
BRAF V600E NSCLC is a unique subset of NSCLC that can respond well to targeted therapy but
@StephenVLiu · 2026-09-10 · OCR
Big congratulations to Dr. @CharuAggarwalMD - winner of the #WCLC26 Daniel Ihde Lectureshi
@StephenVLiu · 2026-09-12 · OCR
#WCLC26 PCI decreased the cumulative incidence of brain metastases but this did not improv
@StephenVLiu · 2026-09-12 · OCR
#WCLC26 PCI decreased the cumulative incidence of brain metastases but this did not improv
@StephenVLiu · 2026-09-12 · OCR
#WCLC26 PCI decreased the cumulative incidence of brain metastases but this did not improv
@StephenVLiu · 2026-09-12 · OCR
Don’t miss the opening plenary at #WCLC26 where we will honor our Distinguished Service Aw
@StephenVLiu · 2026-09-11 · OCR
A beautiful faculty dinner at #WCLC26 with a surprise performance by the amazing Drs. Myun
@StephenVLiu · 2026-09-13 · OCR
A beautiful faculty dinner at #WCLC26 with a surprise performance by the amazing Drs. Myun
@StephenVLiu · 2026-09-13 · OCR
A beautiful faculty dinner at #WCLC26 with a surprise performance by the amazing Drs. Myun
@StephenVLiu · 2026-09-13 · OCR
A beautiful faculty dinner at #WCLC26 with a surprise performance by the amazing Drs. Myun
@StephenVLiu · 2026-09-13 · OCR
As would be expected, much greater toxicity with sacituzumab govitecan + pembro arm vs pem
@StephenVLiu · 2026-09-13 · OCR
Dr. Beung Chul Ahn at #WCLC26 presents results from RAPHAEL trial (KM-07, LU15-12): a phas
@StephenVLiu · 2026-09-13 · OCR
Dr. Beung Chul Ahn at #WCLC26 presents results from RAPHAEL trial (KM-07, LU15-12): a phas
@StephenVLiu · 2026-09-13 · OCR
Dr. Beung Chul Ahn at #WCLC26 presents results from RAPHAEL trial (KM-07, LU15-12): a phas
@StephenVLiu · 2026-09-13 · OCR
Congratulations to Dr. @pompili_cecilia - the #WCLC26 winner of the Robert J. Ginsburg Lec
@StephenVLiu · 2026-09-13 · OCR
Congratulations to Dr. @pompili_cecilia - the #WCLC26 winner of the Robert J. Ginsburg Lec
@StephenVLiu · 2026-09-13 · OCR
Celebrating the start of #WCLC26 with brilliant friends ahead of some major data releases
@StephenVLiu · 2026-09-12 · OCR
Celebrating the start of #WCLC26 with brilliant friends ahead of some major data releases
@StephenVLiu · 2026-09-12 · OCR
Celebrating the start of #WCLC26 with brilliant friends ahead of some major data releases
@StephenVLiu · 2026-09-12 · OCR
Celebrating the start of #WCLC26 with brilliant friends ahead of some major data releases
@StephenVLiu · 2026-09-12 · OCR
Recipient of the Paul A. Bunn Scientific Award at #WCLC26 is @DRCamidge - no one more dese
@StephenVLiu · 2026-09-12 · OCR
Workshop on exercise in lung cancer and the IREX-LUNG International Collaborative Network
@StephenVLiu · 2026-09-12 · OCR
Workshop on exercise in lung cancer and the IREX-LUNG International Collaborative Network
@StephenVLiu · 2026-09-12 · OCR
Nice summary of the blurring boundaries between two curative paradigms, surgery and radiat
@StephenVLiu · 2026-09-10 · OCR
@IASLC No difference in OS between MRI surveillance alone and PCI with MRI surveillance wi
@StephenVLiu · 2026-09-12 · OCR
Dr. @danieltanmd presents REZILIENT 3 at #WCLC26: 1L zipalertinib + chemo vs chemo in EGFR
@StephenVLiu · 2026-09-14 · OCR
Dr. @danieltanmd presents REZILIENT 3 at #WCLC26: 1L zipalertinib + chemo vs chemo in EGFR
@StephenVLiu · 2026-09-14 · OCR
Dr. @danieltanmd presents REZILIENT 3 at #WCLC26: 1L zipalertinib + chemo vs chemo in EGFR
@StephenVLiu · 2026-09-14 · OCR
Congratulations to my friend Dr. Jie Wang on a wonderful #WCLC26 presentation on ris-rez i
@StephenVLiu · 2026-09-13 · OCR
Review of open controversies with targeted thearpy in early stage NSCLC with Dr. Yilong Wu
@StephenVLiu · 2026-09-10 · OCR
Tonight, 9/13/26, at 6pm local time in Seoul at #WCLC26, be sure to join Drs. Tina Cascone
@StephenVLiu · 2026-09-13 · OCR
Great communicators discussing social media at #WCLC26 with Drs. @MattSmeltzer @HegiFiona
@StephenVLiu · 2026-09-12 · OCR
Dr. @mollylisc at #BTGLung2026 highlights a burning question for HER2 mutant NSCLC - what
@StephenVLiu · 2026-09-11 · OCR
At #BTGLung2026 ahead of #WCLC26, Dr. @danieltanmd discusses the gaps in the 1L EGFR NSCLC
@StephenVLiu · 2026-09-10 · OCR
Poster at #WCLC26 from Dr. @SoraElyMD - after 25 years, no new strategies for Pancoast. Ne
@StephenVLiu · 2026-09-13 · OCR
Our #WCLC26 chairs! https://t.co/NH5GTMt3rl
@StephenVLiu · 2026-09-12 · OCR
Great discussion on misinformation on social media at #WCLC26 with Dr. @DrRiyazShah and @N
@StephenVLiu · 2026-09-12 · OCR
Great discussion on misinformation on social media at #WCLC26 with Dr. @DrRiyazShah and @N
@StephenVLiu · 2026-09-12 · OCR
Dr. @LudaBazhenovaMD discusses the EGFR exon 20 space at #WCLC26. Challenging target but n
@StephenVLiu · 2026-09-14 · OCR
Dr. @LudaBazhenovaMD discusses the EGFR exon 20 space at #WCLC26. Challenging target but n
@StephenVLiu · 2026-09-14 · OCR
Dr. @LudaBazhenovaMD discusses the EGFR exon 20 space at #WCLC26. Challenging target but n
@StephenVLiu · 2026-09-14 · OCR
Ready for #WCLC26! https://t.co/i05qoWblnj
@StephenVLiu · 2026-09-12 · OCR
Important point from Dr. Chad Rusthoven at #WCLC26: MAVERICK did not show equivalence with
@StephenVLiu · 2026-09-12 · OCR
All scientific sessions live streamed and live AI powered translation available for all la
@StephenVLiu · 2026-09-12 · OCR
Dr. @GlopesMd leads a discussion on policy and how it truly impacts every aspect of lung c
@StephenVLiu · 2026-09-12 · OCR
Day one of #WCLC26 and if you are in Seoul, the WiFi password is WCLC2026! @IASLC https://
@StephenVLiu · 2026-09-11 · OCR
Dr. @Latinamd at #WCLC26 discusses @IASLC Thoracic Circle - discussion groups to connect a
@StephenVLiu · 2026-09-12 · OCR
Looking forward to this multidisciplinary discussion on the state of early stage NSCLC in
@StephenVLiu · 2026-09-12 · OCR
Wow. Tam-peli with a major improvement in OS over topotecan with median OS 13.3m vs 9.4m
@StephenVLiu · 2026-09-13 · OCR
@IASLC TAISHAN-302 with powerful improvement in OS, PFS, RR with tam-peli over topotecan i
@StephenVLiu · 2026-09-13 · OCR
ARTEMIS-008 improves OS, PFS, RR with ris-rez over topotecan in relapsed SCLC. Another sta
@StephenVLiu · 2026-09-13 · OCR
#WCLC26 PAPILLON arm of 1L amivantamab + chemotherapy in EGFRex20 had superior PFS2 (HR 0.
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 PAPILLON arm of 1L amivantamab + chemotherapy in EGFRex20 had superior PFS2 (HR 0.
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 PAPILLON arm of 1L amivantamab + chemotherapy in EGFRex20 had superior PFS2 (HR 0.
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 Safety profile consistent with ROS1 selectivity. TRAEs in ≥15% of pts included ede
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 Safety profile consistent with ROS1 selectivity. TRAEs in ≥15% of pts included ede
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 Ris-rez toxicity profile more favorable than topotecan control with G3+ TRAEs 61%
@StephenVLiu · 2026-09-13 · OCR
#WCLC26 Ris-rez toxicity profile more favorable than topotecan control with G3+ TRAEs 61%
@StephenVLiu · 2026-09-13 · OCR
Ris-rez vs topotecan - OS benefit across subgroups (including smoking history, chemotherap
@StephenVLiu · 2026-09-13 · OCR
Ris-rez vs topotecan - OS benefit across subgroups (including smoking history, chemotherap
@StephenVLiu · 2026-09-13 · OCR
Ris-rez vs topotecan - OS benefit across subgroups (including smoking history, chemotherap
@StephenVLiu · 2026-09-13 · OCR
#WCLC26 In REZILIENT 3, no separation of OS to date. Safety summary shows dose reduction o
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 In REZILIENT 3, no separation of OS to date. Safety summary shows dose reduction o
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 In REZILIENT 3, no separation of OS to date. Safety summary shows dose reduction o
@StephenVLiu · 2026-09-14 · OCR
#WCLC26 In REZILIENT 3, no separation of OS to date. Safety summary shows dose reduction o
@StephenVLiu · 2026-09-14 · OCR
Happy to see intracranial efficacy as well - icPFS 6.1 vs 4.2 with HR 0.43 favoring tam-pe
@StephenVLiu · 2026-09-13 · OCR
Happy to see intracranial efficacy as well - icPFS 6.1 vs 4.2 with HR 0.43 favoring tam-pe
@StephenVLiu · 2026-09-13 · OCR
King Keytruda survived? I think so . @StephenVLiu @JacobPlieth @RManochakian @IASLC #wclc2
@SuyogCancer · 2026-09-15 · OCR
King Keytruda survived? I think so . @StephenVLiu @JacobPlieth @RManochakian @IASLC #wclc2
@SuyogCancer · 2026-09-15 · OCR
King Keytruda survived? I think so . @StephenVLiu @JacobPlieth @RManochakian @IASLC #wclc2
@SuyogCancer · 2026-09-15 · OCR
King Keytruda survived? I think so . @StephenVLiu @JacobPlieth @RManochakian @IASLC #wclc2
@SuyogCancer · 2026-09-15 · OCR
Post 3rd generation EGFR TKI progression treatment options . Another good summary slide
@SuyogCancer · 2026-09-15 · OCR
This probably is the best summary slide for Harmoni 2 trial data @IASLC @StephenVLiu @RMan
@SuyogCancer · 2026-09-15 · OCR
TAISHAN 302 trial . HR of 0.29. Tam- Peli ( B7-H3 directed ADC ) vs Topotecan . Looks to
@SuyogCancer · 2026-09-13 · OCR
TAISHAN 302 trial . HR of 0.29. Tam- Peli ( B7-H3 directed ADC ) vs Topotecan . Looks to
@SuyogCancer · 2026-09-13 · OCR
TAISHAN 302 trial . HR of 0.29. Tam- Peli ( B7-H3 directed ADC ) vs Topotecan . Looks to
@SuyogCancer · 2026-09-13 · OCR
TAISHAN 302 trial . HR of 0.29. Tam- Peli ( B7-H3 directed ADC ) vs Topotecan . Looks to
@SuyogCancer · 2026-09-13 · OCR
Evoke 03 . Important negative study. SG plus Pembrolizumab in 1st line NSCLC with PDL1 ab
@SuyogCancer · 2026-09-13 · OCR
Evoke 03 . Important negative study. SG plus Pembrolizumab in 1st line NSCLC with PDL1 ab
@SuyogCancer · 2026-09-13 · OCR
Evoke 03 . Important negative study. SG plus Pembrolizumab in 1st line NSCLC with PDL1 ab
@SuyogCancer · 2026-09-13 · OCR
Evoke 03 . Important negative study. SG plus Pembrolizumab in 1st line NSCLC with PDL1 ab
@SuyogCancer · 2026-09-13 · OCR
Good discussion on ADAURA update by @APassaroMD @IASLC MRD is way forward. And post prese
@SuyogCancer · 2026-09-13 · OCR
Good discussion on ADAURA update by @APassaroMD @IASLC MRD is way forward. And post prese
@SuyogCancer · 2026-09-13 · OCR
Good discussion on ADAURA update by @APassaroMD @IASLC MRD is way forward. And post prese
@SuyogCancer · 2026-09-13 · OCR
Good discussion on ADAURA update by @APassaroMD @IASLC MRD is way forward. And post prese
@SuyogCancer · 2026-09-13 · OCR
Nice conclusion for Merveric trial. Awaiting final OS , one may avoid PCI In Limited stage
@SuyogCancer · 2026-09-12 · OCR
Nice conclusion for Merveric trial. Awaiting final OS , one may avoid PCI In Limited stage
@SuyogCancer · 2026-09-12 · OCR
Nice conclusion for Merveric trial. Awaiting final OS , one may avoid PCI In Limited stage
@SuyogCancer · 2026-09-12 · OCR
Nice conclusion for Merveric trial. Awaiting final OS , one may avoid PCI In Limited stage
@SuyogCancer · 2026-09-12 · OCR
And now we have 2nd ADC in second line SCLC . ARTEMIS 008. Ris-Rez ( B7-H3 targeted ADC )
@SuyogCancer · 2026-09-13 · OCR
And now we have 2nd ADC in second line SCLC . ARTEMIS 008. Ris-Rez ( B7-H3 targeted ADC )
@SuyogCancer · 2026-09-13 · OCR
And now we have 2nd ADC in second line SCLC . ARTEMIS 008. Ris-Rez ( B7-H3 targeted ADC )
@SuyogCancer · 2026-09-13 · OCR
And now we have 2nd ADC in second line SCLC . ARTEMIS 008. Ris-Rez ( B7-H3 targeted ADC )
@SuyogCancer · 2026-09-13 · OCR
We learn from every trial Be it positive or not . Excellent discussion on Evoke 03. @I
@SuyogCancer · 2026-09-13 · OCR
We learn from every trial Be it positive or not . Excellent discussion on Evoke 03. @I
@SuyogCancer · 2026-09-13 · OCR
We learn from every trial Be it positive or not . Excellent discussion on Evoke 03. @I
@SuyogCancer · 2026-09-13 · OCR
We learn from every trial Be it positive or not . Excellent discussion on Evoke 03. @I
@SuyogCancer · 2026-09-13 · OCR
8 year update for ADAURA OS . Looks good . @IASLC @StephenVLiu @RManochakian https://t.
@SuyogCancer · 2026-09-13 · OCR
8 year update for ADAURA OS . Looks good . @IASLC @StephenVLiu @RManochakian https://t.
@SuyogCancer · 2026-09-13 · OCR
8 year update for ADAURA OS . Looks good . @IASLC @StephenVLiu @RManochakian https://t.
@SuyogCancer · 2026-09-13 · OCR
8 year update for ADAURA OS . Looks good . @IASLC @StephenVLiu @RManochakian https://t.
@SuyogCancer · 2026-09-13 · OCR
AROSS1 . Zidesamtinib . 1st line phase 1/2 trial data in ROS 1 positive advanced NSCLC .@
@SuyogCancer · 2026-09-14 · OCR
AROSS1 . Zidesamtinib . 1st line phase 1/2 trial data in ROS 1 positive advanced NSCLC .@
@SuyogCancer · 2026-09-14 · OCR
AROSS1 . Zidesamtinib . 1st line phase 1/2 trial data in ROS 1 positive advanced NSCLC .@
@SuyogCancer · 2026-09-14 · OCR
AROSS1 . Zidesamtinib . 1st line phase 1/2 trial data in ROS 1 positive advanced NSCLC .@
@SuyogCancer · 2026-09-14 · OCR
ADC have arrived in second line SCLC . Many options for patients now. Rapidly evolving fie
@SuyogCancer · 2026-09-13 · OCR
ADC have arrived in second line SCLC . Many options for patients now. Rapidly evolving fie
@SuyogCancer · 2026-09-13 · OCR
ADC have arrived in second line SCLC . Many options for patients now. Rapidly evolving fie
@SuyogCancer · 2026-09-13 · OCR
ADC have arrived in second line SCLC . Many options for patients now. Rapidly evolving fie
@SuyogCancer · 2026-09-13 · OCR
Türk Akciğer Kanseri Derneği Yönetim Kurulu üyelerimiz, 12–15 Eylül 2026 tarihleri arasınd
@takdorg · 2026-09-14 · OCR
Türk Akciğer Kanseri Derneği Yönetim Kurulu üyelerimiz, 12–15 Eylül 2026 tarihleri arasınd
@takdorg · 2026-09-14 · OCR
Türk Akciğer Kanseri Derneği Yönetim Kurulu üyelerimiz, 12–15 Eylül 2026 tarihleri arasınd
@takdorg · 2026-09-14 · OCR
Akciğer kanserine ilişkin güncel bilimsel gelişmelerin, tanı ve tedavi yaklaşımlarının ele
@takdorg · 2026-09-14 · OCR
Akciğer kanserine ilişkin güncel bilimsel gelişmelerin, tanı ve tedavi yaklaşımlarının ele
@takdorg · 2026-09-14 · OCR
Akciğer kanserine ilişkin güncel bilimsel gelişmelerin, tanı ve tedavi yaklaşımlarının ele
@takdorg · 2026-09-14 · OCR
1. SWOG S1827 MAVERICK ⭐️Perhaps my TOP pick for most important study that will be present
@TejasPatilMD · 2026-09-11 · OCR
🤔The myelosuppression in REZILIENT3 is strange. This is the same platinum pemetrexed chemo
@TejasPatilMD · 2026-09-14 · OCR
2. HARMONi-2 ⭐️HARMONi-6, presented @ASCO earlier this year showed an OS benefit favoring
@TejasPatilMD · 2026-09-11 · OCR
4. REZILIENT 3 🤓 Permit me to nerd out for a bit. Why are #EGFR Exon 20 insertions so hard
@TejasPatilMD · 2026-09-11 · OCR
5. ARROS-1 ⭐️ The #ROS1 #lungcancer space is getting very competitive! @nuvalent will pres
@TejasPatilMD · 2026-09-11 · OCR
6. DLL3 CAR-T in SCLC ⭐️ Very early data, but extremely intriguing. LB2102, a DLL3-targete
@TejasPatilMD · 2026-09-11 · OCR
10. IRAE prediction using machine learning ⭐️ The ENTIRE OA11 session is filled with incre
@TejasPatilMD · 2026-09-11 · OCR
DESTINY-Lung04 1L Trastuzumab Deruxtecan v PPC, HER2mut NSCLC ✅🔼mPFS 14.3 v 8.3, HR 0.63
@tnewsomdavis · 2026-09-14 · OCR
DESTINY-Lung04 1L Trastuzumab Deruxtecan v PPC, HER2mut NSCLC ✅🔼mPFS 14.3 v 8.3, HR 0.63
@tnewsomdavis · 2026-09-14 · OCR
DESTINY-Lung04 1L Trastuzumab Deruxtecan v PPC, HER2mut NSCLC ✅🔼mPFS 14.3 v 8.3, HR 0.63
@tnewsomdavis · 2026-09-14 · OCR
DESTINY-Lung04 1L Trastuzumab Deruxtecan v PPC, HER2mut NSCLC ✅🔼mPFS 14.3 v 8.3, HR 0.63
@tnewsomdavis · 2026-09-14 · OCR
ARTEMIS-008 Ris-Rez (B7H3 ADC) 2L SCLC Ph3 open label v Topo ✅🔼OS 18m v 10m, HR 0.46❗️ ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
ARTEMIS-008 Ris-Rez (B7H3 ADC) 2L SCLC Ph3 open label v Topo ✅🔼OS 18m v 10m, HR 0.46❗️ ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
ARTEMIS-008 Ris-Rez (B7H3 ADC) 2L SCLC Ph3 open label v Topo ✅🔼OS 18m v 10m, HR 0.46❗️ ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
ARTEMIS-008 Ris-Rez (B7H3 ADC) 2L SCLC Ph3 open label v Topo ✅🔼OS 18m v 10m, HR 0.46❗️ ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
PAPILLON: final OS Chemo+Ami 1L EGFR Ex20 Ins ❗️76% X-over ✅mOS 34 v 27m, HR 0.87 ✅X-over
@tnewsomdavis · 2026-09-14 · OCR
PAPILLON: final OS Chemo+Ami 1L EGFR Ex20 Ins ❗️76% X-over ✅mOS 34 v 27m, HR 0.87 ✅X-over
@tnewsomdavis · 2026-09-14 · OCR
PAPILLON: final OS Chemo+Ami 1L EGFR Ex20 Ins ❗️76% X-over ✅mOS 34 v 27m, HR 0.87 ✅X-over
@tnewsomdavis · 2026-09-14 · OCR
PAPILLON: final OS Chemo+Ami 1L EGFR Ex20 Ins ❗️76% X-over ✅mOS 34 v 27m, HR 0.87 ✅X-over
@tnewsomdavis · 2026-09-14 · OCR
ARROS-1: 1L Zidesamtinib in ROS1+ Ph1/2, n=94 ✅ORR 94%, CR 15% ✅mPFS NR, 90% 1yr PFS ✅ ic
@tnewsomdavis · 2026-09-14 · OCR
ARROS-1: 1L Zidesamtinib in ROS1+ Ph1/2, n=94 ✅ORR 94%, CR 15% ✅mPFS NR, 90% 1yr PFS ✅ ic
@tnewsomdavis · 2026-09-14 · OCR
ARROS-1: 1L Zidesamtinib in ROS1+ Ph1/2, n=94 ✅ORR 94%, CR 15% ✅mPFS NR, 90% 1yr PFS ✅ ic
@tnewsomdavis · 2026-09-14 · OCR
ARROS-1: 1L Zidesamtinib in ROS1+ Ph1/2, n=94 ✅ORR 94%, CR 15% ✅mPFS NR, 90% 1yr PFS ✅ ic
@tnewsomdavis · 2026-09-14 · OCR
ASCO-IASLC Forum Stephen Lam: Obesity & Lung cancer 🔺Obesity = pro-tumour & immunosuppres
@tnewsomdavis · 2026-09-12 · OCR
ASCO-IASLC Forum Stephen Lam: Obesity & Lung cancer 🔺Obesity = pro-tumour & immunosuppres
@tnewsomdavis · 2026-09-12 · OCR
ASCO-IASLC Forum Stephen Lam: Obesity & Lung cancer 🔺Obesity = pro-tumour & immunosuppres
@tnewsomdavis · 2026-09-12 · OCR
ASCO-IASLC Forum Stephen Lam: Obesity & Lung cancer 🔺Obesity = pro-tumour & immunosuppres
@tnewsomdavis · 2026-09-12 · OCR
IMpower030: periop Atezolizumab 👉 Standard neo-adj chemoIO + adj immuno design ❌ Did not
@tnewsomdavis · 2026-09-13 · OCR
IMpower030: periop Atezolizumab 👉 Standard neo-adj chemoIO + adj immuno design ❌ Did not
@tnewsomdavis · 2026-09-13 · OCR
IMpower030: periop Atezolizumab 👉 Standard neo-adj chemoIO + adj immuno design ❌ Did not
@tnewsomdavis · 2026-09-13 · OCR
IMpower030: periop Atezolizumab 👉 Standard neo-adj chemoIO + adj immuno design ❌ Did not
@tnewsomdavis · 2026-09-13 · OCR
TAISHAN-302 Tam-Peli (B7H3 ADC) 2L SCLC Ph3, open label, v Topo ✅🔼OS 13 v 9m, HR 0.46 ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
TAISHAN-302 Tam-Peli (B7H3 ADC) 2L SCLC Ph3, open label, v Topo ✅🔼OS 13 v 9m, HR 0.46 ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
TAISHAN-302 Tam-Peli (B7H3 ADC) 2L SCLC Ph3, open label, v Topo ✅🔼OS 13 v 9m, HR 0.46 ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
TAISHAN-302 Tam-Peli (B7H3 ADC) 2L SCLC Ph3, open label, v Topo ✅🔼OS 13 v 9m, HR 0.46 ✅🔼
@tnewsomdavis · 2026-09-13 · OCR
NAUTIKA1: neo-adj divarasib KRAS G12C 👉 Ph2 ☂️ 👉 Adj chemo/diva (PDL1-) or atezo (PDL1+) 👉
@tnewsomdavis · 2026-09-13 · OCR
NAUTIKA1: neo-adj divarasib KRAS G12C 👉 Ph2 ☂️ 👉 Adj chemo/diva (PDL1-) or atezo (PDL1+) 👉
@tnewsomdavis · 2026-09-13 · OCR
NAUTIKA1: neo-adj divarasib KRAS G12C 👉 Ph2 ☂️ 👉 Adj chemo/diva (PDL1-) or atezo (PDL1+) 👉
@tnewsomdavis · 2026-09-13 · OCR
NAUTIKA1: neo-adj divarasib KRAS G12C 👉 Ph2 ☂️ 👉 Adj chemo/diva (PDL1-) or atezo (PDL1+) 👉
@tnewsomdavis · 2026-09-13 · OCR
My take on ARROS-1 & 1L ROS1 options (From LinkedIn) https://t.co/GXWabXnpPs
@tnewsomdavis · 2026-09-14 · OCR
MAVERICK 👉LS & ES-SCLC 👉PCI v MRI surveillance MRI ✅🔼 CFFS, HR 0.60, both LS & ES ✅No di
@tnewsomdavis · 2026-09-12 · OCR
MAVERICK 👉LS & ES-SCLC 👉PCI v MRI surveillance MRI ✅🔼 CFFS, HR 0.60, both LS & ES ✅No di
@tnewsomdavis · 2026-09-12 · OCR
MAVERICK 👉LS & ES-SCLC 👉PCI v MRI surveillance MRI ✅🔼 CFFS, HR 0.60, both LS & ES ✅No di
@tnewsomdavis · 2026-09-12 · OCR
MAVERICK 👉LS & ES-SCLC 👉PCI v MRI surveillance MRI ✅🔼 CFFS, HR 0.60, both LS & ES ✅No di
@tnewsomdavis · 2026-09-12 · OCR
REZILIENT-3: Zipalertinib 1L Ex20Ins 👉Z+Chemo v Z 64% x-over ✅mPFS 14.5 v 8.5m, HR 0.50 ✅
@tnewsomdavis · 2026-09-14 · OCR
REZILIENT-3: Zipalertinib 1L Ex20Ins 👉Z+Chemo v Z 64% x-over ✅mPFS 14.5 v 8.5m, HR 0.50 ✅
@tnewsomdavis · 2026-09-14 · OCR
REZILIENT-3: Zipalertinib 1L Ex20Ins 👉Z+Chemo v Z 64% x-over ✅mPFS 14.5 v 8.5m, HR 0.50 ✅
@tnewsomdavis · 2026-09-14 · OCR
REZILIENT-3: Zipalertinib 1L Ex20Ins 👉Z+Chemo v Z 64% x-over ✅mPFS 14.5 v 8.5m, HR 0.50 ✅
@tnewsomdavis · 2026-09-14 · OCR
EVOKE-03 Ph3, Saci-Gov+Pembro v Pembro 1L NSCLC PD-L1 >50% SG+Pembro: ❌🔼mPFS 11 v 7m, HR
@tnewsomdavis · 2026-09-13 · OCR
EVOKE-03 Ph3, Saci-Gov+Pembro v Pembro 1L NSCLC PD-L1 >50% SG+Pembro: ❌🔼mPFS 11 v 7m, HR
@tnewsomdavis · 2026-09-13 · OCR
EVOKE-03 Ph3, Saci-Gov+Pembro v Pembro 1L NSCLC PD-L1 >50% SG+Pembro: ❌🔼mPFS 11 v 7m, HR
@tnewsomdavis · 2026-09-13 · OCR
EVOKE-03 Ph3, Saci-Gov+Pembro v Pembro 1L NSCLC PD-L1 >50% SG+Pembro: ❌🔼mPFS 11 v 7m, HR
@tnewsomdavis · 2026-09-13 · OCR
My thoughts on DESTINY-Lung04 and 1L HER2 options (from my LinkedIn, sorry so tiny!) #WCL
@tnewsomdavis · 2026-09-15 · OCR
8yr ADAURA update 🔥 informs cure vs delay-relapse debate 👉 77% pts surv data Overall: 8yr
@tnewsomdavis · 2026-09-13 · OCR
8yr ADAURA update 🔥 informs cure vs delay-relapse debate 👉 77% pts surv data Overall: 8yr
@tnewsomdavis · 2026-09-13 · OCR
8yr ADAURA update 🔥 informs cure vs delay-relapse debate 👉 77% pts surv data Overall: 8yr
@tnewsomdavis · 2026-09-13 · OCR
DeLLphi-309 👉Extended interval Tarla, 2L SCLC 👉Ph2, open label: 10mg Q2W, 20mg Q3W, 30mg Q
@tnewsomdavis · 2026-09-13 · OCR
DeLLphi-309 👉Extended interval Tarla, 2L SCLC 👉Ph2, open label: 10mg Q2W, 20mg Q3W, 30mg Q
@tnewsomdavis · 2026-09-13 · OCR
DeLLphi-309 👉Extended interval Tarla, 2L SCLC 👉Ph2, open label: 10mg Q2W, 20mg Q3W, 30mg Q
@tnewsomdavis · 2026-09-13 · OCR
DeLLphi-309 👉Extended interval Tarla, 2L SCLC 👉Ph2, open label: 10mg Q2W, 20mg Q3W, 30mg Q
@tnewsomdavis · 2026-09-13 · OCR
RAPHAEL: Adjuvant gefitinib St II-IIIB, EGFRmut Korean IIS 👉Vin/Cis vs Pem/Cis/Gefitinib
@tnewsomdavis · 2026-09-13 · OCR
RAPHAEL: Adjuvant gefitinib St II-IIIB, EGFRmut Korean IIS 👉Vin/Cis vs Pem/Cis/Gefitinib
@tnewsomdavis · 2026-09-13 · OCR
RAPHAEL: Adjuvant gefitinib St II-IIIB, EGFRmut Korean IIS 👉Vin/Cis vs Pem/Cis/Gefitinib
@tnewsomdavis · 2026-09-13 · OCR
RAPHAEL: Adjuvant gefitinib St II-IIIB, EGFRmut Korean IIS 👉Vin/Cis vs Pem/Cis/Gefitinib
@tnewsomdavis · 2026-09-13 · OCR
@g_mountzios presenting EVOKE-03. A negative study with another ADC+Pembro as first line t
@TommyJohn00 · 2026-09-13 · OCR
@g_mountzios presenting EVOKE-03. A negative study with another ADC+Pembro as first line t
@TommyJohn00 · 2026-09-13 · OCR
@g_mountzios presenting EVOKE-03. A negative study with another ADC+Pembro as first line t
@TommyJohn00 · 2026-09-13 · OCR
@g_mountzios presenting EVOKE-03. A negative study with another ADC+Pembro as first line t
@TommyJohn00 · 2026-09-13 · OCR
Practice changing #SWOG S18 MAVERICK trial by C Rusthoven. I think this should be seen as
@TommyJohn00 · 2026-09-12 · OCR
Practice changing #SWOG S18 MAVERICK trial by C Rusthoven. I think this should be seen as
@TommyJohn00 · 2026-09-12 · OCR
Practice changing #SWOG S18 MAVERICK trial by C Rusthoven. I think this should be seen as
@TommyJohn00 · 2026-09-12 · OCR
Practice changing #SWOG S18 MAVERICK trial by C Rusthoven. I think this should be seen as
@TommyJohn00 · 2026-09-12 · OCR
If you use cell lines for your #Lungcancer research, check out smart VIKTOR (being demonst
@TommyJohn00 · 2026-09-14 · OCR
If you use cell lines for your #Lungcancer research, check out smart VIKTOR (being demonst
@TommyJohn00 · 2026-09-14 · OCR
Excellent presentation from PhD candidate extraordinaire Sho Waller. Some technical glitch
@TommyJohn00 · 2026-09-13 · OCR
Excellent presentation from PhD candidate extraordinaire Sho Waller. Some technical glitch
@TommyJohn00 · 2026-09-13 · OCR
Excellent presentation from PhD candidate extraordinaire Sho Waller. Some technical glitch
@TommyJohn00 · 2026-09-13 · OCR
#WCLC26 excellent discussion of ADAURA data from @Tony_Calles. Incorporating escalation an
@TommyJohn00 · 2026-09-13 · OCR
#WCLC26 excellent discussion of ADAURA data from @Tony_Calles. Incorporating escalation an
@TommyJohn00 · 2026-09-13 · OCR
#WCLC26 excellent discussion of ADAURA data from @Tony_Calles. Incorporating escalation an
@TommyJohn00 · 2026-09-13 · OCR
#WCLC26 @danieltanmd presenting Rezilient-3 trial. Significant PFS benefit, high crossover
@TommyJohn00 · 2026-09-14 · OCR
#WCLC26 @danieltanmd presenting Rezilient-3 trial. Significant PFS benefit, high crossover
@TommyJohn00 · 2026-09-14 · OCR
#WCLC26 @danieltanmd presenting Rezilient-3 trial. Significant PFS benefit, high crossover
@TommyJohn00 · 2026-09-14 · OCR
#WCLC26 @danieltanmd presenting Rezilient-3 trial. Significant PFS benefit, high crossover
@TommyJohn00 · 2026-09-14 · OCR
Excellent discussion by @Annechiangmd on ADCs in SCLC. How do we pick between these ADCs?
@TommyJohn00 · 2026-09-13 · OCR
Excellent discussion by @Annechiangmd on ADCs in SCLC. How do we pick between these ADCs?
@TommyJohn00 · 2026-09-13 · OCR
Excellent discussion by @Annechiangmd on ADCs in SCLC. How do we pick between these ADCs?
@TommyJohn00 · 2026-09-13 · OCR
@DrRoyHerbst presenting #WCLC26 #ADAURA 8 year survival. At 5 years HR 0.48, at 8 years HR
@TommyJohn00 · 2026-09-13 · OCR
@DrRoyHerbst presenting #WCLC26 #ADAURA 8 year survival. At 5 years HR 0.48, at 8 years HR
@TommyJohn00 · 2026-09-13 · OCR
Lovely night at the @IASLC #WCLC26 faculty dinner catching up with friends and colleagues!
@TommyJohn00 · 2026-09-13 · OCR
Lovely night at the @IASLC #WCLC26 faculty dinner catching up with friends and colleagues!
@TommyJohn00 · 2026-09-13 · OCR
@Mal_Itchins gave a stellar discussion of ARROS1 first line data. Excellent comparison wit
@TommyJohn00 · 2026-09-14 · OCR
@Mal_Itchins gave a stellar discussion of ARROS1 first line data. Excellent comparison wit
@TommyJohn00 · 2026-09-14 · OCR
@Mal_Itchins gave a stellar discussion of ARROS1 first line data. Excellent comparison wit
@TommyJohn00 · 2026-09-14 · OCR
@Mal_Itchins gave a stellar discussion of ARROS1 first line data. Excellent comparison wit
@TommyJohn00 · 2026-09-14 · OCR
@alexdrilon presenting ARROS-1 trial. You don’t often see ORR this high including CRs. Goo
@TommyJohn00 · 2026-09-14 · OCR
@alexdrilon presenting ARROS-1 trial. You don’t often see ORR this high including CRs. Goo
@TommyJohn00 · 2026-09-14 · OCR
@alexdrilon presenting ARROS-1 trial. You don’t often see ORR this high including CRs. Goo
@TommyJohn00 · 2026-09-14 · OCR
TAISHAN-302, Li Zhang - potentially practice changing study in #SCLC. Topotecan is a crap
@TommyJohn00 · 2026-09-13 · OCR
TAISHAN-302, Li Zhang - potentially practice changing study in #SCLC. Topotecan is a crap
@TommyJohn00 · 2026-09-13 · OCR
TAISHAN-302, Li Zhang - potentially practice changing study in #SCLC. Topotecan is a crap
@TommyJohn00 · 2026-09-13 · OCR
TAISHAN-302, Li Zhang - potentially practice changing study in #SCLC. Topotecan is a crap
@TommyJohn00 · 2026-09-13 · OCR
Phase III Artemis study with Riz-Rez. Different ADC, same target. Almost the same results
@TommyJohn00 · 2026-09-13 · OCR
Phase III Artemis study with Riz-Rez. Different ADC, same target. Almost the same results
@TommyJohn00 · 2026-09-13 · OCR
Phase III Artemis study with Riz-Rez. Different ADC, same target. Almost the same results
@TommyJohn00 · 2026-09-13 · OCR
Phase III Artemis study with Riz-Rez. Different ADC, same target. Almost the same results
@TommyJohn00 · 2026-09-13 · OCR
Another excellent #WCLC26 discussion from @LudaBazhenovaMD contextualising Rezilient with
@TommyJohn00 · 2026-09-14 · OCR
Another excellent #WCLC26 discussion from @LudaBazhenovaMD contextualising Rezilient with
@TommyJohn00 · 2026-09-14 · OCR
Another excellent #WCLC26 discussion from @LudaBazhenovaMD contextualising Rezilient with
@TommyJohn00 · 2026-09-14 · OCR
Another excellent #WCLC26 discussion from @LudaBazhenovaMD contextualising Rezilient with
@TommyJohn00 · 2026-09-14 · OCR
@JuliaRotow : Destiny-04 trial. Significant PFS benefit but not OS. Not a lot of cross ove
@TommyJohn00 · 2026-09-14 · OCR
@JuliaRotow : Destiny-04 trial. Significant PFS benefit but not OS. Not a lot of cross ove
@TommyJohn00 · 2026-09-14 · OCR
@JuliaRotow : Destiny-04 trial. Significant PFS benefit but not OS. Not a lot of cross ove
@TommyJohn00 · 2026-09-14 · OCR
@JuliaRotow : Destiny-04 trial. Significant PFS benefit but not OS. Not a lot of cross ove
@TommyJohn00 · 2026-09-14 · OCR
@chulkimMD presenting Papillon final OS update. No stat signif difference but high crossov
@TommyJohn00 · 2026-09-13 · OCR
@chulkimMD presenting Papillon final OS update. No stat signif difference but high crossov
@TommyJohn00 · 2026-09-13 · OCR
@chulkimMD presenting Papillon final OS update. No stat signif difference but high crossov
@TommyJohn00 · 2026-09-13 · OCR
@chulkimMD presenting Papillon final OS update. No stat signif difference but high crossov
@TommyJohn00 · 2026-09-13 · OCR
💊 ⭐ Specially proud of this study in which we have actively participated and to see the ou
@Tony_Calles · 2026-09-14 · OCR
💊 ⭐ Specially proud of this study in which we have actively participated and to see the ou
@Tony_Calles · 2026-09-14 · OCR
💊 ⭐ Specially proud of this study in which we have actively participated and to see the ou
@Tony_Calles · 2026-09-14 · OCR
DUMAS: Preoperative nivolumab + chemotherapy in Pancoast tumor, a rare entity with many su
@Tony_Calles · 2026-09-14 · OCR
DUMAS: Preoperative nivolumab + chemotherapy in Pancoast tumor, a rare entity with many su
@Tony_Calles · 2026-09-14 · OCR
⭐️Impressive feature unlocked in @IASLC App, with direct translation in multiple languages
@Tony_Calles · 2026-09-12 · OCR
EVOKE-03: SG + Pembro did not improve clinical outcomes over Pembro alone but with an incr
@Tony_Calles · 2026-09-13 · OCR
EVOKE-03: SG + Pembro did not improve clinical outcomes over Pembro alone but with an incr
@Tony_Calles · 2026-09-13 · OCR
EVOKE-03: SG + Pembro did not improve clinical outcomes over Pembro alone but with an incr
@Tony_Calles · 2026-09-13 · OCR
EVOKE-03: SG + Pembro did not improve clinical outcomes over Pembro alone but with an incr
@Tony_Calles · 2026-09-13 · OCR
8 years OS update on ADAURA The longest OS follow-up from any global adjuvant Phase III
t
@Tony_Calles · 2026-09-13 · OCR
8 years OS update on ADAURA The longest OS follow-up from any global adjuvant Phase III
t
@Tony_Calles · 2026-09-13 · OCR
8 years OS update on ADAURA The longest OS follow-up from any global adjuvant Phase III
t
@Tony_Calles · 2026-09-13 · OCR
8 years OS update on ADAURA The longest OS follow-up from any global adjuvant Phase III
t
@Tony_Calles · 2026-09-13 · OCR
Moving award to a transformative, inspirational, and giant physician and researcher, Ross
@Tony_Calles · 2026-09-12 · OCR
Moving award to a transformative, inspirational, and giant physician and researcher, Ross
@Tony_Calles · 2026-09-12 · OCR
Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A rand
@Tony_Calles · 2026-09-13 · OCR
Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A rand
@Tony_Calles · 2026-09-13 · OCR
Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A rand
@Tony_Calles · 2026-09-13 · OCR
Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A rand
@Tony_Calles · 2026-09-13 · OCR
Privileged to share the stage with two outstanding experts at the MSD Global SCLC Symposiu
@Tony_Calles · 2026-09-13 · OCR
🧠 MRI surveillance should become the preferred option in patients with SCLC rather than PC
@Tony_Calles · 2026-09-12 · OCR
🧠 MRI surveillance should become the preferred option in patients with SCLC rather than PC
@Tony_Calles · 2026-09-12 · OCR
🧠 MRI surveillance should become the preferred option in patients with SCLC rather than PC
@Tony_Calles · 2026-09-12 · OCR
🧠 MRI surveillance should become the preferred option in patients with SCLC rather than PC
@Tony_Calles · 2026-09-12 · OCR
🇨🇳 phase 3 ARTEMIS-008 trial comparing Ris-Rez versus topotecan for the treatment of relap
@Tony_Calles · 2026-09-13 · OCR
🇨🇳 phase 3 ARTEMIS-008 trial comparing Ris-Rez versus topotecan for the treatment of relap
@Tony_Calles · 2026-09-13 · OCR
🇨🇳 phase 3 ARTEMIS-008 trial comparing Ris-Rez versus topotecan for the treatment of relap
@Tony_Calles · 2026-09-13 · OCR
🇨🇳 phase 3 ARTEMIS-008 trial comparing Ris-Rez versus topotecan for the treatment of relap
@Tony_Calles · 2026-09-13 · OCR
@IASLC UNITE science, education, and global talent against thoracic cancer Welcome introdu
@Tony_Calles · 2026-09-12 · OCR
@IASLC UNITE science, education, and global talent against thoracic cancer Welcome introdu
@Tony_Calles · 2026-09-12 · OCR
Luis Montuenga is the recipient of the #WCLC26 Adi Gazdar Award. Well deserved recognitio
@Tony_Calles · 2026-09-12 · OCR
Excellent discussion on EGFRex 20 mutations in NSCLC by @LudaBazhenovaMD at #WCLC26 @IASLC
@Tony_Calles · 2026-09-14 · OCR
Excellent discussion on EGFRex 20 mutations in NSCLC by @LudaBazhenovaMD at #WCLC26 @IASLC
@Tony_Calles · 2026-09-14 · OCR
So happy and proud to see a true inspiration and a force of nature @JFreemanDaily mentione
@Tony_Calles · 2026-09-14 · OCR
With 76% crossover to Amivantamab, PAPILLON final OS presented longer survival 34 vs 28 mo
@Tony_Calles · 2026-09-13 · OCR
With 76% crossover to Amivantamab, PAPILLON final OS presented longer survival 34 vs 28 mo
@Tony_Calles · 2026-09-13 · OCR
With 76% crossover to Amivantamab, PAPILLON final OS presented longer survival 34 vs 28 mo
@Tony_Calles · 2026-09-13 · OCR
REZILIENT 3: Zipalertinib Plus Chemotherapy for 1 st Line mNSCLC With EGFR Exon 20 Inserti
@Tony_Calles · 2026-09-14 · OCR
REZILIENT 3: Zipalertinib Plus Chemotherapy for 1 st Line mNSCLC With EGFR Exon 20 Inserti
@Tony_Calles · 2026-09-14 · OCR
REZILIENT 3: Zipalertinib Plus Chemotherapy for 1 st Line mNSCLC With EGFR Exon 20 Inserti
@Tony_Calles · 2026-09-14 · OCR
REZILIENT 3: Zipalertinib Plus Chemotherapy for 1 st Line mNSCLC With EGFR Exon 20 Inserti
@Tony_Calles · 2026-09-14 · OCR
Here we are! #WCLC26 #Seoul #lcsm https://t.co/JppSUF0h4n
@Tony_Calles · 2026-09-12 · OCR
PAPILLON final OS at #WCLC26 🦋 First-line amivantamab + chemotherapy achieved the longest
@ulvyeoflas · 2026-09-15 · OCR
PAPILLON final OS at #WCLC26 🦋 First-line amivantamab + chemotherapy achieved the longest
@ulvyeoflas · 2026-09-15 · OCR
MDT-BRIDGE primary analysis at #WCLC26 🫁 Neoadjuvant durvalumab + chemotherapy in resectab
@ulvyeoflas · 2026-09-16 · OCR
MDT-BRIDGE primary analysis at #WCLC26 🫁 Neoadjuvant durvalumab + chemotherapy in resectab
@ulvyeoflas · 2026-09-16 · OCR
MDT-BRIDGE primary analysis at #WCLC26 🫁 Neoadjuvant durvalumab + chemotherapy in resectab
@ulvyeoflas · 2026-09-16 · OCR
8-year OS update from ADAURA 🔥 Adjuvant osimertinib continues to show a durable survival b
@ulvyeoflas · 2026-09-15 · OCR
Final OS results from PAPILLON at #WCLC26 In 1L EGFR exon20ins advanced NSCLC, amivantama
@UOzkerim · 2026-09-13 · OCR
Final OS results from PAPILLON at #WCLC26 In 1L EGFR exon20ins advanced NSCLC, amivantama
@UOzkerim · 2026-09-13 · OCR
Excellent discussion of the evolving 1L landscape for EGFR exon20ins NSCLC at #WCLC26. @Lu
@UOzkerim · 2026-09-14 · OCR
Excellent discussion of the evolving 1L landscape for EGFR exon20ins NSCLC at #WCLC26. @Lu
@UOzkerim · 2026-09-14 · OCR
Excellent discussion of the evolving 1L landscape for EGFR exon20ins NSCLC at #WCLC26. @Lu
@UOzkerim · 2026-09-14 · OCR
Excellent discussion of the evolving 1L landscape for EGFR exon20ins NSCLC at #WCLC26. @Lu
@UOzkerim · 2026-09-14 · OCR
#WCLC26 | MDT-BRIDGE Neoadjuvant durvalumab + platinum-based chemotherapy in resectable/b
@UOzkerim · 2026-09-13 · OCR
#WCLC26 | MDT-BRIDGE Neoadjuvant durvalumab + platinum-based chemotherapy in resectable/b
@UOzkerim · 2026-09-13 · OCR
ARTEMIS-008 at #WCLC26 In relapsed SCLC, the B7-H3 ADC risvutatug rezetecan (Ris-Rez) sig
@UOzkerim · 2026-09-13 · OCR
ARTEMIS-008 at #WCLC26 In relapsed SCLC, the B7-H3 ADC risvutatug rezetecan (Ris-Rez) sig
@UOzkerim · 2026-09-13 · OCR
ARTEMIS-008 at #WCLC26 In relapsed SCLC, the B7-H3 ADC risvutatug rezetecan (Ris-Rez) sig
@UOzkerim · 2026-09-13 · OCR
8-year follow-up from ADAURA at #WCLC26 Adjuvant osimertinib continues to show a sustaine
@UOzkerim · 2026-09-13 · OCR
8-year follow-up from ADAURA at #WCLC26 Adjuvant osimertinib continues to show a sustaine
@UOzkerim · 2026-09-13 · OCR
8-year follow-up from ADAURA at #WCLC26 Adjuvant osimertinib continues to show a sustaine
@UOzkerim · 2026-09-13 · OCR
DESTINY-Lung04 at #WCLC26 In 1L HER2-mutant advanced NSCLC, T-DXd significantly improved
@UOzkerim · 2026-09-14 · OCR
DESTINY-Lung04 at #WCLC26 In 1L HER2-mutant advanced NSCLC, T-DXd significantly improved
@UOzkerim · 2026-09-14 · OCR
DESTINY-Lung04 at #WCLC26 In 1L HER2-mutant advanced NSCLC, T-DXd significantly improved
@UOzkerim · 2026-09-14 · OCR
DESTINY-Lung04 at #WCLC26 In 1L HER2-mutant advanced NSCLC, T-DXd significantly improved
@UOzkerim · 2026-09-14 · OCR
REZILIENT3 at #WCLC26 In 1L EGFR-mutated advanced NSCLC, zipalertinib + chemotherapy sign
@UOzkerim · 2026-09-14 · OCR
REZILIENT3 at #WCLC26 In 1L EGFR-mutated advanced NSCLC, zipalertinib + chemotherapy sign
@UOzkerim · 2026-09-14 · OCR
TAISHAN-302 at #WCLC26 In patients with relapsed SCLC, the B7-H3 ADC Tam-Peli significant
@UOzkerim · 2026-09-12 · OCR
TAISHAN-302 at #WCLC26 In patients with relapsed SCLC, the B7-H3 ADC Tam-Peli significant
@UOzkerim · 2026-09-12 · OCR
EVOKE-03/KEYNOTE-D46 at #WCLC26 In 1L metastatic NSCLC with PD-L1 TPS ≥50%, adding sacitu
@UOzkerim · 2026-09-13 · OCR
EVOKE-03/KEYNOTE-D46 at #WCLC26 In 1L metastatic NSCLC with PD-L1 TPS ≥50%, adding sacitu
@UOzkerim · 2026-09-13 · OCR
EVOKE-03/KEYNOTE-D46 at #WCLC26 In 1L metastatic NSCLC with PD-L1 TPS ≥50%, adding sacitu
@UOzkerim · 2026-09-13 · OCR
EVOKE-03/KEYNOTE-D46 at #WCLC26 In 1L metastatic NSCLC with PD-L1 TPS ≥50%, adding sacitu
@UOzkerim · 2026-09-13 · OCR
ARROS-1 at #WCLC26 Zidesamtinib showed promising activity in TKI-naïve advanced ROS1+ NSC
@UOzkerim · 2026-09-14 · OCR
ARROS-1 at #WCLC26 Zidesamtinib showed promising activity in TKI-naïve advanced ROS1+ NSC
@UOzkerim · 2026-09-14 · OCR
ARROS-1 at #WCLC26 Zidesamtinib showed promising activity in TKI-naïve advanced ROS1+ NSC
@UOzkerim · 2026-09-14 · OCR
📢SWOG S1827/MAVERICK at #WCLC26: In patients with SCLC, MRI surveillance alone resulted i
@UOzkerim · 2026-09-12 · OCR
📢SWOG S1827/MAVERICK at #WCLC26: In patients with SCLC, MRI surveillance alone resulted i
@UOzkerim · 2026-09-12 · OCR
📢SWOG S1827/MAVERICK at #WCLC26: In patients with SCLC, MRI surveillance alone resulted i
@UOzkerim · 2026-09-12 · OCR
That’s a wrap on the 2026 @IASLC Academy! Thank you to @JairBar4 and @ZPiotrowskaMD for th
@UrsWeberMD · 2026-09-11 · OCR
Such a well-deserved honor for my mentor and friend, @DRCamidge. Ross, I wouldn’t be where
@UrsWeberMD · 2026-09-12 · OCR
Such a well-deserved honor for my mentor and friend, @DRCamidge. Ross, I wouldn’t be where
@UrsWeberMD · 2026-09-12 · OCR
Goodbye Seoul. What a terrific city and conference! I’m already looking forward to having
@UrsWeberMD · 2026-09-15
@alexdrilon presents updates from ARROS-1 at @IASLC #WCLC26. The findings in the TKI-naive
@UrsWeberMD · 2026-09-14 · OCR
@alexdrilon presents updates from ARROS-1 at @IASLC #WCLC26. The findings in the TKI-naive
@UrsWeberMD · 2026-09-14 · OCR
@alexdrilon presents updates from ARROS-1 at @IASLC #WCLC26. The findings in the TKI-naive
@UrsWeberMD · 2026-09-14 · OCR
@alexdrilon presents updates from ARROS-1 at @IASLC #WCLC26. The findings in the TKI-naive
@UrsWeberMD · 2026-09-14 · OCR
@LudaBazhenovaMD with an excellent discussion of PAPILLON, REZILIENT-3, and the EGFR exon
@UrsWeberMD · 2026-09-14 · OCR
@LudaBazhenovaMD with an excellent discussion of PAPILLON, REZILIENT-3, and the EGFR exon
@UrsWeberMD · 2026-09-14 · OCR
@LudaBazhenovaMD with an excellent discussion of PAPILLON, REZILIENT-3, and the EGFR exon
@UrsWeberMD · 2026-09-14 · OCR
@LudaBazhenovaMD with an excellent discussion of PAPILLON, REZILIENT-3, and the EGFR exon
@UrsWeberMD · 2026-09-14 · OCR
The results of the @SWOG #MAVERICK trial should put the final nail in the coffin for PCI i
@UrsWeberMD · 2026-09-12 · OCR
The results of the @SWOG #MAVERICK trial should put the final nail in the coffin for PCI i
@UrsWeberMD · 2026-09-12 · OCR
The results of the @SWOG #MAVERICK trial should put the final nail in the coffin for PCI i
@UrsWeberMD · 2026-09-12 · OCR
The results of the @SWOG #MAVERICK trial should put the final nail in the coffin for PCI i
@UrsWeberMD · 2026-09-12 · OCR
Congratulations @chulkimMD on an excellent presentation of the 5-year OS update from PAPIL
@UrsWeberMD · 2026-09-13 · OCR
Primary analysis of periop alectinib in resectable stage IB-IIIB NSCLC (NAUTIKA1) at @IASL
@UrsWeberMD · 2026-09-14 · OCR
Primary analysis of periop alectinib in resectable stage IB-IIIB NSCLC (NAUTIKA1) at @IASL
@UrsWeberMD · 2026-09-14 · OCR
Primary analysis of periop alectinib in resectable stage IB-IIIB NSCLC (NAUTIKA1) at @IASL
@UrsWeberMD · 2026-09-14 · OCR
Primary analysis of periop alectinib in resectable stage IB-IIIB NSCLC (NAUTIKA1) at @IASL
@UrsWeberMD · 2026-09-14 · OCR
Congratulations @JuliaRotow on an excellent presentation of DESTINY-Lung04 at @IASLC #WCLC
@UrsWeberMD · 2026-09-14 · OCR
Congratulations @JuliaRotow on an excellent presentation of DESTINY-Lung04 at @IASLC #WCLC
@UrsWeberMD · 2026-09-14 · OCR
Congratulations @JuliaRotow on an excellent presentation of DESTINY-Lung04 at @IASLC #WCLC
@UrsWeberMD · 2026-09-14 · OCR
Congratulations @JuliaRotow on an excellent presentation of DESTINY-Lung04 at @IASLC #WCLC
@UrsWeberMD · 2026-09-14 · OCR
Shoutout to the good people at @KinkoKorea Samseong Center for getting my poster for the @
@UrsWeberMD · 2026-09-10 · OCR
Time for @IASLC #WCLC2026 Celebration Night! https://t.co/sHp1CiW2ND
@UrsWeberMD · 2026-09-14 · OCR
Zipalertinib with chemo significantly improves mPFS vs chemo alone in EGFR exon 20 inserti
@UrsWeberMD · 2026-09-14 · OCR
Zipalertinib with chemo significantly improves mPFS vs chemo alone in EGFR exon 20 inserti
@UrsWeberMD · 2026-09-14 · OCR
Zipalertinib with chemo significantly improves mPFS vs chemo alone in EGFR exon 20 inserti
@UrsWeberMD · 2026-09-14 · OCR
Zipalertinib with chemo significantly improves mPFS vs chemo alone in EGFR exon 20 inserti
@UrsWeberMD · 2026-09-14 · OCR
Officially up and running (literally) for the @IASLC #WellnessChallenge at #WCLC2026! http
@UrsWeberMD · 2026-09-12 · OCR
ADCs keep beating topotecan in the treatment of relapsed/refractory SCLC, but how many do
@UrsWeberMD · 2026-09-13 · OCR
ADCs keep beating topotecan in the treatment of relapsed/refractory SCLC, but how many do
@UrsWeberMD · 2026-09-13 · OCR
ADCs keep beating topotecan in the treatment of relapsed/refractory SCLC, but how many do
@UrsWeberMD · 2026-09-13 · OCR
ADCs keep beating topotecan in the treatment of relapsed/refractory SCLC, but how many do
@UrsWeberMD · 2026-09-13 · OCR
@DrRoyHerbst presents the 8-year OS update from ADAURA at @IASLC #WCLC26. Impressive curve
@UrsWeberMD · 2026-09-13 · OCR
Great discussion and overview of the current treatment landscape for ROS1+ NSCLC by @Mal_I
@UrsWeberMD · 2026-09-14 · OCR
Great discussion and overview of the current treatment landscape for ROS1+ NSCLC by @Mal_I
@UrsWeberMD · 2026-09-14 · OCR
Great discussion and overview of the current treatment landscape for ROS1+ NSCLC by @Mal_I
@UrsWeberMD · 2026-09-14 · OCR
Great discussion and overview of the current treatment landscape for ROS1+ NSCLC by @Mal_I
@UrsWeberMD · 2026-09-14 · OCR
At #IASLC #WCLC2026 as a STARS Scholar, representing 🇮🇳. Presented a poster: India = 1.41
@urvashi01 · 2026-09-13 · OCR
At #IASLC #WCLC2026 as a STARS Scholar, representing 🇮🇳. Presented a poster: India = 1.41
@urvashi01 · 2026-09-13 · OCR
At #IASLC #WCLC2026 as a STARS Scholar, representing 🇮🇳. Presented a poster: India = 1.41
@urvashi01 · 2026-09-13 · OCR
At #IASLC #WCLC2026 as a STARS Scholar, representing 🇮🇳. Presented a poster: India = 1.41
@urvashi01 · 2026-09-13 · OCR
A shared passion for highlighting the unique needs of young adults with cancer @NarjustFlo
@urvashi01 · 2026-09-15 · OCR
Here’s to greater collaboration between India and Africa on lung cancer care ✅🤝@boldcaleb
@urvashi01 · 2026-09-15 · OCR
Do driver mutations affect survival differently across ethnic and socioeconomic groups in
@VJOncology · 2026-09-13 · OCR
And we're live from #WCLC2026! 🫁 Follow us to see exclusive behind-the-scenes shots from
@VJOncology · 2026-09-12 · OCR
Day 2 of #WCLC26 and we're excited to speak to experts on the latest updates in thoracic o
@VJOncology · 2026-09-13 · OCR
Tomorrow we're heading to #WCLC2026 in Seoul to bring you exciting news in #LungCancer, in
@VJOncology · 2026-09-11 · OCR
We're currently live at #WCLC2026 filming interviews and discussions with leading experts
@VJOncology · 2026-09-14 · OCR
It's day two of #WCLC2026 and we're on-site in Seoul!📍 Check out the latest updates in #L
@VJOncology · 2026-09-13 · OCR
It's the final day of #WCLC26! 🫁 We've really enjoyed our time on-site, interviewing lead
@VJOncology · 2026-09-15 · OCR
🧠 At #WCLC26 Mark Jeng (@mjeng21) discusses two key studies in #NSCLC: CSF circulating tum
@VJOncology · 2026-09-14 · OCR
We’re so ready to meet you at #WCLC26! 📍 Journals Lounge, IALSC Zone, 3F (outside of the
@vs_lim · 2026-09-12 · OCR
We’re so ready to meet you at #WCLC26! 📍 Journals Lounge, IALSC Zone, 3F (outside of the
@vs_lim · 2026-09-12 · OCR
We’re so ready to meet you at #WCLC26! 📍 Journals Lounge, IALSC Zone, 3F (outside of the
@vs_lim · 2026-09-12 · OCR
We’re so ready to meet you at #WCLC26! 📍 Journals Lounge, IALSC Zone, 3F (outside of the
@vs_lim · 2026-09-12 · OCR
❤️ JTO and JTO CRR at the World Conference on Lung Cancer in Seoul #JTO20 @IASLC @JTOonli
@vs_lim · 2026-09-11 · OCR
❤️ JTO and JTO CRR at the World Conference on Lung Cancer in Seoul #JTO20 @IASLC @JTOonli
@vs_lim · 2026-09-11 · OCR
Wondering about reasons papers get rejected, what papers are good fit for JTO and JTO CRR
@vs_lim · 2026-09-12 · OCR
Welcome to Seoul! UNITE for our lung cancer patients! #WCLC26 https://t.co/9cbiHIPDoA
@youngkwangchae · 2026-09-12 · OCR
Welcome to Seoul! UNITE for our lung cancer patients! #WCLC26 https://t.co/9cbiHIPDoA
@youngkwangchae · 2026-09-12 · OCR
Welcome to Seoul! UNITE for our lung cancer patients! #WCLC26 https://t.co/9cbiHIPDoA
@youngkwangchae · 2026-09-12 · OCR
WCLC 2026 Seoul — SCLC just changed forever. 🚨🫁 Two B7-H3 ADCs smashed topotecan on the e
@youngkwangchae · 2026-09-13 · OCR
WCLC "Beyond metastatic: Redefining the role of local therapy" M009 session 5PM-6:15PM I
@youngkwangchae · 2026-09-13 · OCR
Thank you, WCLC 2026 Conference Chairs for an amazing meeting in Seoul! @IASLC #WCLC26 ht
@youngkwangchae · 2026-09-15 · OCR
Thank you, WCLC 2026 Conference Chairs for an amazing meeting in Seoul! @IASLC #WCLC26 ht
@youngkwangchae · 2026-09-15 · OCR
Thank you, WCLC 2026 Conference Chairs for an amazing meeting in Seoul! @IASLC #WCLC26 ht
@youngkwangchae · 2026-09-15 · OCR
Thank you, WCLC 2026 Conference Chairs for an amazing meeting in Seoul! @IASLC #WCLC26 ht
@youngkwangchae · 2026-09-15 · OCR
Great way to kick off #WCLC26 in Seoul at the @IASLC Awards Luncheon. Congrats to all awar
@Yvonne_Diaz_ · 2026-09-12 · OCR
Great way to kick off #WCLC26 in Seoul at the @IASLC Awards Luncheon. Congrats to all awar
@Yvonne_Diaz_ · 2026-09-12 · OCR
Great way to kick off #WCLC26 in Seoul at the @IASLC Awards Luncheon. Congrats to all awar
@Yvonne_Diaz_ · 2026-09-12 · OCR
Great way to kick off #WCLC26 in Seoul at the @IASLC Awards Luncheon. Congrats to all awar
@Yvonne_Diaz_ · 2026-09-12 · OCR
Great to see more studies & focus on our EGFR exon 20 lung cancer population w presentatio
@Yvonne_Diaz_ · 2026-09-14 · OCR
Great to see more studies & focus on our EGFR exon 20 lung cancer population w presentatio
@Yvonne_Diaz_ · 2026-09-14 · OCR
Dr @mal_itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at #WC
@Yvonne_Diaz_ · 2026-09-14 · OCR
Dr @mal_itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at #WC
@Yvonne_Diaz_ · 2026-09-14 · OCR
Dr @mal_itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at #WC
@Yvonne_Diaz_ · 2026-09-14 · OCR
Dr @mal_itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at #WC
@Yvonne_Diaz_ · 2026-09-14 · OCR
Landmark developments in ES-SCLC at #WCLC2026! We are proud that our Team contributed to t
@ZairiEleni · 2026-09-13 · OCR
Landmark developments in ES-SCLC at #WCLC2026! We are proud that our Team contributed to t
@ZairiEleni · 2026-09-13 · OCR
Landmark developments in ES-SCLC at #WCLC2026! We are proud that our Team contributed to t
@ZairiEleni · 2026-09-13 · OCR
Landmark developments in ES-SCLC at #WCLC2026! We are proud that our Team contributed to t
@ZairiEleni · 2026-09-13 · OCR
The city, humanity and the future meet at a crossroads. Proud to present our work at #WCLC
@ZairiEleni · 2026-09-12 · OCR
The city, humanity and the future meet at a crossroads. Proud to present our work at #WCLC
@ZairiEleni · 2026-09-12 · OCR
The city, humanity and the future meet at a crossroads. Proud to present our work at #WCLC
@ZairiEleni · 2026-09-12 · OCR
#ESMO2023 #Madrid 🇪🇸 #WCLC2026 #Seoul 🇰🇷 Different cities, different congresses, the sam
@ZairiEleni · 2026-09-14 · OCR
#ESMO2023 #Madrid 🇪🇸 #WCLC2026 #Seoul 🇰🇷 Different cities, different congresses, the sam
@ZairiEleni · 2026-09-14 · OCR
Before the meeting

Pre-Conference Image Library

🚨 DeLLphi-305 is positive! Tarlatamab + durvalumab as 1L maintenance in ES-SCLC significan
@M_Torasawa · 2026-09-08 · OCR
🚨 DeLLphi-305 is positive! Tarlatamab + durvalumab as 1L maintenance in ES-SCLC significan
@M_Torasawa · 2026-09-08 · OCR
@IASLC #WCLC26 bound! Who else is on the way to Seoul? 🇰🇷 https://t.co/IJC3Dky2CR https:/
@lungoncdoc · 2026-09-09 · OCR
🚨 Landmark development in ES-SCLC! Phase 3 DeLLphi-305 has shown a statistically signific
@SuyogCancer · 2026-09-08 · OCR
🚨 Landmark development in ES-SCLC! Phase 3 DeLLphi-305 has shown a statistically signific
@SuyogCancer · 2026-09-08 · OCR
The PCI question has been answered in a contemporary phase III RCT. Final results remain e
@DrewMoghanaki · 2026-08-20 · OCR
$ABBV RC148 (ABBV-1480) + chemo in 1st-line NSCLC. Squam: ORR 90%, PD-L1<1% ORR 93%, "exce
@JacobPlieth · 2026-09-03 · OCR
JUST IN: DeLLphi-305 study met its primary endpoint of overall survival combining tarlata
@DrChoueiri · 2026-09-08 · OCR
JUST IN: DeLLphi-305 study met its primary endpoint of overall survival combining tarlata
@DrChoueiri · 2026-09-08 · OCR
🔥 #WCLC26 Presidential Symposium 1 🇰🇷 Sunday, September 13, 2026 A major session spanning
@M_Torasawa · 2026-08-19 · OCR
WCLC 2026 is getting closer! 🇰🇷🫁 Eight studies from the Presidential Symposia that I’ll b
@UOzkerim · 2026-08-20 · OCR
And now it shows OS benefit too . Harmoni 2 OS Press release. King Keytruda is having s
@SuyogCancer · 2026-09-03 · OCR
And now it shows OS benefit too . Harmoni 2 OS Press release. King Keytruda is having s
@SuyogCancer · 2026-09-03 · OCR
10 #WCLC26 abstracts beyond the presidentials to watch: 1. FURVENT 2. TRIDENT-3 3. Iza-br
@lungoncdoc · 2026-09-08 · OCR
On our way to Seoul for @IASLC #WCLC26 ✈️ Excited for my first World Lung and first time i
@JamesFanWu · 2026-09-09 · OCR
🧬 #WCLC26 Presidential Symposium 2 🇰🇷 Monday, September 14, 2026 This one is all about o
@M_Torasawa · 2026-08-19 · OCR
Sevabirtinib is now @FDA ✅ in 1L HER2/ERBB2 TKD mutated mNSCLC based off SOHO-01: - ORR:
@OncBrothers · 2026-09-09 · OCR
🔥 The detailed OS results from HARMONi-2, comparing ivonescimab with pembrolizumab in firs
@M_Torasawa · 2026-09-03 · OCR
So here's how I see $SMMT Harmoni-2, in expectation of the #WCLC26 reveal of "stat sig" OS
@JacobPlieth · 2026-09-03 · OCR
We are excited to share new clinical data from our diversified lung cancer pipeline, inclu
@BioNTech_Group · 2026-08-20 · OCR
If you plan to attend #WCLC26 in Seoul, you MUST listen to this great episode! Beyond tr
@BalazsHalmosMD · 2026-09-07 · OCR
If you plan to attend #WCLC26 in Seoul, you MUST listen to this great episode! Beyond tr
@BalazsHalmosMD · 2026-09-07 · OCR
If you plan to attend #WCLC26 in Seoul, you MUST listen to this great episode! Beyond tr
@BalazsHalmosMD · 2026-09-07 · OCR
WCLC 2026: os 40 estudos de câncer de pulmão que estou de olho 👀 @GBOT_Alerta @IASLC #wcl
@FernandoOnco · 2026-08-22 · OCR
WCLC 2026: os 40 estudos de câncer de pulmão que estou de olho 👀 @GBOT_Alerta @IASLC #wcl
@FernandoOnco · 2026-08-22 · OCR
WCLC 2026: os 40 estudos de câncer de pulmão que estou de olho 👀 @GBOT_Alerta @IASLC #wcl
@FernandoOnco · 2026-08-22 · OCR
WCLC 2026: os 40 estudos de câncer de pulmão que estou de olho 👀 @GBOT_Alerta @IASLC #wcl
@FernandoOnco · 2026-08-22 · OCR
🔬 Our work on whole-transcriptome profiling for metastatic recurrence prediction in early-
@RobertoBoreaMD · 2026-08-31 · OCR
🌟Just ahead of #WCLC26, an exquisite cutting-edge Review in @JTOonline on #ADCs in #SCLC
@g_mountzios · 2026-09-05 · OCR
🌟Just ahead of #WCLC26, an exquisite cutting-edge Review in @JTOonline on #ADCs in #SCLC
@g_mountzios · 2026-09-05 · OCR
🌟Just ahead of #WCLC26, an exquisite cutting-edge Review in @JTOonline on #ADCs in #SCLC
@g_mountzios · 2026-09-05 · OCR
🌟Just ahead of #WCLC26, an exquisite cutting-edge Review in @JTOonline on #ADCs in #SCLC
@g_mountzios · 2026-09-05 · OCR
TWO IOs. TWO MAINTENANCE STRATEGIES. ES-SCLC maintenance is evolving. IMforte: Atezolizu
@ChandrakanthMv · 2026-09-09 · OCR
🚨 Who's ready for SCLC updates at #WCLC26?! 🫁 1️⃣ Dr J͟o͟n͟a͟t͟h͟a͟n͟ ͟G͟o͟l͟d͟m͟a͟n͟ pres
@LauraAlderMD · 2026-08-24 · OCR
$SMMT toplined an OS win in Akeso's Harmoni-2 trial yesterday, and there's just 12 days' w
@JacobPlieth · 2026-09-03 · OCR
Are you Psy-ched about #WCLC26 happening in just a few weeks?? Our @IASLC Career Developm
@BalazsHalmosMD · 2026-08-21 · OCR
Are you Psy-ched about #WCLC26 happening in just a few weeks?? Our @IASLC Career Developm
@BalazsHalmosMD · 2026-08-21 · OCR
🚨 DeLLphi-305: Tarlatamab enters 1L maintenance in ES-SCLC Who was treated? Patients with
@DrRishabhOnco · 2026-09-09 · OCR
🚨🔥HOT OFF THE PRESS. JUST #RELEASED. ⭐️#Abstracts of @IASLC #WCLC26 (#World Conference
@RManochakian · 2026-08-20 · OCR
Don’t forget the rules Hotel ➡️ unpack ➡️ wrinkle free spray Done! #WCLC26 https://t
@NarjustFlorezMD · 2026-09-09 · OCR
Our Top 10 #LungCancer abstracts for #WCLC26 in Seoul. Hand-picked, with times, rooms and
@LungSummit · 2026-09-04 · OCR
Younger people with #lungcancer may be more likely to have targetable genetic changes. A
@LungCancerEu · 2026-08-21 · OCR
Potentially practice-changing phase III news in extensive-stage small cell lung cancer. *
@ilyassahinMD · 2026-09-08 · OCR
Dellphi-305 trial of Imfinzi + Imdelltra in 1L ES-SCLC maintenance toplined positive. What
@ByMadeleineA · 2026-09-08 · OCR
Join us for the #EarlyCareer Development Workshop at #WCLC26! 🌏 🫁 🤝 #SpeedMentoring for p
@drsabita · 2026-08-24 · OCR
Nothing like a refreshing early morning run along the Hangang river in #Seoul on Day -2 of
@cspramesh · 2026-09-09 · OCR
Great to see radiotherapy being discussed in a session dedicated to resectable lung cancer
@DrewMoghanaki · 2026-08-20 · OCR
Great to see radiotherapy being discussed in a session dedicated to resectable lung cancer
@DrewMoghanaki · 2026-08-20 · OCR
Great to see radiotherapy being discussed in a session dedicated to resectable lung cancer
@DrewMoghanaki · 2026-08-20 · OCR
📢Very exciting news for ES-SCLC! 🔥 DeLLphi-305 meets its primary OS endpoint with tarlata
@UOzkerim · 2026-09-08 · OCR
🚨 #FDAApproval: The @FDA granted accelerated approval to sevabertinib (Hyrnuo) for treatme
@ASCOPost · 2026-09-09 · OCR
Meanwhile, here's Harmoni, the 2nd-line study $SMMT filed on (14 Nov Pdufa date). #WCLC26
@JacobPlieth · 2026-09-03 · OCR
🚨🔥@OncoAlert Hot off the press. @US_FDA approves: ⭐️#Sevabertinib ❇️For #FirstLine Tx
@RManochakian · 2026-09-09 · OCR
13 days to #WCLC26 @IASLC in Seoul! 🫁 Excited for new data, but let's keep clinical perspe
@ADesaiMD · 2026-09-01 · OCR
@rolfolab at #WCLC2026 🇰🇷 Proud that the Rolfo Lab at @OSUCCC_James is bringing seven abs
@RobertoBoreaMD · 2026-09-08 · OCR
Yep, @sandraturner49 is literally going to be on stage at #WCLC26. So grateful she agreed
@DrewMoghanaki · 2026-08-20 · OCR
Join us at #WCLC2026 for our Join us for the IASLC-EMRO Forum session on Saturday 2-4 PM L
@NaglaAKarimMD · 2026-08-25 · OCR
Join us at #WCLC2026 for our Join us for the IASLC-EMRO Forum session on Saturday 2-4 PM L
@NaglaAKarimMD · 2026-08-25 · OCR
So excited for #WCLC2026 in Seoul (Sept 12–15)! 🇰🇷 The Presidential Symposia lineup looks
@LauraAlderMD · 2026-08-21 · OCR
On my way to @IASLC #WCLC26! First leg DEN -> YVR with @united. It’s looking like a beauti
@UrsWeberMD · 2026-09-09 · OCR
A Tale of Two Realities in Lung 🫁 Cancer A paradox defines the current moment in #lungcan
@KulikovUNIATF · 2026-08-28 · OCR
Want to know what to look for at #WCLC26? Sign up for exclusive insights from @DRCamidge,
@OncLive · 2026-09-08 · OCR
I’ll be attending #WCLC26 in Seoul. WCLC is always an important opportunity to stay curr
@NarjustFlorezMD · 2026-09-09 · OCR
A NEW MAINTENANCE ERA IN ES-SCLC? DeLLphi-305 brings tarlatamab earlier in the treatment
@ChandrakanthMv · 2026-09-09 · OCR
Attended a very interesting meeting as a #keynote speaker immediately before ✈️ 🇰🇷 for #W
@herbloong · 2026-09-09 · OCR
Attended a very interesting meeting as a #keynote speaker immediately before ✈️ 🇰🇷 for #W
@herbloong · 2026-09-09 · OCR
Attended a very interesting meeting as a #keynote speaker immediately before ✈️ 🇰🇷 for #W
@herbloong · 2026-09-09 · OCR
@DoctorJSpicer Impressive for 8 weeks of therapy! Will be interesting to see how next gen
@FordePatrick · 2026-08-22 · OCR
@DoctorJSpicer Impressive for 8 weeks of therapy! Will be interesting to see how next gen
@FordePatrick · 2026-08-22 · OCR
@DoctorJSpicer Impressive for 8 weeks of therapy! Will be interesting to see how next gen
@FordePatrick · 2026-08-22 · OCR
I am honored and grateful to the @IASLC for selecting our study on BRAF class II and III a
@DiFedericoMD · 2026-09-03 · OCR
I am honored and grateful to the @IASLC for selecting our study on BRAF class II and III a
@DiFedericoMD · 2026-09-03 · OCR
3 weeks to the #wclc26 @IASLC I’m preparing a plenary talk on AI for Clinical Decision-Ma
@fabiomoraesmd · 2026-08-22 · OCR
On our way to @IASLC #WCLC2026 very excited with many good developments in the figth again
@LuisRaezMD · 2026-09-09 · OCR
Ready to take your thoracic oncology career further? 🚀 Join us at #WCLC26 on 12 Sept for a
@drsabita · 2026-09-07 · OCR
Ready to take your thoracic oncology career further? 🚀 Join us at #WCLC26 on 12 Sept for a
@drsabita · 2026-09-07 · OCR
Ready to take your thoracic oncology career further? 🚀 Join us at #WCLC26 on 12 Sept for a
@drsabita · 2026-09-07 · OCR
@OncoAlert @weoncologists @GlopesMd @OpenMedKate WCLC 2026 | NAUTIKA1 🇰🇷 Neoadjuvant KRAS
@UOzkerim · 2026-09-06 · OCR
One more flight to get to @IASLC #WCLC26! YVR -> ICN with @AirCanada! https://t.co/JoEaJYI
@UrsWeberMD · 2026-09-09 · OCR
Key updates to watch at #WCLC26 https://t.co/Ls3ck5LGWg #biopharma #lungcancer #oncology #
@BioWorld · 2026-08-31 · OCR
LCRF is going to be at World Conference on Lung Cancer Sept. 12-15. If you are on Instagra
@lcrf_org · 2026-08-19 · OCR
Our team @rolfolab is presenting at #WCLC26 🇰🇷 @IASLC ! Congrats to all the members to th
@rolfolab · 2026-09-08 · OCR
Register now to attend the launch broadcast for JIDEYTRO™ (zidesamtinib), hosted by Dr. Ma
@OncLive · 2026-09-09 · OCR
Lung cancer care is a team effort. From Mexico, SMOT is building bridges across discipline
@JorgeAlatorreA1 · 2026-09-09 · OCR
Lung cancer care is a team effort. From Mexico, SMOT is building bridges across discipline
@JorgeAlatorreA1 · 2026-09-09 · OCR
Join us in Seoul, South Korea, from 12–15 September 2026 at #WCLC26 as we continue to fost
@PfizerOncMed · 2026-09-05 · OCR
One voice can start a conversation. A collective voice can change what comes next. From I
@R2SurviveCancer · 2026-09-08 · OCR
Less than 3 weeks until #WCLC26! Grateful for the opportunity to contribute in 3 roles thi
@LeiDeng3 · 2026-08-23 · OCR
Less than 3 weeks until #WCLC26! Grateful for the opportunity to contribute in 3 roles thi
@LeiDeng3 · 2026-08-23 · OCR
Less than 3 weeks until #WCLC26! Grateful for the opportunity to contribute in 3 roles thi
@LeiDeng3 · 2026-08-23 · OCR
Thank you @EuroRespSoc for an excellent #ERSCongress2026 in Barcelona. We presented 2 abs
@LungCancerEu · 2026-09-09 · OCR
🫁 Catching up on news from #ASCO26 ahead of #WCLC26? 🌟 Don't miss this interview with @ML
@Lung_Cancers · 2026-09-07 · OCR
🧐 At #WCLC26? 🔥 Come to ASCO-IASLC Forum: Beyond Tobacco Exposure - Modern determinants of
@tnewsomdavis · 2026-09-06 · OCR
ADCs. Bispecifics. New possibilities. What comes next for lung cancer care? Join @PatelO
@gotoPER · 2026-08-20 · OCR
Please come to our Latin American session at @iaslc #WCLC26, Saturday September 12th from
@LuisRaezMD · 2026-09-07 · OCR
Please come to our Latin American session at @iaslc #WCLC26, Saturday September 12th from
@LuisRaezMD · 2026-09-07 · OCR
Please come to our Latin American session at @iaslc #WCLC26, Saturday September 12th from
@LuisRaezMD · 2026-09-07 · OCR
Taking a brief break from fellowship interviews to head to Seoul for @IASLC #WCLC26! 🇰🇷🫁
@GarradEvan · 2026-09-07 · OCR
Bispecifics are no longer just a pipeline story. Hemlibra and Vabysmo generated over $10B
@TrialAndThesis · 2026-09-09 · OCR
FDA approval expanded for sevabertinib in HER2 (ERBB2) TKD–mutant advanced NSCLC — now inc
@Dr_ElvinaA · 2026-09-09 · OCR
Today in partnership with @TaihoOncology, we announced zipalertinib + chemo first-line Pha
@CullinanTx · 2026-08-19 · OCR
WCLC 2026 is one week away, and our Panoramic database is behind three studies that span t
@flatironhealth · 2026-09-08 · OCR
Connect with Foundation Medicine at #WCLC26! Visit us to learn about the latest advancemen
@FoundationATCG · 2026-09-02 · OCR
We’re heading to Seoul this week for #WCLC26, hosted by @IASLC Together with our researc
@GuardantHealth · 2026-09-09 · OCR
Join Foundation Medicine for our “Booth Talk Series” at #WCLC26. Hear from our team of exp
@FoundationATCG · 2026-09-08 · OCR
Join Foundation Medicine for our “Booth Talk Series” at #WCLC26. Hear from our team of exp
@FoundationATCG · 2026-09-08 · OCR
Join Foundation Medicine for our “Booth Talk Series” at #WCLC26. Hear from our team of exp
@FoundationATCG · 2026-09-08 · OCR
From Data to Decisions in HER2-Overexpressing #NSCLC: Drs. Planchard (@dplanchard), Horino
@PeerView · 2026-08-19 · OCR
⭕ El GECP presentará 13 pósters científicos en el #WCLC2026. Los trabajos abordan nuevos e
@gecp_org · 2026-08-25 · OCR
⭕ El GECP participará en el #WCLC2026 con cuatro comunicaciones miniorales y un Poster Tou
@gecp_org · 2026-08-19 · OCR
We’re starting to see some important #lungcancer data appearing ahead of #WCLC26 A big re
@EgfrUk · 2026-08-27 · OCR
Ivonescimab: A New Chapter in Global Oncology Development – Akeso Biopharma @AkesoInc h
@OncoDailyBio · 2026-09-09 · OCR
We're looking forward to engaging with the thoracic oncology community at #WCLC26. See wha
@LillyOncMed · 2026-09-07 · OCR
🫁 Catching up on #ASCO26 news ahead of #WCLC26? 👑 Don't miss this insightful interview wi
@Lung_Cancers · 2026-08-22 · OCR
⭕ Se acerca el #WCLC2026. ➡️Del 12 al 15 de septiembre, Seúl reunirá las principales noved
@gecp_org · 2026-09-03 · OCR
Bispecifics are a commercial reality. Hemlibra + Vabysmo: >$10B in 2025. Solid tumors may
@TrialAndThesis · 2026-09-07 · OCR
Let's connect via the @IASLC #WCLC26 app 🫁😊 https://t.co/YJ6aaaEQ5E
@KSamalaMD · 2026-09-09 · OCR
One of my old $SMMT writeups (2/2) The science still holds—ivonescimab safely delivers VE
@SaariPatrick · 2026-09-06 · OCR
One of my old $SMMT writeups (2/2) The science still holds—ivonescimab safely delivers VE
@SaariPatrick · 2026-09-06 · OCR
One of my old $SMMT writeups (2/2) The science still holds—ivonescimab safely delivers VE
@SaariPatrick · 2026-09-06 · OCR
One of my old $SMMT writeups (2/2) The science still holds—ivonescimab safely delivers VE
@SaariPatrick · 2026-09-06 · OCR
Delighted to be part of #WCLC26 in Seoul this September. I’ll be speaking on The Environm
@oceanblue11oct · 2026-08-26 · OCR
SCORED: Our bullish call on $SMMT from Sep 2 closed +18.2%. Akeso's ivonescimab beats Keyt
@InsiderWatchAI · 2026-09-08 · OCR
SCORED: Our bullish call on $SMMT from Sep 2 closed +18.2%. Akeso's ivonescimab beats Keyt
@InsiderWatchAI · 2026-09-08 · OCR
@DrewMoghanaki Come to our Joint ASCO-IASLC Forum at #WCLC26 to find out more on this exac
@tnewsomdavis · 2026-09-06 · OCR
AstraZeneca ($AZN) just announced a Phase 3 win in lung cancer, and the stock barely moved
@TheSFInvestor · 2026-09-09 · OCR
@DrSamuelBHume 3. ivonescimab is currently the top checkpoint inhibitor in clinical trials
@oncarta_org · 2026-09-07 · OCR
From India to Seoul - carrying a simple belief: every patient, everywhere, deserves a fair
@R2SurviveCancer · 2026-09-03 · OCR
Omw to Seoul for #WCLC26 🫁 https://t.co/aQFqzusec7
@KSamalaMD · 2026-09-09 · OCR
Summit Therapeutics up 28% on ivonescimab survival data. Why it matters for stocks: Summi
@InsiderWatchAI · 2026-09-07 · OCR
Summit Therapeutics up 28% on ivonescimab survival data. Why it matters for stocks: Summi
@InsiderWatchAI · 2026-09-07 · OCR
HARMONi-2: #Ivonescimab significantly improved overall survival vs pembrolizumab in PD-L1-
@Onco_Nexus · 2026-09-03 · OCR
Amgen-AstraZeneca Drug Combination Boosts Lung Cancer Survival Rates In Trial Reuters (9/
@jobrx · 2026-09-09 · OCR
💊 AZN STOCK UPDATE | September 2026 🚨 AstraZeneca consolidates at $160 as historic blockb
@Lucky_m_X · 2026-09-09 · OCR
Going to #WCLC2026 in Seoul? Do not miss the #PeerVoice industry symposium. Join Zosia Pio
@PeerVoice · 2026-08-28 · OCR
A look at what's coming up at the 2026 World Conference on Lung Cancer IASLC's annual meet
@GuidelineCent · 2026-08-20 · OCR
full breakdown on linkedin. the off season lives there :) #WCLC26 https://t.co/2CXY6BYbWv
@salgueiromp · 2026-09-01 · OCR
🫁 Just 1 more week until #WCLC26 kicks off in Seoul! 📆 As this year's meeting approaches
@Lung_Cancers · 2026-09-05 · OCR
🫁 Catching up on news from #ASCO26 ahead of #WCLC26? 🌟 Don't miss this insightful intervi
@Lung_Cancers · 2026-08-29 · OCR
China Summit & Dinner In conjunction with WCLC 2026 Seoul 📅 Date • Sept 14 | 6:30–9:00 PM
@eChinaHealth · 2026-09-06 · OCR
Eight Henlius studies are heading to #WCLC26, including new data for our investigational P
@HenliusBiotech · 2026-08-20 · OCR
Eight Henlius studies are heading to #WCLC26, including new data for our investigational P
@HenliusBiotech · 2026-08-20 · OCR
Proud to bring FairLife L.C.C. to #WCLC2026 in Seoul 🇬🇷🌏 We’ll present results from BREAT
@KORINAPATELI · 2026-08-31 · OCR
📣 Registrations are now open! Join us for Thoracic Cancer Highlights from WCLC 2026, wher
@TOGAANZ · 2026-09-03 · OCR
Proud to represent @fairlifelcc . at the #GLCC Annual Meeting in Seoul (9–11 Sept), ahead
@KORINAPATELI · 2026-09-09 · OCR
🎉🎉We’re exhibiting at #WCLC26 in Seoul! Oncology Frontier will be at Booth #325 during WC
@IONCOLOGYLung · 2026-09-08 · OCR
中国の迪哲薬業が、肺がん治療薬ZEGFROVYに関する最新データを、世界肺癌学会議（WCLC）2026で発表する予定とのこと。術後補助療法と一次併用療法の両方に関するデータが共有さ
@NyankoPv · 2026-09-08 · OCR
I’ll be presenting at #WCLC26 in Seoul! 🇰🇷 Our meta-analysis compares pembrolizumab monot
@nazimdmrcn · 2026-08-31 · OCR
🫁 What were the key thoracic cancer takeaways from WCLC 2026? Join us for our webinar exp
@TOGAANZ · 2026-09-09 · OCR
🎗️ Lung Cancer Pipeline Advances BioNTech advances its lung cancer pipeline ahead of WCLC
@cGxPWire · 2026-08-21 · OCR
We’re heading to Seoul for the 2026 World Conference on Lung Cancer (WCLC)! 🫁 📍 Seoul, Ko
@mpha_r · 2026-09-07 · OCR
#mdpiSTD 🫁🌏 Meet MDPI at #WCLC2026 in Seoul, 12–15 Sept! 📚 Visit us at Booth 706 at COEX t
@SurgicalTD_MDPI · 2026-08-21 · OCR
Encouraging news in small-cell lung cancer. Durvalumab + tarlatamab has met the overall-su
@asem_mo · 2026-09-08 · OCR
WCLC 2026 | HARMONi 🇰🇷 With longer follow-up, ivonescimab + chemotherapy continues to show
@UOzkerim · 2026-09-06 · OCR
What does it take to stand out when effective therapies already exist? 💬 #Zidesamtinib, a
@ArcNouvel · 2026-09-08 · OCR
🎗️🧬 WCLC 2026 Data Dizal to present Zegfrovy NSCLC data at WCLC 2026, highlighting new ad
@cGxPWire · 2026-08-22 · OCR
#WCLC2026 China Biopharma data RemeGen — Updated Ph2 data for PD-1/VEGF bispecific RC148
@chuminhua432 · 2026-08-21 · OCR
QLC5508 (B7H3 ADC) update — 🇨🇳 Qilu Pharmaceutical A Ph3 (NCT07802821) just launched: QL
@chuminhua432 · 2026-09-07 · OCR
🇨🇳Kelun-Biotech reported new data for TROP2 ADC sac-TMT at #WCLC2026 for pretreated NSCLC
@chuminhua432 · 2026-08-20 · OCR
🇨🇳Kelun-Biotech reported new data for TROP2 ADC sac-TMT at #WCLC2026 for pretreated NSCLC
@chuminhua432 · 2026-08-20 · OCR
#WCLC2026 China Biopharma data Leads Biolabs — Ph2 results for PD-L1/4-1BB bispecific Opa
@chuminhua432 · 2026-08-21 · OCR
#WCLC2026 🇨🇳China Biopharma data CSPC — Phase 2 data for EGFR ADC SYS6010 + PD-L1 mAb enl
@chuminhua432 · 2026-08-21 · OCR
Looking forward to updated EGFR datasets selected for plenaries at #WCLC26. 8yOS from ADAU
@DrRiyazShah · 2026-08-20 · OCR
2 RCT Plenaries at #WCLC26 using B7-H3 ADC in relapsed SCLC. Looking forward to this https
@DrRiyazShah · 2026-08-20 · OCR
2 RCT Plenaries at #WCLC26 using B7-H3 ADC in relapsed SCLC. Looking forward to this https
@DrRiyazShah · 2026-08-20 · OCR
Really excited to see first line randomised data in Her-2 mutant lung cancer with presenta
@DrRiyazShah · 2026-08-21 · OCR
Really excited to see first line randomised data in Her-2 mutant lung cancer with presenta
@DrRiyazShah · 2026-08-21 · OCR
Updated ARROS-1 at #WCLC26 will be welcome data...... reimbursement in ROS1 definitely lag
@DrRiyazShah · 2026-08-20 · OCR
1/6 Alright! Three weeks to go @iaslc #WCLC26 Presidential Symposium 1 looks like a fascin
@GlopesMd · 2026-08-21 · OCR
WCLC 2026 Presidential Symposium 1 looks like a fascinating Sunday morning in Seoul. Four
@GlopesMd · 2026-08-24 · OCR
#WCLC26 @iaslc Looking forward to meeting you in Seoul On behalf of @Jani_Chinmay I will b
@GlopesMd · 2026-08-22 · OCR
#WCLC26 @iaslc Looking forward to meeting you in Seoul On behalf of @Jani_Chinmay I will b
@GlopesMd · 2026-08-22 · OCR
#WCLC26 @iaslc Looking forward to meeting you in Seoul On behalf of @Jani_Chinmay I will b
@GlopesMd · 2026-08-22 · OCR
#WCLC26 @iaslc Looking forward to meeting you in Seoul On behalf of @Jani_Chinmay I will b
@GlopesMd · 2026-08-22 · OCR
Here we go with our second tweet on @iaslc #wclc26 prep! 1/6 If Presidential Symposium 1
@GlopesMd · 2026-08-22 · OCR
Pleased to be presenting our #WCLC26 study on a very practical precision-oncology question
@GlopesMd · 2026-08-24 · OCR
Visual summary of today’s phase 3 DeLLphi-305 update in ES-SCLC: tarlatamab + durvalumab m
@GlopesMd · 2026-09-08 · OCR
Visual summary of today’s phase 3 DeLLphi-305 update in ES-SCLC: tarlatamab + durvalumab m
@GlopesMd · 2026-09-08 · OCR
Visual summary of today’s phase 3 DeLLphi-305 update in ES-SCLC: tarlatamab + durvalumab m
@GlopesMd · 2026-09-08 · OCR
Visual summary of today’s phase 3 DeLLphi-305 update in ES-SCLC: tarlatamab + durvalumab m
@GlopesMd · 2026-09-08 · OCR
Looking forward to @IASLC #WCLC26 Pleased to be a co-author of OA10.01, led by Alex Spira:
@GlopesMd · 2026-08-24 · OCR
Seoul in a week. Nine trials in two Presidential Symposia will answer questions we have be
@GlopesMd · 2026-09-06 · OCR
COEX is a state of the art convention center and Seoul is the #1 or #2 city in the world i
@GlopesMd · 2026-09-06 · OCR
Before #WCLC26, walk Cheonggyecheon at dusk. Buried under a highway in 1971, dug back out
@GlopesMd · 2026-09-06 · OCR
Experience noraebang while in Seoul for #wclc26 @iaslc @oncoalert @oncodaily @larvol @trib
@GlopesMd · 2026-09-08 · OCR
With less than two weeks to go the two Presidential Symposia at #WCLC26 got the headlines.
@GlopesMd · 2026-08-27 · OCR
As #WCLC26 approaches, I’m thinking about the work that matters most: turning evidence int
@GlopesMd · 2026-09-01 · OCR
1/6 One last post before heading to Seoul for #WCLC26. For history buffs, here is the day
@GlopesMd · 2026-09-09 · OCR
1/6 One last post before heading to Seoul for #WCLC26. For history buffs, here is the day
@GlopesMd · 2026-09-09 · OCR
1/6 One last post before heading to Seoul for #WCLC26. For history buffs, here is the day
@GlopesMd · 2026-09-09 · OCR
1/6 One last post before heading to Seoul for #WCLC26. For history buffs, here is the day
@GlopesMd · 2026-09-09 · OCR
Four years of ATOM: 1.3M estimated doses. 46 countries. 37 medicines + 10 diagnostics. 12
@GlopesMd · 2026-08-29 · OCR
Science without boundaries is a fitting theme for #WCLC26. Progress in lung cancer depends
@GlopesMd · 2026-09-07 · OCR
1. OA14.05 — HARMONi updated OS. Ivonescimab + chemo after a 3rd-gen EGFR TKI: PFS 6.8 vs
@GlopesMd · 2026-08-27 · OCR
About two weeks to go for @IASLC #WCLC26 This one makes me happy. Latin America generating
@GlopesMd · 2026-08-27 · OCR
5. MO12.02 — BH-30643, a macrocyclic EGFR TKI for secondary resistance mutations including
@GlopesMd · 2026-08-27 · OCR
The Presidential Symposia carry the practice-changing phase 3s — PL03 is Monday, 8 a.m. KS
@GlopesMd · 2026-08-27 · OCR
6. OA12.04 — AMIGO-1 (LACOG 0821): 1L amivantamab + lazertinib + pemetrexed, EGFR 19del/L8
@GlopesMd · 2026-08-27 · OCR
2. OA10.01 — Iza-Bren (EGFR×HER3 bispecific ADC), randomized dose expansion in EGFR-mutant
@GlopesMd · 2026-08-27 · OCR
3. OA12.01 — GFH375 (VS-7375) in KRAS G12D NSCLC. First-in-class oral drugging of a non-cy
@GlopesMd · 2026-08-27 · OCR
4. OA12.02 — QLC1101, also KRAS G12D. Read it alongside OA12.01. One active asset is a res
@GlopesMd · 2026-08-27 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd)
@HHorinouchi · 2026-08-21 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Neoadjuvant Chemo-Immunotherapy vs EGFR-TKI in EGFR-Mu
@HHorinouchi · 2026-08-27 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemother
@HHorinouchi · 2026-08-20 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥SOLARA: Anti-Tumor Activity of BH-30643, a Novel Macroc
@HHorinouchi · 2026-08-31 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 COPERNICUS: Subcutaneous Amivantamab+Lazertinib With S
@HHorinouchi · 2026-08-31 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resecta
@HHorinouchi · 2026-08-21 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥SWOG S1827 MAVERICK: Phase III Trial of Brain MRI Surveill
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥ADAURA: Adjuvant Osimertinib in Resected EGFR-Mutated Stag
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥EVOKE-03/KEYNOTE D46: Primary Results from Phase 3: Sacitu
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥DeLLphi-309: Tarlatamab Extended-Interval Dosing Regimens in
@HHorinouchi · 2026-08-21 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Sacituzumab Tirumotecan (Sac-TMT) in Pts With Previously Trea
@HHorinouchi · 2026-08-22 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥REZILIENT3: Zipalertinib Plus Chemotherapy for 1st Line NS
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥ARTEMIS-008: Risvutatug Rezetecan (a B7-H3-Directed ADC) V
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥ASTRES: A Phase 2 Study of Atezolizumab in Locally Advanced,
@HHorinouchi · 2026-08-22 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 SOHO-01: Molecular Landscape of Acquired Resistance to
@HHorinouchi · 2026-08-31 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥HARMONi: Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resis
@HHorinouchi · 2026-08-24 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥STARLORD: Stereotactic Radiotherapy in Locally Advanced Non-S
@HHorinouchi · 2026-08-22 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Phase 2 Study of peri-ope/CRT JS207 (PD-1/VEGF Bispecific Ant
@HHorinouchi · 2026-08-22 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Beamion LUNG-1: Acquired Resistance to Zongertinib Tre
@HHorinouchi · 2026-08-31 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Phase 1 Global Study of Iza-Bren in Patients With Metastatic
@HHorinouchi · 2026-08-22 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 CROWN: Long-Term Safety of Lorlatinib After 7 Years -
@HHorinouchi · 2026-08-31 · OCR
🔥SOLARA: Anti-Tumor Activity of BH-30643, a Novel Macrocyclic EGFR TKI, in Patients With S
@HHorinouchi · 2026-09-09 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥NAUTIKA1: Primary Analysis of Neoadjuvant Alectinib in
@HHorinouchi · 2026-08-27 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥AMIGO-1 (LACOG 0821): A Single-Arm Phase 2 Study of First-Lin
@HHorinouchi · 2026-08-23 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Ivonescimab Plus Chemotherapy for Refractory Leptomeni
@HHorinouchi · 2026-08-31 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Phase II Study of SYS6010 Plus Enlonstobart in Actionable Gen
@HHorinouchi · 2026-08-22 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥ARROS-1: Zidesamtinib in TKI-naive Patients With Advanced/
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Plenary Session 🔥TAISHAN-302: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjuga
@HHorinouchi · 2026-08-20 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥GASTO-1098: Effect of Thymosin a-1 on Treatment Completion an
@HHorinouchi · 2026-08-22 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Safety and Efficacy of QLC1101 in Patients With Advanced NSCL
@HHorinouchi · 2026-08-23 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥IMpower133/SKYSCRAPER-02: Expression and Prognostic Imp
@HHorinouchi · 2026-09-01 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant NSC
@HHorinouchi · 2026-08-23 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Explainable Machine Learning Model to Predict High-Grade Adve
@HHorinouchi · 2026-08-23 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 A Pivotal Phase II Study of Ficonalkib, a 3rd-Generati
@HHorinouchi · 2026-08-31 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemothe
@HHorinouchi · 2026-08-25 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemoth
@HHorinouchi · 2026-08-24 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Efficacy and Safety of HS-10370 Combined With Adebrelimab and
@HHorinouchi · 2026-08-23 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 LUNAR Trial: Health-Related Quality of Life With Tumor
@HHorinouchi · 2026-08-29 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Biallelic Inactivation of KEAP1/STK11 Predicts Benefit
@HHorinouchi · 2026-08-28 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Predicting NSCLC Neoadjuvant Immunotherapy Response Using H&E
@HHorinouchi · 2026-08-23 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Phase 2 Study of Investigational Agents Plus Tislelizu
@HHorinouchi · 2026-08-28 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Post-Surgical Molecular Residual Disease Detection, Ad
@HHorinouchi · 2026-08-30 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥CHIMERA Study: Phase II Study of Perioperative Pembroliz
@HHorinouchi · 2026-08-25 · OCR
🆙#WCLC26 #LCSM Mini Oral 🔥RELEVENT Trial: Updated Survival Outcomes of Ramucirumab in Comb
@HHorinouchi · 2026-08-25 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Impact of Protein Arginine Methyltransferase 5 (PRMT5)
@HHorinouchi · 2026-08-26 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Aut
@HHorinouchi · 2026-08-21 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Role of PET/CT in the Neoadjuvant Chemoimmunotherapy A
@HHorinouchi · 2026-08-27 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥EMPOWER-Lung 1: KRAS G12C Predicts Superior Outcomes Wit
@HHorinouchi · 2026-08-26 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Multi-Omics of ctDNA Shedding Defines Ctnmb Staging and TME H
@HHorinouchi · 2026-08-23 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 STARLET Analysis: Intracranial Tumour Kinetics in EGFR
@HHorinouchi · 2026-08-29 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
@HHorinouchi · 2026-08-27 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Baseline CT-Derived Imaging Biomarkers Predict Risk of
@HHorinouchi · 2026-09-01 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Epigenetic Dysregulation Permits E2F1 Activation-Mediated Neu
@HHorinouchi · 2026-08-21 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 ARTEMIDE-01: Updated Efficacy Results of Rilvegostomig
@HHorinouchi · 2026-08-28 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Firmonertinib for Stage I EGFR-Mutated NSCLC With Mult
@HHorinouchi · 2026-08-27 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥NADIM/NADIM II: Tertiary Lymphoid Structures After Perio
@HHorinouchi · 2026-08-26 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 First-Line YL201 Plus Serplulimab in ES-SCLC and Advan
@HHorinouchi · 2026-09-01 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-
@HHorinouchi · 2026-08-28 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 STARLET Joint Analysis (LUOSICNS/OUTRUN): Health Relat
@HHorinouchi · 2026-08-29 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥A Phase III Randomized Multicenter Trial of Adjuvant Gefitini
@HHorinouchi · 2026-08-21 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Analysis of MTAP Loss Prevalence Between Tissue and Liqu
@HHorinouchi · 2026-08-26 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Peripheral Blood PD-1+ Tfh Cells Predict Response and
@HHorinouchi · 2026-08-28 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Development of a Shared Neoantigen Peptide Library to
@HHorinouchi · 2026-08-28 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Clinicopathologic Characteristics and Histologic Transfo
@HHorinouchi · 2026-08-26 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 LuCa-MERIT-1: Neoadjuvant BNT116 + Cemiplimab + Carbop
@HHorinouchi · 2026-08-27 · OCR
🆙#WCLC26 #LCSM Oral Session 🔥Prioritizing Circulating Proteins for Lung Cancer Risk Strati
@HHorinouchi · 2026-08-23 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥A Grading System for Invasive Mucinous Adenocarcinoma of
@HHorinouchi · 2026-08-26 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥MIST3: Tumour Extrinsic Regulation of Neutrophils Sensit
@HHorinouchi · 2026-08-25 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL
@HHorinouchi · 2026-09-01 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Station-Based Nodal Assessment and Prognosis After Neo
@HHorinouchi · 2026-08-27 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Balancing Efficacy and Toxicity in NSCLC Immunotherapy
@HHorinouchi · 2026-08-28 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 SACTION01: Long-Term Outcomes Following Neoadjuvant SB
@HHorinouchi · 2026-08-27 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 160 mg Furmonertinib for EGFR-Mutated NSCLC With Lepto
@HHorinouchi · 2026-08-31 · OCR
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 Phase II Study of Opamtistomig (LBL-024), a PD-L1/4-1B
@HHorinouchi · 2026-08-28 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Risk Stratification and Surgical Optimization in Lung Ad
@HHorinouchi · 2026-08-26 · OCR
🆙#WCLC26 #LCSM Mini Oral Session 🔥Clinical, Pathologic, and Genomic Characteristics of NRA
@HHorinouchi · 2026-08-26 · OCR
Heading to Seoul for #WCLC26? Before you go, join @StephenVLiu and @NarjustFlorezMD for p
@IASLC · 2026-09-07 · OCR
What does physician wellness really look like in oncology? In a new #LungCancerConsidered
@IASLC · 2026-08-22 · OCR
Explore what’s next in thoracic oncology November 12–14 in São Paulo, #Brazil. 🌎 Connect
@IASLC · 2026-08-18 · OCR
Can’t make it to Seoul? Join #WCLC26 from wherever you are. 🌎 Virtual registration gives
@IASLC · 2026-09-05 · OCR
Lung Cancer Considered in Korean 🇰🇷 Dr. @chulkimMD joins Dr. Hye Ryun Kim and @youngkwang
@IASLC · 2026-08-29 · OCR
🔬 The Presidential Symposia are now live for #WCLC26! Explore some of the most anticipate
@IASLC · 2026-08-20 · OCR
📢 Two IASLC opportunities are now open! 🎓 IASLC Academy: Mentorship, education & research
@IASLC · 2026-09-01 · OCR
Congratulations to IASLC Career Advancement Grant awardee @BenCreelan 🎉! His project will
@IASLC · 2026-09-04 · OCR
🎉 Congratulations to IASLC Young Investigator Grant awardee @BeatrizWills! Her research w
@IASLC · 2026-08-24 · OCR
🌎 Connect with the South American thoracic oncology community on Aug. 21! Join the Thorac
@IASLC · 2026-08-21 · OCR
🎉 Congratulations to Ruth Sudha Moses, a recipient of the IASLC Adi F. Gazdar Fellowship!
@IASLC · 2026-08-31 · OCR
🎉 Congratulations to IASLC Young Investigator Grant awardee @kimyw_snu_pulm! His researc
@IASLC · 2026-09-07 · OCR
What should the future of AI in #lungcancer care look like? IASLC wants to hear from thos
@IASLC · 2026-09-03 · OCR
The management of oligometastatic #LungCancer continues to evolve. Dr. @NarjustFlorezMD i
@IASLC · 2026-09-03 · OCR
🌍 A global approach is essential to improving lung cancer outcomes. In the newest #LungCa
@IASLC · 2026-08-27 · OCR
📣 Reminder: The #NACLC26 Call for Abstracts is open! Share your latest research with the
@IASLC · 2026-09-01 · OCR
One week to go for @IASLC #WCLC26 in Seoul, Korea. Getting there one day early not to find
@Latinamd · 2026-09-08 · OCR
#WCLC26 @IASLC Presidential Symposium 1 Abstracts are out and here is why they matter: ▶️
@Latinamd · 2026-08-27 · OCR
✈️ 18 hours from MIA to Korea means plenty of time to read! So many @iaslc #WCLC26 abstr
@Latinamd · 2026-09-08 · OCR
The place to be for @HemOncFellows and early career faculty attending @IASLC #WCLC26 In Ko
@Latinamd · 2026-09-08 · OCR
🏆 Challenge accepted: packing my @IASLC sneakers to Move, connect, and win prizes at #WCLC
@Latinamd · 2026-09-08 · OCR
🏆 Challenge accepted: packing my @IASLC sneakers to Move, connect, and win prizes at #WCLC
@Latinamd · 2026-09-08 · OCR
🏆 Challenge accepted: packing my @IASLC sneakers to Move, connect, and win prizes at #WCLC
@Latinamd · 2026-09-08 · OCR
#WCLC26 When there is so much to cover that you have to add a 2nd Presidential Symposium.
@Latinamd · 2026-08-27 · OCR
NEWS from Industry: DeLLphi-305 Update in Small Cell Lung Cancer Source: Amgen The Phase
@OncoAlert · 2026-09-08 · OCR
The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 #NSCLC 🇰🇷 We’re kicking off our OncoAlert TOP 10 for
@OncoAlert · 2026-08-31 · OCR
The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 Advanced #NSCLC 🇰🇷 We’re kicking off our OncoAlert TO
@OncoAlert · 2026-09-01 · OCR
FDA News🇺🇸 Sevabertinib Approved in Locally Advanced or met #NSCLC #LungCancer On Septem
@OncoAlert · 2026-09-09 · OCR
The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 Adv #SCLC 🇰🇷 We’re kicking off our OncoAlert TOP 10 f
@OncoAlert · 2026-09-02 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.02Neoadj
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.02Neoadj
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.02Neoadj
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.01 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.01 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.01 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.04 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.04 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.04 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week MO12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week MO12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week MO12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.07 — The
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.07 — The
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.07 — The
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.01 — NAUT
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.01 — NAUT
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.01 — NAUT
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week MO06.01 — NAUT
@OncoAlert · 2026-09-03 · OCR
AcuVox 🚨 is LIVE ANRE READY Visit us👉 https://t.co/exVrdx6n28 Oncology moves fast. The s
@OncoAlert · 2026-09-08 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.02 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week MO12.01 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week MO12.01 —
@OncoAlert · 2026-09-04 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.01A Phase
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.01A Phase
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.01A Phase
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA09.02 — AST
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA09.02 — AST
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA09.02 — AST
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA09.03 — A Ph
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA09.03 — A Ph
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA09.03 — A Ph
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.04 — Neoa
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.04 — Neoa
@OncoAlert · 2026-09-03 · OCR
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week OA04.04 — Neoa
@OncoAlert · 2026-09-03 · OCR
Turning Evidence Into Action to Implement Lung Cancer Policy at WCLC26 - Gilberto Lopes (@
@oncodaily · 2026-09-03 · OCR
What's New Data to be Presented at #WCLC2026 - Amol Akhade @SuyogCancer https://t.co/gS
@oncodaily · 2026-08-22 · OCR
DeLLphi-305 Success and Key Challenges in Global SCLC Access - Misty Shields @Amgen @drsh
@oncodaily · 2026-09-09 · OCR
🫁 Phase III DeLLphi-305 (NCT06211036) showed that tarlatamab + durvalumab significantly im
@oncodaily · 2026-09-08 · OCR
The @US_FDA has expanded the accelerated approval of sevabertinib for HER2 (ERBB2)-mutant,
@oncodaily · 2026-09-09 · OCR
Delighted to be Part of #WCLC26 in Seoul this September - Estela Rodriguez @Latinamd ht
@oncodaily · 2026-08-29 · OCR
@RobertoBoreaMD @ChristianRolfo @OSUCCC_James @IASLC Study on NSCLC Metastatic Recurrence
@oncodaily · 2026-09-01 · OCR
IASLC - Be Part of WCLC 2026 From Wherever You Are @IASLC https://t.co/QCdukXqIej http
@oncodaily · 2026-08-27 · OCR
@NarjustFlorezMD @StephenVLiu A Practical Guide to WCLC 2026 in Seoul - Narjust Florez @N
@oncodaily · 2026-09-07 · OCR
@LeiDeng3 @IASLC Grateful for the Opportunity to Contribute in Three Roles at WCLC26 - Lei
@oncodaily · 2026-08-26 · OCR
@Latinamd @IASLC Delighted to be Part of #WCLC26 in Seoul this September - Estela Rodrigue
@oncodaily · 2026-08-29 · OCR
Laura Alder on SCLC Updates and Speakers of #WCLC26 @LauraAlderMD https://t.co/0cH6cCFaWv
@OncodailyLung · 2026-08-26 · OCR
IASLC - #WCLC26 Full abstracts and Presidential Symposia Titles Are Out Now! @IASLC https
@OncodailyLung · 2026-08-23 · OCR
Honored That Our Work Will Be Presented at the Presidential Symposium 1 of #WCLC26 - Giann
@OncodailyLung · 2026-08-21 · OCR
Looking Forward to Meeting You in Seoul at #WCLC26 - Gilberto Lopes @GlopesMd https://t.c
@OncodailyLung · 2026-08-22 · OCR
IASLC #WCLC26 Presidential Symposium Abstracts Are Out and Here's Why They Matter - Estela
@OncodailyLung · 2026-08-30 · OCR
Gilberto Lopes' Second Tweet on #WCLC26 Preperation @GlopesMd https://t.co/ikyGYQlmuE
@OncodailyLung · 2026-08-25 · OCR
Top Picks for WCLC 2026 - Aakash Desai @ADesaiMD https://t.co/CmZ7sM1gtb
@OncodailyLung · 2026-09-01 · OCR
What a City and the World Conference on Lung Cancer Can Teach Us About Progress - @GlopesM
@OncodailyLung · 2026-09-09 · OCR
Before #WCLC26, Walk Cheonggyecheon at Dusk - GILBERTO de lima LOPES Junior (@GlopesMd) ht
@OncodailyLung · 2026-09-07 · OCR
10 WCLC26 Abstracts Beyond the Presidentials to Watch - Eric Singhi @lungoncdoc https://t
@OncodailyLung · 2026-09-09 · OCR
Can’t Imagine a Better Place for WCLC26 Than COEX and Seoul - Gilberto Lopes @GlopesMd @i
@OncodailyLung · 2026-09-07 · OCR
Key WCLC26 Oral Abstracts - Estelamari Rodriguez @Latinamd https://t.co/BGIkQtxg8d
@OncodailyLung · 2026-09-09 · OCR
SMALL CELL LUNG CANCER B7-H3 ENTRA EN ESCENA DOS NUEVOS ADC: IFINATAMAB DERUXTECAN ( I-D
@pharma_jonpi · 2026-09-08 · OCR
SMALL CELL LUNG CANCER B7-H3 ENTRA EN ESCENA DOS NUEVOS ADC: IFINATAMAB DERUXTECAN ( I-D
@pharma_jonpi · 2026-09-08 · OCR
SMALL CELL LUNG CANCER B7-H3 ENTRA EN ESCENA DOS NUEVOS ADC: IFINATAMAB DERUXTECAN ( I-D
@pharma_jonpi · 2026-09-08 · OCR
SMALL CELL LUNG CANCER ONCOLOG@S Y PACIENTES PODRÍAN TENER EN MESES TRES TREATMENTS SCLC-
@pharma_jonpi · 2026-09-07 · OCR
SMALL CELL LUNG CANCER ONCOLOG@S Y PACIENTES PODRÍAN TENER EN MESES TRES TREATMENTS SCLC-
@pharma_jonpi · 2026-09-07 · OCR
TARLATAMAB YA MARCA EL ESTÁNDAR EN SEGUNDA LÍNEA DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE
@pharma_jonpi · 2026-08-27 · OCR
TARLATAMAB YA MARCA EL ESTÁNDAR EN SEGUNDA LÍNEA DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE
@pharma_jonpi · 2026-08-27 · OCR
TARLATAMAB YA MARCA EL ESTÁNDAR EN SEGUNDA LÍNEA DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE
@pharma_jonpi · 2026-08-27 · OCR
TARLATAMAB YA MARCA EL ESTÁNDAR EN SEGUNDA LÍNEA DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE
@pharma_jonpi · 2026-08-27 · OCR
TARLATAMAB SE CONSOLIDA COMO ESTÁNDAR EN SEGUNDA LÍNEA SMALL CELL LUNG CANCER EXTENSIVE-ST
@pharma_jonpi · 2026-08-28 · OCR
REVÉS PARA ATEZOLIZUMAB ( TECENTRIQ / ROCHE ) EN MANTENIMIENTO SMALL CELL LUNG CANCER ES (
@pharma_jonpi · 2026-09-02 · OCR
REVÉS PARA ATEZOLIZUMAB ( TECENTRIQ / ROCHE ) EN MANTENIMIENTO SMALL CELL LUNG CANCER ES (
@pharma_jonpi · 2026-09-02 · OCR
REVÉS PARA ATEZOLIZUMAB ( TECENTRIQ / ROCHE ) EN MANTENIMIENTO SMALL CELL LUNG CANCER ES (
@pharma_jonpi · 2026-09-02 · OCR
REVÉS PARA ATEZOLIZUMAB ( TECENTRIQ / ROCHE ) EN MANTENIMIENTO SMALL CELL LUNG CANCER ES (
@pharma_jonpi · 2026-09-02 · OCR
SERPLULIMAB SUPERA AL IMFORTE (ATEZOLIZUMAB/LURBINECTEDIN) EN MAINTENANCE FIRTS-LINE SMALL
@pharma_jonpi · 2026-08-25 · OCR
SERPLULIMAB SUPERA AL IMFORTE (ATEZOLIZUMAB/LURBINECTEDIN) EN MAINTENANCE FIRTS-LINE SMALL
@pharma_jonpi · 2026-08-25 · OCR
SERPLULIMAB SUPERA AL IMFORTE (ATEZOLIZUMAB/LURBINECTEDIN) EN MAINTENANCE FIRTS-LINE SMALL
@pharma_jonpi · 2026-08-25 · OCR
SERPLULIMAB SUPERA AL IMFORTE (ATEZOLIZUMAB/LURBINECTEDIN) EN MAINTENANCE FIRTS-LINE SMALL
@pharma_jonpi · 2026-08-25 · OCR
PHARMAMAR Y @JazzPharma , MANTIENEN DEMANDAS CONTRA RK PHARMA Y CONTRA INVAGEN POR INFRING
@pharma_jonpi · 2026-08-31 · OCR
POSIBLE NUEVO TRATAMIENTO DE PRIMERA LINEA DE MANTENIMIENTO SMALL CELL LUNG CANCER YA EST
@pharma_jonpi · 2026-09-08 · OCR
POSIBLE NUEVO TRATAMIENTO DE PRIMERA LINEA DE MANTENIMIENTO SMALL CELL LUNG CANCER YA EST
@pharma_jonpi · 2026-09-08 · OCR
POSIBLE NUEVO TRATAMIENTO DE PRIMERA LINEA DE MANTENIMIENTO SMALL CELL LUNG CANCER YA EST
@pharma_jonpi · 2026-09-08 · OCR
Traveling to Seoul for #WCLC26? Listen to this episode first! Some more tips: Download
@StephenVLiu · 2026-09-07 · OCR
Traveling to Seoul for #WCLC26? Listen to this episode first! Some more tips: Download
@StephenVLiu · 2026-09-07 · OCR
Traveling to Seoul for #WCLC26? Listen to this episode first! Some more tips: Download
@StephenVLiu · 2026-09-07 · OCR
Traveling to Seoul for #WCLC26? Listen to this episode first! Some more tips: Download
@StephenVLiu · 2026-09-07 · OCR
Join us at #WCLC26 on Saturday, September 12 at 2PM KST for this workshop on global commun
@StephenVLiu · 2026-09-09 · OCR
At #WCLC26, be sure to join Drs. Tina Cascone, @bensolomon1 , and me at this very timely @
@StephenVLiu · 2026-09-04 · OCR
Watch next week for a special episode of the @IASLC podcast, Lung Cancer Considered, with
@StephenVLiu · 2026-08-18 · OCR
At #WCLC26, be sure to join Drs. Tina Cascone, @bensolomon1, and me at this @PeerView symp
@StephenVLiu · 2026-08-31 · OCR
In September, we're heading to Seoul for #WCLC26! 🌏🚨 We'll be on-site during the meeting
@VJOncology · 2026-08-22 · OCR
There's less than three weeks to go until #WCLC26 🚨 We'll be on-site to bring you clinica
@VJOncology · 2026-08-25 · OCR
There's less than a month to go until #WCLC26 so make sure you're following @VJOncology an
@VJOncology · 2026-08-19 · OCR
There's only a week to go until #WCLC26! 🚨 We'll be on-site in Seoul to bring you the lat
@VJOncology · 2026-09-05 · OCR
There's less than two weeks to go until #WCLC26 so make sure you're following us @VJOncolo
@VJOncology · 2026-09-02 · OCR
Only two weeks to go until #WCLC26! Make sure you're following us @VJOncology and visit h
@VJOncology · 2026-08-29 · OCR
Three days to go until #WCLC26🚨 Make sure you're following us @VJOncology and check out h
@VJOncology · 2026-09-09 · OCR
Expanded slide